parent_name,parent_smiles,metabolite_smiles,reaction,rule_subset,som,score
Ibrutinib,C=CC(=O)N1CCC[C@@H:1](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,C=CC(=O)N1CCC[C@@:1](O)(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H:1](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,0.02
Ibrutinib,C=CC(=O)N1CCC[C@@H:2](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,C=CC(=O)N1CCC[C:2](=O)C1,N-dealkylation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H:2](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,0.02
Ibrutinib,C=CC(=O)N1CCC[C@@H]([n:1]2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,C=CC(=O)N1CCC[C@@H]([N+:1]2([O-])N=C(c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,N-oxidation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H]([n:1]2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,0.01
Ibrutinib,C=CC(=O)N1CCC[C@@H]([n:1]2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)n[nH:1]2,N-dealkylation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H]([n:1]2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,0.01
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2c3ncnc(N)c3c(-c3ccc(Oc4ccccc4)cc3)[n:1]2)C1,C=CC(=O)N1CCC[C@@H](n2c3ncnc(N)c3c(-c3ccc(Oc4ccccc4)cc3)[n+:1]2C2OC(C(=O)O)C(O)C(O)C2O)C1,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),C=CC(=O)N1CCC[C@@H](n2c3ncnc(N)c3c(-c3ccc(Oc4ccccc4)cc3)[n:1]2)C1,0.0
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3cc[c:6](Oc4ccccc4)cc3)c3c(N)ncnc32)C1,C=CC(=O)N1CCC[C@@H](n2nc(C3C=C[C:6](=O)C=C3)c3c(N)ncnc32)C1,O-dearylation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H](n2nc(-c3cc[c:6](Oc4ccccc4)cc3)c3c(N)ncnc32)C1,0.0
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(O[c:6]4ccccc4)cc3)c3c(N)ncnc32)C1,O=[C:6]1C=CCC=C1,O-dearylation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(O[c:6]4ccccc4)cc3)c3c(N)ncnc32)C1,0.0
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(O[c:8]4ccccc4)cc3)c3c(N)ncnc32)C1,O=[C:8]1C=CCC=C1,O-dearylation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(O[c:8]4ccccc4)cc3)c3c(N)ncnc32)C1,0.0
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cc[cH:1]cc4)cc3)c3c(N)ncnc32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cc[c:1](O)cc4)cc3)c3c(N)ncnc32)C1,aromatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cc[cH:1]cc4)cc3)c3c(N)ncnc32)C1,0.18
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cc[cH:5]cc4)cc3)c3c(N)ncnc32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cc[c:5](O)cc4)cc3)c3c(N)ncnc32)C1,aromatic_hydroxylation_(para_to_oxygen),Phase 1 SyGMa rules,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cc[cH:5]cc4)cc3)c3c(N)ncnc32)C1,0.18
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc[cH:1]c4)cc3)c3c(N)ncnc32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc[c:1](O)c4)cc3)c3c(N)ncnc32)C1,aromatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc[cH:1]c4)cc3)c3c(N)ncnc32)C1,0.01
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cccc[cH:1]4)cc3)c3c(N)ncnc32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cccc[c:1]4O)cc3)c3c(N)ncnc32)C1,aromatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cccc[cH:1]4)cc3)c3c(N)ncnc32)C1,0.02
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cccc[cH:3]4)cc3)c3c(N)ncnc32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cccc[c:3]4O)cc3)c3c(N)ncnc32)C1,aromatic_hydroxylation_(ortho_to_oxygen),Phase 1 SyGMa rules,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cccc[cH:3]4)cc3)c3c(N)ncnc32)C1,0.02
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)[cH:1]c3)c3c(N)ncnc32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)[c:1](O)c3)c3c(N)ncnc32)C1,aromatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)[cH:1]c3)c3c(N)ncnc32)C1,0.01
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)[cH:3]c3)c3c(N)ncnc32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)[c:3](O)c3)c3c(N)ncnc32)C1,aromatic_hydroxylation_(ortho_to_oxygen),Phase 1 SyGMa rules,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)[cH:3]c3)c3c(N)ncnc32)C1,0.01
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)c[cH:1]3)c3c(N)ncnc32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)c[c:1]3O)c3c(N)ncnc32)C1,aromatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)c[cH:1]3)c3c(N)ncnc32)C1,0.0
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)[n:1]cnc32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)[n+:1](C4OC(C(=O)O)C(O)C(O)C4O)cnc32)C1,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)[n:1]cnc32)C1,0.04
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)[n:1]cnc32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)[n+:1]([O-])cnc32)C1,N-oxidation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)[n:1]cnc32)C1,0.0
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)[n:2]cnc32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)[n+:2]([O-])cnc32)C1,N-oxidation_(-N=),Phase 1 SyGMa rules,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)[n:2]cnc32)C1,0.0
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[cH:1]nc32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[c:1](O)nc32)C1,aromatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[cH:1]nc32)C1,0.01
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[cH:5]nc32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[c:5](O)nc32)C1,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[cH:5]nc32)C1,0.01
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nc[n:1]c32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nc[n+:1](C4OC(C(=O)O)C(O)C(O)C4O)c32)C1,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nc[n:1]c32)C1,0.01
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nc[n:1]c32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nc[n+:1]([O-])c32)C1,N-oxidation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nc[n:1]c32)C1,0.0
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nc[n:2]c32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nc[n+:2]([O-])c32)C1,N-oxidation_(-N=),Phase 1 SyGMa rules,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nc[n:2]c32)C1,0.0
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)[CH2:1]1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)[CH:1]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)[CH2:1]1,0.06
Ibrutinib,C=CC(=O)N1[CH2:1][C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC[CH2:2]1,Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@H](CC[CH:2]=O)[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)[CH2:1]1,0.06
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)[CH2:2]1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)[CH:2]1O,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)[CH2:2]1,0.06
Ibrutinib,C=CC(=O)N1[CH2:1]CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)[CH2:2]1,Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@H](CC[CH3:1])[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)[CH2:2]1,0.06
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c([NH2:1])ncnc32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c([NH:1]O)ncnc32)C1,amine hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c([NH2:1])ncnc32)C1,0.03
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c([NH2:2])ncnc32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c([NH:2]C(C)=O)ncnc32)C1,N-acetylation_(aniline),NAT rules (phase 2),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c([NH2:2])ncnc32)C1,0.33
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c([NH2:2])ncnc32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c([NH:2]C4OC(C(=O)O)C(O)C(O)C4O)ncnc32)C1,N-glucuronidation_(aniline),UGT rules (phase 2),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c([NH2:2])ncnc32)C1,0.13
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c([NH2:2])ncnc32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c([NH:2]O)ncnc32)C1,N-oxidation_(aniline),Phase 1 SyGMa rules,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c([NH2:2])ncnc32)C1,0.03
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c([NH2:2])ncnc32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c([NH:2]S(=O)(=O)O)ncnc32)C1,sulfation_(aniline),SULT rules (phase 2),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c([NH2:2])ncnc32)C1,0.05
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c2ncn[c:2]3N)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c2nc[nH][c:2]3=O)C1.N,oxidative_deamination_(aromatic),Phase 1 SyGMa rules,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c2ncn[c:2]3N)C1,0.01
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc([O:7]c4ccccc4)cc3)c3c(N)ncnc32)C1,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc([OH:7])cc3)c3c(N)ncnc32)C1,O-dearylation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc([O:7]c4ccccc4)cc3)c3c(N)ncnc32)C1,0.0
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc([O:7]c4ccccc4)cc3)c3c(N)ncnc32)C1,C=CC(=O)N1CCC[C@@H](n2nc(C3C=CC(=[O:7])C=C3)c3c(N)ncnc32)C1,O-dearylation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc([O:7]c4ccccc4)cc3)c3c(N)ncnc32)C1,0.0
Ibrutinib,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc([O:7]c4ccccc4)cc3)c3c(N)ncnc32)C1,c1ccc([OH:7])cc1,O-dearylation,CYP rules from GLORY (phase 1),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc([O:7]c4ccccc4)cc3)c3c(N)ncnc32)C1,0.0
Ibrutinib,C=CC(=O)N1CC[CH2:1][C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,C=CC(=O)N1CC[CH:1](O)[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)N1CC[CH2:1][C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,0.02
Ibrutinib,C=CC(=O)N1CC[CH2:2][C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,C=CC(=O)N1CC[CH:2](O)[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,aliphatic_hydroxylation_(sec_carbon_in_a_ringB),Phase 1 SyGMa rules,C=CC(=O)N1CC[CH2:2][C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,0.02
Ibrutinib,C=CC(=O)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC[CH2:1]1,C=CC(=O)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC[CH:1]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC[CH2:1]1,0.71
Ibrutinib,C=CC(=O)N1[CH2:1]CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)[CH2:2]1,Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@H](CC[CH3:1])[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),C=CC(=O)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC[CH2:1]1,0.71
Ibrutinib,C=CC(=O)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC[CH2:2]1,C=CC(=O)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC[C:2]1=O,oxidation_(amine_in_a_ring),Phase 1 SyGMa rules,C=CC(=O)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC[CH2:2]1,0.71
Ibrutinib,C=CC(=O)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC[CH2:2]1,C=CC(=O)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC[CH:2]1O,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,C=CC(=O)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC[CH2:2]1,0.71
Ibrutinib,C=CC(=O)N1[CH2:1][C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC[CH2:2]1,Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@H](CC[CH:2]=O)[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),C=CC(=O)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC[CH2:2]1,0.71
Ibrutinib,C=CC(=O)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C[CH2:1]C1,C=CC(=O)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C[CH:1](O)C1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C[CH2:1]C1,0.02
Ibrutinib,C=CC(=O)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C[CH2:2]C1,C=CC(=O)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C[CH:2](O)C1,aliphatic_hydroxylation_(sec_carbon_in_a_ringA),Phase 1 SyGMa rules,C=CC(=O)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C[CH2:2]C1,0.02
Osimertinib,C=CC(=O)N[c:4]1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c([O:7]C)cc1N(C)CCN(C)C,CN(C)CCN(C)C1=CC(=[O:7])C(Nc2nccc(-c3cn(C)c4ccccc34)n2)=C[C:4]1=O,oxidation of 4-substituted anisole to quinone,CYP rules from GLORY (phase 1),C=CC(=O)N[c:4]1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,0.0
Osimertinib,C=CC(=O)Nc1c(N(C)CCN(C)C)cc(OC)c(Nc2nccc(-c3cn(C)c4ccccc34)n2)[cH:1]1,C=CC(=O)Nc1c(N(C)CCN(C)C)cc(OC)c(Nc2nccc(-c3cn(C)c4ccccc34)n2)[c:1]1O,aromatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1c(N(C)CCN(C)C)cc(OC)c(Nc2nccc(-c3cn(C)c4ccccc34)n2)[cH:1]1,0.0
Osimertinib,C=CC(=O)Nc1c(N(C)CCN(C)C)cc(OC)c(Nc2nccc(-c3cn(C)c4ccccc34)n2)[cH:3]1,C=CC(=O)Nc1c(N(C)CCN(C)C)cc(OC)c(Nc2nccc(-c3cn(C)c4ccccc34)n2)[c:3]1O,aromatic_hydroxylation_(ortho_to_2_substituents),Phase 1 SyGMa rules,C=CC(=O)Nc1c(N(C)CCN(C)C)cc(OC)c(Nc2nccc(-c3cn(C)c4ccccc34)n2)[cH:3]1,0.0
Osimertinib,C=CC(=O)Nc1c[c:6](Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)NC1=C[C:6](=O)C(OC)=CC1N(C)CCN(C)C,N-dearylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1c[c:6](Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,0.0
Osimertinib,C=CC(=O)Nc1cc(N[c:2]2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(N)c(OC)cc1N(C)CCN(C)C.Cn1cc(-c2cc[nH][c:2](=O)n2)c2ccccc21,oxidative_deamination_(aromatic),Phase 1 SyGMa rules,C=CC(=O)Nc1cc(N[c:2]2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,0.0
Osimertinib,C=CC(=O)Nc1cc(Nc2nc(-c3cn(C)c4ccccc34)c[cH:1]n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nc(-c3cn(C)c4ccccc34)c[c:1](O)n2)c(OC)cc1N(C)CCN(C)C,aromatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nc(-c3cn(C)c4ccccc34)c[cH:1]n2)c(OC)cc1N(C)CCN(C)C,0.01
Osimertinib,C=CC(=O)Nc1cc(Nc2nc(-c3cn(C)c4ccccc34)c[cH:4]n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nc(-c3cn(C)c4ccccc34)c[c:4](O)n2)c(OC)cc1N(C)CCN(C)C,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,C=CC(=O)Nc1cc(Nc2nc(-c3cn(C)c4ccccc34)c[cH:4]n2)c(OC)cc1N(C)CCN(C)C,0.01
Osimertinib,C=CC(=O)Nc1cc(Nc2nc(-c3cn(C)c4ccccc34)cc[n:1]2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nc(-c3cn(C)c4ccccc34)cc[n+:1]2C2OC(C(=O)O)C(O)C(O)C2O)c(OC)cc1N(C)CCN(C)C,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),C=CC(=O)Nc1cc(Nc2nc(-c3cn(C)c4ccccc34)cc[n:1]2)c(OC)cc1N(C)CCN(C)C,0.02
Osimertinib,C=CC(=O)Nc1cc(Nc2nc(-c3cn(C)c4ccccc34)cc[n:1]2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nc(-c3cn(C)c4ccccc34)cc[n+:1]2[O-])c(OC)cc1N(C)CCN(C)C,N-oxidation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nc(-c3cn(C)c4ccccc34)cc[n:1]2)c(OC)cc1N(C)CCN(C)C,0.0
Osimertinib,C=CC(=O)Nc1cc(Nc2nc(-c3cn(C)c4ccccc34)cc[n:2]2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nc(-c3cn(C)c4ccccc34)cc[n+:2]2[O-])c(OC)cc1N(C)CCN(C)C,N-oxidation_(-N=),Phase 1 SyGMa rules,C=CC(=O)Nc1cc(Nc2nc(-c3cn(C)c4ccccc34)cc[n:2]2)c(OC)cc1N(C)CCN(C)C,0.0
Osimertinib,C=CC(=O)Nc1cc(Nc2nc[cH:1]c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nc[c:1](O)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,aromatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nc[cH:1]c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,0.01
Osimertinib,C=CC(=O)Nc1cc(Nc2nc[cH:5]c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nc[c:5](O)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,aromatic_hydroxylation_(para_to_nitrogen),Phase 1 SyGMa rules,C=CC(=O)Nc1cc(Nc2nc[cH:5]c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,0.01
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3c4ccccc4n(C)[cH:1]3)n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3c4ccccc4n(C)[c:1]3O)n2)c(OC)cc1N(C)CCN(C)C,aromatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3c4ccccc4n(C)[cH:1]3)n2)c(OC)cc1N(C)CCN(C)C,0.05
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3c[n:1](C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3c[nH:1]c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-demethylation_(nCH3),Phase 1 SyGMa rules,C=CC(=O)Nc1cc(Nc2nccc(-c3c[n:1](C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,0.05
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3c[n:1](C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(C3=C[N+:1](C)([O-])c4ccccc43)n2)c(OC)cc1N(C)CCN(C)C,N-oxidation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3c[n:1](C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,0.05
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4c3ccc[cH:1]4)n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4c3ccc[c:1]4O)n2)c(OC)cc1N(C)CCN(C)C,aromatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4c3ccc[cH:1]4)n2)c(OC)cc1N(C)CCN(C)C,0.01
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4c3ccc[cH:3]4)n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4c3ccc[c:3]4O)n2)c(OC)cc1N(C)CCN(C)C,aromatic_hydroxylation_(ortho_to_nitrogen),Phase 1 SyGMa rules,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4c3ccc[cH:3]4)n2)c(OC)cc1N(C)CCN(C)C,0.01
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4c[cH:1]ccc34)n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4c[c:1](O)ccc34)n2)c(OC)cc1N(C)CCN(C)C,aromatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4c[cH:1]ccc34)n2)c(OC)cc1N(C)CCN(C)C,0.07
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4c[cH:5]ccc34)n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4c[c:5](O)ccc34)n2)c(OC)cc1N(C)CCN(C)C,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4c[cH:5]ccc34)n2)c(OC)cc1N(C)CCN(C)C,0.07
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4cc[cH:1]cc34)n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4cc[c:1](O)cc34)n2)c(OC)cc1N(C)CCN(C)C,aromatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4cc[cH:1]cc34)n2)c(OC)cc1N(C)CCN(C)C,0.05
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4cc[cH:5]cc34)n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4cc[c:5](O)cc34)n2)c(OC)cc1N(C)CCN(C)C,aromatic_hydroxylation_(para_to_nitrogen),Phase 1 SyGMa rules,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4cc[cH:5]cc34)n2)c(OC)cc1N(C)CCN(C)C,0.05
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccc[cH:1]c34)n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccc[c:1](O)c34)n2)c(OC)cc1N(C)CCN(C)C,aromatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccc[cH:1]c34)n2)c(OC)cc1N(C)CCN(C)C,0.01
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)[n:1]2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)[n+:1]2C2OC(C(=O)O)C(O)C(O)C2O)c(OC)cc1N(C)CCN(C)C,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)[n:1]2)c(OC)cc1N(C)CCN(C)C,0.01
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)[n:1]2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)[n+:1]2[O-])c(OC)cc1N(C)CCN(C)C,N-oxidation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)[n:1]2)c(OC)cc1N(C)CCN(C)C,0.01
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)[n:2]2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)[n+:2]2[O-])c(OC)cc1N(C)CCN(C)C,N-oxidation_(-N=),Phase 1 SyGMa rules,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)[n:2]2)c(OC)cc1N(C)CCN(C)C,0.01
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)[cH:1]c1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)[c:1](O)c1N(C)CCN(C)C,aromatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)[cH:1]c1N(C)CCN(C)C,0.0
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)[cH:3]c1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)[c:3](O)c1N(C)CCN(C)C,aromatic_hydroxylation_(ortho_to_2_substituents),Phase 1 SyGMa rules,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)[cH:3]c1N(C)CCN(C)C,0.0
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)[CH3:1],C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)[CH2:1]O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)[CH3:1],0.97
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CC[N:1](C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CC[N+:1](C)(C)C1OC(C(=O)O)C(O)C(O)C1O,N-glucuronidation_(N(CH3)2),UGT rules (phase 2),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CC[N:1](C)C,0.31
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CC[N:1](C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CC[N+:1](C)(C)[O-],N-oxidation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CC[N:1](C)C,0.83
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CC[N:1](C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CC[NH:1]C,N-dealkylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CC[N:1](C)C,0.83
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CC[N:1](C)C,C[NH:1]C,N-dealkylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CC[N:1](C)C,0.83
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CC[N:2](C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CC[N+:2](C)(C)[O-],N-oxidation_(RN(CH3)2),Phase 1 SyGMa rules,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CC[N:2](C)C,0.83
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)C[CH2:1]N(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)C[CH:1](O)N(C)C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)C[CH2:1]N(C)C,0.05
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)C[CH2:2]N(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)C[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)C[CH2:2]N(C)C,0.05
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)C[CH2:4]N(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)C[CH2:4]O.CNC,N-dealkylation_(tertiaryN-CH2-alkyl),Phase 1 SyGMa rules,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)C[CH2:4]N(C)C,0.05
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)[CH2:1]CN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)[CH:1](O)CN(C)C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)[CH2:1]CN(C)C,0.68
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)[CH2:2]CN(C)C,CN(C)C[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)[CH2:2]CN(C)C,0.68
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)[CH2:4]CN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1NC.CN(C)C[CH2:4]O,N-dealkylation_(tertiaryN-CH2-alkyl),Phase 1 SyGMa rules,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)[CH2:4]CN(C)C,0.68
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(CCN(C)C)[CH3:1],C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(CCN(C)C)[CH2:1]O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(CCN(C)C)[CH3:1],0.09
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1[N:1](C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1[N+:1](C)([O-])CCN(C)C,N-oxidation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1[N:1](C)CCN(C)C,0.12
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1[N:1](C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1[NH:1]C,N-dealkylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1[N:1](C)CCN(C)C,0.12
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1[N:1](C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1[NH:1]CCN(C)C,N-dealkylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1[N:1](C)CCN(C)C,0.12
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1[N:2](C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1[NH:2]CCN(C)C,N-demethylation_(R-N(CR)CH3),Phase 1 SyGMa rules,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1[N:2](C)CCN(C)C,0.12
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(O[CH3:1])cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(O[CH2:1]O)cc1N(C)CCN(C)C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(O[CH3:1])cc1N(C)CCN(C)C,0.02
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c([O:2]C)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c([OH:2])cc1N(C)CCN(C)C,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c([O:2]C)cc1N(C)CCN(C)C,0.0
Osimertinib,C=CC(=O)N[c:4]1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c([O:7]C)cc1N(C)CCN(C)C,CN(C)CCN(C)C1=CC(=[O:7])C(Nc2nccc(-c3cn(C)c4ccccc34)n2)=C[C:4]1=O,oxidation of 4-substituted anisole to quinone,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c([O:7]C)cc1N(C)CCN(C)C,0.0
Osimertinib,C=CC(=O)Nc1cc(Nc2nccc(-c3cn([CH3:1])c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc(Nc2nccc(-c3cn([CH2:1]O)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc(Nc2nccc(-c3cn([CH3:1])c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,0.79
Osimertinib,C=CC(=O)Nc1cc([NH:1]c2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc([N:1](O)c2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,amine hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)Nc1cc([NH:1]c2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,0.15
Osimertinib,C=CC(=O)Nc1cc([NH:2]c2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)Nc1cc([N:2](c2nccc(-c3cn(C)c4ccccc34)n2)C2OC(C(=O)O)C(O)C(O)C2O)c(OC)cc1N(C)CCN(C)C,N-glucuronidation_(aniline_NH1-R),UGT rules (phase 2),C=CC(=O)Nc1cc([NH:2]c2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,0.05
Ibrutinib,C=CC(=O)[N:1]1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,C=CC(=O)[N+:1]1([O-])CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,N-oxidation,CYP rules from GLORY (phase 1),C=CC(=O)[N:1]1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,0.0
Ibrutinib,C=CC(=O)[N:1]1CCC[C@@H:1](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,C=CC(=O)[NH:1]CCC[CH2:1]n1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21,N-dealkylation,CYP rules from GLORY (phase 1),C=CC(=O)[N:1]1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,0.0
Ibrutinib,C=CC(=O)[N:1]1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C[CH2:1]C1,C=CC(=O)[NH:1]C[C@@H](C[CH3:1])n1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21,N-dealkylation,CYP rules from GLORY (phase 1),C=CC(=O)[N:1]1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,0.0
Osimertinib,C=CC(=O)[NH:1]c1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)[N:1](O)c1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,amine hydroxylation,CYP rules from GLORY (phase 1),C=CC(=O)[NH:1]c1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,0.0
Osimertinib,C=CC(=O)[NH:2]c1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)[N:2](c1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C)C1OC(C(=O)O)C(O)C(O)C1O,N-glucuronidation_(aniline_NH1-R),UGT rules (phase 2),C=CC(=O)[NH:2]c1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,0.0
Osimertinib,C=CC(=O)[NH:8]c1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,C=CC(=O)[NH2:8],oxidation of 4-substituted anisole to quinone,CYP rules from GLORY (phase 1),C=CC(=O)[NH:8]c1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,0.0
Tacrolimus,C=CC[C@@H:1]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@:1]1(O)/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H:1]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H:1]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)[CH2:2]C1=O)[C@H](C)C[C@@H]2OC,C=CC[CH2:1]/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)[C@H](C)C(O)=[CH2:2])[C@H](C)C[C@@H]1OC,deformylation,CYP rules from GLORY (phase 1),C=CC[C@@H:1]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H:2]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)[CH2:1]C1=O)[C@H](C)C[C@@H]2OC,C=CC=[CH:2]/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)[C@H](C)[C@@H](O)[CH3:1])[C@H](C)C[C@@H]1OC,deformylation,CYP rules from GLORY (phase 1),C=CC[C@@H:2]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H:2]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@:2]1(O)/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,C=CC[C@@H:2]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H:2]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)[CH2:1]C1=O)[C@H](C)C[C@@H]2OC,C=CC[CH:2]=C=C(C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)[C@H](C)[C@@H](O)[CH3:1])[C@H](C)C[C@@H]1OC,deformylation,CYP rules from GLORY (phase 1),C=CC[C@@H:2]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H:1](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@@:1](C)(O)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H:1](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H:1](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@:1](O)(OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H:1](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H:3](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C:3](=O)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H:3](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H:1](OC)[C@@H]2[C@@H:1](OC)C[C@@H](C)[C@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[O:2]2,C=CC[C@H](/C=C(\C)C[C@H](C)C[CH2:1]OC)C(=O)C[C@H](O)[C@@H](C)[C@H](OC(=O)[C@@H]1CCCCN1C(=O)C(=O)[C@@](O)([C@H](C)C[CH2:1]OC)[OH:2])/C(C)=C/[C@@H]1CC[C@@H](O)[C@H](OC)C1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@@H]2[C@@H](OC)C[C@@H](C)[C@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[O:2]2,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H:1]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@@:1]2(O)O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H:1]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.03
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H:3]2O[C@@](O)([C:1](=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H:1](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C:3](=O)[C@H](C[CH2:1]C)OC)C(=O)C[C@H](O)[C@@H](C)[C@H](OC(=O)[C@@H]1CCCCN1C(=O)[CH:1]=O)/C(C)=C/[C@@H]1CC[C@@H](O)[C@H](OC)C1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H:3]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.03
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@:2](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C:2](=C(C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)[C@H](C)[C@@H](O)CC1=O,dehydration_next_to_SP2_a,Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@:2](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H:1]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@@:1]3(O)C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H:1]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H:1]3C(=O)O[C@H:3](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[CH2:1]2)[C@H](C)C[C@@H]1OC)C(=O)C[C@H](O)[C@@H](C)[C:3](=O)/C(C)=C/[C@@H]1CC[C@@H](O)[C@H](OC)C1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H:1]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H:1]3C(=O)O[C@H:4](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[CH2:1]2)[C@H](C)C[C@@H]1OC)C(=O)C[C@H](O)[C@@H](C)[C:4](=O)/C(C)=C/[C@@H]1CC[C@@H](O)[C@H](OC)C1,oxidative ester cleavage,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H:1]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H:2]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@@:2]3(O)C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H:2]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H:2]3C(=O)[O:1][C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC=[CH:2]2)[C@H](C)C[C@@H]1OC)C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]1CC[C@@H](O)[C@H](OC)C1)[OH:1],deformylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H:2]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)[C:1](=O)N3[CH2:1]CCC[C@H:2]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)[CH:1]=O)[C@H](C)C[C@@H]1OC)C(=O)C[C@H](O)[C@@H](C)[C@H](OC(=O)[C:2](=O)CCC[CH3:1])/C(C)=C/[C@@H]1CC[C@@H](O)[C@H](OC)C1,N-dealkylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H:2]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H:1](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@:1](O)(/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H:1](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H:1]3C(=O)O[C@H:3](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[CH2:1]2)[C@H](C)C[C@@H]1OC)C(=O)C[C@H](O)[C@@H](C)[C:3](=O)/C(C)=C/[C@@H]1CC[C@@H](O)[C@H](OC)C1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H:3](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3[C:2](=O)O[C@H:4](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[C@H]2[C:2](=O)O)[C@H](C)C[C@@H]1OC)C(=O)C[C@H](O)[C@@H](C)[C@H:4](O)/C(C)=C/[C@@H]1CC[C@@H](O)[C@H](OC)C1,hydrolysis_(ester),Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H:4](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H:1]3C(=O)O[C@H:4](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[CH2:1]2)[C@H](C)C[C@@H]1OC)C(=O)C[C@H](O)[C@@H](C)[C:4](=O)/C(C)=C/[C@@H]1CC[C@@H](O)[C@H](OC)C1,oxidative ester cleavage,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H:4](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[CH3:1])[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[CH2:1]O)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[CH3:1])[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[CH3:2])[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C:2](=O)O)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,carboxylation_(primary_carbon_next_to_SP2),Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[CH3:2])[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[CH3:2])[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[CH2:2]O)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic_hydroxylation_(primary_carbon_next_to_SP2_or_SP1),Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[CH3:2])[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H:1]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@:1]3(O)CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H:1]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H:2]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@:2]3(O)CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H:2]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H:1](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C:1](O)(O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H:1](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.09
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H:1](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@:1](O)(OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H:1](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.03
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H:3](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C:3](=O)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H:3](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.03
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H:1](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@@:1](C)(O)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H:1](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H:1](C)[C@@H](O)C[C:3]1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)[CH2:1]C)[C@H](C)C[C@@H]1OC)[CH:3]=O,deformylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H:1](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)[O:2][C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H:1](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)[OH:2])[C@H](C)C[C@@H]1OC)C(=O)C[C@H](O)[CH2:1]C,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H:1](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)[O:3][C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H:1](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)[OH:3])[C@H](C)C[C@@H]1OC)C(=O)C[C@H](O)[CH2:1]C,oxidative ester cleavage,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H:1](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H:1](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C:1](O)(O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H:1](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H:2](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[CH:2]=CC1=O)[C@H](C)C[C@@H]2OC,dehydration_next_to_SP2_b,Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H:2](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H:1](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@@:1](C)(O)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H:1](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H:3]2O[C@@](O)([C:1](=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H:1](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C:3](=O)[C@H](C[CH2:1]C)OC)C(=O)C[C@H](O)[C@@H](C)[C@H](OC(=O)[C@@H]1CCCCN1C(=O)[CH:1]=O)/C(C)=C/[C@@H]1CC[C@@H](O)[C@H](OC)C1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H:1](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H:1]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@:1]2(O)OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H:1]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H:1](OC)[C@@H]2[C@@H:1](OC)C[C@@H](C)[C@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[O:2]2,C=CC[C@H](/C=C(\C)C[C@H](C)C[CH2:1]OC)C(=O)C[C@H](O)[C@@H](C)[C@H](OC(=O)[C@@H]1CCCCN1C(=O)C(=O)[C@@](O)([C@H](C)C[CH2:1]OC)[OH:2])/C(C)=C/[C@@H]1CC[C@@H](O)[C@H](OC)C1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H:1]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H:3]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C:3]2=O,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H:3]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2O[CH3:1],C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2O[CH2:1]O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2O[CH3:1],0.98
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2[O:2]C,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2[OH:2],O-demethylation,Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2[O:2]C,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)[CH2:1][C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)[CH:1](O)[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)[CH2:1][C@@H]2OC,0.6
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H]([CH3:1])C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H]([CH2:1]O)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H]([CH3:1])C[C@@H]2OC,0.03
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H]([CH3:2])C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H]([C:2](=O)O)C[C@@H]2OC,carboxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H]([CH3:2])C[C@@H]2OC,0.03
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H]([CH3:2])C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H]([CH2:2]O)C[C@@H]2OC,aliphatic_hydroxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H]([CH3:2])C[C@@H]2OC,0.03
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H:1](C)[C@@H](O)C[C:3]1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)[CH2:1]C)[C@H](C)C[C@@H]1OC)[CH:3]=O,deformylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)C[C:3]1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/[CH:1]=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)C[C:3]1=O)[C@H](C)C[C@@H]2OC,CO[C@@H](C[C@@H](C)CC(C)=[CH2:1])[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)[C@H](C)[C@@H](O)C[CH:3]=O)[C@H](C)C[C@@H]1OC,deformylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)C[C:3]1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=[C:1](\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)C[C:3]1=O)[C@H](C)C[C@@H]2OC,CO[C@@H](C[C@@H](C)C[CH2:1]C)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)[C@H](C)[C@@H](O)C[CH:3]=O)[C@H](C)C[C@@H]1OC,deformylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)C[C:3]1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H:2]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)[CH2:1]C1=O)[C@H](C)C[C@@H]2OC,C=CC=[CH:2]/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)[C@H](C)[C@@H](O)[CH3:1])[C@H](C)C[C@@H]1OC,deformylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)[CH2:1]C1=O)[C@H](C)C[C@@H]2OC,0.04
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)[CH2:1]C1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)[CH:1](O)C1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)[CH2:1]C1=O)[C@H](C)C[C@@H]2OC,0.04
Tacrolimus,C=CC[C@@H:2]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)[CH2:1]C1=O)[C@H](C)C[C@@H]2OC,C=CC[CH:2]=C=C(C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)[C@H](C)[C@@H](O)[CH3:1])[C@H](C)C[C@@H]1OC,deformylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)[CH2:1]C1=O)[C@H](C)C[C@@H]2OC,0.04
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)[CH2:2]C1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)[CH:2](O)C1=O)[C@H](C)C[C@@H]2OC,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)[CH2:2]C1=O)[C@H](C)C[C@@H]2OC,0.04
Tacrolimus,C=CC[C@@H:1]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)[CH2:2]C1=O)[C@H](C)C[C@@H]2OC,C=CC[CH2:1]/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)[C@H](C)C(O)=[CH2:2])[C@H](C)C[C@@H]1OC,deformylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)[CH2:2]C1=O)[C@H](C)C[C@@H]2OC,0.04
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H]([OH:2])CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H]([O:2]C3OC(C(=O)O)C(O)C(O)C3O)CC1=O)[C@H](C)C[C@@H]2OC,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H]([OH:2])CC1=O)[C@H](C)C[C@@H]2OC,0.19
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H]([OH:2])CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H]([O:2]S(=O)(=O)O)CC1=O)[C@H](C)C[C@@H]2OC,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H]([OH:2])CC1=O)[C@H](C)C[C@@H]2OC,0.2
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H]([CH3:1])[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H]([CH2:1]O)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H]([CH3:1])[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H]([CH3:2])[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H]([C:2](=O)O)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,carboxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H]([CH3:2])[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H]([CH3:2])[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H]([CH2:2]O)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic_hydroxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H]([CH3:2])[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)[CH2:1]3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)[CH:1]3O)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)[CH2:1]3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.02
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](O[CH3:1])C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](O[CH2:1]O)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](O[CH3:1])C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.83
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H]([O:2]C)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H]([OH:2])C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,O-demethylation,Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H]([O:2]C)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H]([OH:2])[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H]([O:2]C4OC(C(=O)O)C(O)C(O)C4O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H]([OH:2])[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.58
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H]([OH:2])[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H]([O:2]S(=O)(=O)O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H]([OH:2])[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.53
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@H]3C[C@@H](OC)[C@H](O)C[CH2:1]3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@H]3C[C@@H](OC)[C@H](O)C[CH:1]3O)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@H]3C[C@@H](OC)[C@H](O)C[CH2:1]3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@H]3C[C@@H](OC)[C@H](O)[CH2:1]C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@H]3C[C@@H](OC)[C@H](O)[CH:1](O)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@H]3C[C@@H](OC)[C@H](O)[CH2:1]C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@H]3C[C@@H](OC)[C@H](O)[CH2:2]C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@H]3C[C@@H](OC)[C@H](O)[CH:2](O)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic_hydroxylation_(sec_carbon_in_a_ringB),Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@H]3C[C@@H](OC)[C@H](O)[CH2:2]C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=[CH:1]/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)OC(=C(C)[CH:1](O)[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation with allylic rearrangement 1,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=[CH:1]/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=[CH:1]/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](C(=C)[CH:1](O)[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation with allylic rearrangement 1,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=[CH:1]/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/[C:2](C)=[CH:1]/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H]([C:2]3(C)O[CH:1]3[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,epoxidation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=[CH:1]/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/[C:1](C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H]([C:1](C)(O)C=C3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation with allylic rearrangement 1,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/[C:1](C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/[C:2](C)=[CH:1]/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H]([C:2]3(C)O[CH:1]3[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,epoxidation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/[C:2](C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H:2]3C(=O)[O:1][C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC=[CH:2]2)[C@H](C)C[C@@H]1OC)C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]1CC[C@@H](O)[C@H](OC)C1)[OH:1],deformylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)[O:1][C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)[O:2][C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H:1](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)[OH:2])[C@H](C)C[C@@H]1OC)C(=O)C[C@H](O)[CH2:1]C,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)[O:2][C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)[O:3][C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H:1](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)[OH:3])[C@H](C)C[C@@H]1OC)C(=O)C[C@H](O)[CH2:1]C,oxidative ester cleavage,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)[O:3][C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3[C:2](=O)O[C@H:4](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[C@H]2[C:2](=O)O)[C@H](C)C[C@@H]1OC)C(=O)C[C@H](O)[C@@H](C)[C@H:4](O)/C(C)=C/[C@@H]1CC[C@@H](O)[C@H](OC)C1,hydrolysis_(ester),Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3[C:2](=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.04
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)[N:1]3CC[CH2:1]C[C@H]3[C:3](=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)[NH:1]CC[CH3:1])[C@H](C)C[C@@H]1OC)C(=O)C[C@H](O)[C@@H](C)[C@H](O[CH:3]=O)/C(C)=C/[C@@H]1CC[C@@H](O)[C@H](OC)C1,deformylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3[C:3](=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.04
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCC[CH2:1][C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCC[CH:1](O)[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCC[CH2:1][C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCC[CH2:2][C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCC[CH:2](O)[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic_hydroxylation_(sec_carbon_in_a_ringB),Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCC[CH2:2][C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CC[CH2:1]C[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CC[CH:1](O)C[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CC[CH2:1]C[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CC[CH2:2]C[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CC[CH:2](O)C[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic_hydroxylation_(sec_carbon_in_a_ringA),Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CC[CH2:2]C[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3C[CH2:1]CC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3C[CH:1](O)CC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3C[CH2:1]CC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3C[CH2:2]CC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3C[CH:2](O)CC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic_hydroxylation_(sec_carbon_in_a_ringA),Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3C[CH2:2]CC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3[C@@H](CCC[CH2:1]3)C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3[C@@H](CCC[CH:1]3O)C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3[C@@H](CCC[CH2:1]3)C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.02
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3[C@@H](CCC[CH2:2]3)C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3[C@@H](CCC[C:2]3=O)C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,oxidation_(amine_in_a_ring),Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3[C@@H](CCC[CH2:2]3)C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.02
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3[C@@H](CCC[CH2:2]3)C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3[C@@H](CCC[CH:2]3O)C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3[C@@H](CCC[CH2:2]3)C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.02
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)[C:1](=O)N3[C@@H:1](CCC[CH2:2]3)C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)[CH:1]=O)[C@H](C)C[C@@H]1OC)C(=O)C[C@H](O)[C@@H](C)[C@H](OC(=O)[CH2:1]CCC[CH:2]=O)/C(C)=C/[C@@H]1CC[C@@H](O)[C@H](OC)C1,N-dealkylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3[C@@H](CCC[CH2:2]3)C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.02
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)[N:1]3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)[N+:1]3([O-])CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,N-oxidation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)[N:1]3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)[N:1]3C[CH2:1]CC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)[NH:1][C@@H](CC[CH3:1])C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,N-dealkylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)[N:1]3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)[N:1]3CCC[CH2:1][C@H]3[C:1](=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)[NH:1]CCC[CH3:1])[C@H](C)C[C@@H]1OC)C(=O)C[C@H](O)[C@@H](C)[C@H](O[CH:1]=O)/C(C)=C/[C@@H]1CC[C@@H](O)[C@H](OC)C1,N-dealkylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)[N:1]3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)[N:1]3CC[CH2:1]C[C@H]3[C:3](=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)C(=O)[NH:1]CC[CH3:1])[C@H](C)C[C@@H]1OC)C(=O)C[C@H](O)[C@@H](C)[C@H](O[CH:3]=O)/C(C)=C/[C@@H]1CC[C@@H](O)[C@H](OC)C1,deformylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)[N:1]3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)[C:1](=O)N3[CH2:1]CCC[C@H:2]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)[CH:1]=O)[C@H](C)C[C@@H]1OC)C(=O)C[C@H](O)[C@@H](C)[C@H](OC(=O)[C:2](=O)CCC[CH3:1])/C(C)=C/[C@@H]1CC[C@@H](O)[C@H](OC)C1,N-dealkylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)[C:1](=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)[C:1](=O)N3[C@@H:1](CCC[CH2:2]3)C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)[CH:1]=O)[C@H](C)C[C@@H]1OC)C(=O)C[C@H](O)[C@@H](C)[C@H](OC(=O)[CH2:1]CCC[CH:2]=O)/C(C)=C/[C@@H]1CC[C@@H](O)[C@H](OC)C1,N-dealkylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)[C:1](=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)[C:2](=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@H](/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]1O[C@@](O)(C(=O)[C:2](=O)O)[C@H](C)C[C@@H]1OC)C(=O)C[C@H](O)[C@@H](C)[C@H](OC(=O)[C@@H]1CCCCN1)/C(C)=C/[C@@H]1CC[C@@H](O)[C@H](OC)C1,hydrolysis_(tertiary_amide),Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)[C:2](=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@]([OH:2])(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@]([O:2]C3OC(C(=O)O)C(O)C(O)C3O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@]([OH:2])(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.21
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@]([OH:2])(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@]([O:2]S(=O)(=O)O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@]([OH:2])(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.2
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](O[CH3:1])[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](O[CH2:1]O)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](O[CH3:1])[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.98
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H]([O:2]C)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H]([OH:2])[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,O-demethylation,Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H]([O:2]C)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H](C)[CH2:1][C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)[CH:1](O)[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H](C)[CH2:1][C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H]([CH3:1])C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H]([CH2:1]O)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)C[C@H]([CH3:1])C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H]([CH3:2])C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H]([C:2](=O)O)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,carboxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H]([CH3:2])C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)C[C@H]([CH3:2])C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)C[C@H]([CH2:2]O)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic_hydroxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)C[C@H]([CH3:2])C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.0
Tacrolimus,C=CC[C@@H]1/C=C(\C)[CH2:1][C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)[CH:1](O)[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\C)[CH2:1][C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\C)[CH2:2][C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\C)[CH:2](O)[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\C)[CH2:2][C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.01
Tacrolimus,C=CC[C@@H]1/C=C(\[CH3:1])C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\[CH2:1]O)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=C(\[CH3:1])C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.04
Tacrolimus,C=CC[C@@H]1/C=C(\[CH3:2])C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\[C:2](=O)O)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,carboxylation_(primary_carbon_next_to_SP2),Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\[CH3:2])C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.04
Tacrolimus,C=CC[C@@H]1/C=C(\[CH3:2])C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CC[C@@H]1/C=C(\[CH2:2]O)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic_hydroxylation_(primary_carbon_next_to_SP2_or_SP1),Phase 1 SyGMa rules,C=CC[C@@H]1/C=C(\[CH3:2])C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.04
Tacrolimus,C=CC[C@@H]1/C=[C:1](\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=CCC1=C[C:1](C)(O)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation with allylic rearrangement 1,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=[C:1](\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.02
Tacrolimus,C=CC[C@H]1C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]([C@@H](OC)C[C@@H](C)C/[C:1](C)=[CH:2]/1)[C@@H](OC)C[C@H]2C,C=CC[C@H]1C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]([C@@H](OC)C[C@@H](C)C[C:1]3(C)O[CH:2]13)[C@@H](OC)C[C@H]2C,epoxidation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=[C:1](\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.02
Tacrolimus,C=CC[C@@H]1/C=[C:1](\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)C[C:3]1=O)[C@H](C)C[C@@H]2OC,CO[C@@H](C[C@@H](C)C[CH2:1]C)[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)[C@H](C)[C@@H](O)C[CH:3]=O)[C@H](C)C[C@@H]1OC,deformylation,CYP rules from GLORY (phase 1),C=CC[C@@H]1/C=[C:1](\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.02
Tacrolimus,C=CC[C@H]1C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]([C@@H](OC)C[C@@H](C)C/C(C)=[CH:1]/1)[C@@H](OC)C[C@H]2C,C=CC[C@H]1C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@@H](OC)C[C@H]2C)[C@@H](OC)C[C@@H](C)C=C(C)[CH:1]1O,aliphatic hydroxylation with allylic rearrangement 1,CYP rules from GLORY (phase 1),C=CC[C@H]1C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]([C@@H](OC)C[C@@H](C)C/C(C)=[CH:1]/1)[C@@H](OC)C[C@H]2C,0.0
Tacrolimus,C=CC[C@H]1C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]([C@@H](OC)C[C@@H](C)C/C(C)=[CH:1]/1)[C@@H](OC)C[C@H]2C,C=CC[C@H]1C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]([C@@H](OC)C[C@@H](C)CC(=C)[CH:1]1O)[C@@H](OC)C[C@H]2C,aliphatic hydroxylation with allylic rearrangement 1,CYP rules from GLORY (phase 1),C=CC[C@H]1C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]([C@@H](OC)C[C@@H](C)C/C(C)=[CH:1]/1)[C@@H](OC)C[C@H]2C,0.0
Tacrolimus,C=CC[C@@H]1/[CH:1]=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)C[C:3]1=O)[C@H](C)C[C@@H]2OC,CO[C@@H](C[C@@H](C)CC(C)=[CH2:1])[C@H]1O[C@@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)[C@H](C)[C@@H](O)C[CH:3]=O)[C@H](C)C[C@@H]1OC,deformylation,CYP rules from GLORY (phase 1),C=CC[C@H]1C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]([C@@H](OC)C[C@@H](C)C/C(C)=[CH:1]/1)[C@@H](OC)C[C@H]2C,0.0
Tacrolimus,C=CC[C@H]1C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]([C@@H](OC)C[C@@H](C)C/[C:1](C)=[CH:2]/1)[C@@H](OC)C[C@H]2C,C=CC[C@H]1C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]([C@@H](OC)C[C@@H](C)C[C:1]3(C)O[CH:2]13)[C@@H](OC)C[C@H]2C,epoxidation,CYP rules from GLORY (phase 1),C=CC[C@H]1C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]([C@@H](OC)C[C@@H](C)C/C(C)=[CH:2]/1)[C@@H](OC)C[C@H]2C,0.0
Ibrutinib,C=C[C:2](=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,C=C[C:2](=O)O.Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@@H]1CCCNC1,hydrolysis_(tertiary_amide),Phase 1 SyGMa rules,C=C[C:2](=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,0.67
Osimertinib,C=C[C:2](=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,C=C[C:2](=O)O.COc1cc(N(C)CCN(C)C)c(N)cc1Nc1nccc(-c2cn(C)c3ccccc23)n1,hydrolysis_(secondary_amide),Phase 1 SyGMa rules,C=C[C:2](=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,0.06
Tacrolimus,C=C[CH2:1][C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=C[CH:1](O)[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C=C[CH2:1][C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.07
Tacrolimus,C=C[CH2:2][C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,C=C[CH:2](O)[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,not_in_a_ring)",Phase 1 SyGMa rules,C=C[CH2:2][C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.07
Ibrutinib,Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@@H]1CCCN(C(=O)[CH:1]=[CH2:2])C1,Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@@H]1CCCN(C(=O)[CH:1](O)[CH2:2]O)C1,vinyl_oxidation,Phase 1 SyGMa rules,C=[CH:1]C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,0.66
Ibrutinib,Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@@H]1CCCN(C(=O)[CH:1]=[CH2:2])C1,Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@@H]1CCCN(C(=O)[CH:1]2O[CH2:2]2)C1,epoxidation,CYP rules from GLORY (phase 1),C=[CH:1]C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,0.66
Osimertinib,COc1cc(N(C)CCN(C)C)c(NC(=O)[CH:1]=[CH2:2])cc1Nc1nccc(-c2cn(C)c3ccccc23)n1,COc1cc(N(C)CCN(C)C)c(NC(=O)[CH:1](O)[CH2:2]O)cc1Nc1nccc(-c2cn(C)c3ccccc23)n1,vinyl_oxidation,Phase 1 SyGMa rules,C=[CH:1]C(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,0.11
Osimertinib,COc1cc(N(C)CCN(C)C)c(NC(=O)[CH:1]=[CH2:2])cc1Nc1nccc(-c2cn(C)c3ccccc23)n1,COc1cc(N(C)CCN(C)C)c(NC(=O)[CH:1]2O[CH2:2]2)cc1Nc1nccc(-c2cn(C)c3ccccc23)n1,epoxidation,CYP rules from GLORY (phase 1),C=[CH:1]C(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,0.11
Tacrolimus,CO[C@H]1C[C@@H](C)C/C(C)=C/[C@@H](C[CH:1]=[CH2:2])C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]1[C@@H](OC)C[C@H]2C,CO[C@H]1C[C@@H](C)C/C(C)=C/[C@@H](C[CH:1](O)[CH2:2]O)C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]1[C@@H](OC)C[C@H]2C,vinyl_oxidation,Phase 1 SyGMa rules,C=[CH:1]C[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.59
Tacrolimus,CO[C@H]1C[C@@H](C)C/C(C)=C/[C@@H](C[CH:1]=[CH2:2])C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]1[C@@H](OC)C[C@H]2C,CO[C@H]1C[C@@H](C)C/C(C)=C/[C@@H](C[CH:1]2O[CH2:2]2)C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]1[C@@H](OC)C[C@H]2C,epoxidation,CYP rules from GLORY (phase 1),C=[CH:1]C[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,0.59
Linagliptin,CC#CC[n:1]1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CC[N+:1]1([O-])C(N2CCC[C@@H](N)C2)=Nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,N-oxidation,CYP rules from GLORY (phase 1),CC#CC[n:1]1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.04
Linagliptin,CC#CC[n:1]1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,Cc1nc(Cn2c(=O)c3c(nc(N4CCC[C@@H](N)C4)[nH:1]3)n(C)c2=O)nc2ccccc12,N-dealkylation,CYP rules from GLORY (phase 1),CC#CC[n:1]1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.04
Linagliptin,CC#CCn1c(N2CCC[C@@H:1](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@:1](N)(O)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC#CCn1c(N2CCC[C@@H:1](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.75
Linagliptin,CC#CCn1c([N:1]2CCC[C@@H:1](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c([NH:1]CCC[CH2:1]N)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,N-dealkylation,CYP rules from GLORY (phase 1),CC#CCn1c(N2CCC[C@@H:1](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.75
Linagliptin,CC#CCn1c(N2CCC[C@@H:2](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C:2](=O)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,oxidative_deamination_(on_secondary_carbon),Phase 1 SyGMa rules,CC#CCn1c(N2CCC[C@@H:2](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.75
Linagliptin,CC#CCn1c(N2CCC[C@@H:2](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@:2](N)(O)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,CC#CCn1c(N2CCC[C@@H:2](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.75
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)[n:1]c2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)[n+:1](C2OC(C(=O)O)C(O)C(O)C2O)c2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),CC#CCn1c(N2CCC[C@@H](N)C2)[n:1]c2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.01
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)[n:1]c2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)[n+:1]([O-])c2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,N-oxidation,CYP rules from GLORY (phase 1),CC#CCn1c(N2CCC[C@@H](N)C2)[n:1]c2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.0
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)[n:2]c2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)[n+:2]([O-])c2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,N-oxidation_(-N=),Phase 1 SyGMa rules,CC#CCn1c(N2CCC[C@@H](N)C2)[n:2]c2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.0
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)[n:1](Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1C(=O)[N+:1]([O-])(Cc1nc(C)c3ccccc3n1)C(=O)N2C,N-oxidation,CYP rules from GLORY (phase 1),CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)[n:1](Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.0
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)[n:1](Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)[nH:1]c(=O)n2C,N-dealkylation,CYP rules from GLORY (phase 1),CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)[n:1](Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.0
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3c(ccc[cH:1]3)n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3c(ccc[c:1]3O)n1)c(=O)n2C,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3c(ccc[cH:1]3)n1)c(=O)n2C,0.02
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3c[cH:1]ccc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3c[c:1](O)ccc3n1)c(=O)n2C,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3c[cH:1]ccc3n1)c(=O)n2C,0.07
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3c[cH:5]ccc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3c[c:5](O)ccc3n1)c(=O)n2C,aromatic_hydroxylation_(para_to_nitrogen),Phase 1 SyGMa rules,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3c[cH:5]ccc3n1)c(=O)n2C,0.07
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3cc[cH:1]cc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3cc[c:1](O)cc3n1)c(=O)n2C,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3cc[cH:1]cc3n1)c(=O)n2C,0.03
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3cc[cH:5]cc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3cc[c:5](O)cc3n1)c(=O)n2C,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3cc[cH:5]cc3n1)c(=O)n2C,0.03
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccc[cH:1]c3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccc[c:1](O)c3n1)c(=O)n2C,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccc[cH:1]c3n1)c(=O)n2C,0.01
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccc[cH:3]c3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccc[c:3](O)c3n1)c(=O)n2C,aromatic_hydroxylation_(ortho_to_nitrogen),Phase 1 SyGMa rules,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccc[cH:3]c3n1)c(=O)n2C,0.01
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3[n:1]1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3[n+:1]1C1OC(C(=O)O)C(O)C(O)C1O)c(=O)n2C,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3[n:1]1)c(=O)n2C,0.04
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3[n:1]1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3[n+:1]1[O-])c(=O)n2C,N-oxidation,CYP rules from GLORY (phase 1),CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3[n:1]1)c(=O)n2C,0.03
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3[n:2]1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3[n+:2]1[O-])c(=O)n2C,N-oxidation_(-N=),Phase 1 SyGMa rules,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3[n:2]1)c(=O)n2C,0.03
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)[n:1]2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1C(=O)N(Cc1nc(C)c3ccccc3n1)C(=O)[N+:1]2(C)[O-],N-oxidation,CYP rules from GLORY (phase 1),CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)[n:1]2C,0.03
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)[n:1]2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)[nH:1]2,N-demethylation_(nCH3),Phase 1 SyGMa rules,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)[n:1]2C,0.03
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2[CH3:1],CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2[CH2:1]O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2[CH3:1],0.1
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc([CH3:1])c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc([CH2:1]O)c3ccccc3n1)c(=O)n2C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc([CH3:1])c3ccccc3n1)c(=O)n2C,0.76
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc([CH3:2])c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc([C:2](=O)O)c3ccccc3n1)c(=O)n2C,carboxylation_(benzylic_CH3),Phase 1 SyGMa rules,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc([CH3:2])c3ccccc3n1)c(=O)n2C,0.76
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc([CH3:2])c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc([CH2:2]O)c3ccccc3n1)c(=O)n2C,benzylic_hydroxylation_(c-CH3),Phase 1 SyGMa rules,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc([CH3:2])c3ccccc3n1)c(=O)n2C,0.76
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc3ccccc3c(C)[n:1]1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc3ccccc3c(C)[n+:1]1C1OC(C(=O)O)C(O)C(O)C1O)c(=O)n2C,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc3ccccc3c(C)[n:1]1)c(=O)n2C,0.02
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc3ccccc3c(C)[n:1]1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc3ccccc3c(C)[n+:1]1[O-])c(=O)n2C,N-oxidation,CYP rules from GLORY (phase 1),CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc3ccccc3c(C)[n:1]1)c(=O)n2C,0.04
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc3ccccc3c(C)[n:2]1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc3ccccc3c(C)[n+:2]1[O-])c(=O)n2C,N-oxidation_(-N=),Phase 1 SyGMa rules,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc3ccccc3c(C)[n:2]1)c(=O)n2C,0.04
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n([CH2:1]c1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n([CH:1](O)c1nc(C)c3ccccc3n1)c(=O)n2C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n([CH2:1]c1nc(C)c3ccccc3n1)c(=O)n2C,0.06
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n([CH2:2]c1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)[nH]c(=O)n2C.Cc1nc([CH2:2]O)nc2ccccc12,N-dealkylation_(nCH2),Phase 1 SyGMa rules,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n([CH2:2]c1nc(C)c3ccccc3n1)c(=O)n2C,0.06
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n([CH2:2]c1nc(C)c3ccccc3n1)c(=O)n2C,Cc1nc([CH:2]=O)nc2ccccc12,N-dealkylation,CYP rules from GLORY (phase 1),CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n([CH2:2]c1nc(C)c3ccccc3n1)c(=O)n2C,0.06
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)[CH2:1]2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)[CH:1]2O)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC#CCn1c(N2CCC[C@@H](N)[CH2:1]2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.03
Linagliptin,CC#CCn1c(N2[CH2:1][C@H](N)CC[CH2:2]2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,N[C@H](CC[CH:2]=O)[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),CC#CCn1c(N2CCC[C@@H](N)[CH2:1]2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.03
Linagliptin,CC#CCn1c(N2CCC[C@@H](N)[CH2:2]2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H](N)[CH:2]2O)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,CC#CCn1c(N2CCC[C@@H](N)[CH2:2]2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.03
Linagliptin,CC#CCn1c(N2[CH2:1]CC[C@@H](N)[CH2:2]2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,N[C@H](CC[CH3:1])[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),CC#CCn1c(N2CCC[C@@H](N)[CH2:2]2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.03
Linagliptin,CC#CCn1c(N2CCC[C@@H]([NH2:1])C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H]([NH:1]O)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,amine hydroxylation,CYP rules from GLORY (phase 1),CC#CCn1c(N2CCC[C@@H]([NH2:1])C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.12
Linagliptin,CC#CCn1c(N2CCC[C@@H]([NH2:2])C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H]([NH:2]C(C)=O)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,N-acetylation_(aliphatic_NH2),NAT rules (phase 2),CC#CCn1c(N2CCC[C@@H]([NH2:2])C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.89
Linagliptin,CC#CCn1c(N2CCC[C@@H]([NH2:2])C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2CCC[C@@H]([NH:2]C3OC(C(=O)O)C(O)C(O)C3O)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,N-glucuronidation_(aliphatic_NH2),UGT rules (phase 2),CC#CCn1c(N2CCC[C@@H]([NH2:2])C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.1
Linagliptin,CC#CCn1c(N2CC[CH2:1][C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2CC[CH:1](O)[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC#CCn1c(N2CC[CH2:1][C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.04
Linagliptin,CC#CCn1c(N2CC[CH2:2][C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2CC[CH:2](O)[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,aliphatic_hydroxylation_(sec_carbon_in_a_ringB),Phase 1 SyGMa rules,CC#CCn1c(N2CC[CH2:2][C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.04
Linagliptin,CC#CCn1c(N2C[C@H](N)CC[CH2:1]2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2C[C@H](N)CC[CH:1]2O)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC#CCn1c(N2C[C@H](N)CC[CH2:1]2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.08
Linagliptin,CC#CCn1c(N2[CH2:1]CC[C@@H](N)[CH2:2]2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,N[C@H](CC[CH3:1])[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),CC#CCn1c(N2C[C@H](N)CC[CH2:1]2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.08
Linagliptin,CC#CCn1c(N2C[C@H](N)CC[CH2:2]2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2C[C@H](N)CC[C:2]2=O)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,oxidation_(amine_in_a_ring),Phase 1 SyGMa rules,CC#CCn1c(N2C[C@H](N)CC[CH2:2]2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.08
Linagliptin,CC#CCn1c(N2C[C@H](N)CC[CH2:2]2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2C[C@H](N)CC[CH:2]2O)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,CC#CCn1c(N2C[C@H](N)CC[CH2:2]2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.08
Linagliptin,CC#CCn1c(N2[CH2:1][C@H](N)CC[CH2:2]2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,N[C@H](CC[CH:2]=O)[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),CC#CCn1c(N2C[C@H](N)CC[CH2:2]2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.08
Linagliptin,CC#CCn1c(N2C[C@H](N)C[CH2:1]C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2C[C@H](N)C[CH:1](O)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC#CCn1c(N2C[C@H](N)C[CH2:1]C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.04
Linagliptin,CC#CCn1c([N:1]2C[C@H](N)C[CH2:1]C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c([NH:1]C[C@H](N)C[CH3:1])nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,N-dealkylation,CYP rules from GLORY (phase 1),CC#CCn1c(N2C[C@H](N)C[CH2:1]C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.04
Linagliptin,CC#CCn1c(N2C[C@H](N)C[CH2:2]C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c(N2C[C@H](N)C[CH:2](O)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,aliphatic_hydroxylation_(sec_carbon_in_a_ringA),Phase 1 SyGMa rules,CC#CCn1c(N2C[C@H](N)C[CH2:2]C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.04
Linagliptin,CC#CCn1c([N:1]2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#CCn1c([N+:1]2([O-])CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,N-oxidation,CYP rules from GLORY (phase 1),CC#CCn1c([N:1]2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.03
Linagliptin,CC#CCn1c2c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)n(C)c2n[c:2]1N1CCC[C@@H](N)C1,CC#CCn1c2c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)n(C)c2[nH][c:2]1=O.N[C@@H]1CCCNC1,oxidative_deamination_(aromatic),Phase 1 SyGMa rules,CC#CCn1c2c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)n(C)c2n[c:2]1N1CCC[C@@H](N)C1,0.04
Linagliptin,CC#C[CH2:1]n1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#C[CH:1](O)n1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC#C[CH2:1]n1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.08
Linagliptin,CC#C[CH2:2]n1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#C[CH2:2]O.Cc1nc(Cn2c(=O)c3[nH]c(N4CCC[C@@H](N)C4)nc3n(C)c2=O)nc2ccccc12,N-dealkylation_(nCH2),Phase 1 SyGMa rules,CC#C[CH2:2]n1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.08
Linagliptin,CC#C[CH2:2]n1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC#C[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),CC#C[CH2:2]n1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.08
Linagliptin,CC#[C:2]Cn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,CC(Cn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C)=[C:2]=O,"acetylene oxidation, first step",CYP rules from GLORY (phase 1),CC#[C:2]Cn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.05
Linagliptin,CC#[C:2]Cn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,Cc1nc(Cn2c(=O)c3c(nc(N4CCC[C@@H](N)C4)n3CC(C)[C:2](=O)O)n(C)c2=O)nc2ccccc12,"acetylene oxidation, complete oxidation",CYP rules from GLORY (phase 1),CC#[C:2]Cn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,0.05
Darunavir,CC(C)CN(C[C@@H:1](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C:1](O)(O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H:1](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.02
Darunavir,CC(C)CN(C[C@@H:2](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[CH:2]=C(Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,dehydration_next_to_SP2_b,Phase 1 SyGMa rules,CC(C)CN(C[C@@H:2](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.02
Darunavir,CC(C)CN(C[C@@H](O)[C@@H](NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)[CH2:1]c1ccccc1)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@@H](NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)[CH:1](O)c1ccccc1)S(=O)(=O)c1ccc(N)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@@H](NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)[CH2:1]c1ccccc1)S(=O)(=O)c1ccc(N)cc1,0.02
Darunavir,CC(C)CN(C[C@@H](O)[C@@H](NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)[CH2:2]c1ccccc1)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@@H](NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)[CH:2](O)c1ccccc1)S(=O)(=O)c1ccc(N)cc1,benzylic_hydroxylation_(c-CH2-CR),Phase 1 SyGMa rules,CC(C)CN(C[C@@H](O)[C@@H](NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)[CH2:2]c1ccccc1)S(=O)(=O)c1ccc(N)cc1,0.02
Darunavir,CC(C)CN(C[C@@H](O)[C@H:1](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@:1](O)(Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H:1](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.0
Darunavir,CC(C)CN(C[C@@H](O)[C@H:2](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C:2](=O)Cc1ccccc1)S(=O)(=O)c1ccc(N)cc1,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H:2](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.0
Darunavir,CC(C)CN(C[C@@H](O)[C@H:2](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@:2](O)(Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,CC(C)CN(C[C@@H](O)[C@H:2](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.0
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1cc[cH:1]cc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1cc[c:1](O)cc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1cc[cH:1]cc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.66
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1cc[cH:5]cc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1cc[c:5](O)cc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,CC(C)CN(C[C@@H](O)[C@H](Cc1cc[cH:5]cc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.66
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1cc[cH:5][cH:4]c1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CO[c:4]1cc(C[C@H](NC(=O)O[C@H]2CO[C@H]3OCC[C@H]32)[C@H](O)CN(CC(C)C)S(=O)(=O)c2ccc(N)cc2)cc[c:5]1O,aromatic_oxidation,Phase 1 SyGMa rules,CC(C)CN(C[C@@H](O)[C@H](Cc1cc[cH:5]cc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.66
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccc[cH:1]c1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccc[c:1](O)c1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccc[cH:1]c1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.0
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccc[cH:4]c1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccc[c:4](O)c1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,CC(C)CN(C[C@@H](O)[C@H](Cc1ccc[cH:4]c1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.0
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1cc[cH:5][cH:4]c1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CO[c:4]1cc(C[C@H](NC(=O)O[C@H]2CO[C@H]3OCC[C@H]32)[C@H](O)CN(CC(C)C)S(=O)(=O)c2ccc(N)cc2)cc[c:5]1O,aromatic_oxidation,Phase 1 SyGMa rules,CC(C)CN(C[C@@H](O)[C@H](Cc1ccc[cH:4]c1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.0
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1cccc[cH:1]1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1cccc[c:1]1O)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1cccc[cH:1]1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.0
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2O[CH2:1]1)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2O[CH:1]1O)S(=O)(=O)c1ccc(N)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2O[CH2:1]1)S(=O)(=O)c1ccc(N)cc1,0.03
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@@H]1[C@@H:1]2CC[O:1][C@@H]2O[CH2:3]1)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]([CH2:1]CC[OH:1])[CH:3]=O)S(=O)(=O)c1ccc(N)cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2O[CH2:3]1)S(=O)(=O)c1ccc(N)cc1,0.03
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H:1]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@@:1]1(O)CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H:1]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.01
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H:1]1CO[C@H:3]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[CH2:1][C@@H]1CCO[C:3]1=O)S(=O)(=O)c1ccc(N)cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H:1]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.01
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H:1]1C[O:2][C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[CH2:1][C@@H]1CCO[C@@H]1[OH:2])S(=O)(=O)c1ccc(N)cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H:1]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.01
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H:3]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,O=[C:3]1CO[C@H]2OCC[C@H]21,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H:3]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.01
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H:4]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,O[C@H:4]1CO[C@H]2OCC[C@H]21,carbamate cleavage,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H:4]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.01
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@@H]2[C@H]1[CH2:1]C[O:2]2)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@@H]([OH:2])[C@H]1[CH3:1])S(=O)(=O)c1ccc(N)cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@@H]2[C@H]1CC[O:2]2)S(=O)(=O)c1ccc(N)cc1,0.0
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H:1]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@@:1]2(O)OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H:1]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,0.08
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H:3]2OC[CH2:1][C@@H]12)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C:3](=O)[C@H]1[CH3:1])S(=O)(=O)c1ccc(N)cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H:3]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,0.08
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H:1]1CO[C@H:3]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[CH2:1][C@@H]1CCO[C:3]1=O)S(=O)(=O)c1ccc(N)cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H:3]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,0.08
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1C[O:1][C@H]2O[CH2:3]C[C@@H:1]12)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@@H](C[OH:1])[CH2:1]C[CH:3]=O)S(=O)(=O)c1ccc(N)cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H:1]21)S(=O)(=O)c1ccc(N)cc1,0.12
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1C[O:2][C@H]2[O:1]CC[C@@H:1]12)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@@H](C[OH:2])[CH2:1]CC[OH:1])S(=O)(=O)c1ccc(N)cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H:1]21)S(=O)(=O)c1ccc(N)cc1,0.12
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@@H]1[C@@H:1]2CC[O:1][C@@H]2O[CH2:3]1)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]([CH2:1]CC[OH:1])[CH:3]=O)S(=O)(=O)c1ccc(N)cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H:1]21)S(=O)(=O)c1ccc(N)cc1,0.12
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H:1]21)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@:1]21O)S(=O)(=O)c1ccc(N)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H:1]21)S(=O)(=O)c1ccc(N)cc1,0.12
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1cc[c:1](N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1cc[c:1]([N+](=O)[O-])cc1,aniline_to_nitro,Phase 1 SyGMa rules,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1cc[c:1](N)cc1,0.0
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)[cH:1]c1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)[c:1](O)c1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)[cH:1]c1,0.88
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)[cH:3]c1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)[c:3](O)c1,aromatic_hydroxylation_(ortho_to_nitrogen),Phase 1 SyGMa rules,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)[cH:3]c1,0.88
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)c[cH:1]1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)c[c:1]1O,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)c[cH:1]1,0.0
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc([NH2:1])cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc([NH:1]O)cc1,amine hydroxylation,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc([NH2:1])cc1,0.23
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc([NH2:2])cc1,CC(=O)[NH:2]c1ccc(S(=O)(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc2ccccc2)NC(=O)O[C@H]2CO[C@H]3OCC[C@H]32)cc1,N-acetylation_(aniline),NAT rules (phase 2),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc([NH2:2])cc1,0.92
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc([NH2:2])cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc([NH:2]C2OC(C(=O)O)C(O)C(O)C2O)cc1,N-glucuronidation_(aniline),UGT rules (phase 2),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc([NH2:2])cc1,0.75
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc([NH2:2])cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc([NH:2]O)cc1,N-oxidation_(aniline),Phase 1 SyGMa rules,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc([NH2:2])cc1,0.23
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc([NH2:2])cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc([NH:2]S(=O)(=O)O)cc1,sulfation_(aniline),SULT rules (phase 2),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc([NH2:2])cc1,0.57
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H:3]2OC[CH2:1][C@@H]12)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C:3](=O)[C@H]1[CH3:1])S(=O)(=O)c1ccc(N)cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OC[CH2:1][C@H]21)S(=O)(=O)c1ccc(N)cc1,0.07
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@@H]2[C@H]1[CH2:1]C[O:2]2)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@@H]([OH:2])[C@H]1[CH3:1])S(=O)(=O)c1ccc(N)cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OC[CH2:1][C@H]21)S(=O)(=O)c1ccc(N)cc1,0.07
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OC[CH2:1][C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OC[CH:1](O)[C@H]21)S(=O)(=O)c1ccc(N)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OC[CH2:1][C@H]21)S(=O)(=O)c1ccc(N)cc1,0.07
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2O[CH2:1]C[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2O[CH:1](O)C[C@H]21)S(=O)(=O)c1ccc(N)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2O[CH2:1]C[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.04
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1C[O:1][C@H]2O[CH2:3]C[C@@H:1]12)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@@H](C[OH:1])[CH2:1]C[CH:3]=O)S(=O)(=O)c1ccc(N)cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2O[CH2:3]C[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.04
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1C[O:2][C@H]2[O:1]CC[C@@H:1]12)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@@H](C[OH:2])[CH2:1]CC[OH:1])S(=O)(=O)c1ccc(N)cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1C[O:2][C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,0.0
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H:1]1C[O:2][C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[CH2:1][C@@H]1CCO[C@@H]1[OH:2])S(=O)(=O)c1ccc(N)cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1C[O:2][C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,0.0
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[O:2][C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[OH:2])S(=O)(=O)c1ccc(N)cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[O:2][C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.0
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)N[C:2](=O)[O:3][C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,O=[C:2]=[O:3],carbamate cleavage,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[O:3][C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.0
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)N[C:2](=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@@H](N)Cc1ccccc1)S(=O)(=O)c1ccc(N)cc1.O=[C:2](O)O[C@H]1CO[C@H]2OCC[C@H]21,hydrolysis_(urea_or_carbonate),Phase 1 SyGMa rules,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)N[C:2](=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.68
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)N[C:2](=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)N[C:2](=O)O)S(=O)(=O)c1ccc(N)cc1.O[C@H]1CO[C@H]2OCC[C@H]21,hydrolysis_(urea_or_carbonate),Phase 1 SyGMa rules,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)N[C:2](=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.68
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)N[C:2](=O)[O:3][C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,O=[C:2]=[O:3],carbamate cleavage,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)N[C:2](=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.68
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)[NH:1]C(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)[N:1](O)C(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,amine hydroxylation,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)[NH:1]C(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.01
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)[NH:1]C(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)[NH2:1])S(=O)(=O)c1ccc(N)cc1,carbamate cleavage,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)[NH:1]C(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.01
Darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)[NH:1]C(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,O=C(O[C@H]1CO[C@H]2OCC[C@H]21)[NH2:1],N-dealkylation,CYP rules from GLORY (phase 1),CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)[NH:1]C(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.01
Darunavir,CC(C)CN(C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)[OH:2])S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)[O:2]C1OC(C(=O)O)C(O)C(O)C1O)S(=O)(=O)c1ccc(N)cc1,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),CC(C)CN(C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)[OH:2])S(=O)(=O)c1ccc(N)cc1,0.71
Darunavir,CC(C)CN(C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)[OH:2])S(=O)(=O)c1ccc(N)cc1,CC(C)CN(C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)[O:2]S(=O)(=O)O)S(=O)(=O)c1ccc(N)cc1,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),CC(C)CN(C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)[OH:2])S(=O)(=O)c1ccc(N)cc1,0.16
Darunavir,CC(C)CN(S(=O)(=O)c1ccc(N)cc1)[CH2:1][C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21,CC(C)CN(S(=O)(=O)c1ccc(N)cc1)[CH:1](O)[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)CN(S(=O)(=O)c1ccc(N)cc1)[CH2:1][C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21,0.08
Darunavir,CC(C)CN(S(=O)(=O)c1ccc(N)cc1)[CH2:2][C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21,O=C(N[C@@H](Cc1ccccc1)[C@H](O)[CH:2]=O)O[C@H]1CO[C@H]2OCC[C@H]21,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)CN(S(=O)(=O)c1ccc(N)cc1)[CH2:2][C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21,0.08
Darunavir,CC(C)CN(S(=O)(=O)c1ccc(N)cc1)[CH2:4][C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21,CC(C)CNS(=O)(=O)c1ccc(N)cc1.O=C(N[C@@H](Cc1ccccc1)[C@H](O)[CH2:4]O)O[C@H]1CO[C@H]2OCC[C@H]21,N-dealkylation_(tertiaryN-CH2-alkyl),Phase 1 SyGMa rules,CC(C)CN(S(=O)(=O)c1ccc(N)cc1)[CH2:4][C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21,0.08
Darunavir,CC(C)C[N:1](C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)C[N+:1]([O-])(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,N-oxidation,CYP rules from GLORY (phase 1),CC(C)C[N:1](C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.05
Darunavir,CC(C)C[N:1](C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)C[NH:1]S(=O)(=O)c1ccc(N)cc1,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)C[N:1](C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.05
Darunavir,CC(C)C[N:1](C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,Nc1ccc(S(=O)(=O)[NH:1]C[C@@H](O)[C@H](Cc2ccccc2)NC(=O)O[C@H]2CO[C@H]3OCC[C@H]32)cc1,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)C[N:1](C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.05
Sofosbuvir,CC(C)OC(=O)[C@@H](N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1)[CH3:1],CC(C)OC(=O)[C@@H](N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1)[CH2:1]O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@@H](N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1)[CH3:1],0.04
Sofosbuvir,CC(C)OC(=O)[C@H:1](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@@:1](C)(O)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H:1](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.16
Sofosbuvir,CC(C)OC(=O)[C@H:2](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,C=[CH:2]N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,deformylation,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H:2](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.16
Sofosbuvir,CC(C)OC(=O)[C@H:2](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C:2](C)=O,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H:2](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.16
Sofosbuvir,CC(C)OC(=O)[C@H:2](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@@:2](C)(O)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,CC(C)OC(=O)[C@H:2](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.16
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@:1](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N.C[C@@]1(F)[C@H](O)[C@@H](CO[P@@:1](=O)(O)Oc2ccccc2)O[C@H]1n1ccc(=O)[nH]c1=O,hydrolysis_(X=X-X_exclude_phosphate),Phase 1 SyGMa rules,CC(C)OC(=O)[C@H](C)N[P@:1](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.28
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@:1](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@:1](=O)(O)Oc1ccccc1.C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(=O)[nH]c1=O,hydrolysis_(X=X-X_exclude_phosphate),Phase 1 SyGMa rules,CC(C)OC(=O)[C@H](C)N[P@:1](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.28
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@:1](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@@:1](=O)(O)OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O.Oc1ccccc1,hydrolysis_(X=X-X_exclude_phosphate),Phase 1 SyGMa rules,CC(C)OC(=O)[C@H](C)N[P@:1](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.28
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@@](=O)(Oc1ccccc1)O[CH2:1][C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O,CC(C)OC(=O)[C@H](C)N[P@@](=O)(Oc1ccccc1)O[CH:1](O)[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@@](=O)(Oc1ccccc1)O[CH2:1][C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O,0.02
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@@](=O)(Oc1ccccc1)O[CH2:4][C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O,C[C@@]1(F)[C@H](O)[C@@H]([CH2:4]O)O[C@H]1n1ccc(=O)[nH]c1=O,phosphoester cleavage,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@@](=O)(Oc1ccccc1)O[CH2:4][C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O,0.02
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@@](=O)(Oc1ccccc1)[O:3]C[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O,CC(C)OC(=O)[C@H](C)N[P@@](=O)(Oc1ccccc1)[OH:3],phosphoester cleavage,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@@](=O)(Oc1ccccc1)[O:3]C[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O,0.06
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@@H](O)[C@@:1](C)(F)[C@H](n2ccc(=O)[nH]c2=O)[O:2]1)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]([C@@H](O)[CH:1](C)F)[OH:2])Oc1ccccc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@@H](O)[C@@](C)(F)[C@H](n2ccc(=O)[nH]c2=O)[O:2]1)Oc1ccccc1,0.04
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@@H:1](O)[C@@](C)(F)[C@H](n2ccc(=O)[nH]c2=O)[O:2]1)Oc1ccccc1,C[C@](F)([C@H](n1ccc(=O)[nH]c1=O)[OH:2])[CH2:1]O,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@@H](O)[C@@](C)(F)[C@H](n2ccc(=O)[nH]c2=O)[O:2]1)Oc1ccccc1,0.04
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H:1]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@@:1]1(O)O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H:1]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.05
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H:3]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@:1](C)(F)[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C:3](=O)[C@@H](O)[CH:1](C)F)Oc1ccccc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H:3]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.05
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H:1](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@:1](O)(n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H:1](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.05
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H:2](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C:2](=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H:2](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.05
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H:3](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H:3](O)[C@](C)(F)[C@@H]1O)Oc1ccccc1.O=c1cc[nH]c(=O)[nH]1,n-deglycosidation,Phase 1 SyGMa rules,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H:3](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.05
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H:3](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H:1]1O)Oc1ccccc1,C[C@@](F)([CH2:1]O)[C:3](=O)n1ccc(=O)[nH]c1=O,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H:3](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.05
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H]([n:1]2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H]([N+:1]2([O-])C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,N-oxidation,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H]([n:1]2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.0
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H]([n:1]2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,O=c1cc[nH:1]c(=O)[nH]1,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H]([n:1]2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.0
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2c(=O)[nH]c(=O)c[cH:1]2)[C@](C)(F)[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2c(=O)[nH]c(=O)c[c:1]2O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2c(=O)[nH]c(=O)c[cH:1]2)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.01
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2c[cH:1]c(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2c[c:1](O)c(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2c[cH:1]c(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.02
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2c[cH:3]c(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2c[c:3](O)c(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,aromatic_hydroxylation_(ortho_to_oxygen),Phase 1 SyGMa rules,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2c[cH:3]c(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.02
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2c[cH:4]c(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2c[c:4](O)c(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2c[cH:4]c(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.02
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2c[cH:5]c(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2c[c:5](O)c(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,aromatic_hydroxylation_(para_to_oxygen),Phase 1 SyGMa rules,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2c[cH:5]c(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.02
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH:1]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[n:1](C3OC(C(=O)O)C(O)C(O)C3O)c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,N-glucuronidation_(aromatic_-nH-),UGT rules (phase 2),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH:1]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.11
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H:3]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@:1](C)(F)[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C:3](=O)[C@@H](O)[CH:1](C)F)Oc1ccccc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@:1](C)(F)[C@@H]1O)Oc1ccccc1,0.02
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@@H](O)[C@@:1](C)(F)[C@H](n2ccc(=O)[nH]c2=O)[O:2]1)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]([C@@H](O)[CH:1](C)F)[OH:2])Oc1ccccc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@:1](C)(F)[C@@H]1O)Oc1ccccc1,0.02
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](F)([CH3:1])[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](F)([CH2:1]O)[C@@H]1O)Oc1ccccc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](F)([CH3:1])[C@@H]1O)Oc1ccccc1,0.06
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](F)([CH3:2])[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](F)([C:2](=O)O)[C@@H]1O)Oc1ccccc1,carboxylation_(primary_carbon_next_to_quart_carbon),Phase 1 SyGMa rules,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](F)([CH3:2])[C@@H]1O)Oc1ccccc1,0.06
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](F)([CH3:2])[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](F)([CH2:2]O)[C@@H]1O)Oc1ccccc1,aliphatic_hydroxylation_(primary_carbon_next_to_quart_carbon),Phase 1 SyGMa rules,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](F)([CH3:2])[C@@H]1O)Oc1ccccc1,0.06
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H:1]1O)Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C:1]1(O)O)Oc1ccccc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H:1]1O)Oc1ccccc1,0.02
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H:3](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H:1]1O)Oc1ccccc1,C[C@@](F)([CH2:1]O)[C:3](=O)n1ccc(=O)[nH]c1=O,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H:1]1O)Oc1ccccc1,0.02
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@@H:1](O)[C@@](C)(F)[C@H](n2ccc(=O)[nH]c2=O)[O:2]1)Oc1ccccc1,C[C@](F)([C@H](n1ccc(=O)[nH]c1=O)[OH:2])[CH2:1]O,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H:1]1O)Oc1ccccc1,0.02
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)O[c:4]1ccccc1,O[c:4]1ccccc1,phosphoester cleavage,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)O[c:4]1ccccc1,0.01
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1cc[cH:1]cc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1cc[c:1](O)cc1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1cc[cH:1]cc1,0.16
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1cc[cH:5]cc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1cc[c:5](O)cc1,aromatic_hydroxylation_(para_to_oxygen),Phase 1 SyGMa rules,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1cc[cH:5]cc1,0.16
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccc[cH:1]c1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccc[c:1](O)c1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccc[cH:1]c1,0.07
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1cccc[cH:1]1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1cccc[c:1]1O,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1cccc[cH:1]1,0.1
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1cccc[cH:3]1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1cccc[c:3]1O,aromatic_hydroxylation_(ortho_to_oxygen),Phase 1 SyGMa rules,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1cccc[cH:3]1,0.1
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)[O:3]c1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)[OH:3],phosphoester cleavage,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)[O:3]c1ccccc1,0.0
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1[OH:2])Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1[O:2]C1OC(C(=O)O)C(O)C(O)C1O)Oc1ccccc1,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1[OH:2])Oc1ccccc1,0.32
Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1[OH:2])Oc1ccccc1,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1[O:2]S(=O)(=O)O)Oc1ccccc1,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1[OH:2])Oc1ccccc1,0.26
Sofosbuvir,CC(C)OC(=O)[C@H](C)[NH:1][P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,CC(C)OC(=O)[C@H](C)[N:1](O)[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,amine hydroxylation,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)[NH:1][P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.05
Sofosbuvir,CC(C)OC(=O)[C@H](C)[NH:1][P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,C[C@@]1(F)[C@H](O)[C@@H](CO[P@](=O)(Oc2ccccc2)[NH2:1])O[C@H]1n1ccc(=O)[nH]c1=O,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)OC(=O)[C@H](C)[NH:1][P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.05
Sofosbuvir,C[C@H](N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1)[C:2](=O)O[CH:4](C)C,C[C@H](N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1)[C:2](=O)O.C[CH:4](C)O,hydrolysis_(ester),Phase 1 SyGMa rules,CC(C)O[C:2](=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.68
Sofosbuvir,CC(C)O[C:3](=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,CC(C)O[CH:3]=O,deformylation,CYP rules from GLORY (phase 1),CC(C)O[C:3](=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.68
Darunavir,CC(C)[CH2:1]N(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)[CH:1](O)N(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)[CH2:1]N(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.06
Darunavir,CC(C)[CH2:2]N(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)[CH2:2]N(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.06
Darunavir,CC(C)[CH2:4]N(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,CC(C)[CH2:4]O.Nc1ccc(S(=O)(=O)NC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)O[C@H]2CO[C@H]3OCC[C@H]32)cc1,N-dealkylation_(tertiaryN-CH2-alkyl),Phase 1 SyGMa rules,CC(C)[CH2:4]N(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.06
Sofosbuvir,CC(C)[O:2]C(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,C[C@H](N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1)C(=O)[OH:2],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)[O:2]C(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.01
Sofosbuvir,CC(C)[O:3]C(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,C[C@H](N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1)C(=O)[OH:3],oxidative ester cleavage,CYP rules from GLORY (phase 1),CC(C)[O:3]C(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,0.01
Rosuvastatin,CC(C)c1c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c(-c2ccc(F)cc2)nc(N(C)S(C)(=O)=O)[n:1]1,CC(C)c1c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c(-c2ccc(F)cc2)nc(N(C)S(C)(=O)=O)[n+:1]1C1OC(C(=O)O)C(O)C(O)C1O,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),CC(C)c1c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c(-c2ccc(F)cc2)nc(N(C)S(C)(=O)=O)[n:1]1,0.0
Rosuvastatin,CC(C)c1c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c(-c2ccc(F)cc2)nc(N(C)S(C)(=O)=O)[n:1]1,CC(C)c1c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c(-c2ccc(F)cc2)nc(N(C)S(C)(=O)=O)[n+:1]1[O-],N-oxidation,CYP rules from GLORY (phase 1),CC(C)c1c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c(-c2ccc(F)cc2)nc(N(C)S(C)(=O)=O)[n:1]1,0.07
Rosuvastatin,CC(C)c1c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c(-c2ccc(F)cc2)nc(N(C)S(C)(=O)=O)[n:2]1,CC(C)c1c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c(-c2ccc(F)cc2)nc(N(C)S(C)(=O)=O)[n+:2]1[O-],N-oxidation_(-N=),Phase 1 SyGMa rules,CC(C)c1c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c(-c2ccc(F)cc2)nc(N(C)S(C)(=O)=O)[n:2]1,0.07
Atorvastatin,CC(C)c1c(C(=O)Nc2cc[cH:1]cc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1c(C(=O)Nc2cc[c:1](O)cc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)Nc2cc[cH:1]cc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.86
Atorvastatin,CC(C)c1c(C(=O)Nc2cc[cH:5]cc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1c(C(=O)Nc2cc[c:5](O)cc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,aromatic_hydroxylation_(para_to_nitrogen),Phase 1 SyGMa rules,CC(C)c1c(C(=O)Nc2cc[cH:5]cc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.86
Atorvastatin,CC(C)c1c(C(=O)Nc2ccc[cH:1]c2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1c(C(=O)Nc2ccc[c:1](O)c2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)Nc2ccc[cH:1]c2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.0
Atorvastatin,CC(C)c1c(C(=O)Nc2cccc[cH:1]2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1c(C(=O)Nc2cccc[c:1]2O)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)Nc2cccc[cH:1]2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.85
Atorvastatin,CC(C)c1c(C(=O)Nc2cccc[cH:3]2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1c(C(=O)Nc2cccc[c:3]2O)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,aromatic_hydroxylation_(ortho_to_nitrogen),Phase 1 SyGMa rules,CC(C)c1c(C(=O)Nc2cccc[cH:3]2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.85
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2cc[cH:1]cc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2cc[c:1](O)cc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2cc[cH:1]cc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.05
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2cc[cH:5]cc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2cc[c:5](O)cc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2cc[cH:5]cc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.05
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2cc[cH:5][cH:4]c2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,CO[c:4]1cc(-c2c(C(=O)Nc3ccccc3)c(C(C)C)n(CC[C@@H](O)C[C@@H](O)CC(=O)O)c2-c2ccc(F)cc2)cc[c:5]1O,aromatic_oxidation,Phase 1 SyGMa rules,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2cc[cH:5]cc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.05
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccc[cH:1]c2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccc[c:1](O)c2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccc[cH:1]c2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.02
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccc[cH:4]c2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccc[c:4](O)c2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccc[cH:4]c2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.02
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2cc[cH:5][cH:4]c2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,CO[c:4]1cc(-c2c(C(=O)Nc3ccccc3)c(C(C)C)n(CC[C@@H](O)C[C@@H](O)CC(=O)O)c2-c2ccc(F)cc2)cc[c:5]1O,aromatic_oxidation,Phase 1 SyGMa rules,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccc[cH:4]c2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.02
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2cccc[cH:1]2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2cccc[c:1]2O)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2cccc[cH:1]2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.0
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2cc[c:1](F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2cc[c:1](O)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,oxidative dehalogenation benzyl,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2cc[c:1](F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.02
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)[cH:1]c2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)[c:1](O)c2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)[cH:1]c2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.01
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)[cH:4]c2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)[c:4](O)c2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)[cH:4]c2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.01
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)c[cH:1]2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)c[c:1]2O)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)c[cH:1]2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.02
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)[n:1]1CC[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)C1=C(C(=O)Nc2ccccc2)C(c2ccccc2)=C(c2ccc(F)cc2)[N+:1]1([O-])CC[C@@H](O)C[C@@H](O)CC(=O)O,N-oxidation,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)[n:1]1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.0
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)[n:1]1CC[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)[nH:1]1,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)[n:1]1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.0
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H:1](O)C[C@@H](O)CC(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C:1](O)(O)C[C@@H](O)CC(=O)O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H:1](O)C[C@@H](O)CC(=O)O,0.03
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H:1](O)C[C@@H](O)CC(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[CH:1]1C[C@@H](O)CC(=O)O1,cyclization to 6-membered lactone,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H:1](O)C[C@@H](O)CC(=O)O,0.03
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H:2](O)C[C@@H](O)[CH2:5]C(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H:2]1C[C@@H](O)[CH2:5]C(=O)O1,ring_closure_(hydroxyl-6bonds-carboxyl),Phase 1 SyGMa rules,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H:2](O)C[C@@H](O)CC(=O)O,0.03
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H:1](O)CC(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C:1](O)(O)CC(=O)O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H:1](O)CC(=O)O,0.04
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H:2](O)CC(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[CH:2]=CC(=O)O,dehydration_next_to_SP2_b,Phase 1 SyGMa rules,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H:2](O)CC(=O)O,0.04
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)C[C:2](=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)C[C:2](=O)NCC(=O)O,glycination_(aliphatic_carboxyl),Other phase 2 rules,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)C[C:2](=O)O,0.0
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)C[C:2](=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)C[C:2](=O)OC1OC(C(=O)O)C(O)C(O)C1O,O-glucuronidation_(aliphatic_carboxyl),UGT rules (phase 2),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)C[C:2](=O)O,0.0
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)C[C:3](=O)O,O=[CH:3]O,deformylation,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)C[C:3](=O)O,0.7
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)[CH2:1]C(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)[CH:1](O)C(=O)O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)[CH2:1]C(=O)O,0.01
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)[CH2:2]C(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)CC(O)=[CH2:2],deformylation,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)[CH2:2]C(=O)O,0.01
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)[CH2:2]C(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)[CH:2](O)C(=O)O,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,not_in_a_ring)",Phase 1 SyGMa rules,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)[CH2:2]C(=O)O,0.01
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H:2](O)C[C@@H](O)[CH2:5]C(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H:2]1C[C@@H](O)[CH2:5]C(=O)O1,ring_closure_(hydroxyl-6bonds-carboxyl),Phase 1 SyGMa rules,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)[CH2:5]C(=O)O,0.01
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@H](CC(=O)O)[OH:2],CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@H](CC(=O)O)[O:2]C1OC(C(=O)O)C(O)C(O)C1O,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@H](CC(=O)O)[OH:2],0.01
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@H](CC(=O)O)[OH:2],CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@H](CC(=O)O)[O:2]S(=O)(=O)O,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@H](CC(=O)O)[OH:2],0.59
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)[CH2:1][C@@H](O)CC(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)[CH:1](O)[C@@H](O)CC(=O)O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)[CH2:1][C@@H](O)CC(=O)O,0.04
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@H](C[C@@H](O)CC(=O)O)[OH:2],CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@H](C[C@@H](O)CC(=O)O)[O:2]C1OC(C(=O)O)C(O)C(O)C1O,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@H](C[C@@H](O)CC(=O)O)[OH:2],0.15
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@H](C[C@@H](O)CC(=O)O)[OH:2],CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@H](C[C@@H](O)CC(=O)O)[O:2]S(=O)(=O)O,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@H](C[C@@H](O)CC(=O)O)[OH:2],0.21
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1C[CH2:1][C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1C[CH:1](O)[C@@H](O)C[C@@H](O)CC(=O)O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1C[CH2:1][C@@H](O)C[C@@H](O)CC(=O)O,0.02
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1[CH2:1]C[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1[CH:1](O)C[C@@H](O)C[C@@H](O)CC(=O)O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1[CH2:1]C[C@@H](O)C[C@@H](O)CC(=O)O,0.02
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1[CH2:2]C[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1[nH]c(-c2ccc(F)cc2)c(-c2ccccc2)c1C(=O)Nc1ccccc1.O=C(O)C[C@H](O)C[C@H](O)C[CH2:2]O,N-dealkylation_(nCH2),Phase 1 SyGMa rules,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1[CH2:2]C[C@@H](O)C[C@@H](O)CC(=O)O,0.02
Atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1[CH2:2]C[C@@H](O)C[C@@H](O)CC(=O)O,O=C(O)C[C@H](O)C[C@H](O)C[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1[CH2:2]C[C@@H](O)C[C@@H](O)CC(=O)O,0.02
Atorvastatin,CC(C)c1c(C(=O)[NH:1]c2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1c(C(=O)[N:1](O)c2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,amine hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1c(C(=O)[NH:1]c2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.01
Atorvastatin,CC(C)c1c(C(=O)[NH:2]c2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1c(C(=O)[N:2](c2ccccc2)C2OC(C(=O)O)C(O)C(O)C2O)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,N-glucuronidation_(aniline_NH1-R),UGT rules (phase 2),CC(C)c1c(C(=O)[NH:2]c2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.01
Atorvastatin,CC(C)c1c([C:2](=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1c([C:2](=O)O)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O.Nc1ccccc1,hydrolysis_(secondary_amide),Phase 1 SyGMa rules,CC(C)c1c([C:2](=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.05
Rosuvastatin,CC(C)c1n[c:2](N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1[nH][c:2](=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O.CNS(C)(=O)=O,oxidative_deamination_(aromatic),Phase 1 SyGMa rules,CC(C)c1n[c:2](N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,0.06
Cobicistat,CC(C)c1nc(CN(C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)[CH3:1])cs1,CC(C)c1nc(CN(C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)[CH2:1]O)cs1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)[CH3:1])cs1,0.25
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H:1](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@:1](O)(CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H:1](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H:2](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@:2](O)(CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H:2](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H:2](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[CH:2]=CCN2CCOCC2)cs1,deformylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H:2](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H:2](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C:2](=O)CCN1CCOCC1)Cc1ccccc1)OCc1cncs1,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H:2](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C[CH2:1][C@H](Cc2ccccc2)NC(=O)OCc2cncs2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C[CH:1](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)cs1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C[CH2:1][C@H](Cc2ccccc2)NC(=O)OCc2cncs2)cs1,0.08
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)[CH2:1]C[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)[CH:1](O)C[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)cs1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)[CH2:1]C[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)cs1,0.04
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H:1](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@:1](O)(CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H:1](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.04
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H:2](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@:2](O)(CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H:2](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.04
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H:2](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,O=C(N[C@H](CC[C:2](=O)Cc1ccccc1)Cc1ccccc1)OCc1cncs1,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H:2](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.04
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@@H](NC(=O)OCc2cncs2)[CH2:1]c2ccccc2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@@H](NC(=O)OCc2cncs2)[CH:1](O)c2ccccc2)Cc2ccccc2)cs1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@@H](NC(=O)OCc2cncs2)[CH2:1]c2ccccc2)Cc2ccccc2)cs1,0.08
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@@H](NC(=O)OCc2cncs2)[CH2:2]c2ccccc2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@@H](NC(=O)OCc2cncs2)[CH:2](O)c2ccccc2)Cc2ccccc2)cs1,benzylic_hydroxylation_(c-CH2-CR),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@@H](NC(=O)OCc2cncs2)[CH2:2]c2ccccc2)Cc2ccccc2)cs1,0.08
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H:1](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@:1](O)(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H:1](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.04
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H:2](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C:2](=O)Cc2ccccc2)Cc2ccccc2)cs1,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H:2](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.04
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H:2](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@:2](O)(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H:2](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.04
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2cc[cH:1]cc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2cc[c:1](O)cc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2cc[cH:1]cc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.06
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2cc[cH:5]cc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2cc[c:5](O)cc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2cc[cH:5]cc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.06
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2cc[cH:5][cH:4]c2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CO[c:4]1cc(C[C@@H](CC[C@H](Cc2ccccc2)NC(=O)[C@H](CCN2CCOCC2)NC(=O)N(C)Cc2csc(C(C)C)n2)NC(=O)OCc2cncs2)cc[c:5]1O,aromatic_oxidation,Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2cc[cH:5]cc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.06
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccc[cH:1]c2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccc[c:1](O)c2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccc[cH:1]c2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.0
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccc[cH:4]c2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccc[c:4](O)c2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccc[cH:4]c2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.0
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2cc[cH:5][cH:4]c2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CO[c:4]1cc(C[C@@H](CC[C@H](Cc2ccccc2)NC(=O)[C@H](CCN2CCOCC2)NC(=O)N(C)Cc2csc(C(C)C)n2)NC(=O)OCc2cncs2)cc[c:5]1O,aromatic_oxidation,Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccc[cH:4]c2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.0
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2cccc[cH:1]2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2cccc[c:1]2O)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2cccc[cH:1]2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.03
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2c[n:1]cs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2c[n+:1](C3OC(C(=O)O)C(O)C(O)C3O)cs2)Cc2ccccc2)cs1,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2c[n:1]cs2)Cc2ccccc2)cs1,0.08
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2c[n:1]cs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2c[n+:1]([O-])cs2)Cc2ccccc2)cs1,N-oxidation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2c[n:1]cs2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2c[n:2]cs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2c[n+:2]([O-])cs2)Cc2ccccc2)cs1,N-oxidation_(-N=),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2c[n:2]cs2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cn[cH:1]s2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cn[c:1](O)s2)Cc2ccccc2)cs1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cn[cH:1]s2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cn[cH:2]s2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cn[c:2](O)s2)Cc2ccccc2)cs1,aromatic_hydroxylation_(sulfur_containing_5ring),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cn[cH:2]s2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cnc[s:1]2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCC2=CN=C[S:1]2=O)Cc2ccccc2)cs1,S-oxidation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cnc[s:1]2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cnc[s:2]2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCC2=CN=C[S:2]2=O)Cc2ccccc2)cs1,sulfide_oxidation_(c-S-c),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cnc[s:2]2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2cc[cH:1]cc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2cc[c:1](O)cc2)cs1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2cc[cH:1]cc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2cc[cH:5]cc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2cc[c:5](O)cc2)cs1,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2cc[cH:5]cc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2cc[cH:5][cH:4]c2)cs1,CO[c:4]1cc(C[C@@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)NC(=O)[C@H](CCN2CCOCC2)NC(=O)N(C)Cc2csc(C(C)C)n2)cc[c:5]1O,aromatic_oxidation,Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2cc[cH:5]cc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccc[cH:1]c2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccc[c:1](O)c2)cs1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccc[cH:1]c2)cs1,0.02
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccc[cH:4]c2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccc[c:4](O)c2)cs1,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccc[cH:4]c2)cs1,0.02
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2cc[cH:5][cH:4]c2)cs1,CO[c:4]1cc(C[C@@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)NC(=O)[C@H](CCN2CCOCC2)NC(=O)N(C)Cc2csc(C(C)C)n2)cc[c:5]1O,aromatic_oxidation,Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccc[cH:4]c2)cs1,0.02
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2cccc[cH:1]2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2cccc[c:1]2O)cs1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2cccc[cH:1]2)cs1,0.0
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)[cH:1]s1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)[c:1](O)s1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)[cH:1]s1,0.02
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)[cH:2]s1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)[c:2](O)s1,aromatic_hydroxylation_(sulfur_containing_5ring),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)[cH:2]s1,0.02
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)c[s:1]1,CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)=C[S:1]1=O,S-oxidation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)c[s:1]1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)c[s:2]1,CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)=C[S:2]1=O,sulfide_oxidation_(c-S-c),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)c[s:2]1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)[CH2:1]c2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)[CH:1](O)c2ccccc2)cs1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)[CH2:1]c2ccccc2)cs1,0.06
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)[CH2:2]c2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)[CH:2](O)c2ccccc2)cs1,benzylic_hydroxylation_(c-CH2-CR),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)[CH2:2]c2ccccc2)cs1,0.06
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2scn[cH:1]2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2scn[c:1]2O)Cc2ccccc2)cs1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2scn[cH:1]2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)O[CH2:1]c2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)O[CH:1](O)c2cncs2)Cc2ccccc2)cs1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)O[CH2:1]c2cncs2)Cc2ccccc2)cs1,0.04
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)O[CH2:3]c2cncs2)Cc2ccccc2)cs1,O=[CH:3]c1cncs1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)O[CH2:3]c2cncs2)Cc2ccccc2)cs1,0.04
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)O[CH2:4]c2cncs2)Cc2ccccc2)cs1,O[CH2:4]c1cncs1,carbamate cleavage,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)O[CH2:4]c2cncs2)Cc2ccccc2)cs1,0.04
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)[O:2]Cc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)[OH:2])Cc2ccccc2)cs1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)[O:2]Cc2cncs2)Cc2ccccc2)cs1,0.0
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)N[C:2](=O)[O:3]Cc2cncs2)Cc2ccccc2)cs1,O=[C:2]=[O:3],carbamate cleavage,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)[O:3]Cc2cncs2)Cc2ccccc2)cs1,0.0
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)N[C:2](=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@@H](N)Cc2ccccc2)Cc2ccccc2)cs1.O=[C:2](O)OCc1cncs1,hydrolysis_(urea_or_carbonate),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)N[C:2](=O)OCc2cncs2)Cc2ccccc2)cs1,0.6
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)N[C:2](=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)N[C:2](=O)O)Cc2ccccc2)cs1.OCc1cncs1,hydrolysis_(urea_or_carbonate),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)N[C:2](=O)OCc2cncs2)Cc2ccccc2)cs1,0.6
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)N[C:2](=O)[O:3]Cc2cncs2)Cc2ccccc2)cs1,O=[C:2]=[O:3],carbamate cleavage,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)N[C:2](=O)OCc2cncs2)Cc2ccccc2)cs1,0.6
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)[NH:1]C(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)[N:1](O)C(=O)OCc2cncs2)Cc2ccccc2)cs1,amine hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)[NH:1]C(=O)OCc2cncs2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)[NH:1]C(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)[NH2:1])Cc2ccccc2)cs1,carbamate cleavage,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)[NH:1]C(=O)OCc2cncs2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)[NH:1]C(=O)OCc2cncs2)Cc2ccccc2)cs1,O=C(OCc1cncs1)[NH2:1],N-dealkylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)[NH:1]C(=O)OCc2cncs2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)[NH:1][C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)[N:1](O)[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,amine hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)[NH:1][C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)[NH:1][C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)[NH2:1])cs1,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)[NH:1][C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)[C:2](=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)[C:2](=O)O)cs1.N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,hydrolysis_(secondary_amide),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)[C:2](=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.12
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)[C:3](=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,O=C(N[C@H](CC[C@H](Cc1ccccc1)N[CH:3]=O)Cc1ccccc1)OCc1cncs1,deformylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)[C:3](=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.12
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CC[O:4]C[CH2:1]2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,C([CH3:1])[OH:4],N-dealkylation of morpholine,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOC[CH2:1]2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.3
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CC[O:2]C[CH2:1]2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN(CC[OH:2])[CH3:1])C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOC[CH2:1]2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.3
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2C[CH2:3]OC[CH2:1]2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN(C[CH:3]=O)[CH3:1])C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOC[CH2:1]2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.3
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOC[CH2:1]2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOC[CH:1]2O)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOC[CH2:1]2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.3
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2[CH2:1]COC[CH2:2]2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,O=[CH:2]COC[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOC[CH2:1]2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.3
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOC[CH2:2]2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOC[C:2]2=O)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,oxidation_(amine_in_a_ring),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOC[CH2:2]2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.3
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOC[CH2:2]2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOC[CH:2]2O)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOC[CH2:2]2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.3
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2[CH2:1]COC[CH2:2]2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,O=[CH:2]COC[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOC[CH2:2]2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.3
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCO[CH2:1]C2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCO[CH:1](O)C2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCO[CH2:1]C2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.44
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CC[N:1]2CCO[CH2:1]C2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CC[NH:1]CCO[CH3:1])C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCO[CH2:1]C2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.44
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CC[N:1]2CCO[CH2:1]C2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CC[NH:1]C[CH3:1])C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,N-dealkylation of morpholine,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCO[CH2:1]C2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.44
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCO[CH2:3]C2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN(CCO)C[CH2:3]O)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,O-dealkylation_(aliphatic),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCO[CH2:3]C2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.44
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2C[CH2:3]OC[CH2:1]2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN(C[CH:3]=O)[CH3:1])C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCO[CH2:3]C2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.44
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CC[O:2]C[CH2:1]2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN(CC[OH:2])[CH3:1])C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CC[O:2]CC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.04
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CC[O:4]C[CH2:1]2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,C([CH3:1])[OH:4],N-dealkylation of morpholine,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CC[O:4]CC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.04
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CC[N:2]2CC[O:5]CC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CC[NH:2]CC[OH:5])C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,N-dealkylation_(morpholine),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CC[O:5]CC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.04
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CC[N:1]2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,C1C[NH:1]CCO1,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CC[N:1]2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.15
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CC[N:1]2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CC[N+:1]2([O-])CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,N-oxidation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CC[N:1]2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.15
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CC[N:2]2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CC[N+:2]2([O-])CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,N-oxidation_(tertiary_N),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CC[N:2]2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.15
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CC[N:2]2CC[O:5]CC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](CC[NH:2]CC[OH:5])C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,N-dealkylation_(morpholine),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](CC[N:2]2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.15
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](C[CH2:1]N2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](C[CH:1](O)N2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](C[CH2:1]N2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.1
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](C[CH2:2]N2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@@H](C[CH:2]=O)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@@H](C[CH2:2]N2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.1
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](C[CH2:4]N2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,C1COCCN1.CC(C)c1nc(CN(C)C(=O)N[C@@H](C[CH2:4]O)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,N-dealkylation_(tertiaryN-CH2-alkyl),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)C(=O)N[C@@H](C[CH2:4]N2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.1
Cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)[CH2:1]CN2CCOCC2)cs1,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)[CH:1](O)CN2CCOCC2)cs1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)[CH2:1]CN2CCOCC2)cs1,0.03
Cobicistat,CC(C)c1nc(CN(C)C(=O)[NH:1][C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)[N:1](O)[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,amine hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)[NH:1][C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)[NH:1][C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)C(=O)[NH2:1])cs1,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)[NH:1][C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)C(=O)[NH:3][C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@H](CCN1CCOCC1)[NH2:3])Cc1ccccc1)OCc1cncs1,carbamide cleavage,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)C(=O)[NH:3][C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(CN(C)[C:2](=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)[C:2](=O)O)cs1.N[C@@H](CCN1CCOCC1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,hydrolysis_(urea_or_carbonate),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)[C:2](=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.05
Cobicistat,CC(C)c1nc(CN(C)[C:2](=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(CN(C)[CH:2]=O)cs1,carbamide cleavage,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)[C:2](=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.05
Cobicistat,CC(C)c1nc(CN(C)[C:2](=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CNCc1csc(C(C)C)n1.O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@H](CCN1CCOCC1)N[C:2](=O)O)Cc1ccccc1)OCc1cncs1,hydrolysis_(urea_or_carbonate),Phase 1 SyGMa rules,CC(C)c1nc(CN(C)[C:2](=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.05
Cobicistat,CC(C)c1nc(CN(C)[C:2](=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@H](CCN1CCOCC1)N[CH:2]=O)Cc1ccccc1)OCc1cncs1,carbamide cleavage,CYP rules from GLORY (phase 1),CC(C)c1nc(CN(C)[C:2](=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.05
Cobicistat,CC(C)c1nc(C[N:1](C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(C[N+:1](C)([O-])C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,N-oxidation,CYP rules from GLORY (phase 1),CC(C)c1nc(C[N:1](C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(C[N:1](C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(C[NH:1]C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)c1nc(C[N:1](C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(C[N:1](C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,C[NH:1]C(=O)N[C@@H](CCN1CCOCC1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)c1nc(C[N:1](C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(C[N:2](C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(C[NH:2]C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,N-demethylation_(R-N(CR)CH3),Phase 1 SyGMa rules,CC(C)c1nc(C[N:2](C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.01
Cobicistat,CC(C)c1nc(C[N:3](C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc(C[NH:3]C)cs1,carbamide cleavage,CYP rules from GLORY (phase 1),CC(C)c1nc(C[N:3](C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.01
Rosuvastatin,CC(C)c1nc(N(C)S(=O)(=O)[CH3:1])nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1nc(N(C)S(=O)(=O)[CH2:1]O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(N(C)S(=O)(=O)[CH3:1])nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,0.03
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)[n:1]c(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)[n+:1](C2OC(C(=O)O)C(O)C(O)C2O)c(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),CC(C)c1nc(N(C)S(C)(=O)=O)[n:1]c(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,0.01
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)[n:1]c(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)[n+:1]([O-])c(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,N-oxidation,CYP rules from GLORY (phase 1),CC(C)c1nc(N(C)S(C)(=O)=O)[n:1]c(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,0.01
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)[n:2]c(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)[n+:2]([O-])c(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,N-oxidation_(-N=),Phase 1 SyGMa rules,CC(C)c1nc(N(C)S(C)(=O)=O)[n:2]c(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,0.01
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2cc[c:1](F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2cc[c:1](O)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,oxidative dehalogenation benzyl,CYP rules from GLORY (phase 1),CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2cc[c:1](F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,0.06
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)[cH:1]c2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)[c:1](O)c2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)[cH:1]c2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,0.06
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)[cH:4]c2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)[c:4](O)c2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)[cH:4]c2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,0.06
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)c[cH:1]2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)c[c:1]2O)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,aromatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)c[cH:1]2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,0.01
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H:1](O)C[C@@H](O)CC(=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C:1](O)(O)C[C@@H](O)CC(=O)O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H:1](O)C[C@@H](O)CC(=O)O,0.43
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H:1](O)C[C@@H](O)CC(=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[CH:1]1C[C@@H](O)CC(=O)O1,cyclization to 6-membered lactone,CYP rules from GLORY (phase 1),CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H:1](O)C[C@@H](O)CC(=O)O,0.43
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H:2](O)C[C@@H](O)[CH2:5]C(=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H:2]1C[C@@H](O)[CH2:5]C(=O)O1,ring_closure_(hydroxyl-6bonds-carboxyl),Phase 1 SyGMa rules,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H:2](O)C[C@@H](O)CC(=O)O,0.43
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H:2](O)C[C@@H](O)CC(=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[CH:2]=C[C@@H](O)CC(=O)O,dehydration_next_to_SP2_a,Phase 1 SyGMa rules,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H:2](O)C[C@@H](O)CC(=O)O,0.43
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H:1](O)CC(=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C:1](O)(O)CC(=O)O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H:1](O)CC(=O)O,0.01
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H:2](O)CC(=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[CH:2]=CC(=O)O,dehydration_next_to_SP2_b,Phase 1 SyGMa rules,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H:2](O)CC(=O)O,0.01
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)C[C:2](=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)C[C:2](=O)NCC(=O)O,glycination_(aliphatic_carboxyl),Other phase 2 rules,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)C[C:2](=O)O,0.0
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)C[C:2](=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)C[C:2](=O)OC1OC(C(=O)O)C(O)C(O)C1O,O-glucuronidation_(aliphatic_carboxyl),UGT rules (phase 2),CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)C[C:2](=O)O,0.0
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)C[C:3](=O)O,O=[CH:3]O,deformylation,CYP rules from GLORY (phase 1),CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)C[C:3](=O)O,0.68
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)[CH2:1]C(=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)[CH:1](O)C(=O)O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)[CH2:1]C(=O)O,0.01
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)[CH2:2]C(=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)CC(O)=[CH2:2],deformylation,CYP rules from GLORY (phase 1),CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)[CH2:2]C(=O)O,0.01
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)[CH2:2]C(=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)[CH:2](O)C(=O)O,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,not_in_a_ring)",Phase 1 SyGMa rules,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)[CH2:2]C(=O)O,0.01
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H:2](O)C[C@@H](O)[CH2:5]C(=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H:2]1C[C@@H](O)[CH2:5]C(=O)O1,ring_closure_(hydroxyl-6bonds-carboxyl),Phase 1 SyGMa rules,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)[CH2:5]C(=O)O,0.01
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@H](CC(=O)O)[OH:2],CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@H](CC(=O)O)[O:2]C1OC(C(=O)O)C(O)C(O)C1O,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@H](CC(=O)O)[OH:2],0.0
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@H](CC(=O)O)[OH:2],CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@H](CC(=O)O)[O:2]S(=O)(=O)O,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@H](CC(=O)O)[OH:2],0.43
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)[CH2:1][C@@H](O)CC(=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)[CH:1](O)[C@@H](O)CC(=O)O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)[CH2:1][C@@H](O)CC(=O)O,0.01
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@H](C[C@@H](O)CC(=O)O)[OH:2],CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@H](C[C@@H](O)CC(=O)O)[O:2]C1OC(C(=O)O)C(O)C(O)C1O,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@H](C[C@@H](O)CC(=O)O)[OH:2],0.03
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@H](C[C@@H](O)CC(=O)O)[OH:2],CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@H](C[C@@H](O)CC(=O)O)[O:2]S(=O)(=O)O,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@H](C[C@@H](O)CC(=O)O)[OH:2],0.31
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/[CH:1]=[CH:2]/[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1[CH:1]1O[CH:2]1[C@@H](O)C[C@@H](O)CC(=O)O,epoxidation,CYP rules from GLORY (phase 1),CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=[CH:2]/[C@@H](O)C[C@@H](O)CC(=O)O,0.06
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/[CH:1]=C/[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1[CH:1](O)C=C(O)C[C@@H](O)CC(=O)O,aliphatic hydroxylation with allylic rearrangement 1,CYP rules from GLORY (phase 1),CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/[CH:1]=C/[C@@H](O)C[C@@H](O)CC(=O)O,0.03
Rosuvastatin,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/[CH:1]=[CH:2]/[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1[CH:1]1O[CH:2]1[C@@H](O)C[C@@H](O)CC(=O)O,epoxidation,CYP rules from GLORY (phase 1),CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/[CH:1]=C/[C@@H](O)C[C@@H](O)CC(=O)O,0.03
Rosuvastatin,CC(C)c1nc(N(S(C)(=O)=O)[CH3:1])nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1nc(N(S(C)(=O)=O)[CH2:1]O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc(N(S(C)(=O)=O)[CH3:1])nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,0.25
Cobicistat,CC(C)c1nc([CH2:1]N(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc([CH:1](O)N(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(C)c1nc([CH2:1]N(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.2
Cobicistat,CC(C)c1nc([CH2:2]N(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc([CH:2](O)N(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,benzylic_hydroxylation_(c-CH2-N),Phase 1 SyGMa rules,CC(C)c1nc([CH2:2]N(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.2
Cobicistat,CC(C)c1nc([CH2:2]N(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc([CH:2]=O)cs1,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)c1nc([CH2:2]N(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.2
Cobicistat,CC(C)c1nc([CH2:4]N(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CC(C)c1nc([CH2:4]O)cs1.CNC(=O)N[C@@H](CCN1CCOCC1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,N-dealkylation_(tertiaryN-CH2-alkyl),Phase 1 SyGMa rules,CC(C)c1nc([CH2:4]N(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,0.2
Rosuvastatin,CC(C)c1nc([N:1](C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1nc([N+:1](C)([O-])S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,N-oxidation,CYP rules from GLORY (phase 1),CC(C)c1nc([N:1](C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,0.08
Rosuvastatin,CC(C)c1nc([N:1](C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1nc([NH:1]S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,N-dealkylation,CYP rules from GLORY (phase 1),CC(C)c1nc([N:1](C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,0.08
Rosuvastatin,CC(C)c1nc([N:2](C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,CC(C)c1nc([NH:2]S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,N-demethylation_(R-N(CR)CH3),Phase 1 SyGMa rules,CC(C)c1nc([N:2](C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,0.08
Cobicistat,CC(C)c1scc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)[n:1]1,CC(C)c1scc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)[n+:1]1C1OC(C(=O)O)C(O)C(O)C1O,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),CC(C)c1scc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)[n:1]1,0.03
Cobicistat,CC(C)c1scc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)[n:1]1,CC(C)c1scc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)[n+:1]1[O-],N-oxidation,CYP rules from GLORY (phase 1),CC(C)c1scc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)[n:1]1,0.02
Cobicistat,CC(C)c1scc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)[n:2]1,CC(C)c1scc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)[n+:2]1[O-],N-oxidation_(-N=),Phase 1 SyGMa rules,CC(C)c1scc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)[n:2]1,0.02
Darunavir,CC(CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1)[CH3:1],CC(CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1)[CH2:1]O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1)[CH3:1],0.02
Darunavir,CC(CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1)[CH3:2],CC(CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1)[C:2](=O)O,carboxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CC(CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1)[CH3:2],0.02
Darunavir,CC(CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1)[CH3:2],CC(CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1)[CH2:2]O,aliphatic_hydroxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CC(CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1)[CH3:2],0.02
Formoterol,CC(Cc1ccc(O[CH3:1])cc1)NCC(O)c1ccc(O)c(NC=O)c1,CC(Cc1ccc(O[CH2:1]O)cc1)NCC(O)c1ccc(O)c(NC=O)c1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(Cc1ccc(O[CH3:1])cc1)NCC(O)c1ccc(O)c(NC=O)c1,0.75
Formoterol,CC(Cc1ccc([O:2]C)cc1)NCC(O)c1ccc(O)c(NC=O)c1,CC(Cc1ccc([OH:2])cc1)NCC(O)c1ccc(O)c(NC=O)c1,O-demethylation,Phase 1 SyGMa rules,CC(Cc1ccc([O:2]C)cc1)NCC(O)c1ccc(O)c(NC=O)c1,0.01
Formoterol,CC(Cc1ccc([O:7]C)cc1)NCC(O)c1ccc(O)c(NC=O)c1,CC(CC1(O)C=CC(=[O:7])C=C1)NCC(O)c1ccc(O)c(NC=O)c1,oxidation of 4-substituted anisole to quinone (substituent not a leaving group),CYP rules from GLORY (phase 1),CC(Cc1ccc([O:7]C)cc1)NCC(O)c1ccc(O)c(NC=O)c1,0.01
Sofosbuvir,CC(OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1)[CH3:1],CC(OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1)[CH2:1]O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1)[CH3:1],0.01
Atorvastatin,CC(c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O)[CH3:1],CC(c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O)[CH2:1]O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O)[CH3:1],0.02
Atorvastatin,CC(c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O)[CH3:2],CC(c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O)[C:2](=O)O,carboxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CC(c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O)[CH3:2],0.02
Atorvastatin,CC(c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O)[CH3:2],CC(c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O)[CH2:2]O,aliphatic_hydroxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CC(c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O)[CH3:2],0.02
Cobicistat,CC(c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1)[CH3:1],CC(c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1)[CH2:1]O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1)[CH3:1],0.17
Cobicistat,CC(c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1)[CH3:2],CC(c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1)[C:2](=O)O,carboxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CC(c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1)[CH3:2],0.17
Cobicistat,CC(c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1)[CH3:2],CC(c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1)[CH2:2]O,aliphatic_hydroxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CC(c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1)[CH3:2],0.17
Rosuvastatin,CC(c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)[CH3:1],CC(c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)[CH2:1]O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC(c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)[CH3:1],0.2
Rosuvastatin,CC(c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)[CH3:2],CC(c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)[C:2](=O)O,carboxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CC(c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)[CH3:2],0.2
Rosuvastatin,CC(c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)[CH3:2],CC(c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)[CH2:2]O,aliphatic_hydroxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CC(c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)[CH3:2],0.2
Enzalutamide,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)N[CH3:1])c(F)c1,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)N[CH2:1]O)c(F)c1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)N[CH3:1])c(F)c1,0.2
Enzalutamide,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)[NH:1]C)c(F)c1,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)[N:1](C)O)c(F)c1,amine hydroxylation,CYP rules from GLORY (phase 1),CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)[NH:1]C)c(F)c1,0.01
Enzalutamide,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)[NH:1]C)c(F)c1,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)[NH2:1])c(F)c1,N-dealkylation,CYP rules from GLORY (phase 1),CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)[NH:1]C)c(F)c1,0.01
Enzalutamide,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)[NH:2]C)c(F)c1,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)[NH2:2])c(F)c1,N-demethylation_(R-NHCH3),Phase 1 SyGMa rules,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)[NH:2]C)c(F)c1,0.01
Fluticasone Propionate,CC[C:2](=O)O[C@:4]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CC[C:2](=O)O.C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@:4]1(O)C(=O)SCF,hydrolysis_(ester),Phase 1 SyGMa rules,CCC(=O)O[C@:4]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0.01
Fluticasone Propionate,CCC(=O)O[C@@]1(C(=O)SCF)[C@@]2(C)C[C@H](O)[C@@]3(F)[C@@H](C[C@H](F)C4=CC(=O)C=C[C@@]43C)[C@@H]2C[C@H:1]1C,CCC(=O)O[C@@]1(C(=O)SCF)[C@@]2(C)C[C@H](O)[C@@]3(F)[C@@H](C[C@H](F)C4=CC(=O)C=C[C@@]43C)[C@@H]2C[C@:1]1(C)O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCC(=O)O[C@@]1(C(=O)SCF)[C@@]2(C)C[C@H](O)[C@@]3(F)[C@@H](C[C@H](F)C4=CC(=O)C=C[C@@]43C)[C@@H]2C[C@H:1]1C,0.0
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@@]3(C)C=CC(=O)C=C3[C@@H](F)C[C@@H:1]21,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@@]3(C)C=CC(=O)C=C3[C@@H](F)C[C@@:1]21O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@@]3(C)C=CC(=O)C=C3[C@@H](F)C[C@@H:1]21,0.0
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H:1]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@@:1]2(O)[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H:1]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C,0.0
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H:1](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C:1](=O)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,oxidative dehalogenation alkyl,CYP rules from GLORY (phase 1),CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H:1](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0.18
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H:1](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@:1](O)(F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H:1](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0.18
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H:1](O)C[C@@]21C,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C:1](O)(O)C[C@@]21C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H:1](O)C[C@@]21C,0.01
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21[CH3:1],CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21[CH2:1]O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21[CH3:1],0.0
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)[CH2:1][C@@]21C,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)[CH:1](O)[C@@]21C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)[CH2:1][C@@]21C,0.0
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H]([OH:2])C[C@@]21C,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H]([O:2]C3OC(C(=O)O)C(O)C(O)C3O)C[C@@]21C,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H]([OH:2])C[C@@]21C,0.59
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H]([OH:2])C[C@@]21C,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H]([O:2]S(=O)(=O)O)C[C@@]21C,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H]([OH:2])C[C@@]21C,0.21
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4([CH3:1])[C@@]3(F)[C@@H](O)C[C@@]21C,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4([CH2:1]O)[C@@]3(F)[C@@H](O)C[C@@]21C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4([CH3:1])[C@@]3(F)[C@@H](O)C[C@@]21C,0.0
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=[CH:1][C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C[CH:1](SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,"glutathione_conjugation_(alpha,beta-unsaturated_carbonyl)",GST rules (phase 2),CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=[CH:1][C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0.07
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)[CH:1]=[CH:2][C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)[CH:1]5O[CH:2]5[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,epoxidation,CYP rules from GLORY (phase 1),CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=[CH:2][C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0.0
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)[CH:1]=[CH:2][C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)[CH:1]5O[CH:2]5[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,epoxidation,CYP rules from GLORY (phase 1),CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)[CH:1]=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0.0
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)[C:1]4=[CH:2]C(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)[C:1]45O[CH:2]4C(=O)C=C[C@]5(C)[C@@]3(F)[C@@H](O)C[C@@]21C,epoxidation,CYP rules from GLORY (phase 1),CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=[CH:2]C(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0.01
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)[C:1]4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)[C:1]4(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,"glutathione_conjugation_(alpha,beta-unsaturated_carbonyl)",GST rules (phase 2),CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)[C:1]4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0.09
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)[C:1]4=[CH:2]C(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)[C:1]45O[CH:2]4C(=O)C=C[C@]5(C)[C@@]3(F)[C@@H](O)C[C@@]21C,epoxidation,CYP rules from GLORY (phase 1),CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)[C:1]4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0.0
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@H]3[C@](F)([C@@H](O)C[C@@]21C)[C@@]1(C)C=CC(=O)C=C1[C@@H](F)[CH2:1]3,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@H]3[C@](F)([C@@H](O)C[C@@]21C)[C@@]1(C)C=CC(=O)C=C1[C@@H](F)[CH:1]3O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@H]3[C@](F)([C@@H](O)C[C@@]21C)[C@@]1(C)C=CC(=O)C=C1[C@@H](F)[CH2:1]3,0.02
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)[CH2:1][C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)[CH:1](O)[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)[CH2:1][C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0.0
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)SCF)[C@H]([CH3:1])C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CCC(=O)O[C@]1(C(=O)SCF)[C@H]([CH2:1]O)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCC(=O)O[C@]1(C(=O)SCF)[C@H]([CH3:1])C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0.0
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)SCF)[C@H]([CH3:2])C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CCC(=O)O[C@]1(C(=O)SCF)[C@H]([C:2](=O)O)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,carboxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CCC(=O)O[C@]1(C(=O)SCF)[C@H]([CH3:2])C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0.0
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)SCF)[C@H]([CH3:2])C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CCC(=O)O[C@]1(C(=O)SCF)[C@H]([CH2:2]O)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,aliphatic_hydroxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CCC(=O)O[C@]1(C(=O)SCF)[C@H]([CH3:2])C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0.0
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)S[CH2:1]F)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CCC(=O)O[C@]1(C(=O)S[CH:1](O)F)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCC(=O)O[C@]1(C(=O)S[CH2:1]F)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0.02
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)S[CH2:1]F)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CCC(=O)O[C@]1(C(=O)S[CH:1]=O)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,oxidative dehalogenation alkyl,CYP rules from GLORY (phase 1),CCC(=O)O[C@]1(C(=O)S[CH2:1]F)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0.02
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)S[CH2:2]F)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,O=[CH:2]F,S-dealkylation,CYP rules from GLORY (phase 1),CCC(=O)O[C@]1(C(=O)S[CH2:2]F)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0.02
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)[S:1]CF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CCC(=O)O[C@]1(C(=O)[S:1](=O)CF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,S-oxidation,CYP rules from GLORY (phase 1),CCC(=O)O[C@]1(C(=O)[S:1]CF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0.01
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)[S:1]CF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CCC(=O)O[C@]1(C(=O)[SH:1])[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,S-dealkylation,CYP rules from GLORY (phase 1),CCC(=O)O[C@]1(C(=O)[S:1]CF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0.01
Fluticasone Propionate,CCC(=O)O[C@]1(C(=O)[S:2]CF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CCC(=O)O[C@]1(C(=O)[S:2](=O)CF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,sulfide_oxidation_(C-S-C),Phase 1 SyGMa rules,CCC(=O)O[C@]1(C(=O)[S:2]CF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0.01
Budesonide,CCCC1O[C@@H]2C[C@@H]3[C@](C)(C[C@H](O)[C@@H]4[C@@]5(C)C=CC(=O)C=C5CC[C@H:1]43)[C@]2(C(=O)CO)O1,CCCC1O[C@@H]2C[C@@H]3[C@](C)(C[C@H](O)[C@@H]4[C@@]5(C)C=CC(=O)C=C5CC[C@:1]43O)[C@]2(C(=O)CO)O1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCC1O[C@@H]2C[C@@H]3[C@](C)(C[C@H](O)[C@@H]4[C@@]5(C)C=CC(=O)C=C5CC[C@H:1]43)[C@]2(C(=O)CO)O1,0.0
Budesonide,CCCC1O[C@@H]2C[C@H:1]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,CCCC1O[C@@H]2C[C@@:1]3(O)[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCC1O[C@@H]2C[C@H:1]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,0.0
Budesonide,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H:1]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@:1]4(O)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H:1]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,0.01
Budesonide,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H:1](O)C[C@]3(C)[C@]2(C(=O)CO)O1,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C:1](O)(O)C[C@]3(C)[C@]2(C(=O)CO)O1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H:1](O)C[C@]3(C)[C@]2(C(=O)CO)O1,0.0
Budesonide,CCC[CH:3]1O[C@]2(C(=O)CO)[C@@H:1](C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@@:1]32C)O1,CCC[C:3](=O)O[CH2:1]C[C@H]1[C@@H]2CCC3=CC(=O)C=C[C@]3(C)[C@H]2[C@@H](O)C[CH:1]1C,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@:1]3(C)[C@]2(C(=O)CO)O1,0.0
Budesonide,CCCC1O[C@:1]2(C(=O)CO)[C@@H]([CH2:1][C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@@]32C)[O:2]1,CCCC(O[CH:1](C(=O)CO)[C@@]1(C)C[C@H](O)[C@H]2[C@@H](CCC3=CC(=O)C=C[C@@]32C)[C@@H]1[CH3:1])[OH:2],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@:1]2(C(=O)CO)O1,0.02
Budesonide,CCC[CH:3]1O[C@@H]2[CH2:1][C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@:1]2(C(=O)CO)O1,CCC[C:3](=O)O[CH:1](C(=O)CO)[C@@]1(C)C[C@H](O)[C@H]2[C@@H](CCC3=CC(=O)C=C[C@@]32C)[C@@H]1[CH3:1],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@:1]2(C(=O)CO)O1,0.02
Budesonide,CCCC1O[C@@H:3]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)[O:1]1,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1C[C:3](=O)[C@@]2(C(=O)CO)[OH:1],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)[O:1]1,0.0
Budesonide,CCCC1[O:1][C@]2(C(=O)CO)[C@@H](C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@@]32C)[O:2]1,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1C[C@@H]([OH:2])[C@@]2(C(=O)CO)[OH:1],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)[O:1]1,0.0
Budesonide,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)C[OH:2])O1,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)C[O:2]C2OC(C(=O)O)C(O)C(O)C2O)O1,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)C[OH:2])O1,0.31
Budesonide,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)C[OH:2])O1,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)C[O:2]S(=O)(=O)O)O1,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)C[OH:2])O1,0.29
Budesonide,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)[CH2:1]O)O1,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)[CH:1](O)O)O1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)[CH2:1]O)O1,0.14
Budesonide,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)[CH2:2]O)O1,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)[C:2](=O)O)O1,primary_alcohol_oxidation_(aliphatic),Phase 1 SyGMa rules,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)[CH2:2]O)O1,0.14
Budesonide,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3([CH3:1])[C@]2(C(=O)CO)O1,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3([CH2:1]O)[C@]2(C(=O)CO)O1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3([CH3:1])[C@]2(C(=O)CO)O1,0.0
Budesonide,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)[CH2:1][C@]3(C)[C@]2(C(=O)CO)O1,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)[CH:1](O)[C@]3(C)[C@]2(C(=O)CO)O1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)[CH2:1][C@]3(C)[C@]2(C(=O)CO)O1,0.0
Budesonide,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H]([OH:2])C[C@]3(C)[C@]2(C(=O)CO)O1,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H]([O:2]C4OC(C(=O)O)C(O)C(O)C4O)C[C@]3(C)[C@]2(C(=O)CO)O1,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H]([OH:2])C[C@]3(C)[C@]2(C(=O)CO)O1,0.67
Budesonide,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H]([OH:2])C[C@]3(C)[C@]2(C(=O)CO)O1,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H]([O:2]S(=O)(=O)O)C[C@]3(C)[C@]2(C(=O)CO)O1,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H]([OH:2])C[C@]3(C)[C@]2(C(=O)CO)O1,0.27
Budesonide,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5([CH3:1])[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5([CH2:1]O)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5([CH3:1])[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,0.03
Budesonide,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=[CH:1][C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C[CH:1](SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,"glutathione_conjugation_(alpha,beta-unsaturated_carbonyl)",GST rules (phase 2),CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=[CH:1][C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,0.13
Budesonide,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)[CH:1]=[CH:2][C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)[CH:1]6O[CH:2]6[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,epoxidation,CYP rules from GLORY (phase 1),CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=[CH:2][C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,0.0
Budesonide,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)[CH:1]=[CH:2][C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)[CH:1]6O[CH:2]6[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,epoxidation,CYP rules from GLORY (phase 1),CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)[CH:1]=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,0.0
Budesonide,CCCC1O[C@@H]2C[C@H]3[C@@H]4CC[C:1]5=[CH:2]C(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,CCCC1O[C@@H]2C[C@H]3[C@@H]4CC[C:1]56O[CH:2]5C(=O)C=C[C@]6(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,epoxidation,CYP rules from GLORY (phase 1),CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=[CH:2]C(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,0.0
Budesonide,CCCC1O[C@@H]2C[C@H]3[C@@H]4CC[C:1]5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,CCCC1O[C@@H]2C[C@H]3[C@@H]4CC[C:1]5(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,"glutathione_conjugation_(alpha,beta-unsaturated_carbonyl)",GST rules (phase 2),CCCC1O[C@@H]2C[C@H]3[C@@H]4CC[C:1]5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,0.13
Budesonide,CCCC1O[C@@H]2C[C@H]3[C@@H]4CC[C:1]5=[CH:2]C(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,CCCC1O[C@@H]2C[C@H]3[C@@H]4CC[C:1]56O[CH:2]5C(=O)C=C[C@]6(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,epoxidation,CYP rules from GLORY (phase 1),CCCC1O[C@@H]2C[C@H]3[C@@H]4CC[C:1]5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,0.0
Budesonide,CCCC1O[C@@H]2C[C@H]3[C@@H]4C[CH2:1]C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,CCCC1O[C@@H]2C[C@H]3[C@@H]4C[CH:1](O)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCC1O[C@@H]2C[C@H]3[C@@H]4C[CH2:1]C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,0.69
Budesonide,CCCC1O[C@@H]2C[C@H]3[C@@H]4C[CH2:2]C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,CCCC1O[C@@H]2C[C@H]3[C@@H]4C[CH:2](O)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,CCCC1O[C@@H]2C[C@H]3[C@@H]4C[CH2:2]C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,0.69
Budesonide,CCCC1O[C@@H]2C[C@H]3[C@H]4[C@H]([C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1)[C@@]1(C)C=CC(=O)C=C1C[CH2:1]4,CCCC1O[C@@H]2C[C@H]3[C@H]4[C@H]([C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1)[C@@]1(C)C=CC(=O)C=C1C[CH:1]4O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCC1O[C@@H]2C[C@H]3[C@H]4[C@H]([C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1)[C@@]1(C)C=CC(=O)C=C1C[CH2:1]4,0.7
Budesonide,CCCC1O[C@@]2(C(=O)CO)[C@@]3(C)C[C@H](O)[C@H]4[C@@H](CCC5=CC(=O)C=C[C@@]54C)[C@@H]3C[C@H:1]2O1,CCCC1O[C@@]2(C(=O)CO)[C@@]3(C)C[C@H](O)[C@H]4[C@@H](CCC5=CC(=O)C=C[C@@]54C)[C@@H]3C[C@@:1]2(O)O1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCC1O[C@@]2(C(=O)CO)[C@@]3(C)C[C@H](O)[C@H]4[C@@H](CCC5=CC(=O)C=C[C@@]54C)[C@@H]3C[C@H:1]2O1,0.01
Budesonide,CCCC1O[C@@H:3]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)[O:1]1,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1C[C:3](=O)[C@@]2(C(=O)CO)[OH:1],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCCC1O[C@@]2(C(=O)CO)[C@@]3(C)C[C@H](O)[C@H]4[C@@H](CCC5=CC(=O)C=C[C@@]54C)[C@@H]3C[C@H:3]2O1,0.01
Budesonide,CCCC1O[C@H]2[C@@](C(=O)CO)(O1)[C@@]1(C)C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1[CH2:1]2,CCCC1O[C@H]2[C@@](C(=O)CO)(O1)[C@@]1(C)C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1[CH:1]2O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCC1O[C@H]2[C@@](C(=O)CO)(O1)[C@@]1(C)C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1[CH2:1]2,0.0
Budesonide,CCCC1O[C@:1]2(C(=O)CO)[C@@H]([CH2:1][C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@@]32C)[O:2]1,CCCC(O[CH:1](C(=O)CO)[C@@]1(C)C[C@H](O)[C@H]2[C@@H](CCC3=CC(=O)C=C[C@@]32C)[C@@H]1[CH3:1])[OH:2],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCCC1O[C@]2(C(=O)CO)[C@@H](C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@@]32C)[O:2]1,0.01
Budesonide,CCCC1[O:1][C@]2(C(=O)CO)[C@@H](C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@@]32C)[O:2]1,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1C[C@@H]([OH:2])[C@@]2(C(=O)CO)[OH:1],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCCC1O[C@]2(C(=O)CO)[C@@H](C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@@]32C)[O:2]1,0.01
Fingolimod,CCCCCCCCc1ccc(CCC(CO)(CO)[NH2:1])cc1,CCCCCCCCc1ccc(CCC(CO)(CO)[NH:1]O)cc1,amine hydroxylation,CYP rules from GLORY (phase 1),CCCCCCCCc1ccc(CCC(CO)(CO)[NH2:1])cc1,0.07
Fingolimod,CCCCCCCCc1ccc(CCC(CO)(CO)[NH2:2])cc1,CCCCCCCCc1ccc(CCC(CO)(CO)[NH:2]C(C)=O)cc1,N-acetylation_(aliphatic_NH2),NAT rules (phase 2),CCCCCCCCc1ccc(CCC(CO)(CO)[NH2:2])cc1,0.87
Fingolimod,CCCCCCCCc1ccc(CCC(CO)(CO)[NH2:2])cc1,CCCCCCCCc1ccc(CCC(CO)(CO)[NH:2]C2OC(C(=O)O)C(O)C(O)C2O)cc1,N-glucuronidation_(aliphatic_NH2),UGT rules (phase 2),CCCCCCCCc1ccc(CCC(CO)(CO)[NH2:2])cc1,0.16
Fingolimod,CCCCCCCCc1ccc(CCC(N)(CO)CO)[cH:1]c1,CCCCCCCCc1ccc(CCC(N)(CO)CO)[c:1](O)c1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CCCCCCCCc1ccc(CCC(N)(CO)CO)[cH:1]c1,0.01
Fingolimod,CCCCCCCCc1ccc(CCC(N)(CO)CO)c[cH:1]1,CCCCCCCCc1ccc(CCC(N)(CO)CO)c[c:1]1O,aromatic hydroxylation,CYP rules from GLORY (phase 1),CCCCCCCCc1ccc(CCC(N)(CO)CO)c[cH:1]1,0.0
Fingolimod,CCCCCCCCc1ccc(CCC(N)(CO)C[OH:2])cc1,CCCCCCCCc1ccc(CCC(N)(CO)C[O:2]C2OC(C(=O)O)C(O)C(O)C2O)cc1,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),CCCCCCCCc1ccc(CCC(N)(CO)C[OH:2])cc1,0.71
Fingolimod,CCCCCCCCc1ccc(CCC(N)(CO)C[OH:2])cc1,CCCCCCCCc1ccc(CCC(N)(CO)C[O:2]S(=O)(=O)O)cc1,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),CCCCCCCCc1ccc(CCC(N)(CO)C[OH:2])cc1,0.78
Fingolimod,CCCCCCCCc1ccc(CCC(N)(CO)[CH2:1]O)cc1,CCCCCCCCc1ccc(CCC(N)(CO)[CH:1](O)O)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCCCCCCc1ccc(CCC(N)(CO)[CH2:1]O)cc1,0.03
Fingolimod,CCCCCCCCc1ccc(CCC(N)(CO)[CH2:2]O)cc1,CCCCCCCCc1ccc(CCC(N)(CO)[C:2](=O)O)cc1,primary_alcohol_oxidation_(aliphatic),Phase 1 SyGMa rules,CCCCCCCCc1ccc(CCC(N)(CO)[CH2:2]O)cc1,0.03
Fingolimod,CCCCCCCCc1ccc(C[CH2:1]C(N)(CO)CO)cc1,CCCCCCCCc1ccc(C[CH:1](O)C(N)(CO)CO)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCCCCCCc1ccc(C[CH2:1]C(N)(CO)CO)cc1,0.11
Fingolimod,CCCCCCCCc1ccc([CH2:1]CC(N)(CO)CO)cc1,CCCCCCCCc1ccc([CH:1](O)CC(N)(CO)CO)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCCCCCCc1ccc([CH2:1]CC(N)(CO)CO)cc1,0.03
Fingolimod,CCCCCCCCc1ccc([CH2:2]CC(N)(CO)CO)cc1,CCCCCCCCc1ccc([CH:2](O)CC(N)(CO)CO)cc1,benzylic_hydroxylation_(c-CH2-CR),Phase 1 SyGMa rules,CCCCCCCCc1ccc([CH2:2]CC(N)(CO)CO)cc1,0.03
Fingolimod,CCCCCCC[CH2:1]c1ccc(CCC(N)(CO)CO)cc1,CCCCCCC[CH:1](O)c1ccc(CCC(N)(CO)CO)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCCCCC[CH2:1]c1ccc(CCC(N)(CO)CO)cc1,0.79
Fingolimod,CCCCCCC[CH2:2]c1ccc(CCC(N)(CO)CO)cc1,CCCCCCC[CH:2](O)c1ccc(CCC(N)(CO)CO)cc1,benzylic_hydroxylation_(c-CH2-CR),Phase 1 SyGMa rules,CCCCCCC[CH2:2]c1ccc(CCC(N)(CO)CO)cc1,0.79
Fingolimod,CCCCCC[CH2:1]Cc1ccc(CCC(N)(CO)CO)cc1,CCCCCC[CH:1](O)Cc1ccc(CCC(N)(CO)CO)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCCCC[CH2:1]Cc1ccc(CCC(N)(CO)CO)cc1,0.1
Fingolimod,CCCCC[CH2:1]CCc1ccc(CCC(N)(CO)CO)cc1,CCCCC[CH:1](O)CCc1ccc(CCC(N)(CO)CO)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCCC[CH2:1]CCc1ccc(CCC(N)(CO)CO)cc1,0.0
Fingolimod,CCCC[CH2:1]CCCc1ccc(CCC(N)(CO)CO)cc1,CCCC[CH:1](O)CCCc1ccc(CCC(N)(CO)CO)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCC[CH2:1]CCCc1ccc(CCC(N)(CO)CO)cc1,0.04
Ticagrelor,CCCSc1nc(N[C@@H:1]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@:1]2(O)C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H:1]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.75
Ticagrelor,CCCSc1nc(N[C@@H:2]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@:2]2(O)C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,CCCSc1nc(N[C@@H:2]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.75
Ticagrelor,CCCSc1nc(N[C@@H:2]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,O=[C:2]1C[C@H]1c1ccc(F)c(F)c1,N-dealkylation,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H:2]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.75
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H:1]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@@:1]2(O)c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H:1]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.01
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2cc(F)c(F)[cH:1]c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2cc(F)c(F)[c:1](O)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H]2c2cc(F)c(F)[cH:1]c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.02
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2cc(F)c(F)[cH:4]c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2cc(F)c(F)[c:4](O)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,CCCSc1nc(N[C@@H]2C[C@H]2c2cc(F)c(F)[cH:4]c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.02
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2cc(F)c(F)c[cH:1]2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2cc(F)c(F)c[c:1]2O)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H]2c2cc(F)c(F)c[cH:1]2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.03
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2cc[c:1](F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2cc[c:1](O)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,oxidative dehalogenation benzyl,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H]2c2cc[c:1](F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.06
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)[c:1](F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)[c:1](O)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,oxidative dehalogenation benzyl,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)[c:1](F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.02
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)[cH:1]2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)[c:1]2O)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)[cH:1]2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.02
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2c(n1)n([C@@H]1C[C@H](OCCO)[C@@H](O)[C@H]1O)n[n:1]2,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2c(n1)n([C@@H]1C[C@H](OCCO)[C@@H](O)[C@H]1O)n[n+:1]2C1OC(C(=O)O)C(O)C(O)C1O,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2c(n1)n([C@@H]1C[C@H](OCCO)[C@@H](O)[C@H]1O)n[n:1]2,0.01
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2c(n1)n([C@@H]1C[C@H](OCCO)[C@@H](O)[C@H]1O)n[n:1]2,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2c(n1)n([C@@H]1C[C@H](OCCO)[C@@H](O)[C@H]1O)n[n+:1]2[O-],N-oxidation,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2c(n1)n([C@@H]1C[C@H](OCCO)[C@@H](O)[C@H]1O)n[n:1]2,0.01
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2n[n:1]n([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2n[n+:1](C3OC(C(=O)O)C(O)C(O)C3O)n([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2n[n:1]n([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.01
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nn[n:1]([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2c(n1)[N+:1]([O-])([C@@H]1C[C@H](OCCO)[C@@H](O)[C@H]1O)N=N2,N-oxidation,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nn[n:1]([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.0
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nn[n:1]([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nn[nH:1]c2n1,N-dealkylation,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nn[n:1]([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.0
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H:1]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@:1]3(O)C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H:1]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.03
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H:2]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,O=[C:2]1C[C@H](OCCO)[C@@H](O)[C@H]1O,N-dealkylation,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H:2]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.03
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H:1](OCCO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@:1](O)(OCCO)[C@@H](O)[C@H]3O)c2n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H:1](OCCO)[C@@H](O)[C@H]3O)c2n1,0.04
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H:3](OCCO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C:3](=O)[C@@H](O)[C@H]3O)c2n1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H:3](OCCO)[C@@H](O)[C@H]3O)c2n1,0.04
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H:1](O)[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C:1](O)(O)[C@H]3O)c2n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H:1](O)[C@H]3O)c2n1,0.01
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H:1]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C:1]3(O)O)c2n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H:1]3O)c2n1,0.03
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H:2]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn(C3=[CH:2][C@H](O)[C@@H](OCCO)C3)c2n1,dehydration_next_to_SP2_b,Phase 1 SyGMa rules,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H:2]3O)c2n1,0.03
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2[n:1]1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2[n+:1]1C1OC(C(=O)O)C(O)C(O)C1O,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2[n:1]1,0.01
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2[n:1]1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2[n+:1]1[O-],N-oxidation,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2[n:1]1,0.01
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2[n:2]1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2[n+:2]1[O-],N-oxidation_(-N=),Phase 1 SyGMa rules,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2[n:2]1,0.01
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3[OH:2])c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3[O:2]C3OC(C(=O)O)C(O)C(O)C3O)c2n1,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3[OH:2])c2n1,0.42
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H]([OH:2])[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H]([O:2]C4OC(C(=O)O)C(O)C(O)C4O)[C@H]3O)c2n1,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H]([OH:2])[C@H]3O)c2n1,0.7
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCC[OH:2])[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCC[O:2]C4OC(C(=O)O)C(O)C(O)C4O)[C@@H](O)[C@H]3O)c2n1,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCC[OH:2])[C@@H](O)[C@H]3O)c2n1,0.7
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCC[OH:2])[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCC[O:2]S(=O)(=O)O)[C@@H](O)[C@H]3O)c2n1,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCC[OH:2])[C@@H](O)[C@H]3O)c2n1,0.71
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OC[CH2:1]O)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OC[CH:1](O)O)[C@@H](O)[C@H]3O)c2n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OC[CH2:1]O)[C@@H](O)[C@H]3O)c2n1,0.79
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OC[CH2:2]O)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OC[C:2](=O)O)[C@@H](O)[C@H]3O)c2n1,primary_alcohol_oxidation_(aliphatic),Phase 1 SyGMa rules,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OC[CH2:2]O)[C@@H](O)[C@H]3O)c2n1,0.79
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](O[CH2:1]CO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](O[CH:1](O)CO)[C@@H](O)[C@H]3O)c2n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](O[CH2:1]CO)[C@@H](O)[C@H]3O)c2n1,0.63
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](O[CH2:3]CO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](O)[C@@H](O)[C@H]3O)c2n1.OC[CH2:3]O,O-dealkylation_(aliphatic),Phase 1 SyGMa rules,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](O[CH2:3]CO)[C@@H](O)[C@H]3O)c2n1,0.63
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](O[CH2:3]CO)[C@@H](O)[C@H]3O)c2n1,O=[CH:3]CO,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](O[CH2:3]CO)[C@@H](O)[C@H]3O)c2n1,0.63
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H]([O:2]CCO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H]([OH:2])[C@@H](O)[C@H]3O)c2n1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H]([O:2]CCO)[C@@H](O)[C@H]3O)c2n1,0.02
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H]([O:2]CCO)[C@@H](O)[C@H]3O)c2n1,OCC[OH:2],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H]([O:2]CCO)[C@@H](O)[C@H]3O)c2n1,0.02
Ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@H]3[C@H](O)[C@H](O)[C@@H](OCCO)[CH2:1]3)c2n1,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@H]3[C@H](O)[C@H](O)[C@@H](OCCO)[CH:1]3O)c2n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@H]3[C@H](O)[C@H](O)[C@@H](OCCO)[CH2:1]3)c2n1,0.05
Ticagrelor,CCCSc1nc(N[C@H]2[C@H](c3ccc(F)c(F)c3)[CH2:1]2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc(N[C@H]2[C@H](c3ccc(F)c(F)c3)[CH:1]2O)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCCSc1nc(N[C@H]2[C@H](c3ccc(F)c(F)c3)[CH2:1]2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.03
Ticagrelor,CCCSc1nc([NH:1][C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc([N:1](O)[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,amine hydroxylation,CYP rules from GLORY (phase 1),CCCSc1nc([NH:1][C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.02
Ticagrelor,CCCSc1nc([NH:1][C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc([NH2:1])c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,N-dealkylation,CYP rules from GLORY (phase 1),CCCSc1nc([NH:1][C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.02
Ticagrelor,CCCSc1nc([NH:2][C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CCCSc1nc([N:2](C2OC(C(=O)O)C(O)C(O)C2O)[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,N-glucuronidation_(aniline_NH1-R),UGT rules (phase 2),CCCSc1nc([NH:2][C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.03
Ticagrelor,CCCSc1nc2c(nnn2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)[c:2](N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)n1,CCCSc1nc2c(nnn2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)[c:2](=O)[nH]1.N[C@@H]1C[C@H]1c1ccc(F)c(F)c1,oxidative_deamination_(aromatic),Phase 1 SyGMa rules,CCCSc1nc2c(nnn2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)[c:2](N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)n1,0.01
Ticagrelor,CCCSc1nc2c(nnn2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)c(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)[n:1]1,CCCSc1nc2c(nnn2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)c(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)[n+:1]1C1OC(C(=O)O)C(O)C(O)C1O,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),CCCSc1nc2c(nnn2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)c(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)[n:1]1,0.0
Ticagrelor,CCCSc1nc2c(nnn2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)c(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)[n:1]1,CCCSc1nc2c(nnn2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)c(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)[n+:1]1[O-],N-oxidation,CYP rules from GLORY (phase 1),CCCSc1nc2c(nnn2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)c(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)[n:1]1,0.01
Ticagrelor,CCCSc1nc2c(nnn2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)c(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)[n:2]1,CCCSc1nc2c(nnn2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)c(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)[n+:2]1[O-],N-oxidation_(-N=),Phase 1 SyGMa rules,CCCSc1nc2c(nnn2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)c(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)[n:2]1,0.01
Fingolimod,CCC[CH2:1]CCCCc1ccc(CCC(N)(CO)CO)cc1,CCC[CH:1](O)CCCCc1ccc(CCC(N)(CO)CO)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCC[CH2:1]CCCCc1ccc(CCC(N)(CO)CO)cc1,0.04
Budesonide,CCC[CH:1]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,CCC[C:1]1(O)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCC[CH:1]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,0.71
Budesonide,CCC[CH:3]1O[C@]2(C(=O)CO)[C@@H:1](C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@@:1]32C)O1,CCC[C:3](=O)O[CH2:1]C[C@H]1[C@@H]2CCC3=CC(=O)C=C[C@]3(C)[C@H]2[C@@H](O)C[CH:1]1C,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCC[CH:3]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,0.71
Budesonide,CCC[CH:3]1O[C@@H]2[CH2:1][C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@:1]2(C(=O)CO)O1,CCC[C:3](=O)O[CH:1](C(=O)CO)[C@@]1(C)C[C@H](O)[C@H]2[C@@H](CCC3=CC(=O)C=C[C@@]32C)[C@@H]1[CH3:1],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCC[CH:3]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,0.71
Ticagrelor,CCC[S:1]c1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CCC[S:1](=O)c1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,S-oxidation,CYP rules from GLORY (phase 1),CCC[S:1]c1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.09
Ticagrelor,CCC[S:2]c1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CCC[S:2](=O)c1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,sulfide_oxidation_(c-S-C),Phase 1 SyGMa rules,CCC[S:2]c1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.09
Apremilast,CCOc1c(OC)ccc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)[cH:1]1,CCOc1c(OC)ccc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)[c:1]1O,aromatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1c(OC)ccc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)[cH:1]1,0.0
Apremilast,CCOc1c(OC)ccc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)[cH:3]1,CCOc1c(OC)ccc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)[c:3]1O,aromatic_hydroxylation_(ortho_to_2_substituents),Phase 1 SyGMa rules,CCOc1c(OC)ccc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)[cH:3]1,0.0
Apremilast,CCOc1cc([C@@H:1](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,CCOc1cc([C@@:1](O)(CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1cc([C@@H:1](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,0.09
Apremilast,CCOc1cc([C@@H:2](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,CCOc1cc([C:2](=O)CS(C)(=O)=O)ccc1OC,N-dealkylation,CYP rules from GLORY (phase 1),CCOc1cc([C@@H:2](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,0.09
Apremilast,CCOc1cc([C@@H](CS(=O)(=O)[CH3:1])N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,CCOc1cc([C@@H](CS(=O)(=O)[CH2:1]O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1cc([C@@H](CS(=O)(=O)[CH3:1])N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,0.02
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3c(NC(C)=O)cc[cH:1]c3C2=O)ccc1OC,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3c(NC(C)=O)cc[c:1](O)c3C2=O)ccc1OC,aromatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3c(NC(C)=O)cc[cH:1]c3C2=O)ccc1OC,0.02
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3c(NC(C)=O)cc[cH:5]c3C2=O)ccc1OC,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3c(NC(C)=O)cc[c:5](O)c3C2=O)ccc1OC,aromatic_hydroxylation_(para_to_nitrogen),Phase 1 SyGMa rules,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3c(NC(C)=O)cc[cH:5]c3C2=O)ccc1OC,0.02
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3c(NC(C)=O)cccc3[C:2]2=O)ccc1OC,CCOc1cc([C@@H](CS(C)(=O)=O)NC(=O)c2c(NC(C)=O)cccc2[C:2](=O)O)ccc1OC,hydrolysis_(tertiary_amide),Phase 1 SyGMa rules,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3c(NC(C)=O)cccc3[C:2]2=O)ccc1OC,0.15
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3c[cH:1]cc(NC(C)=O)c3C2=O)ccc1OC,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3c[c:1](O)cc(NC(C)=O)c3C2=O)ccc1OC,aromatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3c[cH:1]cc(NC(C)=O)c3C2=O)ccc1OC,0.02
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3c[cH:5]cc(NC(C)=O)c3C2=O)ccc1OC,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3c[c:5](O)cc(NC(C)=O)c3C2=O)ccc1OC,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3c[cH:5]cc(NC(C)=O)c3C2=O)ccc1OC,0.02
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cc[cH:1]c(NC(C)=O)c3C2=O)ccc1OC,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cc[c:1](O)c(NC(C)=O)c3C2=O)ccc1OC,aromatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cc[cH:1]c(NC(C)=O)c3C2=O)ccc1OC,0.04
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cc[cH:5]c(NC(C)=O)c3C2=O)ccc1OC,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cc[c:5](O)c(NC(C)=O)c3C2=O)ccc1OC,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cc[cH:5]c(NC(C)=O)c3C2=O)ccc1OC,0.04
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(=O)[CH3:1])c3C2=O)ccc1OC,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(=O)[CH2:1]O)c3C2=O)ccc1OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(=O)[CH3:1])c3C2=O)ccc1OC,0.64
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(=O)[CH3:2])c3C2=O)ccc1OC,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(=O)[C:2](=O)O)c3C2=O)ccc1OC,carboxylation_(primary_carbon_next_to_SP2),Phase 1 SyGMa rules,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(=O)[CH3:2])c3C2=O)ccc1OC,0.64
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(=O)[CH3:2])c3C2=O)ccc1OC,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(=O)[CH2:2]O)c3C2=O)ccc1OC,aliphatic_hydroxylation_(primary_carbon_next_to_SP2_or_SP1),Phase 1 SyGMa rules,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(=O)[CH3:2])c3C2=O)ccc1OC,0.64
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)[cH:1]cc1OC,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)[c:1](O)cc1OC,aromatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)[cH:1]cc1OC,0.02
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)[cH:5]cc1OC,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)[c:5](O)cc1OC,aromatic_hydroxylation_(para_to_oxygen),Phase 1 SyGMa rules,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)[cH:5]cc1OC,0.02
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)c[cH:1]c1OC,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)c[c:1](O)c1OC,aromatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)c[cH:1]c1OC,0.02
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)c[cH:3]c1OC,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)c[c:3](O)c1OC,aromatic_hydroxylation_(ortho_to_oxygen),Phase 1 SyGMa rules,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)c[cH:3]c1OC,0.02
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1O[CH3:1],CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1O[CH2:1]O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1O[CH3:1],0.79
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1[O:2]C,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1[OH:2],O-demethylation,Phase 1 SyGMa rules,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1[O:2]C,0.0
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1[O:7]C,CCOC1=CC(O)([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)C=CC1=[O:7],oxidation of 4-substituted anisole to quinone (substituent not a leaving group),CYP rules from GLORY (phase 1),CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1[O:7]C,0.0
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3[C:2]2=O)ccc1OC,CCOc1cc([C@@H](CS(C)(=O)=O)NC(=O)c2cccc(NC(C)=O)c2[C:2](=O)O)ccc1OC,hydrolysis_(tertiary_amide),Phase 1 SyGMa rules,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3[C:2]2=O)ccc1OC,0.69
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc([NH:1]C(C)=O)c3C2=O)ccc1OC,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc([N:1](O)C(C)=O)c3C2=O)ccc1OC,amine hydroxylation,CYP rules from GLORY (phase 1),CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc([NH:1]C(C)=O)c3C2=O)ccc1OC,0.02
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc([NH:2]C(C)=O)c3C2=O)ccc1OC,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc([N:2](C(C)=O)C4OC(C(=O)O)C(O)C(O)C4O)c3C2=O)ccc1OC,N-glucuronidation_(aniline_NH1-R),UGT rules (phase 2),CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc([NH:2]C(C)=O)c3C2=O)ccc1OC,0.0
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc([NH:2]C(C)=O)c3C2=O)ccc1OC,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc([NH2:2])c3C2=O)ccc1OC,N-deacetylation,Phase 1 SyGMa rules,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc([NH:2]C(C)=O)c3C2=O)ccc1OC,0.02
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)[N:1]2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,CC(=O)Nc1cccc2c1C(=O)[NH:1]C2=O,N-dealkylation,CYP rules from GLORY (phase 1),CCOc1cc([C@@H](CS(C)(=O)=O)[N:1]2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,0.0
Apremilast,CCOc1cc([C@@H](CS(C)(=O)=O)[N:1]2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,CCOc1cc([C@@H](CS(C)(=O)=O)[N+:1]2([O-])C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,N-oxidation,CYP rules from GLORY (phase 1),CCOc1cc([C@@H](CS(C)(=O)=O)[N:1]2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,0.0
Apremilast,CCOc1cc([C@@H](C[S:1](C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,CCOc1cc([C@@H](C[SH:1](=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,S-dealkylation,CYP rules from GLORY (phase 1),CCOc1cc([C@@H](C[S:1](C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,0.05
Apremilast,CCOc1cc([C@@H](C[S:1](C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,C[SH:1](=O)=O,S-dealkylation,CYP rules from GLORY (phase 1),CCOc1cc([C@@H](C[S:1](C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,0.05
Apremilast,CCOc1cc([C@H](N2C(=O)c3cccc(NC(C)=O)c3C2=O)[CH2:1]S(C)(=O)=O)ccc1OC,CCOc1cc([C@H](N2C(=O)c3cccc(NC(C)=O)c3C2=O)[CH:1](O)S(C)(=O)=O)ccc1OC,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1cc([C@H](N2C(=O)c3cccc(NC(C)=O)c3C2=O)[CH2:1]S(C)(=O)=O)ccc1OC,0.02
Apremilast,CCOc1cc([C@H](N2C(=O)c3cccc(NC(C)=O)c3C2=O)[CH2:2]S(C)(=O)=O)ccc1OC,CCOc1cc([C@H](N2C(=O)c3cccc(NC(C)=O)c3C2=O)[CH:2](O)S(C)(=O)=O)ccc1OC,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,not_in_a_ring)",Phase 1 SyGMa rules,CCOc1cc([C@H](N2C(=O)c3cccc(NC(C)=O)c3C2=O)[CH2:2]S(C)(=O)=O)ccc1OC,0.02
Apremilast,CCOc1cc([C@H](N2C(=O)c3cccc(NC(C)=O)c3C2=O)[CH2:2]S(C)(=O)=O)ccc1OC,CCOc1cc([C@H](N2C(=O)c3cccc(NC(C)=O)c3C2=O)[CH:2]=O)ccc1OC,S-dealkylation,CYP rules from GLORY (phase 1),CCOc1cc([C@H](N2C(=O)c3cccc(NC(C)=O)c3C2=O)[CH2:2]S(C)(=O)=O)ccc1OC,0.02
Dapagliflozin,CCOc1ccc(Cc2c(Cl)ccc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[cH:1]2)cc1,CCOc1ccc(Cc2c(Cl)ccc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[c:1]2O)cc1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1ccc(Cc2c(Cl)ccc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[cH:1]2)cc1,0.0
Dapagliflozin,CCOc1ccc(Cc2c(Cl)ccc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[cH:3]2)cc1,CCOc1ccc(Cc2c(Cl)ccc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[c:3]2O)cc1,aromatic_hydroxylation_(ortho_to_2_substituents),Phase 1 SyGMa rules,CCOc1ccc(Cc2c(Cl)ccc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[cH:3]2)cc1,0.0
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H:1]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,CCOc1ccc(Cc2cc([C@:1]3(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1ccc(Cc2cc([C@@H:1]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,0.04
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H:3]3O[C@H](CO)[C@@H:1](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,CCOc1ccc(Cc2cc([C:3](=O)[C@H](O)[C@@H](O)[CH2:1]O)ccc2Cl)cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCOc1ccc(Cc2cc([C@@H:3]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,0.04
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H]3O[C@H:1](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,CCOc1ccc(Cc2cc([C@@H]3O[C@:1](O)(CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1ccc(Cc2cc([C@@H]3O[C@H:1](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,0.0
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H]3O[C@H:3](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,CCOc1ccc(Cc2cc([C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H:3](O)CO)ccc2Cl)cc1,O-dealkylation_(aliphatic),Phase 1 SyGMa rules,CCOc1ccc(Cc2cc([C@@H]3O[C@H:3](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,0.0
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H]3O[C@H:3](CO)[C@@H](O)[C@H](O)[C@H:1]3O)ccc2Cl)cc1,O=[C:3](CO)[C@@H](O)[C@H](O)[CH2:1]O,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCOc1ccc(Cc2cc([C@@H]3O[C@H:3](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,0.0
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H:3]3O[C@H](CO)[C@@H:1](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,CCOc1ccc(Cc2cc([C:3](=O)[C@H](O)[C@@H](O)[CH2:1]O)ccc2Cl)cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H:1](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,0.0
Dapagliflozin,CCOc1ccc(Cc2cc([C@H]3[C@H](O)[C@@H](O)[C@H:1](O)[C@@H](CO)[O:2]3)ccc2Cl)cc1,CCOc1ccc(Cc2cc([C@@H]([C@H](O)[C@@H](O)[CH2:1]O)[OH:2])ccc2Cl)cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H:1](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,0.0
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H:1](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C:1](O)(O)[C@H](O)[C@H]3O)ccc2Cl)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H:1](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,0.0
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H:1](O)[C@H]3O)ccc2Cl)cc1,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C:1](O)(O)[C@H]3O)ccc2Cl)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H:1](O)[C@H]3O)ccc2Cl)cc1,0.0
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H:1]3O)ccc2Cl)cc1,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C:1]3(O)O)ccc2Cl)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H:1]3O)ccc2Cl)cc1,0.0
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H]3O[C@H:3](CO)[C@@H](O)[C@H](O)[C@H:1]3O)ccc2Cl)cc1,O=[C:3](CO)[C@@H](O)[C@H](O)[CH2:1]O,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H:1]3O)ccc2Cl)cc1,0.0
Dapagliflozin,CCOc1ccc(Cc2cc([C@H]3[C@H:1](O)[C@@H](O)[C@H](O)[C@@H](CO)[O:2]3)ccc2Cl)cc1,OC[C@H]([C@@H](O)[C@H](O)[CH2:1]O)[OH:2],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H:1]3O)ccc2Cl)cc1,0.0
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H:2]3O)ccc2Cl)cc1,CCOc1ccc(Cc2cc(C3=[CH:2][C@@H](O)[C@H](O)[C@@H](CO)O3)ccc2Cl)cc1,dehydration_next_to_SP2_b,Phase 1 SyGMa rules,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H:2]3O)ccc2Cl)cc1,0.0
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[cH:1]cc2Cl)cc1,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[c:1](O)cc2Cl)cc1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[cH:1]cc2Cl)cc1,0.06
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[cH:5]cc2Cl)cc1,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[c:5](O)cc2Cl)cc1,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[cH:5]cc2Cl)cc1,0.06
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c[cH:1]c2Cl)cc1,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c[c:1](O)c2Cl)cc1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c[cH:1]c2Cl)cc1,0.0
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c[cH:4]c2Cl)cc1,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c[c:4](O)c2Cl)cc1,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c[cH:4]c2Cl)cc1,0.0
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc[c:1]2Cl)cc1,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc[c:1]2O)cc1,oxidative dehalogenation benzyl,CYP rules from GLORY (phase 1),CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc[c:1]2Cl)cc1,0.01
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc[c:1]2Cl)cc1,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc[c:1]2SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)cc1,glutathione_conjugation_(aromatic_nucleophilic_substitution),GST rules (phase 2),CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc[c:1]2Cl)cc1,0.11
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)[cH:1]c1,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)[c:1](O)c1,aromatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)[cH:1]c1,0.01
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)c[cH:1]1,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)c[c:1]1O,aromatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)c[cH:1]1,0.02
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)c[cH:3]1,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)c[c:3]1O,aromatic_hydroxylation_(ortho_to_oxygen),Phase 1 SyGMa rules,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)c[cH:3]1,0.02
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H]3O[C@H](C[OH:2])[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,CCOc1ccc(Cc2cc([C@@H]3O[C@H](C[O:2]C4OC(C(=O)O)C(O)C(O)C4O)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),CCOc1ccc(Cc2cc([C@@H]3O[C@H](C[OH:2])[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,0.2
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H]3O[C@H](C[OH:2])[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,CCOc1ccc(Cc2cc([C@@H]3O[C@H](C[O:2]S(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),CCOc1ccc(Cc2cc([C@@H]3O[C@H](C[OH:2])[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,0.46
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H]3O[C@H]([CH2:1]O)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,CCOc1ccc(Cc2cc([C@@H]3O[C@H]([CH:1](O)O)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1ccc(Cc2cc([C@@H]3O[C@H]([CH2:1]O)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,0.19
Dapagliflozin,CCOc1ccc(Cc2cc([C@@H]3O[C@H]([CH2:2]O)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,CCOc1ccc(Cc2cc([C@@H]3O[C@H]([C:2](=O)O)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,primary_alcohol_oxidation_(aliphatic),Phase 1 SyGMa rules,CCOc1ccc(Cc2cc([C@@H]3O[C@H]([CH2:2]O)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,0.19
Dapagliflozin,CCOc1ccc(Cc2cc([C@H]3[C@H](O)[C@@H](O)[C@H:1](O)[C@@H](CO)[O:2]3)ccc2Cl)cc1,CCOc1ccc(Cc2cc([C@@H]([C@H](O)[C@@H](O)[CH2:1]O)[OH:2])ccc2Cl)cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCOc1ccc(Cc2cc([C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)[O:2]3)ccc2Cl)cc1,0.0
Dapagliflozin,CCOc1ccc(Cc2cc([C@H]3[C@H:1](O)[C@@H](O)[C@H](O)[C@@H](CO)[O:2]3)ccc2Cl)cc1,OC[C@H]([C@@H](O)[C@H](O)[CH2:1]O)[OH:2],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CCOc1ccc(Cc2cc([C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)[O:2]3)ccc2Cl)cc1,0.0
Dapagliflozin,CCOc1ccc([CH2:1]c2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,CCOc1ccc([CH:1](O)c2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CCOc1ccc([CH2:1]c2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,0.71
Dapagliflozin,CCOc1ccc([CH2:2]c2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,CCOc1ccc([CH:2](O)c2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,benzylic_hydroxylation_(c-CH2-CR),Phase 1 SyGMa rules,CCOc1ccc([CH2:2]c2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,0.71
Fluticasone Propionate,CC[C:2](=O)O[C@:4]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CC[C:2](=O)O.C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@:4]1(O)C(=O)SCF,hydrolysis_(ester),Phase 1 SyGMa rules,CC[C:2](=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0.17
Fluticasone Propionate,CC[C:3](=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O[CH:3]=O)C(=O)SCF,deformylation,CYP rules from GLORY (phase 1),CC[C:3](=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0.17
Budesonide,CC[CH2:1]C1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,CC[CH:1](O)C1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC[CH2:1]C1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,0.01
Fingolimod,CC[CH2:1]CCCCCc1ccc(CCC(N)(CO)CO)cc1,CC[CH:1](O)CCCCCc1ccc(CCC(N)(CO)CO)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC[CH2:1]CCCCCc1ccc(CCC(N)(CO)CO)cc1,0.08
Ticagrelor,CC[CH2:1]Sc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CC[CH:1](O)Sc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CC[CH2:1]Sc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.09
Ticagrelor,CC[CH2:3]Sc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CC[CH2:3]O.OCCO[C@H]1C[C@@H](n2nnc3c(N[C@@H]4C[C@H]4c4ccc(F)c(F)c4)nc(S)nc32)[C@H](O)[C@@H]1O,S-dealkylation_c-SCH2-R,Phase 1 SyGMa rules,CC[CH2:3]Sc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.09
Apremilast,CC[O:2]c1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,COc1ccc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)cc1[OH:2],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC[O:2]c1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,0.01
Dapagliflozin,CC[O:2]c1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc([OH:2])cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CC[O:2]c1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,0.0
Apremilast,CC[O:7]c1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,COC1=CC(=O)C([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)=CC1=[O:7],oxidation of 4-substituted anisole to quinone,CYP rules from GLORY (phase 1),CC[O:7]c1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,0.01
Dapagliflozin,CC[O:7]c1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,OC[C@H]1O[C@@H](c2ccc(Cl)c(CC3(O)C=CC(=[O:7])C=C3)c2)[C@H](O)[C@@H](O)[C@@H]1O,oxidation of 4-substituted anisole to quinone (substituent not a leaving group),CYP rules from GLORY (phase 1),CC[O:7]c1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,0.0
Cobicistat,CN(Cc1csc([CH:1](C)C)n1)C(=O)N[C@@H](CCN1CCOCC1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,CN(Cc1csc([C:1](C)(C)O)n1)C(=O)N[C@@H](CCN1CCOCC1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CN(Cc1csc([CH:1](C)C)n1)C(=O)N[C@@H](CCN1CCOCC1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,0.22
Cobicistat,CN(Cc1csc([CH:2](C)C)n1)C(=O)N[C@@H](CCN1CCOCC1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,CN(Cc1csc([C:2](C)(C)O)n1)C(=O)N[C@@H](CCN1CCOCC1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,benzylic_hydroxylation_(c-CH1-CH3),Phase 1 SyGMa rules,CN(Cc1csc([CH:2](C)C)n1)C(=O)N[C@@H](CCN1CCOCC1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,0.22
Rosuvastatin,CN(c1nc(-c2ccc(F)cc2)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c([CH:1](C)C)n1)S(C)(=O)=O,CN(c1nc(-c2ccc(F)cc2)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c([C:1](C)(C)O)n1)S(C)(=O)=O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CN(c1nc(-c2ccc(F)cc2)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c([CH:1](C)C)n1)S(C)(=O)=O,0.12
Rosuvastatin,CN(c1nc(-c2ccc(F)cc2)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c([CH:2](C)C)n1)S(C)(=O)=O,CN(c1nc(-c2ccc(F)cc2)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c([C:2](C)(C)O)n1)S(C)(=O)=O,benzylic_hydroxylation_(c-CH1-CH3),Phase 1 SyGMa rules,CN(c1nc(-c2ccc(F)cc2)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c([CH:2](C)C)n1)S(C)(=O)=O,0.12
Tofacitinib,CN(c1ncnc2[nH]ccc12)[C@H]1CN(C(=O)CC#N)CC[C@H:1]1C,CN(c1ncnc2[nH]ccc12)[C@H]1CN(C(=O)CC#N)CC[C@:1]1(C)O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CN(c1ncnc2[nH]ccc12)[C@H]1CN(C(=O)CC#N)CC[C@H:1]1C,0.02
Tofacitinib,CN(c1ncnc2[nH]ccc12)[C@H]1CN(C(=O)CC#N)CC[C@H]1[CH3:1],CN(c1ncnc2[nH]ccc12)[C@H]1CN(C(=O)CC#N)CC[C@H]1[CH2:1]O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CN(c1ncnc2[nH]ccc12)[C@H]1CN(C(=O)CC#N)CC[C@H]1[CH3:1],0.09
Tofacitinib,CN(c1ncnc2[nH]ccc12)[C@H]1CN(C(=O)CC#N)CC[C@H]1[CH3:2],CN(c1ncnc2[nH]ccc12)[C@H]1CN(C(=O)CC#N)CC[C@H]1[C:2](=O)O,carboxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CN(c1ncnc2[nH]ccc12)[C@H]1CN(C(=O)CC#N)CC[C@H]1[CH3:2],0.09
Tofacitinib,CN(c1ncnc2[nH]ccc12)[C@H]1CN(C(=O)CC#N)CC[C@H]1[CH3:2],CN(c1ncnc2[nH]ccc12)[C@H]1CN(C(=O)CC#N)CC[C@H]1[CH2:2]O,aliphatic_hydroxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CN(c1ncnc2[nH]ccc12)[C@H]1CN(C(=O)CC#N)CC[C@H]1[CH3:2],0.09
Imatinib,CN1CCN(Cc2ccc(C(=O)Nc3ccc([CH3:1])c(Nc4nccc(-c5cccnc5)n4)c3)cc2)CC1,CN1CCN(Cc2ccc(C(=O)Nc3ccc([CH2:1]O)c(Nc4nccc(-c5cccnc5)n4)c3)cc2)CC1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CN1CCN(Cc2ccc(C(=O)Nc3ccc([CH3:1])c(Nc4nccc(-c5cccnc5)n4)c3)cc2)CC1,0.72
Imatinib,CN1CCN(Cc2ccc(C(=O)Nc3ccc([CH3:2])c(Nc4nccc(-c5cccnc5)n4)c3)cc2)CC1,CN1CCN(Cc2ccc(C(=O)Nc3ccc([C:2](=O)O)c(Nc4nccc(-c5cccnc5)n4)c3)cc2)CC1,carboxylation_(benzylic_CH3),Phase 1 SyGMa rules,CN1CCN(Cc2ccc(C(=O)Nc3ccc([CH3:2])c(Nc4nccc(-c5cccnc5)n4)c3)cc2)CC1,0.72
Imatinib,CN1CCN(Cc2ccc(C(=O)Nc3ccc([CH3:2])c(Nc4nccc(-c5cccnc5)n4)c3)cc2)CC1,CN1CCN(Cc2ccc(C(=O)Nc3ccc([CH2:2]O)c(Nc4nccc(-c5cccnc5)n4)c3)cc2)CC1,benzylic_hydroxylation_(c-CH3),Phase 1 SyGMa rules,CN1CCN(Cc2ccc(C(=O)Nc3ccc([CH3:2])c(Nc4nccc(-c5cccnc5)n4)c3)cc2)CC1,0.72
Enzalutamide,CNC(=O)c1c(F)cc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)c[cH:1]1,CNC(=O)c1c(F)cc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)c[c:1]1O,aromatic hydroxylation,CYP rules from GLORY (phase 1),CNC(=O)c1c(F)cc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)c[cH:1]1,0.06
Enzalutamide,CNC(=O)c1c[cH:1]c(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,CNC(=O)c1c[c:1](O)c(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,aromatic hydroxylation,CYP rules from GLORY (phase 1),CNC(=O)c1c[cH:1]c(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,0.02
Enzalutamide,CNC(=O)c1c[cH:3]c(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,CNC(=O)c1c[c:3](O)c(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,aromatic_hydroxylation_(ortho_to_nitrogen),Phase 1 SyGMa rules,CNC(=O)c1c[cH:3]c(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,0.02
Enzalutamide,CNC(=O)c1ccc(N2C(=S)N(c3cc(C(F)(F)F)c(C#N)[cH:1]c3)C(=O)C2(C)C)cc1F,CNC(=O)c1ccc(N2C(=S)N(c3cc(C(F)(F)F)c(C#N)[c:1](O)c3)C(=O)C2(C)C)cc1F,aromatic hydroxylation,CYP rules from GLORY (phase 1),CNC(=O)c1ccc(N2C(=S)N(c3cc(C(F)(F)F)c(C#N)[cH:1]c3)C(=O)C2(C)C)cc1F,0.06
Enzalutamide,CNC(=O)c1ccc(N2C(=S)N(c3cc(C(F)(F)F)c(C#N)c[cH:1]3)C(=O)C2(C)C)cc1F,CNC(=O)c1ccc(N2C(=S)N(c3cc(C(F)(F)F)c(C#N)c[c:1]3O)C(=O)C2(C)C)cc1F,aromatic hydroxylation,CYP rules from GLORY (phase 1),CNC(=O)c1ccc(N2C(=S)N(c3cc(C(F)(F)F)c(C#N)c[cH:1]3)C(=O)C2(C)C)cc1F,0.18
Enzalutamide,CNC(=O)c1ccc(N2C(=S)N(c3cc(C(F)(F)F)c(C#N)c[cH:5]3)C(=O)C2(C)C)cc1F,CNC(=O)c1ccc(N2C(=S)N(c3cc(C(F)(F)F)c(C#N)c[c:5]3O)C(=O)C2(C)C)cc1F,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,CNC(=O)c1ccc(N2C(=S)N(c3cc(C(F)(F)F)c(C#N)c[cH:5]3)C(=O)C2(C)C)cc1F,0.18
Enzalutamide,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)[cH:1]3)C(=O)C2(C)C)cc1F,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)[c:1]3O)C(=O)C2(C)C)cc1F,aromatic hydroxylation,CYP rules from GLORY (phase 1),CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)[cH:1]3)C(=O)C2(C)C)cc1F,0.13
Enzalutamide,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)[cH:3]3)C(=O)C2(C)C)cc1F,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)[c:3]3O)C(=O)C2(C)C)cc1F,aromatic_hydroxylation_(ortho_to_2_substituents),Phase 1 SyGMa rules,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)[cH:3]3)C(=O)C2(C)C)cc1F,0.13
Enzalutamide,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)[cH:1]c1F,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)[c:1](O)c1F,aromatic hydroxylation,CYP rules from GLORY (phase 1),CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)[cH:1]c1F,0.03
Enzalutamide,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)[cH:3]c1F,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)[c:3](O)c1F,aromatic_hydroxylation_(ortho_to_nitrogen),Phase 1 SyGMa rules,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)[cH:3]c1F,0.03
Enzalutamide,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)c[c:1]1F,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)c[c:1]1O,oxidative dehalogenation benzyl,CYP rules from GLORY (phase 1),CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)c[c:1]1F,0.02
Enzalutamide,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)[CH3:1])cc1F,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)[CH2:1]O)cc1F,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)[CH3:1])cc1F,0.07
Enzalutamide,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)[CH3:2])cc1F,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)[C:2](=O)O)cc1F,carboxylation_(primary_carbon_next_to_quart_carbon),Phase 1 SyGMa rules,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)[CH3:2])cc1F,0.07
Enzalutamide,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)[CH3:2])cc1F,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)[CH2:2]O)cc1F,aliphatic_hydroxylation_(primary_carbon_next_to_quart_carbon),Phase 1 SyGMa rules,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)[CH3:2])cc1F,0.07
Enzalutamide,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)[C:2](=O)C2(C)C)cc1F,CNC(=O)c1ccc(N(C(=S)Nc2ccc(C#N)c(C(F)(F)F)c2)C(C)(C)[C:2](=O)O)cc1F,hydrolysis_(tertiary_amide),Phase 1 SyGMa rules,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)[C:2](=O)C2(C)C)cc1F,0.18
Enzalutamide,CNC(=O)c1ccc(N2C(=S)N(c3ccc([C:1]#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,CNC(=O)c1ccc(N2C(=S)N(c3ccc([C:1](=N)SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,glutathione_conjugation_(nitrile),GST rules (phase 2),CNC(=O)c1ccc(N2C(=S)N(c3ccc([C:1]#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,0.22
Enzalutamide,CNC(=O)c1ccc(N2C(=S)N(c3ccc([C:1]#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,CNC(=O)c1ccc(N2C(=S)N(c3ccc([C:1](N)=O)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,nitrile_to_amide,Phase 1 SyGMa rules,CNC(=O)c1ccc(N2C(=S)N(c3ccc([C:1]#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,0.08
Enzalutamide,CNC(=O)c1ccc(N2C(=S)[N:1](c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,CNC(=O)c1ccc(N2C(=S)[N+:1]([O-])(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,N-oxidation,CYP rules from GLORY (phase 1),CNC(=O)c1ccc(N2C(=S)[N:1](c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,0.08
Enzalutamide,CNC(=O)c1ccc(N2C(=[S:1])N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,CNC(=O)c1ccc(N2C(=[S:1]=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,S-oxidation,CYP rules from GLORY (phase 1),CNC(=O)c1ccc(N2C(=[S:1])N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,0.32
Enzalutamide,CNC(=O)c1ccc(N2C(C)(C)C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)[C:2]2=S)cc1F,CNC(=O)c1ccc(N2C(C)(C)C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)[C:2]2=O)cc1F,desulfuration of carbon,CYP rules from GLORY (phase 1),CNC(=O)c1ccc(N2C(C)(C)C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)[C:2]2=S)cc1F,0.08
Enzalutamide,CNC(=O)c1ccc([N:1]2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,CNC(=O)c1ccc([N+:1]2([O-])C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,N-oxidation,CYP rules from GLORY (phase 1),CNC(=O)c1ccc([N:1]2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,0.12
Enzalutamide,CN[C:2](=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc([C:2](=O)O)c(F)c1.CN,hydrolysis_(secondary_amide),Phase 1 SyGMa rules,CN[C:2](=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,0.17
Clopidogrel,COC(=O)[C@H:1](c1ccccc1Cl)N1CCc2sccc2C1,COC(=O)[C@:1](O)(c1ccccc1Cl)N1CCc2sccc2C1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COC(=O)[C@H:1](c1ccccc1Cl)N1CCc2sccc2C1,0.01
Clopidogrel,COC(=O)[C@H:2](c1ccccc1Cl)N1CCc2sccc2C1,COC(=O)[C:2](=O)c1ccccc1Cl,N-dealkylation,CYP rules from GLORY (phase 1),COC(=O)[C@H:2](c1ccccc1Cl)N1CCc2sccc2C1,0.01
Clopidogrel,COC(=O)[C@H](c1c(Cl)ccc[cH:1]1)N1CCc2sccc2C1,COC(=O)[C@H](c1c(Cl)ccc[c:1]1O)N1CCc2sccc2C1,aromatic hydroxylation,CYP rules from GLORY (phase 1),COC(=O)[C@H](c1c(Cl)ccc[cH:1]1)N1CCc2sccc2C1,0.01
Clopidogrel,COC(=O)[C@H](c1c[cH:1]ccc1Cl)N1CCc2sccc2C1,COC(=O)[C@H](c1c[c:1](O)ccc1Cl)N1CCc2sccc2C1,aromatic hydroxylation,CYP rules from GLORY (phase 1),COC(=O)[C@H](c1c[cH:1]ccc1Cl)N1CCc2sccc2C1,0.0
Clopidogrel,COC(=O)[C@H](c1c[cH:4]ccc1Cl)N1CCc2sccc2C1,COC(=O)[C@H](c1c[c:4](O)ccc1Cl)N1CCc2sccc2C1,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,COC(=O)[C@H](c1c[cH:4]ccc1Cl)N1CCc2sccc2C1,0.0
Clopidogrel,COC(=O)[C@H](c1cc[cH:1]cc1Cl)N1CCc2sccc2C1,COC(=O)[C@H](c1cc[c:1](O)cc1Cl)N1CCc2sccc2C1,aromatic hydroxylation,CYP rules from GLORY (phase 1),COC(=O)[C@H](c1cc[cH:1]cc1Cl)N1CCc2sccc2C1,0.01
Clopidogrel,COC(=O)[C@H](c1cc[cH:5]cc1Cl)N1CCc2sccc2C1,COC(=O)[C@H](c1cc[c:5](O)cc1Cl)N1CCc2sccc2C1,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,COC(=O)[C@H](c1cc[cH:5]cc1Cl)N1CCc2sccc2C1,0.01
Clopidogrel,COC(=O)[C@H](c1ccc[cH:1]c1Cl)N1CCc2sccc2C1,COC(=O)[C@H](c1ccc[c:1](O)c1Cl)N1CCc2sccc2C1,aromatic hydroxylation,CYP rules from GLORY (phase 1),COC(=O)[C@H](c1ccc[cH:1]c1Cl)N1CCc2sccc2C1,0.0
Clopidogrel,COC(=O)[C@H](c1ccc[cH:4]c1Cl)N1CCc2sccc2C1,COC(=O)[C@H](c1ccc[c:4](O)c1Cl)N1CCc2sccc2C1,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,COC(=O)[C@H](c1ccc[cH:4]c1Cl)N1CCc2sccc2C1,0.0
Clopidogrel,COC(=O)[C@H](c1cccc[c:1]1Cl)N1CCc2sccc2C1,COC(=O)[C@H](c1cccc[c:1]1O)N1CCc2sccc2C1,oxidative dehalogenation benzyl,CYP rules from GLORY (phase 1),COC(=O)[C@H](c1cccc[c:1]1Cl)N1CCc2sccc2C1,0.01
Clopidogrel,COC(=O)[C@H](c1cccc[c:1]1Cl)N1CCc2sccc2C1,COC(=O)[C@H](c1cccc[c:1]1SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)N1CCc2sccc2C1,glutathione_conjugation_(aromatic_nucleophilic_substitution),GST rules (phase 2),COC(=O)[C@H](c1cccc[c:1]1Cl)N1CCc2sccc2C1,0.06
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)N1CCc2c(cc[s:1]2)C1,COC(=O)[C@H](c1ccccc1Cl)N1CCC2=C(C=C[S:1]2=O)C1,thiophene_oxidation,Phase 1 SyGMa rules,COC(=O)[C@H](c1ccccc1Cl)N1CCc2c(cc[s:1]2)C1,0.08
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)N1CCc2c(cc[s:2]2)C1,COC(=O)[C@H](c1ccccc1Cl)N1CCC2=C(C=C[S:2]2=O)C1,sulfide_oxidation_(c-S-c),Phase 1 SyGMa rules,COC(=O)[C@H](c1ccccc1Cl)N1CCc2c(cc[s:2]2)C1,0.08
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)N1CCc2s[cH:1]cc2C1,COC(=O)[C@H](c1ccccc1Cl)N1CCc2s[c:1](O)cc2C1,aromatic hydroxylation,CYP rules from GLORY (phase 1),COC(=O)[C@H](c1ccccc1Cl)N1CCc2s[cH:1]cc2C1,0.78
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)N1CCc2s[cH:2]cc2C1,COC(=O)[C@H](c1ccccc1Cl)N1CCc2s[c:2](O)cc2C1,aromatic_hydroxylation_(sulfur_containing_5ring),Phase 1 SyGMa rules,COC(=O)[C@H](c1ccccc1Cl)N1CCc2s[cH:2]cc2C1,0.78
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sc[cH:1]c2C1,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sc[c:1](O)c2C1,aromatic hydroxylation,CYP rules from GLORY (phase 1),COC(=O)[C@H](c1ccccc1Cl)N1CCc2sc[cH:1]c2C1,0.13
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)[N:1]1CCc2scc[c:1]2C1,COC(=O)[C@H](c1ccccc1Cl)[NH:1]CCc1scc[cH:1]1,N-dealkylation,CYP rules from GLORY (phase 1),COC(=O)[C@H](c1ccccc1Cl)N1CCc2scc[c:1]2C1,0.01
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2[CH2:1]1,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2[CH:1]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2[CH2:1]1,0.06
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)N1[CH2:1]c2ccsc2C[CH2:2]1,O=[CH:2]Cc1sccc1[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2[CH2:1]1,0.06
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2[CH2:2]1,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2[CH:2]1O,benzylic_hydroxylation_(c-CH2-N),Phase 1 SyGMa rules,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2[CH2:2]1,0.06
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)N1[CH2:1]Cc2sccc2[CH2:2]1,O=[CH:2]c1ccsc1C[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2[CH2:2]1,0.06
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)N1Cc2ccsc2C[CH2:1]1,COC(=O)[C@H](c1ccccc1Cl)N1Cc2ccsc2C[CH:1]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COC(=O)[C@H](c1ccccc1Cl)N1Cc2ccsc2C[CH2:1]1,0.04
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)N1[CH2:1]Cc2sccc2[CH2:2]1,O=[CH:2]c1ccsc1C[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),COC(=O)[C@H](c1ccccc1Cl)N1Cc2ccsc2C[CH2:1]1,0.04
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)N1Cc2ccsc2C[CH2:2]1,COC(=O)[C@H](c1ccccc1Cl)N1Cc2ccsc2C[C:2]1=O,oxidation_(amine_in_a_ring),Phase 1 SyGMa rules,COC(=O)[C@H](c1ccccc1Cl)N1Cc2ccsc2C[CH2:2]1,0.04
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)N1Cc2ccsc2C[CH2:2]1,COC(=O)[C@H](c1ccccc1Cl)N1Cc2ccsc2C[CH:2]1O,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,COC(=O)[C@H](c1ccccc1Cl)N1Cc2ccsc2C[CH2:2]1,0.04
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)N1[CH2:1]c2ccsc2C[CH2:2]1,O=[CH:2]Cc1sccc1[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),COC(=O)[C@H](c1ccccc1Cl)N1Cc2ccsc2C[CH2:2]1,0.04
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)N1Cc2ccsc2[CH2:1]C1,COC(=O)[C@H](c1ccccc1Cl)N1Cc2ccsc2[CH:1](O)C1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COC(=O)[C@H](c1ccccc1Cl)N1Cc2ccsc2[CH2:1]C1,0.09
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)[N:1]1Cc2ccsc2[CH2:1]C1,COC(=O)[C@H](c1ccccc1Cl)[NH:1]Cc1ccsc1[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),COC(=O)[C@H](c1ccccc1Cl)N1Cc2ccsc2[CH2:1]C1,0.09
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)N1Cc2ccsc2[CH2:2]C1,COC(=O)[C@H](c1ccccc1Cl)N1Cc2ccsc2[CH:2](O)C1,benzylic_hydroxylation_(c-CH2-CR),Phase 1 SyGMa rules,COC(=O)[C@H](c1ccccc1Cl)N1Cc2ccsc2[CH2:2]C1,0.09
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)[N:1]1CCc2sccc2C1,COC(=O)[C@H](c1ccccc1Cl)[N+:1]1([O-])CCc2sccc2C1,N-oxidation,CYP rules from GLORY (phase 1),COC(=O)[C@H](c1ccccc1Cl)[N:1]1CCc2sccc2C1,0.02
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)[N:1]1CCc2sccc2C1,c1cc2c(s1)CC[NH:1]C2,N-dealkylation,CYP rules from GLORY (phase 1),COC(=O)[C@H](c1ccccc1Cl)[N:1]1CCc2sccc2C1,0.02
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)[N:2]1CCc2sccc2C1,COC(=O)[C@H](c1ccccc1Cl)[N+:2]1([O-])CCc2sccc2C1,N-oxidation_(tertiary_N),Phase 1 SyGMa rules,COC(=O)[C@H](c1ccccc1Cl)[N:2]1CCc2sccc2C1,0.02
Everolimus,CO[C@@H]1/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H](CC[C@H]2C)[CH2:1]1,CO[C@@H]1/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H](CC[C@H]2C)[CH:1]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@@H]1/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H](CC[C@H]2C)[CH2:1]1,0.02
Everolimus,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H:1](OC)C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)CC[C@H]1OCCO,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@:1](O)(OC)C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)CC[C@H]1OCCO,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H:1](OC)C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)CC[C@H]1OCCO,0.02
Everolimus,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H:3](OC)C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)CC[C@H]1OCCO,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C:3](=O)C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)CC[C@H]1OCCO,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H:3](OC)C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)CC[C@H]1OCCO,0.02
Everolimus,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H](O[CH3:1])C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)CC[C@H]1OCCO,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H](O[CH2:1]O)C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)CC[C@H]1OCCO,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H](O[CH3:1])C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)CC[C@H]1OCCO,0.34
Everolimus,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H]([O:2]C)C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)CC[C@H]1OCCO,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H]([OH:2])C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)CC[C@H]1OCCO,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H]([O:2]C)C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)CC[C@H]1OCCO,0.04
Everolimus,CO[C@H]1C[C@@H:1]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@:1]2(O)CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H:1]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.06
Everolimus,CO[C@H]1C[C@@H:3]2CC[C@@H:1](C)[C@@](O)(O2)[C:1](=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C:3](=O)CC[CH2:1]C)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@H](OC(=O)[C@@H]1CCCCN1C(=O)[CH:1]=O)[C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H:3]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.06
Tacrolimus,CO[C@H]1C[C@@H](C)C/C(C)=C/[C@@H](CC=[CH2:1])C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]1[C@@H](OC)C[C@H]2C,CO[C@H]1C[C@@H](C)C/C(C)=C/[C@@H](C=C[CH2:1]O)C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]1[C@@H](OC)C[C@H]2C,aliphatic hydroxylation with allylic rearrangement 1,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H](C)C/C(C)=C/[C@@H](CC=[CH2:1])C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]1[C@@H](OC)C[C@H]2C,0.66
Tacrolimus,CO[C@H]1C[C@@H](C)C/C(C)=C/[C@@H](C[CH:1]=[CH2:2])C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]1[C@@H](OC)C[C@H]2C,CO[C@H]1C[C@@H](C)C/C(C)=C/[C@@H](C[CH:1](O)[CH2:2]O)C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]1[C@@H](OC)C[C@H]2C,vinyl_oxidation,Phase 1 SyGMa rules,CO[C@H]1C[C@@H](C)C/C(C)=C/[C@@H](CC=[CH2:2])C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]1[C@@H](OC)C[C@H]2C,0.66
Tacrolimus,CO[C@H]1C[C@@H](C)C/C(C)=C/[C@@H](C[CH:1]=[CH2:2])C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]1[C@@H](OC)C[C@H]2C,CO[C@H]1C[C@@H](C)C/C(C)=C/[C@@H](C[CH:1]2O[CH2:2]2)C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]1[C@@H](OC)C[C@H]2C,epoxidation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H](C)C/C(C)=C/[C@@H](CC=[CH2:2])C(=O)C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]1[C@@H](OC)C[C@H]2C,0.66
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H:1](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@:1](C)(O)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H:1](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.08
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@:2](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CCC(C)=[C:2](O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,dehydration_next_to_SP2_a,Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@:2](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.09
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H:1]2C(=O)O[C@H:3]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[CH2:1]2)O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C:3](=O)[C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H:1]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.01
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H:1]2C(=O)O[C@H:4]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[CH2:1]2)O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C:4](=O)[C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1,oxidative ester cleavage,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H:1]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.01
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)[C:1](=O)N2[C@@H:1](CCC[CH2:2]2)C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)[CH:1]=O)O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@H](OC(=O)[CH2:1]CCC[CH:2]=O)[C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1,N-dealkylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H:1]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.01
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H:1]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@@:1]2(O)C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H:1]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.01
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H:2]2C(=O)[O:1][C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC=[CH:2]2)O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@@H]([C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1)[OH:1],deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H:2]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.01
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)[C:1](=O)N2[CH2:1]CCC[C@H:2]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)[CH:1]=O)O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@H](OC(=O)[C:2](=O)CCC[CH3:1])[C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1,N-dealkylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H:2]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.01
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H:2]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@@:2]2(O)C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H:2]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.01
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H:1]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@:1](O)([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H:1]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.08
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H:1]2C(=O)O[C@H:3]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[CH2:1]2)O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C:3](=O)[C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H:3]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.08
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2[C:2](=O)O[C@H:4]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2[C:2](=O)O)O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@H:4](O)[C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1,hydrolysis_(ester),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H:4]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.08
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H:1]2C(=O)O[C@H:4]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[CH2:1]2)O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C:4](=O)[C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1,oxidative ester cleavage,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H:4]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.08
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@@H](C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH3:1])CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@@H](C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH2:1]O)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@@H](C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH3:1])CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.01
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@@H](C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH3:2])CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@@H](C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[C:2](=O)O)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,carboxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@@H](C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH3:2])CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.01
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@@H](C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH3:2])CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@@H](C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH2:2]O)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic_hydroxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@@H](C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH3:2])CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.01
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H:1](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@@:1](C)(O)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H:1](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.01
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H:1]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@:1]2(O)CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H:1]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.02
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H:1](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@:1](O)(OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H:1](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.07
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H:3](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C:3](=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H:3](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.07
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H:1](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@:1](O)(OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H:1](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.11
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H:3](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C:3](=O)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H:3](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.11
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH2:2]C(=O)[C@H:1](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)OC([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)=[CH2:2])O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[CH2:1]C,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H:1](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H:1](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@@:1](C)(O)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H:1](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH2:1]C(=O)[C@H:2](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,C=[CH:2]/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH3:1])O1)OC,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H:2](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH2:1]C(=O)[C@H:2](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH3:1])O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)C(C)=C=[CH:2]C,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H:2](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H:2](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@@:2](C)(O)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H:2](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H:1](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C:1](O)(O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H:1](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.13
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H:2](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,COC1=[CH:2]/C(C)=C/[C@@H](C)C(=O)C[C@@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H](CC[C@H]2C)C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C1=O,dehydration_next_to_SP2_both_sides,Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H:2](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.13
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H:1](OC)C(=O)[C@H:2](C)C[C@H](C)/C=C/C=C/C=C/1C,C=[CH:2]C[C@H](C)/C=C/C=C/C=C(\C)[C@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H](CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[CH2:1]OC)[C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)O1)OC,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H:1](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.07
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H:1](OC)C(=O)[C@H:2](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H](CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[CH2:1]OC)[C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)O1)/C(C)=C/C=C/C=C/[C@@H](C)C=[CH:2]C,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H:1](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.07
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H:1](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@:1](O)(OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H:1](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.07
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H:2](OC)C(=O)[C@H:1](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H](CC(=O)[C@H](C)/C=C(\C)C(O)=[CH:2]OC)[C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)O1)/C(C)=C/C=C/C=C/[C@@H](C)C[CH2:1]C,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H:2](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.07
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H:3](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C:3](=O)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H:3](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.07
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H:2](OC)C(=O)[C@H:1](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H](CC(=O)[C@H](C)/C=C(\C)C(O)=[CH:2]OC)[C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)O1)/C(C)=C/C=C/C=C/[C@@H](C)C[CH2:1]C,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H:1](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H:1](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@@:1](C)(O)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H:1](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H:1](OC)C(=O)[C@H:2](C)C[C@H](C)/C=C/C=C/C=C/1C,C=[CH:2]C[C@H](C)/C=C/C=C/C=C(\C)[C@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H](CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[CH2:1]OC)[C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)O1)OC,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H:2](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H:1](OC)C(=O)[C@H:2](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H](CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[CH2:1]OC)[C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)O1)/C(C)=C/C=C/C=C/[C@@H](C)C=[CH:2]C,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H:2](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H:2](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@@:2](C)(O)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H:2](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)[C:3](=O)[C@H](C)C[C@H:1](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H](CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)[CH:3]=O)[C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)O1)/C(C)=C/C=C/C=C/[CH2:1]C,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H:1](C)/C=C/C=C/C=C/1C,0.1
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H:1](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@@:1](C)(O)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H:1](C)/C=C/C=C/C=C/1C,0.1
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H:2](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@@:2](C)(O)/C=C/C=C/C=C/1C,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H:2](C)/C=C/C=C/C=C/1C,0.1
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1[CH3:1],CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1[CH2:1]O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1[CH3:1],0.12
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1[CH3:2],CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1[C:2](=O)O,carboxylation_(primary_carbon_next_to_SP2),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1[CH3:2],0.12
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1[CH3:2],CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1[CH2:2]O,aliphatic_hydroxylation_(primary_carbon_next_to_SP2_or_SP1),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1[CH3:2],0.12
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/[CH:1]=[C:2]/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/[CH:1]2O[C:2]12C,epoxidation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=[C:2]/1C,0.05
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/[CH:1]=C/1C,C=C1[C@@H](OC)C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/[CH:1]1O,aliphatic hydroxylation with allylic rearrangement 1,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/[CH:1]=C/1C,0.11
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/[CH:1]=C/1C,COC1=C(C)[CH:1](O)/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H](CC[C@H]2C)C1,aliphatic hydroxylation with allylic rearrangement 1,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/[CH:1]=C/1C,0.11
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/[CH:1]=[C:2]/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/[CH:1]2O[C:2]12C,epoxidation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/[CH:1]=C/1C,0.11
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/[CH:1]=[CH:2]/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/[CH:1]2O[CH:2]2/C=C/1C,epoxidation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=[CH:2]/C=C/1C,0.07
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/[CH:1]=[CH:2]/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/[CH:1]2O[CH:2]2/C=C/1C,epoxidation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/[CH:1]=C/C=C/1C,0.12
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=[CH:1]/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)CC(C)=C[CH:1](O)/C=C/C=C/1C,aliphatic hydroxylation with allylic rearrangement 1,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=[CH:1]/C=C/C=C/1C,0.1
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/[CH:1]=[CH:2]/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)[CH:1]2O[CH:2]2/C=C/C=C/1C,epoxidation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=[CH:2]/C=C/C=C/1C,0.1
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/[CH:1]=[CH:2]/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)[CH:1]2O[CH:2]2/C=C/C=C/1C,epoxidation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/[CH:1]=C/C=C/C=C/1C,0.11
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H]([CH3:1])/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H]([CH2:1]O)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H]([CH3:1])/C=C/C=C/C=C/1C,0.07
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H]([CH3:2])/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H]([C:2](=O)O)/C=C/C=C/C=C/1C,carboxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H]([CH3:2])/C=C/C=C/C=C/1C,0.07
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H]([CH3:2])/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H]([CH2:2]O)/C=C/C=C/C=C/1C,aliphatic_hydroxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H]([CH3:2])/C=C/C=C/C=C/1C,0.07
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)[C:3](=O)[C@H](C)[CH2:1][C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H](CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)[CH:3]=O)[C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)O1)/C(C)=C/C=C/C=C/[C@@H](C)[CH3:1],deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)[CH2:1][C@H](C)/C=C/C=C/C=C/1C,0.02
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)[CH2:1][C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)[CH:1](O)[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)[CH2:1][C@H](C)/C=C/C=C/C=C/1C,0.02
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H]([CH3:1])C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H]([CH2:1]O)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H]([CH3:1])C[C@H](C)/C=C/C=C/C=C/1C,0.05
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H]([CH3:2])C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H]([C:2](=O)O)C[C@H](C)/C=C/C=C/C=C/1C,carboxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H]([CH3:2])C[C@H](C)/C=C/C=C/C=C/1C,0.05
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H]([CH3:2])C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H]([CH2:2]O)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic_hydroxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H]([CH3:2])C[C@H](C)/C=C/C=C/C=C/1C,0.05
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)[C:3](=O)[C@H](C)[CH2:1][C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H](CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)[CH:3]=O)[C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)O1)/C(C)=C/C=C/C=C/[C@@H](C)[CH3:1],deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)[C:3](=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.12
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)[C:3](=O)[C@H](C)C[C@H:1](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H](CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)[CH:3]=O)[C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)O1)/C(C)=C/C=C/C=C/[CH2:1]C,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)[C:3](=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.12
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=[C:1](\C)[C@@H](O)[C@@H](OC)[C:3](=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H](CC(=O)[C@H](C)/C=[CH:1]\C)[C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)[CH:3]=O,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)[C:3](=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.12
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](O[CH3:1])C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](O[CH2:1]O)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](O[CH3:1])C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.22
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H]([O:2]C)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H]([OH:2])C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H]([O:2]C)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.02
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H]([OH:2])[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H]([O:2]C2OC(C(=O)O)C(O)C(O)C2O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H]([OH:2])[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.24
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H]([OH:2])[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H]([O:2]S(=O)(=O)O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H]([OH:2])[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.34
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\[CH3:1])[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\[CH2:1]O)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\[CH3:1])[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\[CH3:2])[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\[C:2](=O)O)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,carboxylation_(primary_carbon_next_to_SP2),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\[CH3:2])[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\[CH3:2])[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\[CH2:2]O)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic_hydroxylation_(primary_carbon_next_to_SP2_or_SP1),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\[CH3:2])[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=[C:1](\C)[C@@H](O)[C@@H](OC)[C:3](=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H](CC(=O)[C@H](C)/C=[CH:1]\C)[C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)[CH:3]=O,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=[C:1](\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.05
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)C[C:3](=O)[C@H](C)/C=[C:1](\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H](C[CH:3]=O)[C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)[CH2:1]C,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=[C:1](\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.05
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=[C:1](\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)C(C)=C[C:1](C)(O)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation with allylic rearrangement 1,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=[C:1](\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.05
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/[CH:1]=[C:2](\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)[CH:1]2O[C:2]2(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,epoxidation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=[C:2](\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.05
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/[CH:1]=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,C=C1[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H](OC)C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)[CH:1]1O,aliphatic hydroxylation with allylic rearrangement 1,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/[CH:1]=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.02
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)C[C:3](=O)[C@H](C)/[CH:1]=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H](C[CH:3]=O)[C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)C(C)=[CH2:1],deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/[CH:1]=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.02
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/[CH:1]=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H](OC)C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)[CH:1](O)C(C)=C1O,aliphatic hydroxylation with allylic rearrangement 1,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/[CH:1]=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.02
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/[CH:1]=[C:2](\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)[CH:1]2O[C:2]2(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,epoxidation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/[CH:1]=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.02
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H]([CH3:1])/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H]([CH2:1]O)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H]([CH3:1])/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.05
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H]([CH3:2])/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H]([C:2](=O)O)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,carboxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H]([CH3:2])/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.05
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H]([CH3:2])/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H]([CH2:2]O)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic_hydroxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H]([CH3:2])/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.05
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)C[C:3](=O)[C@H](C)/[CH:1]=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H](C[CH:3]=O)[C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)C(C)=[CH2:1],deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)C[C:3](=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.02
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)C[C:3](=O)[C@H](C)/C=[C:1](\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H](C[CH:3]=O)[C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)[CH2:1]C,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)C[C:3](=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.02
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)[O:1][C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)C[C:3](=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)[OH:1])O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)[CH:3]=O,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)C[C:3](=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.02
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH2:1]C(=O)[C@H:2](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,C=[CH:2]/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH3:1])O1)OC,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH2:1]C(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH2:1]C(=O)[C@H:2](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH3:1])O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)C(C)=C=[CH:2]C,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH2:1]C(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)[O:2][C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH2:1]C(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)[OH:2])O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)[CH3:1],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH2:1]C(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)[O:3][C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH2:1]C(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)[OH:3])O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)[CH3:1],oxidative ester cleavage,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH2:1]C(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH2:1]C(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH:1](O)C(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH2:1]C(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH2:2]C(=O)[C@H:1](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)OC([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)=[CH2:2])O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[CH2:1]C,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH2:2]C(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH2:2]C(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH:2](O)C(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH2:2]C(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)[CH2:1]2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)[CH:1]2O)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)[CH2:1]2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](O[CH3:1])C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](O[CH2:1]O)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](O[CH3:1])C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.58
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H]([O:2]C)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H]([OH:2])C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H]([O:2]C)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.01
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCC[OH:2])[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCC[O:2]C3OC(C(=O)O)C(O)C(O)C3O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCC[OH:2])[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.53
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCC[OH:2])[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCC[O:2]S(=O)(=O)O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCC[OH:2])[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.73
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC[CH2:1]O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC[CH:1](O)O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC[CH2:1]O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.31
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC[CH2:2]O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC[C:2](=O)O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,primary_alcohol_oxidation_(aliphatic),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC[CH2:2]O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.31
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O[CH2:1]CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O[CH:1](O)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O[CH2:1]CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.2
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O[CH2:3]CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C.OC[CH2:3]O,O-dealkylation_(aliphatic),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O[CH2:3]CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.2
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O[CH2:3]CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,O=[CH:3]CO,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O[CH2:3]CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.2
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H]([O:2]CCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H]([OH:2])[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H]([O:2]CCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.02
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H]([O:2]CCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,OCC[OH:2],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H]([O:2]CCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.02
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@H]2C[C@@H](OC)[C@H](OCCO)C[CH2:1]2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@H]2C[C@@H](OC)[C@H](OCCO)C[CH:1]2O)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@H]2C[C@@H](OC)[C@H](OCCO)C[CH2:1]2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.04
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@H]2C[C@@H](OC)[C@H](OCCO)[CH2:1]C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@H]2C[C@@H](OC)[C@H](OCCO)[CH:1](O)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@H]2C[C@@H](OC)[C@H](OCCO)[CH2:1]C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.02
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@H]2C[C@@H](OC)[C@H](OCCO)[CH2:2]C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@H]2C[C@@H](OC)[C@H](OCCO)[CH:2](O)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic_hydroxylation_(sec_carbon_in_a_ringB),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@H]2C[C@@H](OC)[C@H](OCCO)[CH2:2]C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.02
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)[CH2:1][C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)[CH:1](O)[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)[CH2:1][C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.0
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H:2]2C(=O)[O:1][C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC=[CH:2]2)O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@@H]([C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1)[OH:1],deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)[O:1][C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.01
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)[O:1][C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)C[C:3](=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)[OH:1])O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)[CH:3]=O,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)[O:1][C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.01
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)[O:2][C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH2:1]C(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)[OH:2])O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)[CH3:1],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)[O:2][C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.01
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)[O:3][C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)[CH2:1]C(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2C(=O)[OH:3])O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)[CH3:1],oxidative ester cleavage,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)[O:3][C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.01
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)[N:1]2CCC[CH2:1][C@H]2[C:1](=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)[NH:1]CCC[CH3:1])O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@H](O[CH:1]=O)[C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1,N-dealkylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2[C:1](=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.17
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2[C:2](=O)O[C@H:4]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)N2CCCC[C@H]2[C:2](=O)O)O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@H:4](O)[C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1,hydrolysis_(ester),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2[C:2](=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.17
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)[N:1]2CC[CH2:1]C[C@H]2[C:3](=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)[NH:1]CC[CH3:1])O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@H](O[CH:3]=O)[C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2[C:3](=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.17
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCC[CH2:1][C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCC[CH:1](O)[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCC[CH2:1][C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.0
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCC[CH2:2][C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCC[CH:2](O)[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic_hydroxylation_(sec_carbon_in_a_ringB),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCC[CH2:2][C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.0
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)[N:1]2CC[CH2:1]C[C@H]2[C:3](=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)C(=O)[NH:1]CC[CH3:1])O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@H](O[CH:3]=O)[C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1,deformylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CC[CH2:1]C[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.01
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CC[CH2:1]C[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CC[CH:1](O)C[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CC[CH2:1]C[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.01
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CC[CH2:2]C[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CC[CH:2](O)C[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic_hydroxylation_(sec_carbon_in_a_ringA),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CC[CH2:2]C[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.01
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2C[CH2:1]CC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2C[CH:1](O)CC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2C[CH2:1]CC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.0
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)[N:1]2C[CH2:1]CC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)[NH:1][C@@H](CC[CH3:1])C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,N-dealkylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2C[CH2:1]CC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.0
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2C[CH2:2]CC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2C[CH:2](O)CC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic_hydroxylation_(sec_carbon_in_a_ringA),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2C[CH2:2]CC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.0
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)[C:1](=O)N2[CH2:1]CCC[C@H:2]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)[CH:1]=O)O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@H](OC(=O)[C:2](=O)CCC[CH3:1])[C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1,N-dealkylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2[C@@H](CCC[CH2:1]2)C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.02
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2[C@@H](CCC[CH2:1]2)C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2[C@@H](CCC[CH:1]2O)C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2[C@@H](CCC[CH2:1]2)C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.02
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)[C:1](=O)N2[C@@H:1](CCC[CH2:2]2)C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)[CH:1]=O)O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@H](OC(=O)[CH2:1]CCC[CH:2]=O)[C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1,N-dealkylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2[C@@H](CCC[CH2:2]2)C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.02
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2[C@@H](CCC[CH2:2]2)C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2[C@@H](CCC[C:2]2=O)C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,oxidation_(amine_in_a_ring),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2[C@@H](CCC[CH2:2]2)C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.02
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2[C@@H](CCC[CH2:2]2)C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2[C@@H](CCC[CH:2]2O)C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2[C@@H](CCC[CH2:2]2)C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.02
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)[N:1]2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)[N+:1]2([O-])CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,N-oxidation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)[N:1]2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.0
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)[C:2](=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C@@H]1CC[C@@H](C)[C@](O)(C(=O)[C:2](=O)O)O1)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@H](OC(=O)[C@@H]1CCCCN1)[C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1,hydrolysis_(tertiary_amide),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)[C:2](=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.01
Everolimus,CO[C@H]1C[C@@H:3]2CC[C@@H:1](C)[C@@](O)(O2)[C:1](=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@@H](C[C:3](=O)CC[CH2:1]C)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@H](OC(=O)[C@@H]1CCCCN1C(=O)[CH:1]=O)[C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)[C:1](=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.03
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@]([OH:2])(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@]([O:2]C3OC(C(=O)O)C(O)C(O)C3O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@]([OH:2])(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.22
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@]([OH:2])(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@]([O:2]S(=O)(=O)O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@]([OH:2])(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.26
Everolimus,CO[C@@H]1/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@@]2(O)[C@H](C)C[CH2:1][C@@H]([CH2:1]1)[O:2]2,CO[C@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@H](OC(=O)[C@@H]1CCCCN1C(=O)C(=O)[C@@](O)([C@H](C)C[CH3:1])[OH:2])[C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1)[CH3:1],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H](C)[C@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H]([C@H](C)C[C@@H]3CC[C@@H](OCCO)[C@H](OC)C3)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C)[O:2]2,0.01
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H]([CH3:1])[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H]([CH2:1]O)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2CC[C@@H]([CH3:1])[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.09
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H]([CH3:2])[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H]([C:2](=O)O)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,carboxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H]([CH3:2])[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.09
Everolimus,CO[C@H]1C[C@@H]2CC[C@@H]([CH3:2])[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2CC[C@@H]([CH2:2]O)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic_hydroxylation_(primary_carbon_next_to_tert_carbon),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2CC[C@@H]([CH3:2])[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.09
Everolimus,CO[C@H]1C[C@@H]2C[CH2:1][C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2C[CH:1](O)[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@@H]2C[CH2:1][C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.08
Everolimus,CO[C@H]1C[C@@H]2C[CH2:2][C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CO[C@H]1C[C@@H]2C[CH:2](O)[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,aliphatic_hydroxylation_(sec_carbon_in_a_ringB),Phase 1 SyGMa rules,CO[C@H]1C[C@@H]2C[CH2:2][C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0.08
Everolimus,CO[C@@H]1/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@@]2(O)[C@H](C)C[CH2:1][C@@H]([CH2:1]1)[O:2]2,CO[C@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@H](OC(=O)[C@@H]1CCCCN1C(=O)C(=O)[C@@](O)([C@H](C)C[CH3:1])[OH:2])[C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1)[CH3:1],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),CO[C@H]1C[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H]([C@H](C)C[C@@H]3CC[C@@H](OCCO)[C@H](OC)C3)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C)[C@H](C)C[CH2:1]2,0.1
Everolimus,CO[C@H]1C[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H]([C@H](C)C[C@@H]3CC[C@@H](OCCO)[C@H](OC)C3)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C)[C@H](C)C[CH2:1]2,CO[C@H]1C[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H]([C@H](C)C[C@@H]3CC[C@@H](OCCO)[C@H](OC)C3)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C)[C@H](C)C[CH:1]2O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),CO[C@H]1C[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H]([C@H](C)C[C@@H]3CC[C@@H](OCCO)[C@H](OC)C3)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C)[C@H](C)C[CH2:1]2,0.1
Everolimus,CO[C@H]1C[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H]([C@H](C)C[C@@H]3CC[C@@H](OCCO)[C@H](OC)C3)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C)[C@H](C)C[CH2:2]2,CO[C@H]1C[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H]([C@H](C)C[C@@H]3CC[C@@H](OCCO)[C@H](OC)C3)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C)[C@H](C)C[CH:2]2O,aliphatic_hydroxylation_(sec_carbon_in_a_ringB),Phase 1 SyGMa rules,CO[C@H]1C[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H]([C@H](C)C[C@@H]3CC[C@@H](OCCO)[C@H](OC)C3)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C)[C@H](C)C[CH2:2]2,0.1
Esomeprazole,COc1c(C)cnc(C[S@+]([O-])c2nc3c(ccc(OC)[cH:1]3)[nH]2)c1C,COc1c(C)cnc(C[S@+]([O-])c2nc3c(ccc(OC)[c:1]3O)[nH]2)c1C,aromatic hydroxylation,CYP rules from GLORY (phase 1),COc1c(C)cnc(C[S@+]([O-])c2nc3c(ccc(OC)[cH:1]3)[nH]2)c1C,0.12
Esomeprazole,COc1c(C)cnc(C[S@+]([O-])c2nc3c(ccc(OC)[cH:3]3)[nH]2)c1C,COc1c(C)cnc(C[S@+]([O-])c2nc3c(ccc(OC)[c:3]3O)[nH]2)c1C,aromatic_hydroxylation_(ortho_to_2_substituents),Phase 1 SyGMa rules,COc1c(C)cnc(C[S@+]([O-])c2nc3c(ccc(OC)[cH:3]3)[nH]2)c1C,0.12
Esomeprazole,COc1c(C)cnc(C[S@+]([O-])c2nc3cc(OC)[cH:1]cc3[nH]2)c1C,COc1c(C)cnc(C[S@+]([O-])c2nc3cc(OC)[c:1](O)cc3[nH]2)c1C,aromatic hydroxylation,CYP rules from GLORY (phase 1),COc1c(C)cnc(C[S@+]([O-])c2nc3cc(OC)[cH:1]cc3[nH]2)c1C,0.2
Esomeprazole,COc1c(C)cnc(C[S@+]([O-])c2nc3cc(OC)[cH:5]cc3[nH]2)c1C,COc1c(C)cnc(C[S@+]([O-])c2nc3cc(OC)[c:5](O)cc3[nH]2)c1C,aromatic_hydroxylation_(para_to_nitrogen),Phase 1 SyGMa rules,COc1c(C)cnc(C[S@+]([O-])c2nc3cc(OC)[cH:5]cc3[nH]2)c1C,0.2
Esomeprazole,COc1c(C)cnc(C[S@+]([O-])c2nc3cc(O[CH3:1])ccc3[nH]2)c1C,COc1c(C)cnc(C[S@+]([O-])c2nc3cc(O[CH2:1]O)ccc3[nH]2)c1C,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COc1c(C)cnc(C[S@+]([O-])c2nc3cc(O[CH3:1])ccc3[nH]2)c1C,0.67
Esomeprazole,COc1c(C)cnc(C[S@+]([O-])c2nc3cc([O:2]C)ccc3[nH]2)c1C,COc1c(C)cnc(C[S@+]([O-])c2nc3cc([OH:2])ccc3[nH]2)c1C,O-demethylation,Phase 1 SyGMa rules,COc1c(C)cnc(C[S@+]([O-])c2nc3cc([O:2]C)ccc3[nH]2)c1C,0.0
Osimertinib,COc1cc(N(C)CCN(C)C)c(NC(=O)C=[CH2:1])cc1Nc1nccc(-c2cn(C)c3ccccc23)n1,COc1cc(N(C)CCN(C)C)c(NC(=O)C[CH2:1]SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)cc1Nc1nccc(-c2cn(C)c3ccccc23)n1,"glutathione_conjugation_(alpha,beta-unsaturated_carbonyl)",GST rules (phase 2),COc1cc(N(C)CCN(C)C)c(NC(=O)C=[CH2:1])cc1Nc1nccc(-c2cn(C)c3ccccc23)n1,0.99
Osimertinib,COc1cc(N(C)CCN(C)C)c(NC(=O)[CH:1]=[CH2:2])cc1Nc1nccc(-c2cn(C)c3ccccc23)n1,COc1cc(N(C)CCN(C)C)c(NC(=O)[CH:1](O)[CH2:2]O)cc1Nc1nccc(-c2cn(C)c3ccccc23)n1,vinyl_oxidation,Phase 1 SyGMa rules,COc1cc(N(C)CCN(C)C)c(NC(=O)C=[CH2:2])cc1Nc1nccc(-c2cn(C)c3ccccc23)n1,0.09
Osimertinib,COc1cc(N(C)CCN(C)C)c(NC(=O)[CH:1]=[CH2:2])cc1Nc1nccc(-c2cn(C)c3ccccc23)n1,COc1cc(N(C)CCN(C)C)c(NC(=O)[CH:1]2O[CH2:2]2)cc1Nc1nccc(-c2cn(C)c3ccccc23)n1,epoxidation,CYP rules from GLORY (phase 1),COc1cc(N(C)CCN(C)C)c(NC(=O)C=[CH2:2])cc1Nc1nccc(-c2cn(C)c3ccccc23)n1,0.09
Esomeprazole,COc1cc2nc([S@@+]([O-])Cc3ncc(C)c(OC)c3C)[nH]c2[cH:1]c1,COc1cc2nc([S@@+]([O-])Cc3ncc(C)c(OC)c3C)[nH]c2[c:1](O)c1,aromatic hydroxylation,CYP rules from GLORY (phase 1),COc1cc2nc([S@@+]([O-])Cc3ncc(C)c(OC)c3C)[nH]c2[cH:1]c1,0.05
Esomeprazole,COc1cc2nc([S@@+]([O-])Cc3ncc(C)c(OC)c3C)[nH]c2[cH:3]c1,COc1cc2nc([S@@+]([O-])Cc3ncc(C)c(OC)c3C)[nH]c2[c:3](O)c1,aromatic_hydroxylation_(ortho_to_nitrogen),Phase 1 SyGMa rules,COc1cc2nc([S@@+]([O-])Cc3ncc(C)c(OC)c3C)[nH]c2[cH:3]c1,0.05
Apixaban,C[O:7]c1cc[c:4](-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,O=[C:4]1C=CC(=[O:7])C=C1,oxidation of 4-substituted anisole to quinone,CYP rules from GLORY (phase 1),COc1cc[c:4](-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,0.02
Apixaban,COc1ccc(-[n:1]2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,COc1ccc([N+:1]2([O-])N=C(C(N)=O)C3=C2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,N-oxidation,CYP rules from GLORY (phase 1),COc1ccc(-[n:1]2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,0.02
Apixaban,COc1ccc(-n2c3c(c(C(N)=O)[n:1]2)CCN(c2ccc(N4CCCCC4=O)cc2)C3=O)cc1,COc1ccc(-n2c3c(c(C(N)=O)[n+:1]2C2OC(C(=O)O)C(O)C(O)C2O)CCN(c2ccc(N4CCCCC4=O)cc2)C3=O)cc1,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),COc1ccc(-n2c3c(c(C(N)=O)[n:1]2)CCN(c2ccc(N4CCCCC4=O)cc2)C3=O)cc1,0.02
Apixaban,COc1ccc(-n2nc(C(=O)[NH2:1])c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,COc1ccc(-n2nc(C(=O)[NH:1]O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,amine hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(=O)[NH2:1])c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,0.03
Apixaban,COc1ccc(-n2nc(C(=O)[NH2:2])c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,COc1ccc(-n2nc(C(=O)[NH:2]C3OC(C(=O)O)C(O)C(O)C3O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,N-glucuronidation_(aliphatic_NH2),UGT rules (phase 2),COc1ccc(-n2nc(C(=O)[NH2:2])c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,0.01
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4C(=O)CCC[CH2:1]4)cc2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4C(=O)CCC[CH:1]4O)cc2)CC3)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4C(=O)CCC[CH2:1]4)cc2)CC3)cc1,0.88
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4C(=O)CCC[CH2:2]4)cc2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4C(=O)CCC[C:2]4=O)cc2)CC3)cc1,oxidation_(amine_in_a_ring),Phase 1 SyGMa rules,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4C(=O)CCC[CH2:2]4)cc2)CC3)cc1,0.88
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4C(=O)CCC[CH2:2]4)cc2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4C(=O)CCC[CH:2]4O)cc2)CC3)cc1,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4C(=O)CCC[CH2:2]4)cc2)CC3)cc1,0.88
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4[C:1](=O)CCC[CH2:2]4)cc2)CC3)cc1,O=[CH:1]CCC[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4C(=O)CCC[CH2:2]4)cc2)CC3)cc1,0.88
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)[cH:1]c2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)[c:1](O)c2)CC3)cc1,aromatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)[cH:1]c2)CC3)cc1,0.01
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)[cH:3]c2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)[c:3](O)c2)CC3)cc1,aromatic_hydroxylation_(ortho_to_nitrogen),Phase 1 SyGMa rules,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)[cH:3]c2)CC3)cc1,0.01
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)c[cH:1]2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)c[c:1]2O)CC3)cc1,aromatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)c[cH:1]2)CC3)cc1,0.0
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)c[cH:3]2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)c[c:3]2O)CC3)cc1,aromatic_hydroxylation_(ortho_to_nitrogen),Phase 1 SyGMa rules,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)c[cH:3]2)CC3)cc1,0.0
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)[cH:1]c1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)[c:1](O)c1,aromatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)[cH:1]c1,0.03
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)[cH:3]c1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)[c:3](O)c1,aromatic_hydroxylation_(ortho_to_nitrogen),Phase 1 SyGMa rules,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)[cH:3]c1,0.03
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)c[cH:1]1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)c[c:1]1O,aromatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)c[cH:1]1,0.01
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)c[cH:3]1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)c[c:3]1O,aromatic_hydroxylation_(ortho_to_oxygen),Phase 1 SyGMa rules,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)c[cH:3]1,0.01
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)C[CH2:1]3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)C[CH:1]3O)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)C[CH2:1]3)cc1,0.01
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)C[CH2:2]3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)C[CH:2]3O)cc1,benzylic_hydroxylation_(c-CH2-CR),Phase 1 SyGMa rules,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)C[CH2:2]3)cc1,0.01
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)[CH2:1]C3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)[CH:1](O)C3)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)[CH2:1]C3)cc1,0.08
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2[C:1](=O)N(c2ccc(N4CCCCC4=O)cc2)[CH2:2]C3)cc1,COc1ccc(-n2nc(C(N)=O)c(C[CH:2]=O)c2[CH:1]=O)cc1,N-dealkylation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)[CH2:2]C3)cc1,0.08
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)[CH2:2]C3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)[C:2](=O)C3)cc1,oxidation_(amine_in_a_ring),Phase 1 SyGMa rules,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)[CH2:2]C3)cc1,0.08
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)[CH2:2]C3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)[CH:2](O)C3)cc1,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)[CH2:2]C3)cc1,0.08
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4[C:1](=O)CCC[CH2:2]4)cc2)CC3)cc1,O=[CH:1]CCC[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCC[C:1]4=O)cc2)CC3)cc1,0.81
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCC[C:2]4=O)cc2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(NCCCC[C:2](=O)O)cc2)CC3)cc1,hydrolysis_(tertiary_amide),Phase 1 SyGMa rules,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCC[C:2]4=O)cc2)CC3)cc1,0.81
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4C[CH2:1]CC[C:3]4=O)cc2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N(C[CH3:1])[CH:3]=O)cc2)CC3)cc1,deformylation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCC[C:3]4=O)cc2)CC3)cc1,0.81
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCC[CH2:1]C4=O)cc2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCC[CH:1](O)C4=O)cc2)CC3)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCC[CH2:1]C4=O)cc2)CC3)cc1,0.7
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCC[CH2:2]C4=O)cc2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCC[CH:2](O)C4=O)cc2)CC3)cc1,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCC[CH2:2]C4=O)cc2)CC3)cc1,0.7
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc([N:1]4CCC[CH2:2]C4=O)cc2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc([NH:1]CCC=[CH2:2])cc2)CC3)cc1,deformylation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCC[CH2:2]C4=O)cc2)CC3)cc1,0.7
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CC[CH2:1]CC4=O)cc2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CC[CH:1](O)CC4=O)cc2)CC3)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CC[CH2:1]CC4=O)cc2)CC3)cc1,0.71
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CC[CH2:2]CC4=O)cc2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CC[CH:2](O)CC4=O)cc2)CC3)cc1,aliphatic_hydroxylation_(sec_carbon_in_a_ringA),Phase 1 SyGMa rules,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CC[CH2:2]CC4=O)cc2)CC3)cc1,0.71
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4C[CH2:1]CC[C:3]4=O)cc2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N(C[CH3:1])[CH:3]=O)cc2)CC3)cc1,deformylation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4C[CH2:1]CCC4=O)cc2)CC3)cc1,0.73
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4C[CH2:1]CCC4=O)cc2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4C[CH:1](O)CCC4=O)cc2)CC3)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4C[CH2:1]CCC4=O)cc2)CC3)cc1,0.73
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc([N:1]4C[CH2:1]CCC4=O)cc2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc([NH:1]C(=O)CC[CH3:1])cc2)CC3)cc1,N-dealkylation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4C[CH2:1]CCC4=O)cc2)CC3)cc1,0.73
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4C[CH2:2]CCC4=O)cc2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4C[CH:2](O)CCC4=O)cc2)CC3)cc1,aliphatic_hydroxylation_(sec_carbon_in_a_ringA),Phase 1 SyGMa rules,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4C[CH2:2]CCC4=O)cc2)CC3)cc1,0.73
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc([N:1]4CCCCC4=O)cc2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc([N+:1]4([O-])CCCCC4=O)cc2)CC3)cc1,N-oxidation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc([N:1]4CCCCC4=O)cc2)CC3)cc1,0.01
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc([N:1]4CCC[CH2:2]C4=O)cc2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc([NH:1]CCC=[CH2:2])cc2)CC3)cc1,deformylation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc([N:1]4CCCCC4=O)cc2)CC3)cc1,0.01
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)[N:1](c2ccc(N4CCCCC4=O)cc2)C[CH2:1]3)cc1,COc1ccc(-n2nc(C(N)=O)c([CH3:1])c2C(=O)[NH:1]c2ccc(N3CCCCC3=O)cc2)cc1,N-dealkylation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2C(=O)[N:1](c2ccc(N4CCCCC4=O)cc2)CC3)cc1,0.01
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)[N:1](c2ccc(N4CCCCC4=O)cc2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)[N+:1]([O-])(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,N-oxidation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2C(=O)[N:1](c2ccc(N4CCCCC4=O)cc2)CC3)cc1,0.01
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2[C:1](=O)N(c2ccc(N4CCCCC4=O)cc2)[CH2:2]C3)cc1,COc1ccc(-n2nc(C(N)=O)c(C[CH:2]=O)c2[CH:1]=O)cc1,N-dealkylation,CYP rules from GLORY (phase 1),COc1ccc(-n2nc(C(N)=O)c3c2[C:1](=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,0.09
Apixaban,COc1ccc(-n2nc(C(N)=O)c3c2[C:2](=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,COc1ccc(-n2nc(C(N)=O)c(CCNc3ccc(N4CCCCC4=O)cc3)c2[C:2](=O)O)cc1,hydrolysis_(tertiary_amide),Phase 1 SyGMa rules,COc1ccc(-n2nc(C(N)=O)c3c2[C:2](=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,0.09
Apixaban,COc1ccc(-n2nc([C:2](N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,COc1ccc(-n2nc([C:2](=O)O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,hydrolysis_(primary_amide),Phase 1 SyGMa rules,COc1ccc(-n2nc([C:2](N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,0.68
Formoterol,COc1ccc(CC(C)NCC(O)[c:4]2ccc(O)c(NC=O)c2)cc1,COc1ccc(CC(C)NCC(O)[C:4]2(O)C=CC(=O)C(NC=O)=C2)cc1,oxidation of 4-substituted phenol to quinone (substituent not a leaving group),CYP rules from GLORY (phase 1),COc1ccc(CC(C)NCC(O)[c:4]2ccc(O)c(NC=O)c2)cc1,0.01
Formoterol,COc1ccc(CC(C)NCC(O)c2cc(NC=O)c(O)[cH:1]c2)cc1,COc1ccc(CC(C)NCC(O)c2cc(NC=O)c(O)[c:1](O)c2)cc1,aromatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(CC(C)NCC(O)c2cc(NC=O)c(O)[cH:1]c2)cc1,0.08
Formoterol,COc1ccc(CC(C)NCC(O)c2cc(NC=O)c(O)[cH:3]c2)cc1,COc1ccc(CC(C)NCC(O)c2cc(NC=O)c(O)[c:3](O)c2)cc1,aromatic_hydroxylation_(ortho_to_oxygen),Phase 1 SyGMa rules,COc1ccc(CC(C)NCC(O)c2cc(NC=O)c(O)[cH:3]c2)cc1,0.08
Formoterol,COc1ccc(CC(C)NCC(O)c2cc(NC=O)c(O)c[cH:1]2)cc1,COc1ccc(CC(C)NCC(O)c2cc(NC=O)c(O)c[c:1]2O)cc1,aromatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(CC(C)NCC(O)c2cc(NC=O)c(O)c[cH:1]2)cc1,0.02
Formoterol,COc1ccc(CC(C)NCC(O)c2cc(NC=O)c(O)c[cH:5]2)cc1,COc1ccc(CC(C)NCC(O)c2cc(NC=O)c(O)c[c:5]2O)cc1,aromatic_hydroxylation_(para_to_nitrogen),Phase 1 SyGMa rules,COc1ccc(CC(C)NCC(O)c2cc(NC=O)c(O)c[cH:5]2)cc1,0.02
Formoterol,COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)[cH:1]2)cc1,COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)[c:1]2O)cc1,aromatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)[cH:1]2)cc1,0.03
Formoterol,COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)[cH:3]2)cc1,COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)[c:3]2O)cc1,aromatic_hydroxylation_(ortho_to_2_substituents),Phase 1 SyGMa rules,COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)[cH:3]2)cc1,0.03
Formoterol,COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)[cH:1]c1,COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)[c:1](O)c1,aromatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)[cH:1]c1,0.0
Formoterol,COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)c[cH:1]1,COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)c[c:1]1O,aromatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)c[cH:1]1,0.03
Formoterol,COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)c[cH:3]1,COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)c[c:3]1O,aromatic_hydroxylation_(ortho_to_oxygen),Phase 1 SyGMa rules,COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)c[cH:3]1,0.03
Formoterol,COc1ccc(CC(C)NCC(O)c2ccc(O)c(N[CH:1]=O)c2)cc1,COc1ccc(CC(C)NCC(O)c2ccc(O)c(N[C:1](=O)O)c2)cc1,aldehyde oxidation,CYP rules from GLORY (phase 1),COc1ccc(CC(C)NCC(O)c2ccc(O)c(N[CH:1]=O)c2)cc1,0.35
Formoterol,COc1ccc(CC(C)NCC(O)c2ccc(O)c(N[CH:2]=O)c2)cc1,O=[C:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),COc1ccc(CC(C)NCC(O)c2ccc(O)c(N[CH:2]=O)c2)cc1,0.35
Formoterol,COc1ccc(CC(C)NCC(O)c2ccc(O)c([NH:1]C=O)c2)cc1,COc1ccc(CC(C)NCC(O)c2ccc(O)c([N:1](O)C=O)c2)cc1,amine hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(CC(C)NCC(O)c2ccc(O)c([NH:1]C=O)c2)cc1,0.11
Formoterol,COc1ccc(CC(C)NCC(O)c2ccc(O)c([NH:1]C=O)c2)cc1,COc1ccc(CC(C)NCC(O)c2ccc(O)c([NH2:1])c2)cc1,N-dealkylation,CYP rules from GLORY (phase 1),COc1ccc(CC(C)NCC(O)c2ccc(O)c([NH:1]C=O)c2)cc1,0.11
Formoterol,COc1ccc(CC(C)NCC(O)c2ccc(O)c([NH:2]C=O)c2)cc1,COc1ccc(CC(C)NCC(O)c2ccc(O)c([N:2](C=O)C3OC(C(=O)O)C(O)C(O)C3O)c2)cc1,N-glucuronidation_(aniline_NH1-R),UGT rules (phase 2),COc1ccc(CC(C)NCC(O)c2ccc(O)c([NH:2]C=O)c2)cc1,0.02
Formoterol,COc1ccc(CC(C)NCC(O)c2ccc(O)c([NH:2]C=O)c2)cc1,COc1ccc(CC(C)NCC(O)c2ccc(O)c([NH2:2])c2)cc1,N-deformylation,Phase 1 SyGMa rules,COc1ccc(CC(C)NCC(O)c2ccc(O)c([NH:2]C=O)c2)cc1,0.11
Formoterol,COc1ccc(CC(C)NCC(O)c2ccc([OH:2])c(NC=O)c2)cc1,COc1ccc(CC(C)NCC(O)c2ccc([O:2]C)c(NC=O)c2)cc1,methylation_(aromatic_OH),MT rules (phase 2),COc1ccc(CC(C)NCC(O)c2ccc([OH:2])c(NC=O)c2)cc1,0.35
Formoterol,COc1ccc(CC(C)NCC(O)c2ccc([OH:2])c(NC=O)c2)cc1,COc1ccc(CC(C)NCC(O)c2ccc([O:2]C3OC(C(=O)O)C(O)C(O)C3O)c(NC=O)c2)cc1,O-glucuronidation_(aromatic_hydroxyl),UGT rules (phase 2),COc1ccc(CC(C)NCC(O)c2ccc([OH:2])c(NC=O)c2)cc1,0.78
Formoterol,COc1ccc(CC(C)NCC(O)c2ccc([OH:2])c(NC=O)c2)cc1,COc1ccc(CC(C)NCC(O)c2ccc([O:2]S(=O)(=O)O)c(NC=O)c2)cc1,sulfation_(aromatic_hydroxyl),SULT rules (phase 2),COc1ccc(CC(C)NCC(O)c2ccc([OH:2])c(NC=O)c2)cc1,0.98
Formoterol,COc1ccc(CC(C)NCC(c2ccc(O)c(NC=O)c2)[OH:2])cc1,COc1ccc(CC(C)NCC(c2ccc(O)c(NC=O)c2)[O:2]C2OC(C(=O)O)C(O)C(O)C2O)cc1,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),COc1ccc(CC(C)NCC(c2ccc(O)c(NC=O)c2)[OH:2])cc1,0.37
Formoterol,COc1ccc(CC(C)NCC(c2ccc(O)c(NC=O)c2)[OH:2])cc1,COc1ccc(CC(C)NCC(c2ccc(O)c(NC=O)c2)[O:2]S(=O)(=O)O)cc1,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),COc1ccc(CC(C)NCC(c2ccc(O)c(NC=O)c2)[OH:2])cc1,0.13
Formoterol,COc1ccc(CC(C)NC[CH:1](O)c2ccc(O)c(NC=O)c2)cc1,COc1ccc(CC(C)NC[C:1](O)(O)c2ccc(O)c(NC=O)c2)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(CC(C)NC[CH:1](O)c2ccc(O)c(NC=O)c2)cc1,0.43
Formoterol,COc1ccc(CC(C)NC[CH:2](O)c2ccc(O)c(NC=O)c2)cc1,COc1ccc(CC(C)NC=[CH:2]c2ccc(O)c(NC=O)c2)cc1,dehydration_next_to_SP2_a,Phase 1 SyGMa rules,COc1ccc(CC(C)NC[CH:2](O)c2ccc(O)c(NC=O)c2)cc1,0.43
Formoterol,COc1ccc(CC(C)N[CH2:1]C(O)c2ccc(O)c(NC=O)c2)cc1,COc1ccc(CC(C)N[CH:1](O)C(O)c2ccc(O)c(NC=O)c2)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(CC(C)N[CH2:1]C(O)c2ccc(O)c(NC=O)c2)cc1,0.22
Formoterol,COc1ccc(CC(C)N[CH2:2]C(O)c2ccc(O)c(NC=O)c2)cc1,O=CNc1cc(C(O)[CH:2]=O)ccc1O,N-dealkylation,CYP rules from GLORY (phase 1),COc1ccc(CC(C)N[CH2:2]C(O)c2ccc(O)c(NC=O)c2)cc1,0.22
Formoterol,COc1ccc(CC(C)N[CH2:3]C(O)c2ccc(O)c(NC=O)c2)cc1,COc1ccc(CC(C)N)cc1.O=CNc1cc(C(O)[CH2:3]O)ccc1O,N-dealkylation_(R-NHCH2-alkyl),Phase 1 SyGMa rules,COc1ccc(CC(C)N[CH2:3]C(O)c2ccc(O)c(NC=O)c2)cc1,0.22
Formoterol,COc1ccc(CC(C)[NH:1]CC(O)c2ccc(O)c(NC=O)c2)cc1,COc1ccc(CC(C)[N:1](O)CC(O)c2ccc(O)c(NC=O)c2)cc1,amine hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(CC(C)[NH:1]CC(O)c2ccc(O)c(NC=O)c2)cc1,0.11
Formoterol,COc1ccc(CC(C)[NH:1]CC(O)c2ccc(O)c(NC=O)c2)cc1,COc1ccc(CC(C)[NH2:1])cc1,N-dealkylation,CYP rules from GLORY (phase 1),COc1ccc(CC(C)[NH:1]CC(O)c2ccc(O)c(NC=O)c2)cc1,0.11
Formoterol,COc1ccc(CC(C)[NH:1]CC(O)c2ccc(O)c(NC=O)c2)cc1,O=CNc1cc(C(O)C[NH2:1])ccc1O,N-dealkylation,CYP rules from GLORY (phase 1),COc1ccc(CC(C)[NH:1]CC(O)c2ccc(O)c(NC=O)c2)cc1,0.11
Formoterol,COc1ccc(CC(NCC(O)c2ccc(O)c(NC=O)c2)[CH3:1])cc1,COc1ccc(CC(NCC(O)c2ccc(O)c(NC=O)c2)[CH2:1]O)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(CC(NCC(O)c2ccc(O)c(NC=O)c2)[CH3:1])cc1,0.03
Formoterol,COc1ccc(C[CH:1](C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,COc1ccc(C[C:1](C)(O)NCC(O)c2ccc(O)c(NC=O)c2)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc(C[CH:1](C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,0.17
Formoterol,COc1ccc(C[CH:2](C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,COc1ccc(C[C:2](C)(O)NCC(O)c2ccc(O)c(NC=O)c2)cc1,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,COc1ccc(C[CH:2](C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,0.17
Formoterol,COc1ccc(C[CH:2](C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,COc1ccc(C[C:2](C)=O)cc1,N-dealkylation,CYP rules from GLORY (phase 1),COc1ccc(C[CH:2](C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,0.17
Apremilast,COc1ccc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)cc1OC[CH3:1],COc1ccc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)cc1OC[CH2:1]O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)cc1OC[CH3:1],0.01
Apremilast,COc1ccc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)cc1O[CH2:1]C,COc1ccc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)cc1O[CH:1](C)O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)cc1O[CH2:1]C,0.76
Apremilast,COc1ccc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)cc1O[CH2:3]C,COc1ccc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)cc1O.C[CH2:3]O,O-dealkylation_(aromatic),Phase 1 SyGMa rules,COc1ccc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)cc1O[CH2:3]C,0.76
Apremilast,COc1ccc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)cc1O[CH2:3]C,C[CH:3]=O,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),COc1ccc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)cc1O[CH2:3]C,0.76
Formoterol,COc1ccc([CH2:1]C(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,COc1ccc([CH:1](O)C(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc([CH2:1]C(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,0.05
Formoterol,COc1ccc([CH2:2]C(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,COc1ccc([CH:2](O)C(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,benzylic_hydroxylation_(c-CH2-CR),Phase 1 SyGMa rules,COc1ccc([CH2:2]C(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,0.05
Esomeprazole,COc1ccc2[nH]c([S@@+:1]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,COc1ccc2[nH]c([S@+:1](=O)([O-])Cc3ncc(C)c(OC)c3C)nc2c1,S-oxidation,CYP rules from GLORY (phase 1),COc1ccc2[nH]c([S@@+:1]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,0.38
Esomeprazole,COc1ccc2[nH]c([S@@+]([O-])Cc3c(C)c(OC)c(C)c[n:1]3)nc2c1,COc1ccc2[nH]c([S@@+]([O-])Cc3c(C)c(OC)c(C)c[n+:1]3C3OC(C(=O)O)C(O)C(O)C3O)nc2c1,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),COc1ccc2[nH]c([S@@+]([O-])Cc3c(C)c(OC)c(C)c[n:1]3)nc2c1,0.06
Esomeprazole,COc1ccc2[nH]c([S@@+]([O-])Cc3c(C)c(OC)c(C)c[n:1]3)nc2c1,COc1ccc2[nH]c([S@@+]([O-])Cc3c(C)c(OC)c(C)c[n+:1]3[O-])nc2c1,N-oxidation,CYP rules from GLORY (phase 1),COc1ccc2[nH]c([S@@+]([O-])Cc3c(C)c(OC)c(C)c[n:1]3)nc2c1,0.1
Esomeprazole,COc1ccc2[nH]c([S@@+]([O-])Cc3c(C)c(OC)c(C)c[n:2]3)nc2c1,COc1ccc2[nH]c([S@@+]([O-])Cc3c(C)c(OC)c(C)c[n+:2]3[O-])nc2c1,N-oxidation_(-N=),Phase 1 SyGMa rules,COc1ccc2[nH]c([S@@+]([O-])Cc3c(C)c(OC)c(C)c[n:2]3)nc2c1,0.1
Esomeprazole,COc1ccc2[nH]c([S@@+]([O-])Cc3n[cH:1]c(C)c(OC)c3C)nc2c1,COc1ccc2[nH]c([S@@+]([O-])Cc3n[c:1](O)c(C)c(OC)c3C)nc2c1,aromatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc2[nH]c([S@@+]([O-])Cc3n[cH:1]c(C)c(OC)c3C)nc2c1,0.04
Esomeprazole,COc1ccc2[nH]c([S@@+]([O-])Cc3n[cH:5]c(C)c(OC)c3C)nc2c1,COc1ccc2[nH]c([S@@+]([O-])Cc3n[c:5](O)c(C)c(OC)c3C)nc2c1,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,COc1ccc2[nH]c([S@@+]([O-])Cc3n[cH:5]c(C)c(OC)c3C)nc2c1,0.04
Esomeprazole,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)[n:1]c2c1,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)[n+:1](C3OC(C(=O)O)C(O)C(O)C3O)c2c1,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)[n:1]c2c1,0.06
Esomeprazole,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)[n:1]c2c1,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)[n+:1]([O-])c2c1,N-oxidation,CYP rules from GLORY (phase 1),COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)[n:1]c2c1,0.02
Esomeprazole,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)[n:2]c2c1,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)[n+:2]([O-])c2c1,N-oxidation_(-N=),Phase 1 SyGMa rules,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)[n:2]c2c1,0.02
Esomeprazole,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3[CH3:1])nc2c1,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3[CH2:1]O)nc2c1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3[CH3:1])nc2c1,0.31
Esomeprazole,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3[CH3:2])nc2c1,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3[C:2](=O)O)nc2c1,carboxylation_(benzylic_CH3),Phase 1 SyGMa rules,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3[CH3:2])nc2c1,0.31
Esomeprazole,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3[CH3:2])nc2c1,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3[CH2:2]O)nc2c1,benzylic_hydroxylation_(c-CH3),Phase 1 SyGMa rules,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3[CH3:2])nc2c1,0.31
Esomeprazole,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(O[CH3:1])c3C)nc2c1,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(O[CH2:1]O)c3C)nc2c1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(O[CH3:1])c3C)nc2c1,0.41
Esomeprazole,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c([O:2]C)c3C)nc2c1,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c([OH:2])c3C)nc2c1,O-demethylation,Phase 1 SyGMa rules,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c([O:2]C)c3C)nc2c1,0.0
Esomeprazole,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc([CH3:1])c(OC)c3C)nc2c1,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc([CH2:1]O)c(OC)c3C)nc2c1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc2[nH]c([S@@+]([O-])Cc3ncc([CH3:1])c(OC)c3C)nc2c1,0.62
Esomeprazole,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc([CH3:2])c(OC)c3C)nc2c1,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc([C:2](=O)O)c(OC)c3C)nc2c1,carboxylation_(benzylic_CH3),Phase 1 SyGMa rules,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc([CH3:2])c(OC)c3C)nc2c1,0.62
Esomeprazole,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc([CH3:2])c(OC)c3C)nc2c1,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc([CH2:2]O)c(OC)c3C)nc2c1,benzylic_hydroxylation_(c-CH3),Phase 1 SyGMa rules,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc([CH3:2])c(OC)c3C)nc2c1,0.62
Esomeprazole,COc1ccc2[nH]c([S@@+]([O-])[CH2:1]c3ncc(C)c(OC)c3C)nc2c1,COc1ccc2[nH]c([S@@+]([O-])[CH:1](O)c3ncc(C)c(OC)c3C)nc2c1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),COc1ccc2[nH]c([S@@+]([O-])[CH2:1]c3ncc(C)c(OC)c3C)nc2c1,0.13
Esomeprazole,COc1ccc2[nH]c([S@@+]([O-])[CH2:3]c3ncc(C)c(OC)c3C)nc2c1,COc1c(C)cnc([CH2:3]O)c1C.COc1ccc2[nH]c([SH+][O-])nc2c1,S-dealkylation_c-SCH2-R,Phase 1 SyGMa rules,COc1ccc2[nH]c([S@@+]([O-])[CH2:3]c3ncc(C)c(OC)c3C)nc2c1,0.13
Esomeprazole,COc1ccc2c(c1)nc([S@@+]([O-])Cc1ncc(C)c(OC)c1C)[nH:1]2,COc1ccc2c(c1)nc([S@@+]([O-])Cc1ncc(C)c(OC)c1C)[n:1]2C1OC(C(=O)O)C(O)C(O)C1O,N-glucuronidation_(aromatic_-nH-),UGT rules (phase 2),COc1ccc2c(c1)nc([S@@+]([O-])Cc1ncc(C)c(OC)c1C)[nH:1]2,0.06
Cinacalcet,C[C@@H:1](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,C[C@@:1](O)(NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H:1](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,0.81
Dolutegravir,C[C@@H:1]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,C[C@:1]1(O)CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H:1]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,0.04
Cinacalcet,C[C@@H:2](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,C[C:2](=O)c1cccc2ccccc12,N-dealkylation,CYP rules from GLORY (phase 1),C[C@@H:2](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,0.81
Dolutegravir,C[C@@H:2]1CCO[C@H:1]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3[C:1](=O)N21,C[C:2](=O)CCO[CH2:1]Cn1cc(C(=O)NCc2ccc(F)cc2F)c(=O)c(O)c1[CH:1]=O,N-dealkylation,CYP rules from GLORY (phase 1),C[C@@H:2]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,0.04
Dolutegravir,C[C@@H:2]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,C[C@:2]1(O)CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,C[C@@H:2]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,0.04
Cinacalcet,C[C@@H](NCCCc1cc(C(F)(F)F)c[cH:1]c1)c1cccc2ccccc12,C[C@@H](NCCCc1cc(C(F)(F)F)c[c:1](O)c1)c1cccc2ccccc12,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H](NCCCc1cc(C(F)(F)F)c[cH:1]c1)c1cccc2ccccc12,0.02
Cinacalcet,C[C@@H](NCCCc1cc(C(F)(F)F)c[cH:4]c1)c1cccc2ccccc12,C[C@@H](NCCCc1cc(C(F)(F)F)c[c:4](O)c1)c1cccc2ccccc12,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,C[C@@H](NCCCc1cc(C(F)(F)F)c[cH:4]c1)c1cccc2ccccc12,0.02
Cinacalcet,C[C@@H](NCCCc1cc(C(F)(F)F)cc[cH:1]1)c1cccc2ccccc12,C[C@@H](NCCCc1cc(C(F)(F)F)cc[c:1]1O)c1cccc2ccccc12,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H](NCCCc1cc(C(F)(F)F)cc[cH:1]1)c1cccc2ccccc12,0.02
Cinacalcet,C[C@@H](NCCCc1cc(C(F)(F)F)cc[cH:5]1)c1cccc2ccccc12,C[C@@H](NCCCc1cc(C(F)(F)F)cc[c:5]1O)c1cccc2ccccc12,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,C[C@@H](NCCCc1cc(C(F)(F)F)cc[cH:5]1)c1cccc2ccccc12,0.02
Cinacalcet,C[C@@H](NCCCc1cc[cH:1]c(C(F)(F)F)c1)c1cccc2ccccc12,C[C@@H](NCCCc1cc[c:1](O)c(C(F)(F)F)c1)c1cccc2ccccc12,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H](NCCCc1cc[cH:1]c(C(F)(F)F)c1)c1cccc2ccccc12,0.05
Cinacalcet,C[C@@H](NCCCc1cc[cH:5]c(C(F)(F)F)c1)c1cccc2ccccc12,C[C@@H](NCCCc1cc[c:5](O)c(C(F)(F)F)c1)c1cccc2ccccc12,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,C[C@@H](NCCCc1cc[cH:5]c(C(F)(F)F)c1)c1cccc2ccccc12,0.05
Cinacalcet,C[C@@H](NCCCc1cccc(C(F)(F)F)[cH:1]1)c1cccc2ccccc12,C[C@@H](NCCCc1cccc(C(F)(F)F)[c:1]1O)c1cccc2ccccc12,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H](NCCCc1cccc(C(F)(F)F)[cH:1]1)c1cccc2ccccc12,0.02
Cinacalcet,C[C@@H](NCCCc1cccc(C(F)(F)F)[cH:3]1)c1cccc2ccccc12,C[C@@H](NCCCc1cccc(C(F)(F)F)[c:3]1O)c1cccc2ccccc12,aromatic_hydroxylation_(ortho_to_2_substituents),Phase 1 SyGMa rules,C[C@@H](NCCCc1cccc(C(F)(F)F)[cH:3]1)c1cccc2ccccc12,0.02
Cinacalcet,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1c2ccccc2cc[cH:1]1,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1c2ccccc2cc[c:1]1O,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1c2ccccc2cc[cH:1]1,0.01
Cinacalcet,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1c2ccccc2cc[cH:5]1,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1c2ccccc2cc[c:5]1O,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1c2ccccc2cc[cH:5]1,0.01
Cinacalcet,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1c[cH:1]cc2ccccc12,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1c[c:1](O)cc2ccccc12,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1c[cH:1]cc2ccccc12,0.61
Cinacalcet,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1c[cH:5]cc2ccccc12,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1c[c:5](O)cc2ccccc12,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1c[cH:5]cc2ccccc12,0.61
Cinacalcet,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cc[cH:1]c2ccccc12,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cc[c:1](O)c2ccccc12,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cc[cH:1]c2ccccc12,0.84
Cinacalcet,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cc[cH:5]c2ccccc12,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cc[c:5](O)c2ccccc12,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cc[cH:5]c2ccccc12,0.84
Cinacalcet,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2c1ccc[cH:1]2,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2c1ccc[c:1]2O,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2c1ccc[cH:1]2,0.8
Cinacalcet,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2c[cH:1]ccc12,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2c[c:1](O)ccc12,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2c[cH:1]ccc12,0.71
Cinacalcet,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2c[cH:5]ccc12,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2c[c:5](O)ccc12,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2c[cH:5]ccc12,0.71
Cinacalcet,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2cc[cH:1]cc12,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2cc[c:1](O)cc12,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2cc[cH:1]cc12,0.05
Cinacalcet,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2cc[cH:5]cc12,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2cc[c:5](O)cc12,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2cc[cH:5]cc12,0.05
Cinacalcet,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccc[cH:1]c12,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccc[c:1](O)c12,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccc[cH:1]c12,0.04
Cinacalcet,C[C@@H](NCC[CH2:1]c1cccc(C(F)(F)F)c1)c1cccc2ccccc12,C[C@@H](NCC[CH:1](O)c1cccc(C(F)(F)F)c1)c1cccc2ccccc12,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H](NCC[CH2:1]c1cccc(C(F)(F)F)c1)c1cccc2ccccc12,0.1
Cinacalcet,C[C@@H](NCC[CH2:2]c1cccc(C(F)(F)F)c1)c1cccc2ccccc12,C[C@@H](NCC[CH:2](O)c1cccc(C(F)(F)F)c1)c1cccc2ccccc12,benzylic_hydroxylation_(c-CH2-CR),Phase 1 SyGMa rules,C[C@@H](NCC[CH2:2]c1cccc(C(F)(F)F)c1)c1cccc2ccccc12,0.1
Cinacalcet,C[C@@H](NC[CH2:1]Cc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,C[C@@H](NC[CH:1](O)Cc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H](NC[CH2:1]Cc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,0.03
Cinacalcet,C[C@@H](N[CH2:1]CCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,C[C@@H](N[CH:1](O)CCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H](N[CH2:1]CCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,0.8
Cinacalcet,C[C@@H](N[CH2:2]CCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,O=[CH:2]CCc1cccc(C(F)(F)F)c1,N-dealkylation,CYP rules from GLORY (phase 1),C[C@@H](N[CH2:2]CCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,0.8
Cinacalcet,C[C@@H](N[CH2:3]CCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,C[C@@H](N)c1cccc2ccccc12.O[CH2:3]CCc1cccc(C(F)(F)F)c1,N-dealkylation_(R-NHCH2-alkyl),Phase 1 SyGMa rules,C[C@@H](N[CH2:3]CCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,0.8
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)C[C@@H:1]1N(C)c1ncnc2[nH]ccc12,C[C@@H]1CCN(C(=O)CC#N)C[C@:1]1(O)N(C)c1ncnc2[nH]ccc12,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H]1CCN(C(=O)CC#N)C[C@@H:1]1N(C)c1ncnc2[nH]ccc12,0.1
Tofacitinib,C[C@@H]1CC[N:1](C(=O)CC#N)C[C@@H:1]1N(C)c1ncnc2[nH]ccc12,C[C@H](CC[NH:1]C(=O)CC#N)[CH2:1]N(C)c1ncnc2[nH]ccc12,N-dealkylation,CYP rules from GLORY (phase 1),C[C@@H]1CCN(C(=O)CC#N)C[C@@H:1]1N(C)c1ncnc2[nH]ccc12,0.1
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)C[C@@H:2]1N(C)c1ncnc2[nH]ccc12,C[C@@H]1CCN(C(=O)CC#N)C[C:2]1=O,N-dealkylation,CYP rules from GLORY (phase 1),C[C@@H]1CCN(C(=O)CC#N)C[C@@H:2]1N(C)c1ncnc2[nH]ccc12,0.1
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)C[C@@H:2]1N(C)c1ncnc2[nH]ccc12,C[C@@H]1CCN(C(=O)CC#N)C[C@:2]1(O)N(C)c1ncnc2[nH]ccc12,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,C[C@@H]1CCN(C(=O)CC#N)C[C@@H:2]1N(C)c1ncnc2[nH]ccc12,0.1
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)[c:2]1ncnc2[nH]ccc21,CN[C@H]1CN(C(=O)CC#N)CC[C@H]1C.O=[c:2]1[nH]cnc2[nH]ccc21,oxidative_deamination_(aromatic),Phase 1 SyGMa rules,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)[c:2]1ncnc2[nH]ccc21,0.02
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1c2cc[nH]c2nc[n:1]1,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1c2cc[nH]c2nc[n+:1]1C1OC(C(=O)O)C(O)C(O)C1O,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1c2cc[nH]c2nc[n:1]1,0.04
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1c2cc[nH]c2nc[n:1]1,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1c2cc[nH]c2nc[n+:1]1[O-],N-oxidation,CYP rules from GLORY (phase 1),C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1c2cc[nH]c2nc[n:1]1,0.03
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1c2cc[nH]c2nc[n:2]1,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1c2cc[nH]c2nc[n+:2]1[O-],N-oxidation_(-N=),Phase 1 SyGMa rules,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1c2cc[nH]c2nc[n:2]1,0.03
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1n[cH:1]nc2[nH]ccc12,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1n[c:1](O)nc2[nH]ccc12,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1n[cH:1]nc2[nH]ccc12,0.06
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1n[cH:5]nc2[nH]ccc12,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1n[c:5](O)nc2[nH]ccc12,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1n[cH:5]nc2[nH]ccc12,0.06
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1nc[n:1]c2[nH]ccc12,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1nc[n+:1](C2OC(C(=O)O)C(O)C(O)C2O)c2[nH]ccc12,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1nc[n:1]c2[nH]ccc12,0.19
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1nc[n:1]c2[nH]ccc12,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1nc[n+:1]([O-])c2[nH]ccc12,N-oxidation,CYP rules from GLORY (phase 1),C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1nc[n:1]c2[nH]ccc12,0.04
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1nc[n:2]c2[nH]ccc12,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1nc[n+:2]([O-])c2[nH]ccc12,N-oxidation_(-N=),Phase 1 SyGMa rules,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1nc[n:2]c2[nH]ccc12,0.04
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH][cH:1]cc12,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH][c:1](O)cc12,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH][cH:1]cc12,0.66
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]c[cH:1]c12,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]c[c:1](O)c12,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]c[cH:1]c12,0.01
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2c1cc[nH:1]2,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2c1cc[n:1]2C1OC(C(=O)O)C(O)C(O)C1O,N-glucuronidation_(aromatic_-nH-),UGT rules (phase 2),C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2c1cc[nH:1]2,0.12
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(c1ncnc2[nH]ccc12)[CH3:1],C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(c1ncnc2[nH]ccc12)[CH2:1]O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(c1ncnc2[nH]ccc12)[CH3:1],0.66
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1[N:1](C)c1ncnc2[nH]ccc12,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1[N+:1](C)([O-])c1ncnc2[nH]ccc12,N-oxidation,CYP rules from GLORY (phase 1),C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1[N:1](C)c1ncnc2[nH]ccc12,0.65
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1[N:1](C)c1ncnc2[nH]ccc12,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1[NH:1]c1ncnc2[nH]ccc12,N-dealkylation,CYP rules from GLORY (phase 1),C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1[N:1](C)c1ncnc2[nH]ccc12,0.65
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1[N:1](C)c1ncnc2[nH]ccc12,C[NH:1]c1ncnc2[nH]ccc12,N-dealkylation,CYP rules from GLORY (phase 1),C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1[N:1](C)c1ncnc2[nH]ccc12,0.65
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1[N:2](C)c1ncnc2[nH]ccc12,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1[NH:2]c1ncnc2[nH]ccc12,N-demethylation_(R-N(CR)CH3),Phase 1 SyGMa rules,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1[N:2](C)c1ncnc2[nH]ccc12,0.65
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)[CH2:1][C@@H]1N(C)c1ncnc2[nH]ccc12,C[C@@H]1CCN(C(=O)CC#N)[CH:1](O)[C@@H]1N(C)c1ncnc2[nH]ccc12,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H]1CCN(C(=O)CC#N)[CH2:1][C@@H]1N(C)c1ncnc2[nH]ccc12,0.05
Tofacitinib,C[C@@H]1C[CH2:2]N(C(=O)CC#N)[CH2:1][C@@H]1N(C)c1ncnc2[nH]ccc12,C[C@H](C[CH:2]=O)[C@@H](N(C)c1ncnc2[nH]ccc12)[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),C[C@@H]1CCN(C(=O)CC#N)[CH2:1][C@@H]1N(C)c1ncnc2[nH]ccc12,0.05
Tofacitinib,C[C@@H]1CCN(C(=O)CC#N)[CH2:2][C@@H]1N(C)c1ncnc2[nH]ccc12,C[C@@H]1CCN(C(=O)CC#N)[CH:2](O)[C@@H]1N(C)c1ncnc2[nH]ccc12,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,C[C@@H]1CCN(C(=O)CC#N)[CH2:2][C@@H]1N(C)c1ncnc2[nH]ccc12,0.05
Tofacitinib,C[C@@H]1C[CH2:1]N(C(=O)CC#N)[CH2:2][C@@H]1N(C)c1ncnc2[nH]ccc12,C[C@H](C[CH3:1])[C@@H](N(C)c1ncnc2[nH]ccc12)[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),C[C@@H]1CCN(C(=O)CC#N)[CH2:2][C@@H]1N(C)c1ncnc2[nH]ccc12,0.05
Tofacitinib,C[C@@H]1CCN(C(=O)C[C:1]#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,C[C@@H]1CCN(C(=O)C[C:1](=N)SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C[C@@H]1N(C)c1ncnc2[nH]ccc12,glutathione_conjugation_(nitrile),GST rules (phase 2),C[C@@H]1CCN(C(=O)C[C:1]#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,0.27
Tofacitinib,C[C@@H]1CCN(C(=O)C[C:1]#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,C[C@@H]1CCN(C(=O)C[C:1](N)=O)C[C@@H]1N(C)c1ncnc2[nH]ccc12,nitrile_to_amide,Phase 1 SyGMa rules,C[C@@H]1CCN(C(=O)C[C:1]#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,0.77
Tofacitinib,C[C@@H]1CCN(C(=O)[CH2:1]C#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,C[C@@H]1CCN(C(=O)[CH:1](O)C#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H]1CCN(C(=O)[CH2:1]C#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,0.65
Tofacitinib,C[C@@H]1CCN([C:2](=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,C[C@@H]1CCNC[C@@H]1N(C)c1ncnc2[nH]ccc12.N#CC[C:2](=O)O,hydrolysis_(tertiary_amide),Phase 1 SyGMa rules,C[C@@H]1CCN([C:2](=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,0.07
Dolutegravir,C[C@@H]1CCO[C@@H]2N1C(=O)c1c(O)c(=O)c(C(=O)NCc3ccc(F)cc3F)cn1[CH2:1]2,C[C@@H]1CCO[C@@H]2N1C(=O)c1c(O)c(=O)c(C(=O)NCc3ccc(F)cc3F)cn1[CH:1]2O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@@H]2N1C(=O)c1c(O)c(=O)c(C(=O)NCc3ccc(F)cc3F)cn1[CH2:1]2,0.04
Dolutegravir,C[C@@H]1CCO[C@@H]2N1C(=O)c1c(O)c(=O)c(C(=O)NCc3ccc(F)cc3F)cn1[CH2:2]2,C[C@@H]1CCO[C@@H]([CH2:2]O)N1C(=O)c1[nH]cc(C(=O)NCc2ccc(F)cc2F)c(=O)c1O,N-dealkylation_(nCH2),Phase 1 SyGMa rules,C[C@@H]1CCO[C@@H]2N1C(=O)c1c(O)c(=O)c(C(=O)NCc3ccc(F)cc3F)cn1[CH2:2]2,0.04
Dolutegravir,C[C@@H]1CCO[C@@H]2N1C(=O)c1c(O)c(=O)c(C(=O)NCc3ccc(F)cc3F)cn1[CH2:2]2,C[C@@H]1CCO[C@@H]2N1C(=O)c1c(O)c(=O)c(C(=O)NCc3ccc(F)cc3F)cn1[CH:2]2O,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,C[C@@H]1CCO[C@@H]2N1C(=O)c1c(O)c(=O)c(C(=O)NCc3ccc(F)cc3F)cn1[CH2:2]2,0.04
Dolutegravir,C[C@@H]1CCO[C@H:1]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,C[C@@H]1CCO[C@@:1]2(O)Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H:1]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,0.05
Dolutegravir,C[C@@H:1]1CCO[C@H:2]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3[C:1](=O)N12,C[CH2:1]CCO[C:2](=O)Cn1cc(C(=O)NCc2ccc(F)cc2F)c(=O)c(O)c1[CH:1]=O,N-dealkylation,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H:2]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,0.05
Dolutegravir,C[C@H]1N2C(=O)c3c(O)c(=O)c(C(=O)NCc4ccc(F)cc4F)cn3C[C@@H:3]2OC[CH2:1]1,C[C@@H](N1C(=O)c2c(O)c(=O)c(C(=O)NCc3ccc(F)cc3F)cn2C[C:3]1=O)[CH3:1],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H:3]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,0.05
Dolutegravir,C[C@@H]1CCO[C@H]2C[n:1]3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,C[C@@H]1CCO[C@H]2C[N+:1]3([O-])C=C(C(=O)NCc4ccc(F)cc4F)C(=O)C(O)=C3C(=O)N12,N-oxidation,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H]2C[n:1]3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,0.02
Dolutegravir,C[C@@H]1CCO[C@H:1]2C[n:1]3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,C[C@@H]1CCO[CH2:1]N1C(=O)c1c(O)c(=O)c(C(=O)NCc2ccc(F)cc2F)c[nH:1]1,N-dealkylation,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H]2C[n:1]3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,0.02
Dolutegravir,C[C@@H]1CCO[C@H]2Cn3c(c(O)c(=O)c(C(=O)NCc4ccc(F)cc4F)[cH:1]3)C(=O)N12,C[C@@H]1CCO[C@H]2Cn3c(c(O)c(=O)c(C(=O)NCc4ccc(F)cc4F)[c:1]3O)C(=O)N12,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H]2Cn3c(c(O)c(=O)c(C(=O)NCc4ccc(F)cc4F)[cH:1]3)C(=O)N12,0.03
Dolutegravir,C[C@@H]1CCO[C@H]2Cn3c(c(O)c(=O)c(C(=O)NCc4ccc(F)cc4F)[cH:5]3)C(=O)N12,C[C@@H]1CCO[C@H]2Cn3c(c(O)c(=O)c(C(=O)NCc4ccc(F)cc4F)[c:5]3O)C(=O)N12,aromatic_hydroxylation_(para_to_oxygen),Phase 1 SyGMa rules,C[C@@H]1CCO[C@H]2Cn3c(c(O)c(=O)c(C(=O)NCc4ccc(F)cc4F)[cH:5]3)C(=O)N12,0.03
Dolutegravir,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4c(F)cc(F)c[cH:1]4)c(=O)c(O)c3C(=O)N12,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4c(F)cc(F)c[c:1]4O)c(=O)c(O)c3C(=O)N12,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4c(F)cc(F)c[cH:1]4)c(=O)c(O)c3C(=O)N12,0.0
Dolutegravir,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4c[cH:1]c(F)cc4F)c(=O)c(O)c3C(=O)N12,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4c[c:1](O)c(F)cc4F)c(=O)c(O)c3C(=O)N12,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4c[cH:1]c(F)cc4F)c(=O)c(O)c3C(=O)N12,0.03
Dolutegravir,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4c[cH:4]c(F)cc4F)c(=O)c(O)c3C(=O)N12,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4c[c:4](O)c(F)cc4F)c(=O)c(O)c3C(=O)N12,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4c[cH:4]c(F)cc4F)c(=O)c(O)c3C(=O)N12,0.03
Dolutegravir,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4cc[c:1](F)cc4F)c(=O)c(O)c3C(=O)N12,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4cc[c:1](O)cc4F)c(=O)c(O)c3C(=O)N12,oxidative dehalogenation benzyl,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4cc[c:1](F)cc4F)c(=O)c(O)c3C(=O)N12,0.08
Dolutegravir,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)[cH:1]c4F)c(=O)c(O)c3C(=O)N12,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)[c:1](O)c4F)c(=O)c(O)c3C(=O)N12,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)[cH:1]c4F)c(=O)c(O)c3C(=O)N12,0.03
Dolutegravir,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)[cH:4]c4F)c(=O)c(O)c3C(=O)N12,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)[c:4](O)c4F)c(=O)c(O)c3C(=O)N12,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)[cH:4]c4F)c(=O)c(O)c3C(=O)N12,0.03
Dolutegravir,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)c[c:1]4F)c(=O)c(O)c3C(=O)N12,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)c[c:1]4O)c(=O)c(O)c3C(=O)N12,oxidative dehalogenation benzyl,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)c[c:1]4F)c(=O)c(O)c3C(=O)N12,0.02
Dolutegravir,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)[N:1]12,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)[N+:1]12[O-],N-oxidation,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)[N:1]12,0.04
Dolutegravir,C[C@@H]1CC[O:1][C@H]2[CH2:1]n3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)[N:1]12,C[C@H](CC[OH:1])[NH:1]C(=O)c1c(O)c(=O)c(C(=O)NCc2ccc(F)cc2F)cn1[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)[N:1]12,0.04
Dolutegravir,C[C@@H]1CC[O:2][C@H]2[CH2:1]n3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)[N:1]12,C[C@H](CC[OH:2])[NH:1]C(=O)c1c(O)c(=O)c(C(=O)NCc2ccc(F)cc2F)cn1[CH3:1],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)[N:1]12,0.04
Dolutegravir,C[C@@H]1C[CH2:3]O[C@H]2[CH2:1]n3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)[N:1]12,C[C@H](C[CH:3]=O)[NH:1]C(=O)c1c(O)c(=O)c(C(=O)NCc2ccc(F)cc2F)cn1[CH3:1],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)[N:1]12,0.04
Dolutegravir,C[C@@H]1[CH2:1]CO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)[N:1]21,O=C(NCc1ccc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)[NH:1][C@@H](OC[CH3:1])C2,N-dealkylation,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)[N:1]12,0.04
Dolutegravir,C[C@@H:2]1CCO[C@H:1]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3[C:1](=O)N21,C[C:2](=O)CCO[CH2:1]Cn1cc(C(=O)NCc2ccc(F)cc2F)c(=O)c(O)c1[CH:1]=O,N-dealkylation,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3[C:1](=O)N12,0.05
Dolutegravir,C[C@@H:1]1CCO[C@H:2]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3[C:1](=O)N12,C[CH2:1]CCO[C:2](=O)Cn1cc(C(=O)NCc2ccc(F)cc2F)c(=O)c(O)c1[CH:1]=O,N-dealkylation,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3[C:1](=O)N12,0.05
Dolutegravir,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3[C:2](=O)N12,C[C@@H]1CCO[C@@H](Cn2cc(C(=O)NCc3ccc(F)cc3F)c(=O)c(O)c2[C:2](=O)O)N1,hydrolysis_(tertiary_amide),Phase 1 SyGMa rules,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3[C:2](=O)N12,0.05
Dolutegravir,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c([OH:2])c3C(=O)N12,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c([O:2]C)c3C(=O)N12,methylation_(aromatic_OH),MT rules (phase 2),C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c([OH:2])c3C(=O)N12,0.19
Dolutegravir,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c([OH:2])c3C(=O)N12,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c([O:2]C4OC(C(=O)O)C(O)C(O)C4O)c3C(=O)N12,O-glucuronidation_(aromatic_hydroxyl),UGT rules (phase 2),C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c([OH:2])c3C(=O)N12,0.79
Dolutegravir,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c([OH:2])c3C(=O)N12,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c([O:2]S(=O)(=O)O)c3C(=O)N12,sulfation_(aromatic_hydroxyl),SULT rules (phase 2),C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c([OH:2])c3C(=O)N12,0.24
Dolutegravir,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)N[CH2:1]c4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)N[CH:1](O)c4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H]2Cn3cc(C(=O)N[CH2:1]c4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,0.63
Dolutegravir,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)N[CH2:2]c4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,O=[CH:2]c1ccc(F)cc1F,N-dealkylation,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H]2Cn3cc(C(=O)N[CH2:2]c4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,0.63
Dolutegravir,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)N[CH2:3]c4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,C[C@@H]1CCO[C@H]2Cn3cc(C(N)=O)c(=O)c(O)c3C(=O)N12.O[CH2:3]c1ccc(F)cc1F,N-dealkylation_(R-NHCH2-alkyl),Phase 1 SyGMa rules,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)N[CH2:3]c4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,0.63
Dolutegravir,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)[NH:1]Cc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)[N:1](O)Cc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,amine hydroxylation,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H]2Cn3cc(C(=O)[NH:1]Cc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,0.01
Dolutegravir,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)[NH:1]Cc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)[NH2:1])c(=O)c(O)c3C(=O)N12,N-dealkylation,CYP rules from GLORY (phase 1),C[C@@H]1CCO[C@H]2Cn3cc(C(=O)[NH:1]Cc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,0.01
Dolutegravir,C[C@@H]1CCO[C@H]2Cn3cc([C:2](=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,C[C@@H]1CCO[C@H]2Cn3cc([C:2](=O)O)c(=O)c(O)c3C(=O)N12.NCc1ccc(F)cc1F,hydrolysis_(secondary_amide),Phase 1 SyGMa rules,C[C@@H]1CCO[C@H]2Cn3cc([C:2](=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,0.06
Tofacitinib,C[C@H]1[C@@H](N(C)c2ncnc3[nH]ccc23)C[N:1](C(=O)CC#N)C[CH2:1]1,C[C@@H]([C@H](C[NH:1]C(=O)CC#N)N(C)c1ncnc2[nH]ccc12)[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),C[C@@H]1CC[N:1](C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,0.0
Tofacitinib,C[C@@H]1CC[N:1](C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,C[C@@H]1CC[N+:1]([O-])(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,N-oxidation,CYP rules from GLORY (phase 1),C[C@@H]1CC[N:1](C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,0.0
Dolutegravir,C[C@H]1N2C(=O)c3c(O)c(=O)c(C(=O)NCc4ccc(F)cc4F)cn3C[C@@H]2[O:2]C[CH2:1]1,C[C@@H](N1C(=O)c2c(O)c(=O)c(C(=O)NCc3ccc(F)cc3F)cn2C[C@@H]1[OH:2])[CH3:1],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C[C@@H]1CC[O:2][C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,0.01
Dolutegravir,C[C@@H]1CC[O:2][C@H]2[CH2:1]n3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)[N:1]12,C[C@H](CC[OH:2])[NH:1]C(=O)c1c(O)c(=O)c(C(=O)NCc2ccc(F)cc2F)cn1[CH3:1],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C[C@@H]1CC[O:2][C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,0.01
Fluticasone Propionate,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C[CH3:1])C(=O)SCF,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C[CH2:1]O)C(=O)SCF,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C[CH3:1])C(=O)SCF,0.02
Fluticasone Propionate,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C[CH3:3])C(=O)SCF,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C[C:3](=O)O)C(=O)SCF,carboxylation_(primary_carbon_next_to_sec_carbon),Phase 1 SyGMa rules,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C[CH3:3])C(=O)SCF,0.02
Fluticasone Propionate,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C[CH3:3])C(=O)SCF,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C[CH2:3]O)C(=O)SCF,aliphatic_hydroxylation_(primary_carbon_next_to_sec_carbon),Phase 1 SyGMa rules,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C[CH3:3])C(=O)SCF,0.02
Fluticasone Propionate,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)[CH2:1]C)C(=O)SCF,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)[CH:1](C)O)C(=O)SCF,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)[CH2:1]C)C(=O)SCF,0.0
Fluticasone Propionate,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)[CH2:2]C)C(=O)SCF,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)[CH:2](C)O)C(=O)SCF,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,not_in_a_ring)",Phase 1 SyGMa rules,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)[CH2:2]C)C(=O)SCF,0.0
Tofacitinib,C[C@@H]1C[CH2:1]N(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,C[C@@H]1C[CH:1](O)N(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H]1C[CH2:1]N(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,0.06
Tofacitinib,C[C@@H]1C[CH2:1]N(C(=O)CC#N)[CH2:2][C@@H]1N(C)c1ncnc2[nH]ccc12,C[C@H](C[CH3:1])[C@@H](N(C)c1ncnc2[nH]ccc12)[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),C[C@@H]1C[CH2:1]N(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,0.06
Dolutegravir,C[C@@H]1C[CH2:1]O[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,C[C@@H]1C[CH:1](O)O[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@@H]1C[CH2:1]O[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,0.08
Tofacitinib,C[C@@H]1C[CH2:2]N(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,C[C@@H]1C[C:2](=O)N(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,oxidation_(amine_in_a_ring),Phase 1 SyGMa rules,C[C@@H]1C[CH2:2]N(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,0.06
Tofacitinib,C[C@@H]1C[CH2:2]N(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,C[C@@H]1C[CH:2](O)N(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,C[C@@H]1C[CH2:2]N(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,0.06
Tofacitinib,C[C@@H]1C[CH2:2]N(C(=O)CC#N)[CH2:1][C@@H]1N(C)c1ncnc2[nH]ccc12,C[C@H](C[CH:2]=O)[C@@H](N(C)c1ncnc2[nH]ccc12)[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),C[C@@H]1C[CH2:2]N(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,0.06
Dolutegravir,C[C@@H]1C[CH2:3]O[C@H]2[CH2:1]n3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)[N:1]12,C[C@H](C[CH:3]=O)[NH:1]C(=O)c1c(O)c(=O)c(C(=O)NCc2ccc(F)cc2F)cn1[CH3:1],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C[C@@H]1C[CH2:3]O[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,0.08
Sofosbuvir,C[C@H](N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1)C(=O)O[CH:1](C)C,C[C@H](N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1)C(=O)O[C:1](C)(C)O,aliphatic_hydroxylation_(tert_carbon_linked_to_two_CH3_groups),Phase 1 SyGMa rules,C[C@H](N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1)C(=O)O[CH:1](C)C,0.0
Sofosbuvir,C[C@H](N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1)C(=O)O[CH:3](C)C,C[C:3](C)=O,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C[C@H](N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1)C(=O)O[CH:3](C)C,0.0
Sofosbuvir,C[C@H](N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1)C(=O)O[CH:4](C)C,C[C:4](C)=O,oxidative ester cleavage,CYP rules from GLORY (phase 1),C[C@H](N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1)C(=O)O[CH:4](C)C,0.0
Sofosbuvir,C[C@H](N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1)[C:2](=O)O[CH:4](C)C,C[C@H](N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1)[C:2](=O)O.C[CH:4](C)O,hydrolysis_(ester),Phase 1 SyGMa rules,C[C@H](N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1)C(=O)O[CH:4](C)C,0.0
Cinacalcet,C[C@H](c1cccc2ccccc12)[NH:1]CCCc1cccc(C(F)(F)F)c1,C[C@H](c1cccc2ccccc12)[N:1](O)CCCc1cccc(C(F)(F)F)c1,amine hydroxylation,CYP rules from GLORY (phase 1),C[C@H](c1cccc2ccccc12)[NH:1]CCCc1cccc(C(F)(F)F)c1,0.13
Cinacalcet,C[C@H](c1cccc2ccccc12)[NH:1]CCCc1cccc(C(F)(F)F)c1,C[C@H](c1cccc2ccccc12)[NH2:1],N-dealkylation,CYP rules from GLORY (phase 1),C[C@H](c1cccc2ccccc12)[NH:1]CCCc1cccc(C(F)(F)F)c1,0.13
Cinacalcet,C[C@H](c1cccc2ccccc12)[NH:1]CCCc1cccc(C(F)(F)F)c1,FC(F)(F)c1cccc(CCC[NH2:1])c1,N-dealkylation,CYP rules from GLORY (phase 1),C[C@H](c1cccc2ccccc12)[NH:1]CCCc1cccc(C(F)(F)F)c1,0.13
Dolutegravir,C[C@H]1N2C(=O)c3c(O)c(=O)c(C(=O)NCc4ccc(F)cc4F)cn3C[C@@H:3]2OC[CH2:1]1,C[C@@H](N1C(=O)c2c(O)c(=O)c(C(=O)NCc3ccc(F)cc3F)cn2C[C:3]1=O)[CH3:1],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C[C@H]1N2C(=O)c3c(O)c(=O)c(C(=O)NCc4ccc(F)cc4F)cn3C[C@@H]2OC[CH2:1]1,0.01
Dolutegravir,C[C@H]1N2C(=O)c3c(O)c(=O)c(C(=O)NCc4ccc(F)cc4F)cn3C[C@@H]2[O:2]C[CH2:1]1,C[C@@H](N1C(=O)c2c(O)c(=O)c(C(=O)NCc3ccc(F)cc3F)cn2C[C@@H]1[OH:2])[CH3:1],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C[C@H]1N2C(=O)c3c(O)c(=O)c(C(=O)NCc4ccc(F)cc4F)cn3C[C@@H]2OC[CH2:1]1,0.01
Dolutegravir,C[C@H]1N2C(=O)c3c(O)c(=O)c(C(=O)NCc4ccc(F)cc4F)cn3C[C@@H]2OC[CH2:1]1,C[C@H]1N2C(=O)c3c(O)c(=O)c(C(=O)NCc4ccc(F)cc4F)cn3C[C@@H]2OC[CH:1]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@H]1N2C(=O)c3c(O)c(=O)c(C(=O)NCc4ccc(F)cc4F)cn3C[C@@H]2OC[CH2:1]1,0.01
Dolutegravir,C[C@H]1N2C(=O)c3c(O)c(=O)c(C(=O)NCc4ccc(F)cc4F)cn3C[C@@H]2OC[CH2:2]1,C[C@H]1N2C(=O)c3c(O)c(=O)c(C(=O)NCc4ccc(F)cc4F)cn3C[C@@H]2OC[CH:2]1O,aliphatic_hydroxylation_(sec_carbon_in_a_ringB),Phase 1 SyGMa rules,C[C@H]1N2C(=O)c3c(O)c(=O)c(C(=O)NCc4ccc(F)cc4F)cn3C[C@@H]2OC[CH2:2]1,0.01
Tofacitinib,C[C@H]1[C@@H](N(C)c2ncnc3[nH]ccc23)CN(C(=O)CC#N)C[CH2:1]1,C[C@H]1[C@@H](N(C)c2ncnc3[nH]ccc23)CN(C(=O)CC#N)C[CH:1]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@H]1[C@@H](N(C)c2ncnc3[nH]ccc23)CN(C(=O)CC#N)C[CH2:1]1,0.04
Tofacitinib,C[C@H]1[C@@H](N(C)c2ncnc3[nH]ccc23)CN(C(=O)CC#N)C[CH2:2]1,C[C@H]1[C@@H](N(C)c2ncnc3[nH]ccc23)CN(C(=O)CC#N)C[CH:2]1O,aliphatic_hydroxylation_(sec_carbon_in_a_ringB),Phase 1 SyGMa rules,C[C@H]1[C@@H](N(C)c2ncnc3[nH]ccc23)CN(C(=O)CC#N)C[CH2:2]1,0.04
Abiraterone,C[C@]12C(=CC[C@@H]3[C@@H]1CC[C@]1(C)C(c4cccnc4)=CC[C@@H]31)C[C@@H](O)C[CH2:1]2,C[C@]12C(=CC[C@@H]3[C@@H]1CC[C@]1(C)C(c4cccnc4)=CC[C@@H]31)C[C@@H](O)C[CH:1]2O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@]12C(=CC[C@@H]3[C@@H]1CC[C@]1(C)C(c4cccnc4)=CC[C@@H]31)C[C@@H](O)C[CH2:1]2,0.07
Abiraterone,C[C@]12C(=CC[C@@H]3[C@@H]1CC[C@]1(C)C(c4cccnc4)=CC[C@@H]31)C[C@@H](O)C[CH2:2]2,C[C@]12C(=CC[C@@H]3[C@@H]1CC[C@]1(C)C(c4cccnc4)=CC[C@@H]31)C[C@@H](O)C[CH:2]2O,aliphatic_hydroxylation_(sec_carbon_in_a_ringB),Phase 1 SyGMa rules,C[C@]12C(=CC[C@@H]3[C@@H]1CC[C@]1(C)C(c4cccnc4)=CC[C@@H]31)C[C@@H](O)C[CH2:2]2,0.07
Budesonide,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1C[C@H]1OC(CC[CH3:1])O[C@]12C(=O)CO,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1C[C@H]1OC(CC[CH2:1]O)O[C@]12C(=O)CO,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1C[C@H]1OC(CC[CH3:1])O[C@]12C(=O)CO,0.09
Budesonide,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1C[C@H]1OC(CC[CH3:3])O[C@]12C(=O)CO,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1C[C@H]1OC(CC[C:3](=O)O)O[C@]12C(=O)CO,carboxylation_(primary_carbon_next_to_sec_carbon),Phase 1 SyGMa rules,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1C[C@H]1OC(CC[CH3:3])O[C@]12C(=O)CO,0.09
Budesonide,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1C[C@H]1OC(CC[CH3:3])O[C@]12C(=O)CO,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1C[C@H]1OC(CC[CH2:3]O)O[C@]12C(=O)CO,aliphatic_hydroxylation_(primary_carbon_next_to_sec_carbon),Phase 1 SyGMa rules,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1C[C@H]1OC(CC[CH3:3])O[C@]12C(=O)CO,0.09
Budesonide,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1C[C@H]1OC(C[CH2:1]C)O[C@]12C(=O)CO,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1C[C@H]1OC(C[CH:1](C)O)O[C@]12C(=O)CO,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1C[C@H]1OC(C[CH2:1]C)O[C@]12C(=O)CO,0.7
Budesonide,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1C[C@H]1OC(C[CH2:2]C)O[C@]12C(=O)CO,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1C[C@H]1OC(C[CH:2](C)O)O[C@]12C(=O)CO,"aliphatic_hydroxylation_(sec_carbon,next_to_CH3)",Phase 1 SyGMa rules,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1C[C@H]1OC(C[CH2:2]C)O[C@]12C(=O)CO,0.7
Abiraterone,C[C@]12CC[C@H:1](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,C[C@]12CC[C:1](O)(O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@]12CC[C@H:1](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,0.53
Abiraterone,C[C@]12CC[C@H:2](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,C[C@]12CC[CH:2]=CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,dehydration_next_to_SP2_b,Phase 1 SyGMa rules,C[C@]12CC[C@H:2](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,0.53
Abiraterone,C[C@]12CC[C@H](O)CC1=CC[C@@H:1]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@H]21,C[C@]12CC[C@H](O)CC1=CC[C@:1]1(O)[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@H]21,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@]12CC[C@H](O)CC1=CC[C@@H:1]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@H]21,0.02
Abiraterone,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC=[C:1]2c1cccnc1,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1C=C[C:1]2(O)c1cccnc1,aliphatic hydroxylation with allylic rearrangement 1,CYP rules from GLORY (phase 1),C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC=[C:1]2c1cccnc1,0.12
Abiraterone,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1C[CH:1]=[C:2]2c1cccnc1,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1C[CH:1]1O[C:2]21c1cccnc1,epoxidation,CYP rules from GLORY (phase 1),C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC=[C:2]2c1cccnc1,0.12
Abiraterone,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cc[cH:1]nc3)=CC[C@@H]12,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cc[c:1](O)nc3)=CC[C@@H]12,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cc[cH:1]nc3)=CC[C@@H]12,0.15
Abiraterone,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cc[cH:5]nc3)=CC[C@@H]12,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cc[c:5](O)nc3)=CC[C@@H]12,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cc[cH:5]nc3)=CC[C@@H]12,0.15
Abiraterone,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3ccc[n:1]c3)=CC[C@@H]12,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3ccc[n+:1](C4OC(C(=O)O)C(O)C(O)C4O)c3)=CC[C@@H]12,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3ccc[n:1]c3)=CC[C@@H]12,0.19
Abiraterone,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3ccc[n:1]c3)=CC[C@@H]12,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3ccc[n+:1]([O-])c3)=CC[C@@H]12,N-oxidation,CYP rules from GLORY (phase 1),C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3ccc[n:1]c3)=CC[C@@H]12,0.2
Abiraterone,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3ccc[n:2]c3)=CC[C@@H]12,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3ccc[n+:2]([O-])c3)=CC[C@@H]12,N-oxidation_(-N=),Phase 1 SyGMa rules,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3ccc[n:2]c3)=CC[C@@H]12,0.2
Abiraterone,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccn[cH:1]3)=CC[C@@H]12,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccn[c:1]3O)=CC[C@@H]12,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccn[cH:1]3)=CC[C@@H]12,0.08
Abiraterone,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H:1]12,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@:1]12O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H:1]12,0.03
Abiraterone,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=C[CH2:1][C@@H]12,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=C[CH:1](O)[C@@H]12,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=C[CH2:1][C@@H]12,0.02
Abiraterone,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=C[CH2:2][C@@H]12,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=C[CH:2](O)[C@@H]12,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=C[CH2:2][C@@H]12,0.02
Abiraterone,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1C[CH:1]=[C:2]2c1cccnc1,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1C[CH:1]1O[C:2]21c1cccnc1,epoxidation,CYP rules from GLORY (phase 1),C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=[CH:1]C[C@@H]12,0.16
Abiraterone,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cnc[cH:1]c3)=CC[C@@H]12,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cnc[c:1](O)c3)=CC[C@@H]12,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cnc[cH:1]c3)=CC[C@@H]12,0.13
Abiraterone,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cnc[cH:4]c3)=CC[C@@H]12,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cnc[c:4](O)c3)=CC[C@@H]12,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cnc[cH:4]c3)=CC[C@@H]12,0.13
Abiraterone,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cncc[cH:1]3)=CC[C@@H]12,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cncc[c:1]3O)=CC[C@@H]12,aromatic hydroxylation,CYP rules from GLORY (phase 1),C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cncc[cH:1]3)=CC[C@@H]12,0.05
Abiraterone,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2([CH3:1])C(c3cccnc3)=CC[C@@H]12,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2([CH2:1]O)C(c3cccnc3)=CC[C@@H]12,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2([CH3:1])C(c3cccnc3)=CC[C@@H]12,0.02
Abiraterone,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2C[CH2:1][C@]2(C)C(c3cccnc3)=CC[C@@H]12,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2C[CH:1](O)[C@]2(C)C(c3cccnc3)=CC[C@@H]12,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2C[CH2:1][C@]2(C)C(c3cccnc3)=CC[C@@H]12,0.02
Abiraterone,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2C[CH2:2][C@]2(C)C(c3cccnc3)=CC[C@@H]12,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2C[CH:2](O)[C@]2(C)C(c3cccnc3)=CC[C@@H]12,aliphatic_hydroxylation_(sec_carbon_in_a_ringB),Phase 1 SyGMa rules,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2C[CH2:2][C@]2(C)C(c3cccnc3)=CC[C@@H]12,0.02
Abiraterone,C[C@]12CC[C@H](O)CC1=CC[C@H]1[C@@H]3CC=C(c4cccnc4)[C@@]3(C)CC[C@@H:1]12,C[C@]12CC[C@H](O)CC1=CC[C@H]1[C@@H]3CC=C(c4cccnc4)[C@@]3(C)CC[C@@:1]12O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@]12CC[C@H](O)CC1=CC[C@H]1[C@@H]3CC=C(c4cccnc4)[C@@]3(C)CC[C@@H:1]12,0.02
Abiraterone,C[C@]12CC[C@H](O)CC1=CC[C@H]1[C@@H]3CC=C(c4cccnc4)[C@@]3(C)C[CH2:1][C@@H]12,C[C@]12CC[C@H](O)CC1=CC[C@H]1[C@@H]3CC=C(c4cccnc4)[C@@]3(C)C[CH:1](O)[C@@H]12,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@]12CC[C@H](O)CC1=CC[C@H]1[C@@H]3CC=C(c4cccnc4)[C@@]3(C)C[CH2:1][C@@H]12,0.03
Abiraterone,C[C@]12CC[C@H](O)CC1=C[CH2:1][C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,C[C@]12CC[C@H](O)CC1=C[CH:1](O)[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@]12CC[C@H](O)CC1=C[CH2:1][C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,0.15
Abiraterone,C[C@]12CC[C@H](O)CC1=C[CH2:2][C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,C[C@]12CC[C@H](O)CC1=C[CH:2](O)[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,C[C@]12CC[C@H](O)CC1=C[CH2:2][C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,0.15
Abiraterone,C[C@]12CC[C@H](O)CC1=[CH:1]C[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,C[C@]12CC[C@H](O)C=C1[CH:1](O)C[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,aliphatic hydroxylation with allylic rearrangement 1,CYP rules from GLORY (phase 1),C[C@]12CC[C@H](O)CC1=[CH:1]C[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,0.22
Abiraterone,C[C@]12CC[C@H]3[C@@H](C[CH:1]=[C:2]4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1,C[C@]12CC[C@H]3[C@@H](C[CH:1]4O[C:2]45C[C@@H](O)CC[C@]35C)[C@@H]1CC=C2c1cccnc1,epoxidation,CYP rules from GLORY (phase 1),C[C@]12CC[C@H](O)CC1=[CH:1]C[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,0.22
Abiraterone,C[C@]12CC[C@H](O)[CH2:1]C1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,C[C@]12CC[C@H](O)[CH:1](O)C1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@]12CC[C@H](O)[CH2:1]C1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,0.04
Abiraterone,C[C@]12CC[C@H](O)[CH2:2]C1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,C[C@]12CC[C@H](O)[CH:2](O)C1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,C[C@]12CC[C@H](O)[CH2:2]C1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,0.04
Abiraterone,C[C@]12CC[C@H]([OH:2])CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,C[C@]12CC[C@H]([O:2]C3OC(C(=O)O)C(O)C(O)C3O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),C[C@]12CC[C@H]([OH:2])CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,0.56
Abiraterone,C[C@]12CC[C@H]([OH:2])CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,C[C@]12CC[C@H]([O:2]S(=O)(=O)O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),C[C@]12CC[C@H]([OH:2])CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,0.81
Abiraterone,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43[CH3:1])[C@@H]1CC=C2c1cccnc1,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43[CH2:1]O)[C@@H]1CC=C2c1cccnc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43[CH3:1])[C@@H]1CC=C2c1cccnc1,0.01
Abiraterone,C[C@]12CC[C@H]3[C@@H](CC=[C:1]4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1,C[C@]12CC[C@H]3[C@@H](C=C[C:1]4(O)C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1,aliphatic hydroxylation with allylic rearrangement 1,CYP rules from GLORY (phase 1),C[C@]12CC[C@H]3[C@@H](CC=[C:1]4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1,0.42
Abiraterone,C[C@]12CC[C@H]3[C@@H](C[CH:1]=[C:2]4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1,C[C@]12CC[C@H]3[C@@H](C[CH:1]4O[C:2]45C[C@@H](O)CC[C@]35C)[C@@H]1CC=C2c1cccnc1,epoxidation,CYP rules from GLORY (phase 1),C[C@]12CC[C@H]3[C@@H](CC=[C:2]4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1,0.42
Abiraterone,C[C@]12C[CH2:1][C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,C[C@]12C[CH:1](O)[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[C@]12C[CH2:1][C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,0.06
Abiraterone,C[C@]12C[CH2:2][C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,C[C@]12C[CH:2](O)[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,aliphatic_hydroxylation_(sec_carbon_in_a_ringB),Phase 1 SyGMa rules,C[C@]12C[CH2:2][C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,0.06
Fingolimod,C[CH2:1]CCCCCCc1ccc(CCC(N)(CO)CO)cc1,C[CH:1](O)CCCCCCc1ccc(CCC(N)(CO)CO)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[CH2:1]CCCCCCc1ccc(CCC(N)(CO)CO)cc1,0.18
Ticagrelor,C[CH2:1]CSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,C[CH:1](O)CSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[CH2:1]CSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.05
Dapagliflozin,C[CH2:1]Oc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,C[CH:1](O)Oc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[CH2:1]Oc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,0.86
Fingolimod,C[CH2:2]CCCCCCc1ccc(CCC(N)(CO)CO)cc1,C[CH:2](O)CCCCCCc1ccc(CCC(N)(CO)CO)cc1,"aliphatic_hydroxylation_(sec_carbon,next_to_CH3)",Phase 1 SyGMa rules,C[CH2:2]CCCCCCc1ccc(CCC(N)(CO)CO)cc1,0.18
Ticagrelor,C[CH2:2]CSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,C[CH:2](O)CSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,"aliphatic_hydroxylation_(sec_carbon,next_to_CH3)",Phase 1 SyGMa rules,C[CH2:2]CSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,0.05
Dapagliflozin,C[CH2:3]Oc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,C[CH2:3]O.OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,O-dealkylation_(aromatic),Phase 1 SyGMa rules,C[CH2:3]Oc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,0.86
Dapagliflozin,C[CH2:3]Oc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,C[CH:3]=O,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C[CH2:3]Oc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,0.86
Darunavir,C[CH:1](C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,C[C:1](C)(O)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[CH:1](C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,0.65
Atorvastatin,C[CH:1](C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,C[C:1](C)(O)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),C[CH:1](C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.03
Atorvastatin,C[CH:2](C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,C[C:2](C)(O)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,benzylic_hydroxylation_(c-CH1-CH3),Phase 1 SyGMa rules,C[CH:2](C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0.03
Clopidogrel,C[O:2]C(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,O=C([C@H](c1ccccc1Cl)N1CCc2sccc2C1)[OH:2],hydrolysis_(methoxyester),Phase 1 SyGMa rules,C[O:2]C(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,0.01
Apixaban,C[O:2]c1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,NC(=O)c1nn(-c2ccc([OH:2])cc2)c2c1CCN(c1ccc(N3CCCCC3=O)cc1)C2=O,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),C[O:2]c1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,0.0
Clopidogrel,C[O:3]C(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,O=C([C@H](c1ccccc1Cl)N1CCc2sccc2C1)[OH:3],oxidative ester cleavage,CYP rules from GLORY (phase 1),C[O:3]C(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,0.01
Apixaban,C[O:7]c1cc[c:4](-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,O=[C:4]1C=CC(=[O:7])C=C1,oxidation of 4-substituted anisole to quinone,CYP rules from GLORY (phase 1),C[O:7]c1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,0.0
Dabigatran,C[n:1]1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,C[N+:1]1([O-])C(CNc2ccc(C(=N)N)cc2)=Nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,N-oxidation,CYP rules from GLORY (phase 1),C[n:1]1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,0.0
Dabigatran,C[n:1]1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,N=C(N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)O)c4ccccn4)ccc3[nH:1]2)cc1,N-dealkylation,CYP rules from GLORY (phase 1),C[n:1]1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,0.0
Imatinib,Cc1c(Nc2nccc(-c3cccnc3)n2)cc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)c[cH:1]1,Cc1c(Nc2nccc(-c3cccnc3)n2)cc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)c[c:1]1O,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1c(Nc2nccc(-c3cccnc3)n2)cc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)c[cH:1]1,0.01
Imatinib,Cc1c[cH:1]c(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1c[c:1](O)c(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1c[cH:1]c(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.01
Imatinib,Cc1c[cH:5]c(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1c[c:5](O)c(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,aromatic_hydroxylation_(para_to_nitrogen),Phase 1 SyGMa rules,Cc1c[cH:5]c(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.01
Nilotinib ,Cc1c[n:1](-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,CC1=C[N+:1]([O-])(c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)C=N1,N-oxidation,CYP rules from GLORY (phase 1),Cc1c[n:1](-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,0.17
Rilpivirine,Cc1cc(/C=C/C#N)[cH:1]c(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,Cc1cc(/C=C/C#N)[c:1](O)c(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1cc(/C=C/C#N)[cH:1]c(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,0.1
Rilpivirine,Cc1cc(/C=C/C#N)[cH:5]c(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,Cc1cc(/C=C/C#N)[c:5](O)c(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,Cc1cc(/C=C/C#N)[cH:5]c(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,0.1
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)[c:6]1Nc1ccnc(Nc2ccc(C#N)cc2)n1,CC1=CC(/C=C/C#N)C=C(C)[C:6]1=O,N-dearylation,CYP rules from GLORY (phase 1),Cc1cc(/C=C/C#N)cc(C)[c:6]1Nc1ccnc(Nc2ccc(C#N)cc2)n1,0.02
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)c1N[c:2]1ccnc(Nc2ccc(C#N)cc2)n1,Cc1cc(/C=C/C#N)cc(C)c1N.N#Cc1ccc(Nc2ncc[c:2](=O)[nH]2)cc1,oxidative_deamination_(aromatic),Phase 1 SyGMa rules,Cc1cc(/C=C/C#N)cc(C)c1N[c:2]1ccnc(Nc2ccc(C#N)cc2)n1,0.0
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)c1Nc1c[cH:1]nc(Nc2ccc(C#N)cc2)n1,Cc1cc(/C=C/C#N)cc(C)c1Nc1c[c:1](O)nc(Nc2ccc(C#N)cc2)n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1cc(/C=C/C#N)cc(C)c1Nc1c[cH:1]nc(Nc2ccc(C#N)cc2)n1,0.0
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)c1Nc1cc[n:1]c(Nc2ccc(C#N)cc2)n1,Cc1cc(/C=C/C#N)cc(C)c1Nc1cc[n+:1](C2OC(C(=O)O)C(O)C(O)C2O)c(Nc2ccc(C#N)cc2)n1,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),Cc1cc(/C=C/C#N)cc(C)c1Nc1cc[n:1]c(Nc2ccc(C#N)cc2)n1,0.02
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)c1Nc1cc[n:1]c(Nc2ccc(C#N)cc2)n1,Cc1cc(/C=C/C#N)cc(C)c1Nc1cc[n+:1]([O-])c(Nc2ccc(C#N)cc2)n1,N-oxidation,CYP rules from GLORY (phase 1),Cc1cc(/C=C/C#N)cc(C)c1Nc1cc[n:1]c(Nc2ccc(C#N)cc2)n1,0.03
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)c1Nc1cc[n:2]c(Nc2ccc(C#N)cc2)n1,Cc1cc(/C=C/C#N)cc(C)c1Nc1cc[n+:2]([O-])c(Nc2ccc(C#N)cc2)n1,N-oxidation_(-N=),Phase 1 SyGMa rules,Cc1cc(/C=C/C#N)cc(C)c1Nc1cc[n:2]c(Nc2ccc(C#N)cc2)n1,0.03
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccn[c:2](Nc2ccc(C#N)cc2)n1,Cc1cc(/C=C/C#N)cc(C)c1Nc1cc[nH][c:2](=O)n1.N#Cc1ccc(N)cc1,oxidative_deamination_(aromatic),Phase 1 SyGMa rules,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccn[c:2](Nc2ccc(C#N)cc2)n1,0.01
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(N[c:6]2ccc(C#N)cc2)n1,N#CC1C=C[C:6](=O)C=C1,N-dearylation,CYP rules from GLORY (phase 1),Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(N[c:6]2ccc(C#N)cc2)n1,0.0
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)[cH:1]c2)n1,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)[c:1](O)c2)n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)[cH:1]c2)n1,0.03
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)c[cH:1]2)n1,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)c[c:1]2O)n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)c[cH:1]2)n1,0.03
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)c[cH:3]2)n1,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)c[c:3]2O)n1,aromatic_hydroxylation_(ortho_to_nitrogen),Phase 1 SyGMa rules,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)c[cH:3]2)n1,0.03
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)[n:1]1,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)[n+:1]1C1OC(C(=O)O)C(O)C(O)C1O,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)[n:1]1,0.04
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)[n:1]1,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)[n+:1]1[O-],N-oxidation,CYP rules from GLORY (phase 1),Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)[n:1]1,0.0
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)[n:2]1,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)[n+:2]1[O-],N-oxidation_(-N=),Phase 1 SyGMa rules,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)[n:2]1,0.0
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc([C:1]#N)cc2)n1,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc([C:1](=N)SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)cc2)n1,glutathione_conjugation_(nitrile),GST rules (phase 2),Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc([C:1]#N)cc2)n1,0.25
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc([C:1]#N)cc2)n1,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc([C:1](N)=O)cc2)n1,nitrile_to_amide,Phase 1 SyGMa rules,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc([C:1]#N)cc2)n1,0.02
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc([NH:1]c2ccc(C#N)cc2)n1,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc([N:1](O)c2ccc(C#N)cc2)n1,amine hydroxylation,CYP rules from GLORY (phase 1),Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc([NH:1]c2ccc(C#N)cc2)n1,0.28
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc([NH:2]c2ccc(C#N)cc2)n1,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc([N:2](c2ccc(C#N)cc2)C2OC(C(=O)O)C(O)C(O)C2O)n1,N-glucuronidation_(aniline_NH1-R),UGT rules (phase 2),Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc([NH:2]c2ccc(C#N)cc2)n1,0.37
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)c1Nc1nc(Nc2ccc(C#N)cc2)nc[cH:1]1,Cc1cc(/C=C/C#N)cc(C)c1Nc1nc(Nc2ccc(C#N)cc2)nc[c:1]1O,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1cc(/C=C/C#N)cc(C)c1Nc1nc(Nc2ccc(C#N)cc2)nc[cH:1]1,0.01
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)c1Nc1nc(Nc2ccc(C#N)cc2)nc[cH:5]1,Cc1cc(/C=C/C#N)cc(C)c1Nc1nc(Nc2ccc(C#N)cc2)nc[c:5]1O,aromatic_hydroxylation_(para_to_nitrogen),Phase 1 SyGMa rules,Cc1cc(/C=C/C#N)cc(C)c1Nc1nc(Nc2ccc(C#N)cc2)nc[cH:5]1,0.01
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)c1[NH:1]c1ccnc(Nc2ccc(C#N)cc2)n1,Cc1cc(/C=C/C#N)cc(C)c1[N:1](O)c1ccnc(Nc2ccc(C#N)cc2)n1,amine hydroxylation,CYP rules from GLORY (phase 1),Cc1cc(/C=C/C#N)cc(C)c1[NH:1]c1ccnc(Nc2ccc(C#N)cc2)n1,0.1
Rilpivirine,Cc1cc(/C=C/C#N)cc(C)c1[NH:2]c1ccnc(Nc2ccc(C#N)cc2)n1,Cc1cc(/C=C/C#N)cc(C)c1[N:2](c1ccnc(Nc2ccc(C#N)cc2)n1)C1OC(C(=O)O)C(O)C(O)C1O,N-glucuronidation_(aniline_NH1-R),UGT rules (phase 2),Cc1cc(/C=C/C#N)cc(C)c1[NH:2]c1ccnc(Nc2ccc(C#N)cc2)n1,0.18
Rilpivirine,Cc1cc(/C=C/C#N)cc([CH3:1])c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,Cc1cc(/C=C/C#N)cc([CH2:1]O)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Cc1cc(/C=C/C#N)cc([CH3:1])c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,0.31
Rilpivirine,Cc1cc(/C=C/C#N)cc([CH3:2])c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,Cc1cc(/C=C/C#N)cc([C:2](=O)O)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,carboxylation_(benzylic_CH3),Phase 1 SyGMa rules,Cc1cc(/C=C/C#N)cc([CH3:2])c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,0.31
Rilpivirine,Cc1cc(/C=C/C#N)cc([CH3:2])c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,Cc1cc(/C=C/C#N)cc([CH2:2]O)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,benzylic_hydroxylation_(c-CH3),Phase 1 SyGMa rules,Cc1cc(/C=C/C#N)cc([CH3:2])c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,0.31
Rilpivirine,Cc1cc(/C=C/[C:1]#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,Cc1cc(/C=C/[C:1](=N)SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,glutathione_conjugation_(nitrile),GST rules (phase 2),Cc1cc(/C=C/[C:1]#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,0.18
Rilpivirine,Cc1cc(/C=C/[C:1]#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,Cc1cc(/C=C/[C:1](N)=O)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,nitrile_to_amide,Phase 1 SyGMa rules,Cc1cc(/C=C/[C:1]#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,0.27
Rilpivirine,Cc1cc(/[CH:1]=[CH:2]/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,Cc1cc([CH:1]2O[CH:2]2C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,epoxidation,CYP rules from GLORY (phase 1),Cc1cc(/C=[CH:2]/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,0.39
Rilpivirine,Cc1cc(/[CH:1]=[CH:2]/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,Cc1cc([CH:1]2O[CH:2]2C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,epoxidation,CYP rules from GLORY (phase 1),Cc1cc(/[CH:1]=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,0.44
Nilotinib ,Cc1ccc(C(=O)Nc2cc(-n3cc(C)[n:1]c3)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(C(=O)Nc2cc(-n3cc(C)[n+:1](C4OC(C(=O)O)C(O)C(O)C4O)c3)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),Cc1ccc(C(=O)Nc2cc(-n3cc(C)[n:1]c3)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,0.28
Nilotinib ,Cc1ccc(C(=O)Nc2cc(-n3cc(C)[n:1]c3)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(C(=O)Nc2cc(-n3cc(C)[n+:1]([O-])c3)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,N-oxidation,CYP rules from GLORY (phase 1),Cc1ccc(C(=O)Nc2cc(-n3cc(C)[n:1]c3)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,0.08
Nilotinib ,Cc1ccc(C(=O)Nc2cc(-n3cc(C)[n:2]c3)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(C(=O)Nc2cc(-n3cc(C)[n+:2]([O-])c3)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,N-oxidation_(-N=),Phase 1 SyGMa rules,Cc1ccc(C(=O)Nc2cc(-n3cc(C)[n:2]c3)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,0.08
Nilotinib ,Cc1ccc(C(=O)Nc2cc(-n3cnc(C)[cH:1]3)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(C(=O)Nc2cc(-n3cnc(C)[c:1]3O)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1ccc(C(=O)Nc2cc(-n3cnc(C)[cH:1]3)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,0.08
Nilotinib ,Cc1ccc(C(=O)Nc2cc(-n3cnc([CH3:1])c3)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(C(=O)Nc2cc(-n3cnc([CH2:1]O)c3)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Cc1ccc(C(=O)Nc2cc(-n3cnc([CH3:1])c3)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,0.44
Nilotinib ,Cc1ccc(C(=O)Nc2cc(-n3cnc([CH3:2])c3)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(C(=O)Nc2cc(-n3cnc([C:2](=O)O)c3)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,carboxylation_(benzylic_CH3),Phase 1 SyGMa rules,Cc1ccc(C(=O)Nc2cc(-n3cnc([CH3:2])c3)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,0.44
Nilotinib ,Cc1ccc(C(=O)Nc2cc(-n3cnc([CH3:2])c3)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(C(=O)Nc2cc(-n3cnc([CH2:2]O)c3)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,benzylic_hydroxylation_(c-CH3),Phase 1 SyGMa rules,Cc1ccc(C(=O)Nc2cc(-n3cnc([CH3:2])c3)cc(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,0.44
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)[cH:1]c2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)[c:1](O)c2)cc1Nc1nccc(-c2cccnc2)n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)[cH:1]c2)cc1Nc1nccc(-c2cccnc2)n1,0.0
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)c[cH:1]2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)c[c:1]2O)cc1Nc1nccc(-c2cccnc2)n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)c[cH:1]2)cc1Nc1nccc(-c2cccnc2)n1,0.0
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)[cH:1]c1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)[c:1](O)c1Nc1nccc(-c2cccnc2)n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)[cH:1]c1Nc1nccc(-c2cccnc2)n1,0.0
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)[cH:3]c1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)[c:3](O)c1Nc1nccc(-c2cccnc2)n1,aromatic_hydroxylation_(ortho_to_2_substituents),Phase 1 SyGMa rules,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)[cH:3]c1Nc1nccc(-c2cccnc2)n1,0.0
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)c[c:6]1Nc1nccc(-c2cccnc2)n1,CC1=CCC(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)=C[C:6]1=O,N-dearylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)c[c:6]1Nc1nccc(-c2cccnc2)n1,0.0
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1N[c:2]1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1N.O=[c:2]1nc(-c2cccnc2)cc[nH]1,oxidative_deamination_(aromatic),Phase 1 SyGMa rules,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1N[c:2]1nccc(-c2cccnc2)n1,0.01
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)c[cH:1]n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)c[c:1](O)n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)c[cH:1]n1,0.02
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)c[cH:4]n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)c[c:4](O)n1,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)c[cH:4]n1,0.02
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cc[n:1]1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cc[n+:1]1C1OC(C(=O)O)C(O)C(O)C1O,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cc[n:1]1,0.0
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cc[n:1]1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cc[n+:1]1[O-],N-oxidation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cc[n:1]1,0.02
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cc[n:2]1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cc[n+:2]1[O-],N-oxidation_(-N=),Phase 1 SyGMa rules,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cc[n:2]1,0.02
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc[cH:1]c(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc[c:1](O)c(-c2cccnc2)n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc[cH:1]c(-c2cccnc2)n1,0.0
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc[cH:5]c(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc[c:5](O)c(-c2cccnc2)n1,aromatic_hydroxylation_(para_to_nitrogen),Phase 1 SyGMa rules,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc[cH:5]c(-c2cccnc2)n1,0.0
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cc[cH:1]nc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cc[c:1](O)nc2)n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cc[cH:1]nc2)n1,0.02
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cc[cH:5]nc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cc[c:5](O)nc2)n1,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cc[cH:5]nc2)n1,0.02
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2ccc[n:1]c2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2ccc[n+:1](C3OC(C(=O)O)C(O)C(O)C3O)c2)n1,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2ccc[n:1]c2)n1,0.02
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2ccc[n:1]c2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2ccc[n+:1]([O-])c2)n1,N-oxidation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2ccc[n:1]c2)n1,0.64
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2ccc[n:2]c2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2ccc[n+:2]([O-])c2)n1,N-oxidation_(-N=),Phase 1 SyGMa rules,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2ccc[n:2]c2)n1,0.64
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccn[cH:1]2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccn[c:1]2O)n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccn[cH:1]2)n1,0.0
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)[n:1]1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)[n+:1]1C1OC(C(=O)O)C(O)C(O)C1O,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)[n:1]1,0.02
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)[n:1]1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)[n+:1]1[O-],N-oxidation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)[n:1]1,0.01
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)[n:2]1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)[n+:2]1[O-],N-oxidation_(-N=),Phase 1 SyGMa rules,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)[n:2]1,0.01
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cnc[cH:1]c2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cnc[c:1](O)c2)n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cnc[cH:1]c2)n1,0.01
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cnc[cH:4]c2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cnc[c:4](O)c2)n1,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cnc[cH:4]c2)n1,0.01
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cncc[cH:1]2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cncc[c:1]2O)n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cncc[cH:1]2)n1,0.0
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1[NH:1]c1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1[N:1](O)c1nccc(-c2cccnc2)n1,amine hydroxylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1[NH:1]c1nccc(-c2cccnc2)n1,0.02
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1[NH:2]c1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1[N:2](c1nccc(-c2cccnc2)n1)C1OC(C(=O)O)C(O)C(O)C1O,N-glucuronidation_(aniline_NH1-R),UGT rules (phase 2),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1[NH:2]c1nccc(-c2cccnc2)n1,0.11
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3[CH2:1]CN(C)C[CH2:2]3)cc2)cc1Nc1nccc(-c2cccnc2)n1,CN(C[CH3:1])C[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)C[CH2:1]3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.91
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CC[N:1](C)C[CH2:1]3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN(CC[NH:1]C)[CH3:1])cc2)cc1Nc1nccc(-c2cccnc2)n1,N-dealkylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)C[CH2:1]3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.91
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)C[CH2:1]3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)C[CH:1]3O)cc2)cc1Nc1nccc(-c2cccnc2)n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)C[CH2:1]3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.91
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3[CH2:1]CN(C)C[CH2:2]3)cc2)cc1Nc1nccc(-c2cccnc2)n1,CN(C[CH3:1])C[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)C[CH2:2]3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.91
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)C[CH2:2]3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)C[C:2]3=O)cc2)cc1Nc1nccc(-c2cccnc2)n1,oxidation_(amine_in_a_ring),Phase 1 SyGMa rules,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)C[CH2:2]3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.91
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)C[CH2:2]3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)C[CH:2]3O)cc2)cc1Nc1nccc(-c2cccnc2)n1,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)C[CH2:2]3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.91
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3C[CH2:1]N(C)[CH2:2]C3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN(C[CH3:1])C[CH:2]=O)cc2)cc1Nc1nccc(-c2cccnc2)n1,N-dealkylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)[CH2:1]C3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.89
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)[CH2:1]C3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)[CH:1](O)C3)cc2)cc1Nc1nccc(-c2cccnc2)n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)[CH2:1]C3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.89
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3C[CH2:1]N(C)[CH2:2]C3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN(C[CH3:1])C[CH:2]=O)cc2)cc1Nc1nccc(-c2cccnc2)n1,N-dealkylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN(C)[CH2:2]C3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.89
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)[CH2:2]C3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)[C:2](=O)C3)cc2)cc1Nc1nccc(-c2cccnc2)n1,oxidation_(amine_in_a_ring),Phase 1 SyGMa rules,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)[CH2:2]C3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.89
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)[CH2:2]C3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)[CH:2](O)C3)cc2)cc1Nc1nccc(-c2cccnc2)n1,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)[CH2:2]C3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.89
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CCN([CH3:1])CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CCN([CH2:1]O)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CCN([CH3:1])CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.9
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CC[N:1](C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CC[N+:1](C)(C4OC(C(=O)O)C(O)C(O)C4O)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,N-glucuronidation_(NCH3_in_a_ring),UGT rules (phase 2),Cc1ccc(NC(=O)c2ccc(CN3CC[N:1](C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.76
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CC[N:1](C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CC[N+:1](C)([O-])CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,N-oxidation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CC[N:1](C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.82
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CC[N:1](C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CC[NH:1]CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,N-dealkylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CC[N:1](C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.82
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CC[N:2](C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CC[N+:2](C)([O-])CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,N-oxidation_(tertiary_NCH3),Phase 1 SyGMa rules,Cc1ccc(NC(=O)c2ccc(CN3CC[N:2](C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.82
Imatinib,Cc1ccc(NC(=O)c2ccc(CN3CC[N:2](C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(CN3CC[NH:2]CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,N-demethylation_(R-N(CR)CH3),Phase 1 SyGMa rules,Cc1ccc(NC(=O)c2ccc(CN3CC[N:2](C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.82
Imatinib,Cc1ccc(NC(=O)c2ccc(C[N:5]3CC[N:2](C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(C[NH:5]CC[NH:2]C)cc2)cc1Nc1nccc(-c2cccnc2)n1,N-dealkylation of piperazine,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(CN3CC[N:2](C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.82
Imatinib,Cc1ccc(NC(=O)c2ccc(C[N:1]3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,CN1CC[NH:1]CC1,N-dealkylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(C[N:1]3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.04
Imatinib,Cc1ccc(NC(=O)c2ccc(C[N:1]3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(C[N+:1]3([O-])CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,N-oxidation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(C[N:1]3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.04
Imatinib,Cc1ccc(NC(=O)c2ccc(C[N:1]3CCN(C)[CH2:1]C3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(C[NH:1]CCN(C)[CH3:1])cc2)cc1Nc1nccc(-c2cccnc2)n1,N-dealkylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(C[N:1]3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.04
Imatinib,Cc1ccc(NC(=O)c2ccc(C[N:2]3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(C[N+:2]3([O-])CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,N-oxidation_(tertiary_N),Phase 1 SyGMa rules,Cc1ccc(NC(=O)c2ccc(C[N:2]3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.04
Imatinib,Cc1ccc(NC(=O)c2ccc(C[N:5]3CC[N:2](C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc(C[NH:5]CC[NH:2]C)cc2)cc1Nc1nccc(-c2cccnc2)n1,N-dealkylation of piperazine,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc(C[N:5]3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.04
Imatinib,Cc1ccc(NC(=O)c2ccc([CH2:1]N3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc([CH:1](O)N3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc([CH2:1]N3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.81
Imatinib,Cc1ccc(NC(=O)c2ccc([CH2:2]N3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc([CH:2](O)N3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,benzylic_hydroxylation_(c-CH2-N),Phase 1 SyGMa rules,Cc1ccc(NC(=O)c2ccc([CH2:2]N3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.81
Imatinib,Cc1ccc(NC(=O)c2ccc([CH2:2]N3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc(NC(=O)c2ccc([CH:2]=O)cc2)cc1Nc1nccc(-c2cccnc2)n1,N-dealkylation,CYP rules from GLORY (phase 1),Cc1ccc(NC(=O)c2ccc([CH2:2]N3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.81
Imatinib,Cc1ccc(NC(=O)c2ccc([CH2:4]N3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,CN1CCNCC1.Cc1ccc(NC(=O)c2ccc([CH2:4]O)cc2)cc1Nc1nccc(-c2cccnc2)n1,N-dealkylation_(tertiaryN-CH2-alkyl),Phase 1 SyGMa rules,Cc1ccc(NC(=O)c2ccc([CH2:4]N3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.81
Imatinib,Cc1ccc(N[C:2](=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,CN1CCN(Cc2ccc([C:2](=O)O)cc2)CC1.Cc1ccc(N)cc1Nc1nccc(-c2cccnc2)n1,hydrolysis_(secondary_amide),Phase 1 SyGMa rules,Cc1ccc(N[C:2](=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.06
Imatinib,Cc1ccc([NH:1]C(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc([N:1](O)C(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,amine hydroxylation,CYP rules from GLORY (phase 1),Cc1ccc([NH:1]C(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.0
Imatinib,Cc1ccc([NH:2]C(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Cc1ccc([N:2](C(=O)c2ccc(CN3CCN(C)CC3)cc2)C2OC(C(=O)O)C(O)C(O)C2O)cc1Nc1nccc(-c2cccnc2)n1,N-glucuronidation_(aniline_NH1-R),UGT rules (phase 2),Cc1ccc([NH:2]C(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0.0
Dasatinib,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)[n:1]c(C)n2)s1,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)[n+:1](C3OC(C(=O)O)C(O)C(O)C3O)c(C)n2)s1,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)[n:1]c(C)n2)s1,0.0
Dasatinib,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)[n:1]c(C)n2)s1,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)[n+:1]([O-])c(C)n2)s1,N-oxidation,CYP rules from GLORY (phase 1),Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)[n:1]c(C)n2)s1,0.0
Dasatinib,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)[n:2]c(C)n2)s1,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)[n+:2]([O-])c(C)n2)s1,N-oxidation_(-N=),Phase 1 SyGMa rules,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)[n:2]c(C)n2)s1,0.0
Dasatinib,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)nc(C)[n:1]2)s1,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)nc(C)[n+:1]2C2OC(C(=O)O)C(O)C(O)C2O)s1,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)nc(C)[n:1]2)s1,0.01
Dasatinib,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)nc(C)[n:1]2)s1,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)nc(C)[n+:1]2[O-])s1,N-oxidation,CYP rules from GLORY (phase 1),Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)nc(C)[n:1]2)s1,0.0
Dasatinib,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)nc(C)[n:2]2)s1,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)nc(C)[n+:2]2[O-])s1,N-oxidation_(-N=),Phase 1 SyGMa rules,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)nc(C)[n:2]2)s1,0.0
Dasatinib,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)nc([CH3:1])n2)s1,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)nc([CH2:1]O)n2)s1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)nc([CH3:1])n2)s1,0.0
Dasatinib,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)nc([CH3:2])n2)s1,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)nc([C:2](=O)O)n2)s1,carboxylation_(benzylic_CH3),Phase 1 SyGMa rules,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)nc([CH3:2])n2)s1,0.0
Dasatinib,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)nc([CH3:2])n2)s1,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)nc([CH2:2]O)n2)s1,benzylic_hydroxylation_(c-CH3),Phase 1 SyGMa rules,Cc1cccc(Cl)c1NC(=O)c1cnc(Nc2cc(N3CCN(CCO)CC3)nc([CH3:2])n2)s1,0.0
Nilotinib ,Cc1cn(-c2cc(C(F)(F)F)cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)[cH:1]2)cn1,Cc1cn(-c2cc(C(F)(F)F)cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)[c:1]2O)cn1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1cn(-c2cc(C(F)(F)F)cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)[cH:1]2)cn1,0.01
Nilotinib ,Cc1cn(-c2cc(C(F)(F)F)cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)[cH:5]2)cn1,Cc1cn(-c2cc(C(F)(F)F)cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)[c:5]2O)cn1,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,Cc1cn(-c2cc(C(F)(F)F)cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)[cH:5]2)cn1,0.01
Nilotinib ,Cc1cn(-c2cc(C(F)(F)F)cc([NH:1]C(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)c2)cn1,Cc1cn(-c2cc(C(F)(F)F)cc([N:1](O)C(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)c2)cn1,amine hydroxylation,CYP rules from GLORY (phase 1),Cc1cn(-c2cc(C(F)(F)F)cc([NH:1]C(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)c2)cn1,0.08
Nilotinib ,Cc1cn(-c2cc(C(F)(F)F)cc([NH:2]C(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)c2)cn1,Cc1cn(-c2cc(C(F)(F)F)cc([N:2](C(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)C3OC(C(=O)O)C(O)C(O)C3O)c2)cn1,N-glucuronidation_(aniline_NH1-R),UGT rules (phase 2),Cc1cn(-c2cc(C(F)(F)F)cc([NH:2]C(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)c2)cn1,0.05
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3cc(Nc4nccc(-c5cccnc5)n4)c(C)[cH:1]c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3cc(Nc4nccc(-c5cccnc5)n4)c(C)[c:1](O)c3)cc(C(F)(F)F)c2)cn1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1cn(-c2cc(NC(=O)c3cc(Nc4nccc(-c5cccnc5)n4)c(C)[cH:1]c3)cc(C(F)(F)F)c2)cn1,0.01
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3cc(Nc4nccc(-c5cccnc5)n4)c(C)c[cH:1]3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3cc(Nc4nccc(-c5cccnc5)n4)c(C)c[c:1]3O)cc(C(F)(F)F)c2)cn1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1cn(-c2cc(NC(=O)c3cc(Nc4nccc(-c5cccnc5)n4)c(C)c[cH:1]3)cc(C(F)(F)F)c2)cn1,0.0
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3cc(Nc4nccc(-c5cccnc5)n4)c(C)c[cH:5]3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3cc(Nc4nccc(-c5cccnc5)n4)c(C)c[c:5]3O)cc(C(F)(F)F)c2)cn1,aromatic_hydroxylation_(para_to_nitrogen),Phase 1 SyGMa rules,Cc1cn(-c2cc(NC(=O)c3cc(Nc4nccc(-c5cccnc5)n4)c(C)c[cH:5]3)cc(C(F)(F)F)c2)cn1,0.0
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)[c:6](Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,CC1=CCC(C(=O)Nc2cc(-n3cnc(C)c3)cc(C(F)(F)F)c2)=C[C:6]1=O,N-dearylation,CYP rules from GLORY (phase 1),Cc1cn(-c2cc(NC(=O)c3ccc(C)[c:6](Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,0.01
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(N[c:2]4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(N)c3)cc(C(F)(F)F)c2)cn1.O=[c:2]1nc(-c2cccnc2)cc[nH]1,oxidative_deamination_(aromatic),Phase 1 SyGMa rules,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(N[c:2]4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,0.0
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nc(-c5cccnc5)c[cH:1]n4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nc(-c5cccnc5)c[c:1](O)n4)c3)cc(C(F)(F)F)c2)cn1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nc(-c5cccnc5)c[cH:1]n4)c3)cc(C(F)(F)F)c2)cn1,0.01
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nc(-c5cccnc5)c[cH:4]n4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nc(-c5cccnc5)c[c:4](O)n4)c3)cc(C(F)(F)F)c2)cn1,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nc(-c5cccnc5)c[cH:4]n4)c3)cc(C(F)(F)F)c2)cn1,0.01
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nc(-c5cccnc5)cc[n:1]4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nc(-c5cccnc5)cc[n+:1]4C4OC(C(=O)O)C(O)C(O)C4O)c3)cc(C(F)(F)F)c2)cn1,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nc(-c5cccnc5)cc[n:1]4)c3)cc(C(F)(F)F)c2)cn1,0.0
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nc(-c5cccnc5)cc[n:1]4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nc(-c5cccnc5)cc[n+:1]4[O-])c3)cc(C(F)(F)F)c2)cn1,N-oxidation,CYP rules from GLORY (phase 1),Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nc(-c5cccnc5)cc[n:1]4)c3)cc(C(F)(F)F)c2)cn1,0.02
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nc(-c5cccnc5)cc[n:2]4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nc(-c5cccnc5)cc[n+:2]4[O-])c3)cc(C(F)(F)F)c2)cn1,N-oxidation_(-N=),Phase 1 SyGMa rules,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nc(-c5cccnc5)cc[n:2]4)c3)cc(C(F)(F)F)c2)cn1,0.02
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nc[cH:1]c(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nc[c:1](O)c(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nc[cH:1]c(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,0.01
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nc[cH:5]c(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nc[c:5](O)c(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,aromatic_hydroxylation_(para_to_nitrogen),Phase 1 SyGMa rules,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nc[cH:5]c(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,0.01
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cc[cH:1]nc5)n4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cc[c:1](O)nc5)n4)c3)cc(C(F)(F)F)c2)cn1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cc[cH:1]nc5)n4)c3)cc(C(F)(F)F)c2)cn1,0.05
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cc[cH:5]nc5)n4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cc[c:5](O)nc5)n4)c3)cc(C(F)(F)F)c2)cn1,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cc[cH:5]nc5)n4)c3)cc(C(F)(F)F)c2)cn1,0.05
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5ccc[n:1]c5)n4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5ccc[n+:1](C6OC(C(=O)O)C(O)C(O)C6O)c5)n4)c3)cc(C(F)(F)F)c2)cn1,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5ccc[n:1]c5)n4)c3)cc(C(F)(F)F)c2)cn1,0.02
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5ccc[n:1]c5)n4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5ccc[n+:1]([O-])c5)n4)c3)cc(C(F)(F)F)c2)cn1,N-oxidation,CYP rules from GLORY (phase 1),Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5ccc[n:1]c5)n4)c3)cc(C(F)(F)F)c2)cn1,0.46
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5ccc[n:2]c5)n4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5ccc[n+:2]([O-])c5)n4)c3)cc(C(F)(F)F)c2)cn1,N-oxidation_(-N=),Phase 1 SyGMa rules,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5ccc[n:2]c5)n4)c3)cc(C(F)(F)F)c2)cn1,0.46
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccn[cH:1]5)n4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccn[c:1]5O)n4)c3)cc(C(F)(F)F)c2)cn1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccn[cH:1]5)n4)c3)cc(C(F)(F)F)c2)cn1,0.0
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)[n:1]4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)[n+:1]4C4OC(C(=O)O)C(O)C(O)C4O)c3)cc(C(F)(F)F)c2)cn1,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)[n:1]4)c3)cc(C(F)(F)F)c2)cn1,0.02
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)[n:1]4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)[n+:1]4[O-])c3)cc(C(F)(F)F)c2)cn1,N-oxidation,CYP rules from GLORY (phase 1),Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)[n:1]4)c3)cc(C(F)(F)F)c2)cn1,0.01
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)[n:2]4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)[n+:2]4[O-])c3)cc(C(F)(F)F)c2)cn1,N-oxidation_(-N=),Phase 1 SyGMa rules,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)[n:2]4)c3)cc(C(F)(F)F)c2)cn1,0.01
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)[cH:1]3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)[c:1]3O)cc(C(F)(F)F)c2)cn1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)[cH:1]3)cc(C(F)(F)F)c2)cn1,0.01
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)[cH:3]3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)[c:3]3O)cc(C(F)(F)F)c2)cn1,aromatic_hydroxylation_(ortho_to_2_substituents),Phase 1 SyGMa rules,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)[cH:3]3)cc(C(F)(F)F)c2)cn1,0.01
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)[cH:1]c(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)[c:1](O)c(C(F)(F)F)c2)cn1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)[cH:1]c(C(F)(F)F)c2)cn1,0.04
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)[cH:5]c(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)[c:5](O)c(C(F)(F)F)c2)cn1,aromatic_hydroxylation_(para_to_nitrogen),Phase 1 SyGMa rules,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)[cH:5]c(C(F)(F)F)c2)cn1,0.04
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)[cH:1]2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)[c:1]2O)cn1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)[cH:1]2)cn1,0.04
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)[cH:5]2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)[c:5]2O)cn1,aromatic_hydroxylation_(para_to_nitrogen),Phase 1 SyGMa rules,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)[cH:5]2)cn1,0.04
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)[cH:1]n1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)[c:1](O)n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)[cH:1]n1,0.17
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)[cH:2]n1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)[c:2](=O)[nH]1,aromatic_oxidation_(nitrogen_containing_5ring),Phase 1 SyGMa rules,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)[cH:2]n1,0.17
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnc[cH:1]c5)n4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnc[c:1](O)c5)n4)c3)cc(C(F)(F)F)c2)cn1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnc[cH:1]c5)n4)c3)cc(C(F)(F)F)c2)cn1,0.0
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnc[cH:4]c5)n4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnc[c:4](O)c5)n4)c3)cc(C(F)(F)F)c2)cn1,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnc[cH:4]c5)n4)c3)cc(C(F)(F)F)c2)cn1,0.0
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cncc[cH:1]5)n4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cncc[c:1]5O)n4)c3)cc(C(F)(F)F)c2)cn1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cncc[cH:1]5)n4)c3)cc(C(F)(F)F)c2)cn1,0.0
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c([NH:1]c4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c([N:1](O)c4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,amine hydroxylation,CYP rules from GLORY (phase 1),Cc1cn(-c2cc(NC(=O)c3ccc(C)c([NH:1]c4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,0.17
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc(C)c([NH:2]c4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc(C)c([N:2](c4nccc(-c5cccnc5)n4)C4OC(C(=O)O)C(O)C(O)C4O)c3)cc(C(F)(F)F)c2)cn1,N-glucuronidation_(aniline_NH1-R),UGT rules (phase 2),Cc1cn(-c2cc(NC(=O)c3ccc(C)c([NH:2]c4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,0.17
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc([CH3:1])c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc([CH2:1]O)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Cc1cn(-c2cc(NC(=O)c3ccc([CH3:1])c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,0.32
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc([CH3:2])c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc([C:2](=O)O)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,carboxylation_(benzylic_CH3),Phase 1 SyGMa rules,Cc1cn(-c2cc(NC(=O)c3ccc([CH3:2])c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,0.32
Nilotinib ,Cc1cn(-c2cc(NC(=O)c3ccc([CH3:2])c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,Cc1cn(-c2cc(NC(=O)c3ccc([CH2:2]O)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,benzylic_hydroxylation_(c-CH3),Phase 1 SyGMa rules,Cc1cn(-c2cc(NC(=O)c3ccc([CH3:2])c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,0.32
Nilotinib ,Cc1cn(-c2cc(N[C:2](=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,Cc1ccc([C:2](=O)O)cc1Nc1nccc(-c2cccnc2)n1.Cc1cn(-c2cc(N)cc(C(F)(F)F)c2)cn1,hydrolysis_(secondary_amide),Phase 1 SyGMa rules,Cc1cn(-c2cc(N[C:2](=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,0.22
Linagliptin,Cc1nc(Cn2c(=O)c3c(nc(N4CCC[C@@H](N)C4)n3CC#C[CH3:1])n(C)c2=O)nc2ccccc12,Cc1nc(Cn2c(=O)c3c(nc(N4CCC[C@@H](N)C4)n3CC#C[CH2:1]O)n(C)c2=O)nc2ccccc12,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Cc1nc(Cn2c(=O)c3c(nc(N4CCC[C@@H](N)C4)n3CC#C[CH3:1])n(C)c2=O)nc2ccccc12,0.86
Linagliptin,Cc1nc(Cn2c(=O)c3c(nc(N4CCC[C@@H](N)C4)n3CC#C[CH3:2])n(C)c2=O)nc2ccccc12,Cc1nc(Cn2c(=O)c3c(nc(N4CCC[C@@H](N)C4)n3CC#C[C:2](=O)O)n(C)c2=O)nc2ccccc12,carboxylation_(primary_carbon_next_to_SP2),Phase 1 SyGMa rules,Cc1nc(Cn2c(=O)c3c(nc(N4CCC[C@@H](N)C4)n3CC#C[CH3:2])n(C)c2=O)nc2ccccc12,0.86
Linagliptin,Cc1nc(Cn2c(=O)c3c(nc(N4CCC[C@@H](N)C4)n3CC#C[CH3:2])n(C)c2=O)nc2ccccc12,Cc1nc(Cn2c(=O)c3c(nc(N4CCC[C@@H](N)C4)n3CC#C[CH2:2]O)n(C)c2=O)nc2ccccc12,aliphatic_hydroxylation_(primary_carbon_next_to_SP2_or_SP1),Phase 1 SyGMa rules,Cc1nc(Cn2c(=O)c3c(nc(N4CCC[C@@H](N)C4)n3CC#C[CH3:2])n(C)c2=O)nc2ccccc12,0.86
Dasatinib,Cc1nc(N2CCN(CCO)CC2)c[c:2](Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)n1,Cc1cccc(Cl)c1NC(=O)c1cnc(N)s1.Cc1nc(N2CCN(CCO)CC2)c[c:2](=O)[nH]1,oxidative_deamination_(aromatic),Phase 1 SyGMa rules,Cc1nc(N2CCN(CCO)CC2)c[c:2](Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)n1,0.0
Dasatinib,Cc1nc(N2CCN(CCO)CC2)cc([NH:1]c2ncc(C(=O)Nc3c(C)cccc3Cl)s2)n1,Cc1nc(N2CCN(CCO)CC2)cc([N:1](O)c2ncc(C(=O)Nc3c(C)cccc3Cl)s2)n1,amine hydroxylation,CYP rules from GLORY (phase 1),Cc1nc(N2CCN(CCO)CC2)cc([NH:1]c2ncc(C(=O)Nc3c(C)cccc3Cl)s2)n1,0.0
Dasatinib,Cc1nc(N2CCN(CCO)CC2)cc([NH:2]c2ncc(C(=O)Nc3c(C)cccc3Cl)s2)n1,Cc1nc(N2CCN(CCO)CC2)cc([N:2](c2ncc(C(=O)Nc3c(C)cccc3Cl)s2)C2OC(C(=O)O)C(O)C(O)C2O)n1,N-glucuronidation_(aniline_NH1-R),UGT rules (phase 2),Cc1nc(N2CCN(CCO)CC2)cc([NH:2]c2ncc(C(=O)Nc3c(C)cccc3Cl)s2)n1,0.11
Dasatinib,Cc1nc(N[c:2]2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,Cc1cccc(Cl)c1NC(=O)c1c[nH][c:2](=O)s1.Cc1nc(N)cc(N2CCN(CCO)CC2)n1,oxidative_deamination_(aromatic),Phase 1 SyGMa rules,Cc1nc(N[c:2]2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,0.0
Dasatinib,Cc1nc(Nc2n[cH:1]c(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,Cc1nc(Nc2n[c:1](O)c(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1nc(Nc2n[cH:1]c(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,0.0
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)c[cH:1]cc3Cl)s2)cc(N2CCN(CCO)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)c[c:1](O)cc3Cl)s2)cc(N2CCN(CCO)CC2)n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(C)c[cH:1]cc3Cl)s2)cc(N2CCN(CCO)CC2)n1,0.97
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)c[cH:5]cc3Cl)s2)cc(N2CCN(CCO)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)c[c:5](O)cc3Cl)s2)cc(N2CCN(CCO)CC2)n1,aromatic_hydroxylation_(para_to_nitrogen),Phase 1 SyGMa rules,Cc1nc(Nc2ncc(C(=O)Nc3c(C)c[cH:5]cc3Cl)s2)cc(N2CCN(CCO)CC2)n1,0.97
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cc[cH:1]c3Cl)s2)cc(N2CCN(CCO)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cc[c:1](O)c3Cl)s2)cc(N2CCN(CCO)CC2)n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(C)cc[cH:1]c3Cl)s2)cc(N2CCN(CCO)CC2)n1,0.02
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cc[cH:5]c3Cl)s2)cc(N2CCN(CCO)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cc[c:5](O)c3Cl)s2)cc(N2CCN(CCO)CC2)n1,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cc[cH:5]c3Cl)s2)cc(N2CCN(CCO)CC2)n1,0.02
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)ccc[c:1]3Cl)s2)cc(N2CCN(CCO)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)ccc[c:1]3O)s2)cc(N2CCN(CCO)CC2)n1,oxidative dehalogenation benzyl,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(C)ccc[c:1]3Cl)s2)cc(N2CCN(CCO)CC2)n1,0.0
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)ccc[c:1]3Cl)s2)cc(N2CCN(CCO)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)ccc[c:1]3SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)s2)cc(N2CCN(CCO)CC2)n1,glutathione_conjugation_(aromatic_nucleophilic_substitution),GST rules (phase 2),Cc1nc(Nc2ncc(C(=O)Nc3c(C)ccc[c:1]3Cl)s2)cc(N2CCN(CCO)CC2)n1,0.05
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)[s:1]2)cc(N2CCN(CCO)CC2)n1,Cc1nc(NC2=NC=C(C(=O)Nc3c(C)cccc3Cl)[S:1]2=O)cc(N2CCN(CCO)CC2)n1,S-oxidation,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)[s:1]2)cc(N2CCN(CCO)CC2)n1,0.0
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)[s:2]2)cc(N2CCN(CCO)CC2)n1,Cc1nc(NC2=NC=C(C(=O)Nc3c(C)cccc3Cl)[S:2]2=O)cc(N2CCN(CCO)CC2)n1,sulfide_oxidation_(c-S-c),Phase 1 SyGMa rules,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)[s:2]2)cc(N2CCN(CCO)CC2)n1,0.0
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)[cH:1]c(N2CCN(CCO)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)[c:1](O)c(N2CCN(CCO)CC2)n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)[cH:1]c(N2CCN(CCO)CC2)n1,0.0
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)[cH:5]c(N2CCN(CCO)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)[c:5](O)c(N2CCN(CCO)CC2)n1,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)[cH:5]c(N2CCN(CCO)CC2)n1,0.0
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)c[c:2](N2CCN(CCO)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)c[c:2](=O)[nH]1.OCCN1CCNCC1,oxidative_deamination_(aromatic),Phase 1 SyGMa rules,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)c[c:2](N2CCN(CCO)CC2)n1,0.0
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)C[CH2:1]2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)C[CH:1]2O)n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)C[CH2:1]2)n1,0.0
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2[CH2:1]CN(CCO)C[CH2:2]2)n1,O=[CH:2]CN(CCO)C[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)C[CH2:1]2)n1,0.0
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)C[CH2:2]2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)C[C:2]2=O)n1,oxidation_(amine_in_a_ring),Phase 1 SyGMa rules,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)C[CH2:2]2)n1,0.0
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)C[CH2:2]2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)C[CH:2]2O)n1,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)C[CH2:2]2)n1,0.0
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2[CH2:1]CN(CCO)C[CH2:2]2)n1,O=[CH:2]CN(CCO)C[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)C[CH2:2]2)n1,0.0
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2C[CH2:1]N(CCO)[CH2:2]C2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N(C[CH3:1])C[CH:2]=O)n1,N-dealkylation,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)[CH2:1]C2)n1,0.0
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)[CH2:1]C2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)[CH:1](O)C2)n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)[CH2:1]C2)n1,0.0
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc([N:1]2CCN(CCO)[CH2:1]C2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc([NH:1]CCN(CCO)[CH3:1])n1,N-dealkylation,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)[CH2:1]C2)n1,0.0
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2C[CH2:1]N(CCO)[CH2:2]C2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N(C[CH3:1])C[CH:2]=O)n1,N-dealkylation,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)[CH2:2]C2)n1,0.0
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)[CH2:2]C2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)[C:2](=O)C2)n1,oxidation_(amine_in_a_ring),Phase 1 SyGMa rules,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)[CH2:2]C2)n1,0.0
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)[CH2:2]C2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)[CH:2](O)C2)n1,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)[CH2:2]C2)n1,0.0
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CC[OH:2])CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CC[O:2]C3OC(C(=O)O)C(O)C(O)C3O)CC2)n1,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CC[OH:2])CC2)n1,0.86
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CC[OH:2])CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CC[O:2]S(=O)(=O)O)CC2)n1,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CC[OH:2])CC2)n1,0.84
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(C[CH2:1]O)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(C[CH:1](O)O)CC2)n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(C[CH2:1]O)CC2)n1,0.64
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(C[CH2:2]O)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(C[C:2](=O)O)CC2)n1,primary_alcohol_oxidation_(aliphatic),Phase 1 SyGMa rules,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(C[CH2:2]O)CC2)n1,0.64
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN([CH2:1]CO)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN([CH:1](O)CO)CC2)n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN([CH2:1]CO)CC2)n1,0.59
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN([CH2:2]CO)CC2)n1,O=[CH:2]CO,N-dealkylation,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN([CH2:2]CO)CC2)n1,0.59
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN([CH2:4]CO)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCNCC2)n1.OC[CH2:4]O,N-dealkylation_(tertiaryN-CH2-alkyl),Phase 1 SyGMa rules,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN([CH2:4]CO)CC2)n1,0.59
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CC[N:1](CCO)C[CH2:1]2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N(CC[NH:1]CCO)[CH3:1])n1,N-dealkylation,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CC[N:1](CCO)CC2)n1,0.68
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CC[N:1](CCO)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CC[N+:1]([O-])(CCO)CC2)n1,N-oxidation,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CC[N:1](CCO)CC2)n1,0.68
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CC[N:1](CCO)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CC[NH:1]CC2)n1,N-dealkylation,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CC[N:1](CCO)CC2)n1,0.68
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CC[N:2](CCO)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CC[N+:2]([O-])(CCO)CC2)n1,N-oxidation_(tertiary_N),Phase 1 SyGMa rules,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CC[N:2](CCO)CC2)n1,0.68
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc([N:2]2CC[N:5](CCO)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc([NH:2]CC[NH:5]CCO)n1,N-dealkylation of piperazine,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CC[N:5](CCO)CC2)n1,0.68
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc([N:1]2CCN(CCO)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc([N+:1]2([O-])CCN(CCO)CC2)n1,N-oxidation,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc([N:1]2CCN(CCO)CC2)n1,0.0
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc([N:2]2CC[N:5](CCO)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc([NH:2]CC[NH:5]CCO)n1,N-dealkylation of piperazine,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc([N:2]2CCN(CCO)CC2)n1,0.0
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)cc[cH:1]c3C)s2)cc(N2CCN(CCO)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)cc[c:1](O)c3C)s2)cc(N2CCN(CCO)CC2)n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)cc[cH:1]c3C)s2)cc(N2CCN(CCO)CC2)n1,0.03
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)cccc3[CH3:1])s2)cc(N2CCN(CCO)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)cccc3[CH2:1]O)s2)cc(N2CCN(CCO)CC2)n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)cccc3[CH3:1])s2)cc(N2CCN(CCO)CC2)n1,0.7
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)cccc3[CH3:2])s2)cc(N2CCN(CCO)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)cccc3[C:2](=O)O)s2)cc(N2CCN(CCO)CC2)n1,carboxylation_(benzylic_CH3),Phase 1 SyGMa rules,Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)cccc3[CH3:2])s2)cc(N2CCN(CCO)CC2)n1,0.7
Dasatinib,Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)cccc3[CH3:2])s2)cc(N2CCN(CCO)CC2)n1,Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)cccc3[CH2:2]O)s2)cc(N2CCN(CCO)CC2)n1,benzylic_hydroxylation_(c-CH3),Phase 1 SyGMa rules,Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)cccc3[CH3:2])s2)cc(N2CCN(CCO)CC2)n1,0.7
Dasatinib,Cc1nc(Nc2ncc(C(=O)[NH:1]c3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,Cc1nc(Nc2ncc(C(=O)[N:1](O)c3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,amine hydroxylation,CYP rules from GLORY (phase 1),Cc1nc(Nc2ncc(C(=O)[NH:1]c3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,0.02
Dasatinib,Cc1nc(Nc2ncc(C(=O)[NH:2]c3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,Cc1nc(Nc2ncc(C(=O)[N:2](c3c(C)cccc3Cl)C3OC(C(=O)O)C(O)C(O)C3O)s2)cc(N2CCN(CCO)CC2)n1,N-glucuronidation_(aniline_NH1-R),UGT rules (phase 2),Cc1nc(Nc2ncc(C(=O)[NH:2]c3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,0.01
Dasatinib,Cc1nc(Nc2ncc([C:2](=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,Cc1cccc(Cl)c1N.Cc1nc(Nc2ncc([C:2](=O)O)s2)cc(N2CCN(CCO)CC2)n1,hydrolysis_(secondary_amide),Phase 1 SyGMa rules,Cc1nc(Nc2ncc([C:2](=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,0.0
Dasatinib,Cc1nc(Nc2sc(C(=O)Nc3c(C)cccc3Cl)c[n:1]2)cc(N2CCN(CCO)CC2)n1,Cc1nc(Nc2sc(C(=O)Nc3c(C)cccc3Cl)c[n+:1]2C2OC(C(=O)O)C(O)C(O)C2O)cc(N2CCN(CCO)CC2)n1,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),Cc1nc(Nc2sc(C(=O)Nc3c(C)cccc3Cl)c[n:1]2)cc(N2CCN(CCO)CC2)n1,0.0
Dasatinib,Cc1nc(Nc2sc(C(=O)Nc3c(C)cccc3Cl)c[n:1]2)cc(N2CCN(CCO)CC2)n1,Cc1nc(Nc2sc(C(=O)Nc3c(C)cccc3Cl)c[n+:1]2[O-])cc(N2CCN(CCO)CC2)n1,N-oxidation,CYP rules from GLORY (phase 1),Cc1nc(Nc2sc(C(=O)Nc3c(C)cccc3Cl)c[n:1]2)cc(N2CCN(CCO)CC2)n1,0.0
Dasatinib,Cc1nc(Nc2sc(C(=O)Nc3c(C)cccc3Cl)c[n:2]2)cc(N2CCN(CCO)CC2)n1,Cc1nc(Nc2sc(C(=O)Nc3c(C)cccc3Cl)c[n+:2]2[O-])cc(N2CCN(CCO)CC2)n1,N-oxidation_(-N=),Phase 1 SyGMa rules,Cc1nc(Nc2sc(C(=O)Nc3c(C)cccc3Cl)c[n:2]2)cc(N2CCN(CCO)CC2)n1,0.0
Dabigatran,Cn1c(CNc2ccc(C(=N)N)[cH:1]c2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,Cn1c(CNc2ccc(C(=N)N)[c:1](O)c2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cn1c(CNc2ccc(C(=N)N)[cH:1]c2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,0.04
Dabigatran,Cn1c(CNc2ccc(C(=N)N)c[cH:1]2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,Cn1c(CNc2ccc(C(=N)N)c[c:1]2O)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cn1c(CNc2ccc(C(=N)N)c[cH:1]2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,0.02
Dabigatran,Cn1c(CNc2ccc(C(=N)N)c[cH:3]2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,Cn1c(CNc2ccc(C(=N)N)c[c:3]2O)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,aromatic_hydroxylation_(ortho_to_nitrogen),Phase 1 SyGMa rules,Cn1c(CNc2ccc(C(=N)N)c[cH:3]2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,0.02
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)[n:1]c2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)[n+:1](C2OC(C(=O)O)C(O)C(O)C2O)c2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),Cn1c(CNc2ccc(C(=N)N)cc2)[n:1]c2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,0.0
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)[n:1]c2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)[n+:1]([O-])c2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,N-oxidation,CYP rules from GLORY (phase 1),Cn1c(CNc2ccc(C(=N)N)cc2)[n:1]c2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,0.01
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)[n:2]c2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)[n+:2]([O-])c2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,N-oxidation_(-N=),Phase 1 SyGMa rules,Cn1c(CNc2ccc(C(=N)N)cc2)[n:2]c2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,0.01
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2c1ccc(C(=O)N(CCC(=O)O)c1ccccn1)[cH:1]2,Cn1c(CNc2ccc(C(=N)N)cc2)nc2c1ccc(C(=O)N(CCC(=O)O)c1ccccn1)[c:1]2O,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cn1c(CNc2ccc(C(=N)N)cc2)nc2c1ccc(C(=O)N(CCC(=O)O)c1ccccn1)[cH:1]2,0.0
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2c1ccc(C(=O)N(CCC(=O)O)c1ccccn1)[cH:3]2,Cn1c(CNc2ccc(C(=N)N)cc2)nc2c1ccc(C(=O)N(CCC(=O)O)c1ccccn1)[c:3]2O,aromatic_hydroxylation_(ortho_to_2_substituents),Phase 1 SyGMa rules,Cn1c(CNc2ccc(C(=N)N)cc2)nc2c1ccc(C(=O)N(CCC(=O)O)c1ccccn1)[cH:3]2,0.0
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)[c:2]3ccccn3)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)NCCC(=O)O)ccc21.O=[c:2]1cccc[nH]1,oxidative_deamination_(aromatic),Phase 1 SyGMa rules,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)[c:2]3ccccn3)ccc21,0.0
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3c[cH:1]ccn3)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3c[c:1](O)ccn3)ccc21,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3c[cH:1]ccn3)ccc21,0.12
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3cc[cH:1]cn3)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3cc[c:1](O)cn3)ccc21,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3cc[cH:1]cn3)ccc21,0.22
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3cc[cH:5]cn3)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3cc[c:5](O)cn3)ccc21,aromatic_hydroxylation_(para_to_nitrogen),Phase 1 SyGMa rules,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3cc[cH:5]cn3)ccc21,0.22
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccc[cH:1]n3)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccc[c:1](O)n3)ccc21,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccc[cH:1]n3)ccc21,0.06
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3cccc[n:1]3)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3cccc[n+:1]3C3OC(C(=O)O)C(O)C(O)C3O)ccc21,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3cccc[n:1]3)ccc21,0.01
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3cccc[n:1]3)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3cccc[n+:1]3[O-])ccc21,N-oxidation,CYP rules from GLORY (phase 1),Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3cccc[n:1]3)ccc21,0.02
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3cccc[n:2]3)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3cccc[n+:2]3[O-])ccc21,N-oxidation_(-N=),Phase 1 SyGMa rules,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3cccc[n:2]3)ccc21,0.02
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)[cH:1]cc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)[c:1](O)cc21,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)[cH:1]cc21,0.01
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)[cH:5]cc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)[c:5](O)cc21,aromatic_hydroxylation_(para_to_nitrogen),Phase 1 SyGMa rules,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)[cH:5]cc21,0.01
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)c[cH:1]c21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)c[c:1](O)c21,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)c[cH:1]c21,0.01
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)c[cH:3]c21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)c[c:3](O)c21,aromatic_hydroxylation_(ortho_to_nitrogen),Phase 1 SyGMa rules,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)c[cH:3]c21,0.01
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3nccc[cH:1]3)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3nccc[c:1]3O)ccc21,aromatic hydroxylation,CYP rules from GLORY (phase 1),Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3nccc[cH:1]3)ccc21,0.02
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3nccc[cH:3]3)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3nccc[c:3]3O)ccc21,aromatic_hydroxylation_(ortho_to_nitrogen),Phase 1 SyGMa rules,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3nccc[cH:3]3)ccc21,0.02
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CC[C:2](=O)O)c3ccccn3)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CC[C:2](=O)NCC(=O)O)c3ccccn3)ccc21,glycination_(aliphatic_carboxyl),Other phase 2 rules,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CC[C:2](=O)O)c3ccccn3)ccc21,0.06
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CC[C:2](=O)O)c3ccccn3)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CC[C:2](=O)OC3OC(C(=O)O)C(O)C(O)C3O)c3ccccn3)ccc21,O-glucuronidation_(aliphatic_carboxyl),UGT rules (phase 2),Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CC[C:2](=O)O)c3ccccn3)ccc21,0.0
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CC[C:3](=O)O)c3ccccn3)ccc21,O=[CH:3]O,deformylation,CYP rules from GLORY (phase 1),Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CC[C:3](=O)O)c3ccccn3)ccc21,0.07
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(C[CH2:1]C(=O)O)c3ccccn3)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(C[CH:1](O)C(=O)O)c3ccccn3)ccc21,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(C[CH2:1]C(=O)O)c3ccccn3)ccc21,0.06
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(C[CH2:2]C(=O)O)c3ccccn3)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(C=[CH2:2])c3ccccn3)ccc21,deformylation,CYP rules from GLORY (phase 1),Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(C[CH2:2]C(=O)O)c3ccccn3)ccc21,0.06
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(C[CH2:2]C(=O)O)c3ccccn3)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(C[CH:2](O)C(=O)O)c3ccccn3)ccc21,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,not_in_a_ring)",Phase 1 SyGMa rules,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(C[CH2:2]C(=O)O)c3ccccn3)ccc21,0.06
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(c3ccccn3)[CH2:1]CC(=O)O)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(c3ccccn3)[C:1](=O)O)ccc21,beta-oxidation,Phase 1 SyGMa rules,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(c3ccccn3)[CH2:1]CC(=O)O)ccc21,0.24
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(c3ccccn3)[CH2:1]CC(=O)O)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(c3ccccn3)[CH:1](O)CC(=O)O)ccc21,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(c3ccccn3)[CH2:1]CC(=O)O)ccc21,0.24
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(c3ccccn3)[CH2:2]CC(=O)O)ccc21,O=C(O)C[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(c3ccccn3)[CH2:2]CC(=O)O)ccc21,0.24
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(c3ccccn3)[CH2:4]CC(=O)O)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)Nc3ccccn3)ccc21.O=C(O)C[CH2:4]O,N-dealkylation_(tertiaryN-CH2-alkyl),Phase 1 SyGMa rules,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(c3ccccn3)[CH2:4]CC(=O)O)ccc21,0.24
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)[N:1](CCC(=O)O)c3ccccn3)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)[N+:1]([O-])(CCC(=O)O)c3ccccn3)ccc21,N-oxidation,CYP rules from GLORY (phase 1),Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)[N:1](CCC(=O)O)c3ccccn3)ccc21,0.02
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)[N:1](CCC(=O)O)c3ccccn3)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)[NH:1]c3ccccn3)ccc21,N-dealkylation,CYP rules from GLORY (phase 1),Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)[N:1](CCC(=O)O)c3ccccn3)ccc21,0.02
Dabigatran,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc([C:2](=O)N(CCC(=O)O)c3ccccn3)ccc21,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc([C:2](=O)O)ccc21.O=C(O)CCNc1ccccn1,hydrolysis_(tertiary_amide),Phase 1 SyGMa rules,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc([C:2](=O)N(CCC(=O)O)c3ccccn3)ccc21,0.11
Dabigatran,Cn1c(CNc2ccc(C(=N)[NH2:1])cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,Cn1c(CNc2ccc(C(=N)[NH:1]O)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,amine hydroxylation,CYP rules from GLORY (phase 1),Cn1c(CNc2ccc(C(=N)[NH2:1])cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,0.2
Dabigatran,Cn1c(CNc2ccc(C(=N)[NH2:2])cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,Cn1c(CNc2ccc(C(=N)[NH:2]C3OC(C(=O)O)C(O)C(O)C3O)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,N-glucuronidation_(aliphatic_NH2),UGT rules (phase 2),Cn1c(CNc2ccc(C(=N)[NH2:2])cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,0.09
Dabigatran,Cn1c(C[NH:1]c2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,Cn1c(C[N:1](O)c2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,amine hydroxylation,CYP rules from GLORY (phase 1),Cn1c(C[NH:1]c2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,0.09
Dabigatran,Cn1c(C[NH:1]c2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,N=C(N)c1ccc([NH2:1])cc1,N-dealkylation,CYP rules from GLORY (phase 1),Cn1c(C[NH:1]c2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,0.09
Dabigatran,Cn1c(C[NH:2]c2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,Cn1c(C[N:2](c2ccc(C(=N)N)cc2)C2OC(C(=O)O)C(O)C(O)C2O)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,N-glucuronidation_(aniline_NH1-R),UGT rules (phase 2),Cn1c(C[NH:2]c2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,0.06
Dabigatran,Cn1c([CH2:1]Nc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,Cn1c([CH:1](O)Nc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Cn1c([CH2:1]Nc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,0.25
Dabigatran,Cn1c([CH2:2]Nc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,Cn1c([CH:2]=O)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,N-dealkylation,CYP rules from GLORY (phase 1),Cn1c([CH2:2]Nc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,0.25
Dabigatran,Cn1c([CH2:3]Nc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,Cn1c([CH2:3]O)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21.N=C(N)c1ccc(N)cc1,N-dealkylation_(R-NHCH2-alkyl),Phase 1 SyGMa rules,Cn1c([CH2:3]Nc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,0.25
Cinacalcet,FC(F)(F)c1cccc(CCCN[C@@H](c2cccc3ccccc23)[CH3:1])c1,O[CH2:1][C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,aliphatic hydroxylation,CYP rules from GLORY (phase 1),FC(F)(F)c1cccc(CCCN[C@@H](c2cccc3ccccc23)[CH3:1])c1,0.08
Dabigatran,N=C(N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)O)c4ccccn4)ccc3n2[CH3:1])cc1,N=C(N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)O)c4ccccn4)ccc3n2[CH2:1]O)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),N=C(N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)O)c4ccccn4)ccc3n2[CH3:1])cc1,0.23
Apixaban,NC(=O)c1nn(-c2ccc(O[CH3:1])cc2)c2c1CCN(c1ccc(N3CCCCC3=O)cc1)C2=O,NC(=O)c1nn(-c2ccc(O[CH2:1]O)cc2)c2c1CCN(c1ccc(N3CCCCC3=O)cc1)C2=O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),NC(=O)c1nn(-c2ccc(O[CH3:1])cc2)c2c1CCN(c1ccc(N3CCCCC3=O)cc1)C2=O,0.84
Fingolimod,NC(CO)(CO)CCc1ccc(CCCCCCC[CH3:1])cc1,NC(CO)(CO)CCc1ccc(CCCCCCC[CH2:1]O)cc1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),NC(CO)(CO)CCc1ccc(CCCCCCC[CH3:1])cc1,0.93
Fingolimod,NC(CO)(CO)CCc1ccc(CCCCCCC[CH3:3])cc1,NC(CO)(CO)CCc1ccc(CCCCCCC[C:3](=O)O)cc1,carboxylation_(primary_carbon_next_to_sec_carbon),Phase 1 SyGMa rules,NC(CO)(CO)CCc1ccc(CCCCCCC[CH3:3])cc1,0.93
Fingolimod,NC(CO)(CO)CCc1ccc(CCCCCCC[CH3:3])cc1,NC(CO)(CO)CCc1ccc(CCCCCCC[CH2:3]O)cc1,aliphatic_hydroxylation_(primary_carbon_next_to_sec_carbon),Phase 1 SyGMa rules,NC(CO)(CO)CCc1ccc(CCCCCCC[CH3:3])cc1,0.93
Sitagliptin,N[C@@H:1](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,N[C@@:1](O)(CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,aliphatic hydroxylation,CYP rules from GLORY (phase 1),N[C@@H:1](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,0.07
Sitagliptin,N[C@@H:2](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,N[C@@:2](O)(CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,N[C@@H:2](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,0.07
Sitagliptin,N[C@@H:2](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,O=C(C[C:2](=O)Cc1cc(F)c(F)cc1F)N1CCn2c(nnc2C(F)(F)F)C1,N-dealkylation,CYP rules from GLORY (phase 1),N[C@@H:2](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,0.07
Sitagliptin,N[C@@H](CC(=O)N1Cc2nnc(C(F)(F)F)[n:1]2C[CH2:1]1)Cc1cc(F)c(F)cc1F,N[C@@H](CC(=O)N(Cc1nnc(C(F)(F)F)[nH:1]1)[CH3:1])Cc1cc(F)c(F)cc1F,N-dealkylation,CYP rules from GLORY (phase 1),N[C@@H](CC(=O)N1CC[n:1]2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,0.02
Sitagliptin,N[C@@H](CC(=O)N1CC[n:1]2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,N[C@@H](CC(=O)N1CC[N+:1]2([O-])C(=NN=C2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,N-oxidation,CYP rules from GLORY (phase 1),N[C@@H](CC(=O)N1CC[n:1]2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,0.02
Sitagliptin,N[C@@H](CC(=O)N1CCn2c(C(F)(F)F)n[n:1]c2C1)Cc1cc(F)c(F)cc1F,N[C@@H](CC(=O)N1CCn2c(C(F)(F)F)n[n+:1](C3OC(C(=O)O)C(O)C(O)C3O)c2C1)Cc1cc(F)c(F)cc1F,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),N[C@@H](CC(=O)N1CCn2c(C(F)(F)F)n[n:1]c2C1)Cc1cc(F)c(F)cc1F,0.0
Sitagliptin,N[C@@H](CC(=O)[N:1]1CCn2c(C(F)(F)F)nn[c:1]2C1)Cc1cc(F)c(F)cc1F,N[C@@H](CC(=O)[NH:1]CCn1c(C(F)(F)F)nn[cH:1]1)Cc1cc(F)c(F)cc1F,N-dealkylation,CYP rules from GLORY (phase 1),N[C@@H](CC(=O)N1CCn2c(C(F)(F)F)nn[c:1]2C1)Cc1cc(F)c(F)cc1F,0.03
Sitagliptin,N[C@@H](CC(=O)N1CCn2c(C(F)(F)F)nnc2[CH2:1]1)Cc1cc(F)c(F)cc1F,N[C@@H](CC(=O)N1CCn2c(C(F)(F)F)nnc2[CH:1]1O)Cc1cc(F)c(F)cc1F,aliphatic hydroxylation,CYP rules from GLORY (phase 1),N[C@@H](CC(=O)N1CCn2c(C(F)(F)F)nnc2[CH2:1]1)Cc1cc(F)c(F)cc1F,0.69
Sitagliptin,N[C@@H](CC(=O)N1[CH2:1]c2nnc(C(F)(F)F)n2C[CH2:2]1)Cc1cc(F)c(F)cc1F,O=[CH:2]Cn1c(C(F)(F)F)nnc1[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),N[C@@H](CC(=O)N1CCn2c(C(F)(F)F)nnc2[CH2:1]1)Cc1cc(F)c(F)cc1F,0.69
Sitagliptin,N[C@@H](CC(=O)N1CCn2c(C(F)(F)F)nnc2[CH2:2]1)Cc1cc(F)c(F)cc1F,N[C@@H](CC(=O)N1CCn2c(C(F)(F)F)nnc2[CH:2]1O)Cc1cc(F)c(F)cc1F,benzylic_hydroxylation_(c-CH2-N),Phase 1 SyGMa rules,N[C@@H](CC(=O)N1CCn2c(C(F)(F)F)nnc2[CH2:2]1)Cc1cc(F)c(F)cc1F,0.69
Sitagliptin,N[C@@H](CC(=O)N1[CH2:1]Cn2c(C(F)(F)F)nnc2[CH2:2]1)Cc1cc(F)c(F)cc1F,O=[CH:2]c1nnc(C(F)(F)F)n1C[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),N[C@@H](CC(=O)N1CCn2c(C(F)(F)F)nnc2[CH2:2]1)Cc1cc(F)c(F)cc1F,0.69
Sitagliptin,N[C@@H](CC(=O)N1CCn2c(n[n:1]c2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,N[C@@H](CC(=O)N1CCn2c(n[n+:1](C3OC(C(=O)O)C(O)C(O)C3O)c2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),N[C@@H](CC(=O)N1CCn2c(n[n:1]c2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,0.01
Sitagliptin,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1c(F)cc(F)c(F)[cH:1]1,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1c(F)cc(F)c(F)[c:1]1O,aromatic hydroxylation,CYP rules from GLORY (phase 1),N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1c(F)cc(F)c(F)[cH:1]1,0.06
Sitagliptin,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1c[c:1](F)c(F)cc1F,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1c[c:1](O)c(F)cc1F,oxidative dehalogenation benzyl,CYP rules from GLORY (phase 1),N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1c[c:1](F)c(F)cc1F,0.04
Sitagliptin,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)[c:1](F)cc1F,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)[c:1](O)cc1F,oxidative dehalogenation benzyl,CYP rules from GLORY (phase 1),N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)[c:1](F)cc1F,0.08
Sitagliptin,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)[cH:1]c1F,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)[c:1](O)c1F,aromatic hydroxylation,CYP rules from GLORY (phase 1),N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)[cH:1]c1F,0.04
Sitagliptin,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)[cH:4]c1F,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)[c:4](O)c1F,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)[cH:4]c1F,0.04
Sitagliptin,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)c[c:1]1F,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)c[c:1]1O,oxidative dehalogenation benzyl,CYP rules from GLORY (phase 1),N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)c[c:1]1F,0.1
Sitagliptin,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)[CH2:1]c1cc(F)c(F)cc1F,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)[CH:1](O)c1cc(F)c(F)cc1F,aliphatic hydroxylation,CYP rules from GLORY (phase 1),N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)[CH2:1]c1cc(F)c(F)cc1F,0.07
Sitagliptin,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)[CH2:2]c1cc(F)c(F)cc1F,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)[CH:2](O)c1cc(F)c(F)cc1F,benzylic_hydroxylation_(c-CH2-CR),Phase 1 SyGMa rules,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)[CH2:2]c1cc(F)c(F)cc1F,0.07
Sitagliptin,N[C@@H](CC(=O)N1Cc2nnc(C(F)(F)F)n2C[CH2:1]1)Cc1cc(F)c(F)cc1F,N[C@@H](CC(=O)N1Cc2nnc(C(F)(F)F)n2C[CH:1]1O)Cc1cc(F)c(F)cc1F,aliphatic hydroxylation,CYP rules from GLORY (phase 1),N[C@@H](CC(=O)N1Cc2nnc(C(F)(F)F)n2C[CH2:1]1)Cc1cc(F)c(F)cc1F,0.08
Sitagliptin,N[C@@H](CC(=O)N1[CH2:1]Cn2c(C(F)(F)F)nnc2[CH2:2]1)Cc1cc(F)c(F)cc1F,O=[CH:2]c1nnc(C(F)(F)F)n1C[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),N[C@@H](CC(=O)N1Cc2nnc(C(F)(F)F)n2C[CH2:1]1)Cc1cc(F)c(F)cc1F,0.08
Sitagliptin,N[C@@H](CC(=O)N1Cc2nnc(C(F)(F)F)n2C[CH2:2]1)Cc1cc(F)c(F)cc1F,N[C@@H](CC(=O)N1Cc2nnc(C(F)(F)F)n2C[C:2]1=O)Cc1cc(F)c(F)cc1F,oxidation_(amine_in_a_ring),Phase 1 SyGMa rules,N[C@@H](CC(=O)N1Cc2nnc(C(F)(F)F)n2C[CH2:2]1)Cc1cc(F)c(F)cc1F,0.08
Sitagliptin,N[C@@H](CC(=O)N1Cc2nnc(C(F)(F)F)n2C[CH2:2]1)Cc1cc(F)c(F)cc1F,N[C@@H](CC(=O)N1Cc2nnc(C(F)(F)F)n2C[CH:2]1O)Cc1cc(F)c(F)cc1F,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,N[C@@H](CC(=O)N1Cc2nnc(C(F)(F)F)n2C[CH2:2]1)Cc1cc(F)c(F)cc1F,0.08
Sitagliptin,N[C@@H](CC(=O)N1[CH2:1]c2nnc(C(F)(F)F)n2C[CH2:2]1)Cc1cc(F)c(F)cc1F,O=[CH:2]Cn1c(C(F)(F)F)nnc1[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),N[C@@H](CC(=O)N1Cc2nnc(C(F)(F)F)n2C[CH2:2]1)Cc1cc(F)c(F)cc1F,0.08
Sitagliptin,N[C@@H](CC(=O)N1Cc2nnc(C(F)(F)F)n2[CH2:1]C1)Cc1cc(F)c(F)cc1F,N[C@@H](CC(=O)N1Cc2nnc(C(F)(F)F)n2[CH:1](O)C1)Cc1cc(F)c(F)cc1F,aliphatic hydroxylation,CYP rules from GLORY (phase 1),N[C@@H](CC(=O)N1Cc2nnc(C(F)(F)F)n2[CH2:1]C1)Cc1cc(F)c(F)cc1F,0.1
Sitagliptin,N[C@@H](CC(=O)[N:1]1Cc2nnc(C(F)(F)F)n2[CH2:1]C1)Cc1cc(F)c(F)cc1F,N[C@@H](CC(=O)[NH:1]Cc1nnc(C(F)(F)F)n1[CH3:1])Cc1cc(F)c(F)cc1F,N-dealkylation,CYP rules from GLORY (phase 1),N[C@@H](CC(=O)N1Cc2nnc(C(F)(F)F)n2[CH2:1]C1)Cc1cc(F)c(F)cc1F,0.1
Sitagliptin,N[C@@H](CC(=O)N1Cc2nnc(C(F)(F)F)n2[CH2:2]C1)Cc1cc(F)c(F)cc1F,N[C@@H](CC(=O)N(Cc1nnc(C(F)(F)F)[nH]1)C[CH2:2]O)Cc1cc(F)c(F)cc1F,N-dealkylation_(nCH2),Phase 1 SyGMa rules,N[C@@H](CC(=O)N1Cc2nnc(C(F)(F)F)n2[CH2:2]C1)Cc1cc(F)c(F)cc1F,0.1
Sitagliptin,N[C@@H](CC(=O)N1Cc2nnc(C(F)(F)F)n2[CH2:2]C1)Cc1cc(F)c(F)cc1F,N[C@@H](CC(=O)N1Cc2nnc(C(F)(F)F)n2[CH:2](O)C1)Cc1cc(F)c(F)cc1F,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,N[C@@H](CC(=O)N1Cc2nnc(C(F)(F)F)n2[CH2:2]C1)Cc1cc(F)c(F)cc1F,0.1
Sitagliptin,N[C@@H](CC(=O)[N:1]1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,N[C@@H](CC(=O)[N+:1]1([O-])CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,N-oxidation,CYP rules from GLORY (phase 1),N[C@@H](CC(=O)[N:1]1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,0.0
Sitagliptin,N[C@H](Cc1cc(F)c(F)cc1F)C[C:2](=O)N1CCn2c(nnc2C(F)(F)F)C1,FC(F)(F)c1nnc2n1CCNC2.N[C@H](Cc1cc(F)c(F)cc1F)C[C:2](=O)O,hydrolysis_(tertiary_amide),Phase 1 SyGMa rules,N[C@H](Cc1cc(F)c(F)cc1F)C[C:2](=O)N1CCn2c(nnc2C(F)(F)F)C1,0.09
Sitagliptin,N[C@H](Cc1cc(F)c(F)cc1F)C[C:3](=O)N1CCn2c(nnc2C(F)(F)F)C1,O=[CH:3]N1CCn2c(nnc2C(F)(F)F)C1,deformylation,CYP rules from GLORY (phase 1),N[C@H](Cc1cc(F)c(F)cc1F)C[C:3](=O)N1CCn2c(nnc2C(F)(F)F)C1,0.09
Sitagliptin,N[C@H](Cc1cc(F)c(F)cc1F)[CH2:1]C(=O)N1CCn2c(nnc2C(F)(F)F)C1,N[C@H](Cc1cc(F)c(F)cc1F)[CH:1](O)C(=O)N1CCn2c(nnc2C(F)(F)F)C1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),N[C@H](Cc1cc(F)c(F)cc1F)[CH2:1]C(=O)N1CCn2c(nnc2C(F)(F)F)C1,0.02
Sitagliptin,N[C@H](Cc1cc(F)c(F)cc1F)[CH2:2]C(=O)N1CCn2c(nnc2C(F)(F)F)C1,NC(Cc1cc(F)c(F)cc1F)=[CH2:2],deformylation,CYP rules from GLORY (phase 1),N[C@H](Cc1cc(F)c(F)cc1F)[CH2:2]C(=O)N1CCn2c(nnc2C(F)(F)F)C1,0.02
Sitagliptin,N[C@H](Cc1cc(F)c(F)cc1F)[CH2:2]C(=O)N1CCn2c(nnc2C(F)(F)F)C1,N[C@H](Cc1cc(F)c(F)cc1F)[CH:2](O)C(=O)N1CCn2c(nnc2C(F)(F)F)C1,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,not_in_a_ring)",Phase 1 SyGMa rules,N[C@H](Cc1cc(F)c(F)cc1F)[CH2:2]C(=O)N1CCn2c(nnc2C(F)(F)F)C1,0.02
Abacavir,N[c:2]1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,N.O=[c:2]1nc2c(ncn2[C@H]2C=C[C@@H](CO)C2)c(NC2CC2)[nH]1,oxidative_deamination_(aromatic),Phase 1 SyGMa rules,N[c:2]1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,0.01
Lenalidomide,Nc1c2c(cc[cH:1]1)C(=O)N(C1CCC(=O)NC1=O)C2,Nc1c2c(cc[c:1]1O)C(=O)N(C1CCC(=O)NC1=O)C2,aromatic hydroxylation,CYP rules from GLORY (phase 1),Nc1c2c(cc[cH:1]1)C(=O)N(C1CCC(=O)NC1=O)C2,0.21
Pomalidomide,Nc1c2c(cc[cH:1]1)C(=O)N(C1CCC(=O)NC1=O)C2=O,Nc1c2c(cc[c:1]1O)C(=O)N(C1CCC(=O)NC1=O)C2=O,aromatic hydroxylation,CYP rules from GLORY (phase 1),Nc1c2c(cc[cH:1]1)C(=O)N(C1CCC(=O)NC1=O)C2=O,0.26
Lenalidomide,Nc1c2c(cc[cH:5]1)C(=O)N(C1CCC(=O)NC1=O)C2,Nc1c2c(cc[c:5]1O)C(=O)N(C1CCC(=O)NC1=O)C2,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,Nc1c2c(cc[cH:5]1)C(=O)N(C1CCC(=O)NC1=O)C2,0.21
Pomalidomide,Nc1c2c(cc[cH:5]1)C(=O)N(C1CCC(=O)NC1=O)C2=O,Nc1c2c(cc[c:5]1O)C(=O)N(C1CCC(=O)NC1=O)C2=O,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,Nc1c2c(cc[cH:5]1)C(=O)N(C1CCC(=O)NC1=O)C2=O,0.26
Pomalidomide,Nc1c[cH:1]cc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,Nc1c[c:1](O)cc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,aromatic hydroxylation,CYP rules from GLORY (phase 1),Nc1c[cH:1]cc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,0.28
Lenalidomide,Nc1c[cH:1]cc2c1CN(C1CCC(=O)NC1=O)C2=O,Nc1c[c:1](O)cc2c1CN(C1CCC(=O)NC1=O)C2=O,aromatic hydroxylation,CYP rules from GLORY (phase 1),Nc1c[cH:1]cc2c1CN(C1CCC(=O)NC1=O)C2=O,0.21
Pomalidomide,Nc1c[cH:5]cc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,Nc1c[c:5](O)cc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,Nc1c[cH:5]cc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,0.28
Lenalidomide,Nc1c[cH:5]cc2c1CN(C1CCC(=O)NC1=O)C2=O,Nc1c[c:5](O)cc2c1CN(C1CCC(=O)NC1=O)C2=O,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,Nc1c[cH:5]cc2c1CN(C1CCC(=O)NC1=O)C2=O,0.21
Pomalidomide,Nc1cc[cH:1]c2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,Nc1cc[c:1](O)c2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,aromatic hydroxylation,CYP rules from GLORY (phase 1),Nc1cc[cH:1]c2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,0.04
Lenalidomide,Nc1cc[cH:1]c2c1CN(C1CCC(=O)NC1=O)C2=O,Nc1cc[c:1](O)c2c1CN(C1CCC(=O)NC1=O)C2=O,aromatic hydroxylation,CYP rules from GLORY (phase 1),Nc1cc[cH:1]c2c1CN(C1CCC(=O)NC1=O)C2=O,0.07
Pomalidomide,Nc1cc[cH:5]c2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,Nc1cc[c:5](O)c2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,aromatic_hydroxylation_(para_to_nitrogen),Phase 1 SyGMa rules,Nc1cc[cH:5]c2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,0.04
Lenalidomide,Nc1cc[cH:5]c2c1CN(C1CCC(=O)NC1=O)C2=O,Nc1cc[c:5](O)c2c1CN(C1CCC(=O)NC1=O)C2=O,aromatic_hydroxylation_(para_to_nitrogen),Phase 1 SyGMa rules,Nc1cc[cH:5]c2c1CN(C1CCC(=O)NC1=O)C2=O,0.07
Lenalidomide,Nc1cccc2[c:1]1C[N:1](C1CCC(=O)NC1=O)C2=O,Nc1cccc(C(=O)[NH:1]C2CCC(=O)NC2=O)[cH:1]1,N-dealkylation,CYP rules from GLORY (phase 1),Nc1cccc2[c:1]1CN(C1CCC(=O)NC1=O)C2=O,0.0
Pomalidomide,Nc1cccc2c1C(=O)N(C1C(=O)NC(=O)C[CH2:1]1)C2=O,Nc1cccc2c1C(=O)N(C1C(=O)NC(=O)C[CH:1]1O)C2=O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Nc1cccc2c1C(=O)N(C1C(=O)NC(=O)C[CH2:1]1)C2=O,0.01
Pomalidomide,Nc1cccc2c1C(=O)N(C1C(=O)NC(=O)C[CH2:2]1)C2=O,Nc1cccc2c1C(=O)N(C1C(=O)NC(=O)C[CH:2]1O)C2=O,aliphatic_hydroxylation_(sec_carbon_in_a_ringB),Phase 1 SyGMa rules,Nc1cccc2c1C(=O)N(C1C(=O)NC(=O)C[CH2:2]1)C2=O,0.01
Pomalidomide,Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)[C:2]2=O,Nc1cccc([C:2](=O)O)c1C(=O)NC1CCC(=O)NC1=O,hydrolysis_(tertiary_amide),Phase 1 SyGMa rules,Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)[C:2]2=O,0.02
Pomalidomide,Nc1cccc2c1C(=O)N(C1CCC(=O)N[C:2]1=O)C2=O,NC(=O)CCC(N1C(=O)c2cccc(N)c2C1=O)[C:2](=O)O,hydrolysis_(secondary_amide),Phase 1 SyGMa rules,Nc1cccc2c1C(=O)N(C1CCC(=O)N[C:2]1=O)C2=O,0.08
Pomalidomide,Nc1cccc2c1C(=O)N(C1C[CH2:1]C(=O)N[C:3]1=O)C2=O,O=C(N[CH:3]=O)[CH3:1],deformylation,CYP rules from GLORY (phase 1),Nc1cccc2c1C(=O)N(C1CCC(=O)N[C:3]1=O)C2=O,0.08
Pomalidomide,Nc1cccc2c1C(=O)N(C1C[CH2:2]C(=O)[NH:1]C1=O)C2=O,Nc1cccc2c1C(=O)N(C(C=[CH2:2])C(=O)[NH2:1])C2=O,deformylation,CYP rules from GLORY (phase 1),Nc1cccc2c1C(=O)N(C1CCC(=O)[NH:1]C1=O)C2=O,0.02
Pomalidomide,Nc1cccc2c1C(=O)N(C1CCC(=O)[NH:1]C1=O)C2=O,Nc1cccc2c1C(=O)N(C1CCC(=O)[N:1](C3OC(C(=O)O)C(O)C(O)C3O)C1=O)C2=O,N-glucuronidation_(NH_in_a_ring),UGT rules (phase 2),Nc1cccc2c1C(=O)N(C1CCC(=O)[NH:1]C1=O)C2=O,0.29
Pomalidomide,Nc1cccc2c1C(=O)N(C1CCC(=O)[NH:1]C1=O)C2=O,Nc1cccc2c1C(=O)N(C1CCC(=O)[N:1](O)C1=O)C2=O,amine hydroxylation,CYP rules from GLORY (phase 1),Nc1cccc2c1C(=O)N(C1CCC(=O)[NH:1]C1=O)C2=O,0.02
Pomalidomide,Nc1cccc2c1C(=O)N([CH:2]1CCC(=O)[NH:1]C1=O)C2=O,Nc1cccc2c1C(=O)N([CH:2]=CCC(=O)[NH2:1])C2=O,deformylation,CYP rules from GLORY (phase 1),Nc1cccc2c1C(=O)N(C1CCC(=O)[NH:1]C1=O)C2=O,0.02
Pomalidomide,Nc1cccc2c1C(=O)N(C1CC[C:2](=O)NC1=O)C2=O,NC(=O)C(CC[C:2](=O)O)N1C(=O)c2cccc(N)c2C1=O,hydrolysis_(secondary_amide),Phase 1 SyGMa rules,Nc1cccc2c1C(=O)N(C1CC[C:2](=O)NC1=O)C2=O,0.14
Pomalidomide,Nc1cccc2c1C(=O)N([CH:1]1CC[C:3](=O)NC1=O)C2=O,Nc1cccc2c1C(=O)N([CH2:1]C(=O)N[CH:3]=O)C2=O,deformylation,CYP rules from GLORY (phase 1),Nc1cccc2c1C(=O)N(C1CC[C:3](=O)NC1=O)C2=O,0.14
Pomalidomide,Nc1cccc2c1C(=O)N(C1C[CH2:1]C(=O)NC1=O)C2=O,Nc1cccc2c1C(=O)N(C1C[CH:1](O)C(=O)NC1=O)C2=O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Nc1cccc2c1C(=O)N(C1C[CH2:1]C(=O)NC1=O)C2=O,0.55
Pomalidomide,Nc1cccc2c1C(=O)N(C1C[CH2:1]C(=O)N[C:3]1=O)C2=O,O=C(N[CH:3]=O)[CH3:1],deformylation,CYP rules from GLORY (phase 1),Nc1cccc2c1C(=O)N(C1C[CH2:1]C(=O)NC1=O)C2=O,0.55
Pomalidomide,Nc1cccc2c1C(=O)N(C1C[CH2:2]C(=O)[NH:1]C1=O)C2=O,Nc1cccc2c1C(=O)N(C(C=[CH2:2])C(=O)[NH2:1])C2=O,deformylation,CYP rules from GLORY (phase 1),Nc1cccc2c1C(=O)N(C1C[CH2:2]C(=O)NC1=O)C2=O,0.55
Pomalidomide,Nc1cccc2c1C(=O)N(C1C[CH2:2]C(=O)NC1=O)C2=O,Nc1cccc2c1C(=O)N(C1C[CH:2](O)C(=O)NC1=O)C2=O,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,Nc1cccc2c1C(=O)N(C1C[CH2:2]C(=O)NC1=O)C2=O,0.55
Pomalidomide,Nc1cccc2c1C(=O)N([CH:1]1CCC(=O)NC1=O)C2=O,Nc1cccc2c1C(=O)N([C:1]1(O)CCC(=O)NC1=O)C2=O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Nc1cccc2c1C(=O)N([CH:1]1CCC(=O)NC1=O)C2=O,0.06
Pomalidomide,Nc1cccc2c1C(=O)N([CH:1]1CC[C:3](=O)NC1=O)C2=O,Nc1cccc2c1C(=O)N([CH2:1]C(=O)N[CH:3]=O)C2=O,deformylation,CYP rules from GLORY (phase 1),Nc1cccc2c1C(=O)N([CH:1]1CCC(=O)NC1=O)C2=O,0.06
Pomalidomide,Nc1cccc2c1C(=O)N([CH:2]1CCC(=O)NC1=O)C2=O,Nc1cccc2c1C(=O)N([C:2]1(O)CCC(=O)NC1=O)C2=O,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,Nc1cccc2c1C(=O)N([CH:2]1CCC(=O)NC1=O)C2=O,0.06
Pomalidomide,Nc1cccc2c1C(=O)N([CH:2]1CCC(=O)[NH:1]C1=O)C2=O,Nc1cccc2c1C(=O)N([CH:2]=CCC(=O)[NH2:1])C2=O,deformylation,CYP rules from GLORY (phase 1),Nc1cccc2c1C(=O)N([CH:2]1CCC(=O)NC1=O)C2=O,0.06
Pomalidomide,Nc1cccc2c1C(=O)N([CH:2]1CCC(=O)NC1=O)C2=O,O=C1CC[C:2](=O)C(=O)N1,N-dealkylation,CYP rules from GLORY (phase 1),Nc1cccc2c1C(=O)N([CH:2]1CCC(=O)NC1=O)C2=O,0.06
Pomalidomide,Nc1cccc2c1C(=O)[N:1](C1CCC(=O)NC1=O)C2=O,Nc1cccc2c1C(=O)[N+:1]([O-])(C1CCC(=O)NC1=O)C2=O,N-oxidation,CYP rules from GLORY (phase 1),Nc1cccc2c1C(=O)[N:1](C1CCC(=O)NC1=O)C2=O,0.02
Pomalidomide,Nc1cccc2c1C(=O)[N:1](C1CCC(=O)NC1=O)C2=O,Nc1cccc2c1C(=O)[NH:1]C2=O,N-dealkylation,CYP rules from GLORY (phase 1),Nc1cccc2c1C(=O)[N:1](C1CCC(=O)NC1=O)C2=O,0.02
Lenalidomide,Nc1cccc2c1CN(C1C(=O)NC(=O)C[CH2:1]1)C2=O,Nc1cccc2c1CN(C1C(=O)NC(=O)C[CH:1]1O)C2=O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Nc1cccc2c1CN(C1C(=O)NC(=O)C[CH2:1]1)C2=O,0.01
Lenalidomide,Nc1cccc2c1CN(C1C(=O)NC(=O)C[CH2:2]1)C2=O,Nc1cccc2c1CN(C1C(=O)NC(=O)C[CH:2]1O)C2=O,aliphatic_hydroxylation_(sec_carbon_in_a_ringB),Phase 1 SyGMa rules,Nc1cccc2c1CN(C1C(=O)NC(=O)C[CH2:2]1)C2=O,0.01
Lenalidomide,Nc1cccc2c1[CH2:2]N(C1CCC(=O)NC1=O)[C:1]2=O,Nc1cccc([CH:1]=O)c1[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),Nc1cccc2c1CN(C1CCC(=O)NC1=O)[C:1]2=O,0.07
Lenalidomide,Nc1cccc2c1CN(C1CCC(=O)NC1=O)[C:2]2=O,Nc1cccc([C:2](=O)O)c1CNC1CCC(=O)NC1=O,hydrolysis_(tertiary_amide),Phase 1 SyGMa rules,Nc1cccc2c1CN(C1CCC(=O)NC1=O)[C:2]2=O,0.07
Lenalidomide,Nc1cccc2c1CN(C1CCC(=O)N[C:2]1=O)C2=O,NC(=O)CCC(N1Cc2c(N)cccc2C1=O)[C:2](=O)O,hydrolysis_(secondary_amide),Phase 1 SyGMa rules,Nc1cccc2c1CN(C1CCC(=O)N[C:2]1=O)C2=O,0.14
Lenalidomide,Nc1cccc2c1CN(C1C[CH2:1]C(=O)N[C:3]1=O)C2=O,O=C(N[CH:3]=O)[CH3:1],deformylation,CYP rules from GLORY (phase 1),Nc1cccc2c1CN(C1CCC(=O)N[C:3]1=O)C2=O,0.14
Lenalidomide,Nc1cccc2c1CN(C1C[CH2:2]C(=O)[NH:1]C1=O)C2=O,Nc1cccc2c1CN(C(C=[CH2:2])C(=O)[NH2:1])C2=O,deformylation,CYP rules from GLORY (phase 1),Nc1cccc2c1CN(C1CCC(=O)[NH:1]C1=O)C2=O,0.1
Lenalidomide,Nc1cccc2c1CN(C1CCC(=O)[NH:1]C1=O)C2=O,Nc1cccc2c1CN(C1CCC(=O)[N:1](C3OC(C(=O)O)C(O)C(O)C3O)C1=O)C2=O,N-glucuronidation_(NH_in_a_ring),UGT rules (phase 2),Nc1cccc2c1CN(C1CCC(=O)[NH:1]C1=O)C2=O,0.29
Lenalidomide,Nc1cccc2c1CN(C1CCC(=O)[NH:1]C1=O)C2=O,Nc1cccc2c1CN(C1CCC(=O)[N:1](O)C1=O)C2=O,amine hydroxylation,CYP rules from GLORY (phase 1),Nc1cccc2c1CN(C1CCC(=O)[NH:1]C1=O)C2=O,0.1
Lenalidomide,Nc1cccc2c1CN([CH:2]1CCC(=O)[NH:1]C1=O)C2=O,Nc1cccc2c1CN([CH:2]=CCC(=O)[NH2:1])C2=O,deformylation,CYP rules from GLORY (phase 1),Nc1cccc2c1CN(C1CCC(=O)[NH:1]C1=O)C2=O,0.1
Lenalidomide,Nc1cccc2c1CN(C1CC[C:2](=O)NC1=O)C2=O,NC(=O)C(CC[C:2](=O)O)N1Cc2c(N)cccc2C1=O,hydrolysis_(secondary_amide),Phase 1 SyGMa rules,Nc1cccc2c1CN(C1CC[C:2](=O)NC1=O)C2=O,0.21
Lenalidomide,Nc1cccc2c1CN([CH:1]1CC[C:3](=O)NC1=O)C2=O,Nc1cccc2c1CN([CH2:1]C(=O)N[CH:3]=O)C2=O,deformylation,CYP rules from GLORY (phase 1),Nc1cccc2c1CN(C1CC[C:3](=O)NC1=O)C2=O,0.21
Lenalidomide,Nc1cccc2c1CN(C1C[CH2:1]C(=O)NC1=O)C2=O,Nc1cccc2c1CN(C1C[CH:1](O)C(=O)NC1=O)C2=O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Nc1cccc2c1CN(C1C[CH2:1]C(=O)NC1=O)C2=O,0.19
Lenalidomide,Nc1cccc2c1CN(C1C[CH2:1]C(=O)N[C:3]1=O)C2=O,O=C(N[CH:3]=O)[CH3:1],deformylation,CYP rules from GLORY (phase 1),Nc1cccc2c1CN(C1C[CH2:1]C(=O)NC1=O)C2=O,0.19
Lenalidomide,Nc1cccc2c1CN(C1C[CH2:2]C(=O)[NH:1]C1=O)C2=O,Nc1cccc2c1CN(C(C=[CH2:2])C(=O)[NH2:1])C2=O,deformylation,CYP rules from GLORY (phase 1),Nc1cccc2c1CN(C1C[CH2:2]C(=O)NC1=O)C2=O,0.19
Lenalidomide,Nc1cccc2c1CN(C1C[CH2:2]C(=O)NC1=O)C2=O,Nc1cccc2c1CN(C1C[CH:2](O)C(=O)NC1=O)C2=O,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,Nc1cccc2c1CN(C1C[CH2:2]C(=O)NC1=O)C2=O,0.19
Lenalidomide,Nc1cccc2c1CN([CH:1]1CCC(=O)NC1=O)C2=O,Nc1cccc2c1CN([C:1]1(O)CCC(=O)NC1=O)C2=O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Nc1cccc2c1CN([CH:1]1CCC(=O)NC1=O)C2=O,0.13
Lenalidomide,Nc1cccc2c1CN([CH:1]1CC[C:3](=O)NC1=O)C2=O,Nc1cccc2c1CN([CH2:1]C(=O)N[CH:3]=O)C2=O,deformylation,CYP rules from GLORY (phase 1),Nc1cccc2c1CN([CH:1]1CCC(=O)NC1=O)C2=O,0.13
Lenalidomide,Nc1cccc2c1CN([CH:2]1CCC(=O)NC1=O)C2=O,Nc1cccc2c1CN([C:2]1(O)CCC(=O)NC1=O)C2=O,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,Nc1cccc2c1CN([CH:2]1CCC(=O)NC1=O)C2=O,0.13
Lenalidomide,Nc1cccc2c1CN([CH:2]1CCC(=O)[NH:1]C1=O)C2=O,Nc1cccc2c1CN([CH:2]=CCC(=O)[NH2:1])C2=O,deformylation,CYP rules from GLORY (phase 1),Nc1cccc2c1CN([CH:2]1CCC(=O)NC1=O)C2=O,0.13
Lenalidomide,Nc1cccc2c1CN([CH:2]1CCC(=O)NC1=O)C2=O,O=C1CC[C:2](=O)C(=O)N1,N-dealkylation,CYP rules from GLORY (phase 1),Nc1cccc2c1CN([CH:2]1CCC(=O)NC1=O)C2=O,0.13
Lenalidomide,Nc1cccc2c1C[N:1](C1CCC(=O)NC1=O)C2=O,Nc1cccc2c1C[N+:1]([O-])(C1CCC(=O)NC1=O)C2=O,N-oxidation,CYP rules from GLORY (phase 1),Nc1cccc2c1C[N:1](C1CCC(=O)NC1=O)C2=O,0.02
Lenalidomide,Nc1cccc2c1C[N:1](C1CCC(=O)NC1=O)C2=O,Nc1cccc2c1C[NH:1]C2=O,N-dealkylation,CYP rules from GLORY (phase 1),Nc1cccc2c1C[N:1](C1CCC(=O)NC1=O)C2=O,0.02
Pomalidomide,Nc1cccc2c1[C:2](=O)N(C1CCC(=O)NC1=O)C2=O,Nc1cccc(C(=O)NC2CCC(=O)NC2=O)c1[C:2](=O)O,hydrolysis_(tertiary_amide),Phase 1 SyGMa rules,Nc1cccc2c1[C:2](=O)N(C1CCC(=O)NC1=O)C2=O,0.02
Lenalidomide,Nc1cccc2c1[CH2:1]N(C1CCC(=O)NC1=O)C2=O,Nc1cccc2c1[CH:1](O)N(C1CCC(=O)NC1=O)C2=O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Nc1cccc2c1[CH2:1]N(C1CCC(=O)NC1=O)C2=O,0.21
Lenalidomide,Nc1cccc2c1[CH2:2]N(C1CCC(=O)NC1=O)[C:1]2=O,Nc1cccc([CH:1]=O)c1[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),Nc1cccc2c1[CH2:2]N(C1CCC(=O)NC1=O)C2=O,0.21
Lenalidomide,Nc1cccc2c1[CH2:2]N(C1CCC(=O)NC1=O)C2=O,Nc1cccc2c1[CH:2](O)N(C1CCC(=O)NC1=O)C2=O,benzylic_hydroxylation_(c-CH2-N),Phase 1 SyGMa rules,Nc1cccc2c1[CH2:2]N(C1CCC(=O)NC1=O)C2=O,0.21
Abacavir,Nc1nc(NC2CC2)c2c(n1)n([C@H]1C=C[C@@H](CO)C1)c[n:1]2,Nc1nc(NC2CC2)c2c(n1)n([C@H]1C=C[C@@H](CO)C1)c[n+:1]2C1OC(C(=O)O)C(O)C(O)C1O,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),Nc1nc(NC2CC2)c2c(n1)n([C@H]1C=C[C@@H](CO)C1)c[n:1]2,0.0
Abacavir,Nc1nc(NC2CC2)c2c(n1)n([C@H]1C=C[C@@H](CO)C1)c[n:1]2,Nc1nc(NC2CC2)c2c(n1)n([C@H]1C=C[C@@H](CO)C1)c[n+:1]2[O-],N-oxidation,CYP rules from GLORY (phase 1),Nc1nc(NC2CC2)c2c(n1)n([C@H]1C=C[C@@H](CO)C1)c[n:1]2,0.0
Abacavir,Nc1nc(NC2CC2)c2c(n1)n([C@H]1C=C[C@@H](CO)C1)c[n:2]2,Nc1nc(NC2CC2)c2c(n1)n([C@H]1C=C[C@@H](CO)C1)c[n+:2]2[O-],N-oxidation_(-N=),Phase 1 SyGMa rules,Nc1nc(NC2CC2)c2c(n1)n([C@H]1C=C[C@@H](CO)C1)c[n:2]2,0.0
Abacavir,Nc1nc(NC2CC2)c2n[cH:1]n([C@H]3C=C[C@@H](CO)C3)c2n1,Nc1nc(NC2CC2)c2n[c:1](O)n([C@H]3C=C[C@@H](CO)C3)c2n1,aromatic hydroxylation,CYP rules from GLORY (phase 1),Nc1nc(NC2CC2)c2n[cH:1]n([C@H]3C=C[C@@H](CO)C3)c2n1,0.12
Abacavir,Nc1nc(NC2CC2)c2n[cH:2]n([C@H]3C=C[C@@H](CO)C3)c2n1,Nc1nc(NC2CC2)c2[nH][c:2](=O)n([C@H]3C=C[C@@H](CO)C3)c2n1,aromatic_oxidation_(nitrogen_containing_5ring),Phase 1 SyGMa rules,Nc1nc(NC2CC2)c2n[cH:2]n([C@H]3C=C[C@@H](CO)C3)c2n1,0.12
Abacavir,Nc1nc(NC2CC2)c2nc[n:1]([C@H]3C=C[C@@H](CO)C3)c2n1,Nc1nc(NC2CC2)c2c(n1)[N+:1]([O-])([C@H]1C=C[C@@H](CO)C1)C=N2,N-oxidation,CYP rules from GLORY (phase 1),Nc1nc(NC2CC2)c2nc[n:1]([C@H]3C=C[C@@H](CO)C3)c2n1,0.0
Abacavir,Nc1nc(NC2CC2)c2nc[n:1]([C@H]3C=C[C@@H](CO)C3)c2n1,Nc1nc(NC2CC2)c2nc[nH:1]c2n1,N-dealkylation,CYP rules from GLORY (phase 1),Nc1nc(NC2CC2)c2nc[n:1]([C@H]3C=C[C@@H](CO)C3)c2n1,0.0
Abacavir,Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=[CH:1]3)c2n1,Nc1nc(NC2CC2)c2ncn([C@@H]3CC(CO)=C[CH:1]3O)c2n1,aliphatic hydroxylation with allylic rearrangement 1,CYP rules from GLORY (phase 1),Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=[CH:1]3)c2n1,0.06
Abacavir,Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)[CH:1]=[CH:2]3)c2n1,Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)[CH:1]4O[CH:2]34)c2n1,epoxidation,CYP rules from GLORY (phase 1),Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=[CH:2]3)c2n1,0.06
Abacavir,Nc1nc(NC2CC2)c2ncn([C@H:1]3C=C[C@@H](CO)C3)c2n1,Nc1nc(NC2CC2)c2ncn([C@@:1]3(O)C=C[C@@H](CO)C3)c2n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Nc1nc(NC2CC2)c2ncn([C@H:1]3C=C[C@@H](CO)C3)c2n1,0.12
Abacavir,Nc1nc(NC2CC2)c2ncn([C@H:2]3C=C[C@@H](CO)C3)c2n1,O=[C:2]1C=C[C@@H](CO)C1,N-dealkylation,CYP rules from GLORY (phase 1),Nc1nc(NC2CC2)c2ncn([C@H:2]3C=C[C@@H](CO)C3)c2n1,0.12
Abacavir,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H:1](CO)C3)c2n1,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@:1](O)(CO)C3)c2n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H:1](CO)C3)c2n1,0.06
Abacavir,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H:2](CO)C3)c2n1,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@:2](O)(CO)C3)c2n1,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H:2](CO)C3)c2n1,0.06
Abacavir,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2[n:1]1,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2[n+:1]1C1OC(C(=O)O)C(O)C(O)C1O,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2[n:1]1,0.0
Abacavir,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2[n:1]1,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2[n+:1]1[O-],N-oxidation,CYP rules from GLORY (phase 1),Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2[n:1]1,0.01
Abacavir,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2[n:2]1,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2[n+:2]1[O-],N-oxidation_(-N=),Phase 1 SyGMa rules,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2[n:2]1,0.01
Abacavir,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)[CH2:1]3)c2n1,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)[CH:1]3O)c2n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)[CH2:1]3)c2n1,0.03
Abacavir,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](C[OH:2])C3)c2n1,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](C[O:2]C4OC(C(=O)O)C(O)C(O)C4O)C3)c2n1,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](C[OH:2])C3)c2n1,0.9
Abacavir,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](C[OH:2])C3)c2n1,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](C[O:2]S(=O)(=O)O)C3)c2n1,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](C[OH:2])C3)c2n1,0.8
Abacavir,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H]([CH2:1]O)C3)c2n1,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H]([CH:1](O)O)C3)c2n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H]([CH2:1]O)C3)c2n1,0.72
Abacavir,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H]([CH2:2]O)C3)c2n1,Nc1nc(NC2CC2)c2ncn([C@H]3C=CC(=[CH2:2])C3)c2n1,dehydration_next_to_SP2_b,Phase 1 SyGMa rules,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H]([CH2:2]O)C3)c2n1,0.72
Abacavir,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H]([CH2:2]O)C3)c2n1,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H]([C:2](=O)O)C3)c2n1,primary_alcohol_oxidation_(aliphatic),Phase 1 SyGMa rules,Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H]([CH2:2]O)C3)c2n1,0.72
Abacavir,Nc1nc(NC2CC2)c2ncn([C@H]3C=[CH:1][C@@H](CO)C3)c2n1,Nc1nc(NC2CC2)c2ncn(C3=C[CH:1](O)[C@@H](CO)C3)c2n1,aliphatic hydroxylation with allylic rearrangement 1,CYP rules from GLORY (phase 1),Nc1nc(NC2CC2)c2ncn([C@H]3C=[CH:1][C@@H](CO)C3)c2n1,0.09
Abacavir,Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)[CH:1]=[CH:2]3)c2n1,Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)[CH:1]4O[CH:2]34)c2n1,epoxidation,CYP rules from GLORY (phase 1),Nc1nc(NC2CC2)c2ncn([C@H]3C=[CH:1][C@@H](CO)C3)c2n1,0.09
Abacavir,Nc1nc(NC2C[CH2:1]2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,Nc1nc(NC2C[CH:1]2O)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Nc1nc(NC2C[CH2:1]2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,0.03
Abacavir,Nc1nc(NC2C[CH2:2]2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,Nc1nc(NC2C[CH:2]2O)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,aliphatic_hydroxylation_(sec_carbon_in_a_ringB),Phase 1 SyGMa rules,Nc1nc(NC2C[CH2:2]2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,0.03
Abacavir,Nc1nc(N[CH:1]2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,Nc1nc(N[C:1]2(O)CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),Nc1nc(N[CH:1]2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,0.12
Abacavir,Nc1nc(N[CH:2]2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,Nc1nc(N[C:2]2(O)CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,Nc1nc(N[CH:2]2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,0.12
Abacavir,Nc1nc(N[CH:2]2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,O=[C:2]1CC1,N-dealkylation,CYP rules from GLORY (phase 1),Nc1nc(N[CH:2]2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,0.12
Abacavir,Nc1nc([NH:1]C2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,Nc1nc([N:1](O)C2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,amine hydroxylation,CYP rules from GLORY (phase 1),Nc1nc([NH:1]C2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,0.03
Abacavir,Nc1nc([NH:1]C2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,Nc1nc([NH2:1])c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,N-dealkylation,CYP rules from GLORY (phase 1),Nc1nc([NH:1]C2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,0.03
Abacavir,Nc1nc([NH:2]C2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,Nc1nc([N:2](C2CC2)C2OC(C(=O)O)C(O)C(O)C2O)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,N-glucuronidation_(aniline_NH1-R),UGT rules (phase 2),Nc1nc([NH:2]C2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,0.03
Abacavir,Nc1nc2c(ncn2[C@H]2C=C[C@@H](CO)C2)[c:2](NC2CC2)n1,NC1CC1.Nc1nc2c(ncn2[C@H]2C=C[C@@H](CO)C2)[c:2](=O)[nH]1,oxidative_deamination_(aromatic),Phase 1 SyGMa rules,Nc1nc2c(ncn2[C@H]2C=C[C@@H](CO)C2)[c:2](NC2CC2)n1,0.01
Abacavir,Nc1nc2c(ncn2[C@H]2C=C[C@@H](CO)C2)c(NC2CC2)[n:1]1,Nc1nc2c(ncn2[C@H]2C=C[C@@H](CO)C2)c(NC2CC2)[n+:1]1C1OC(C(=O)O)C(O)C(O)C1O,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),Nc1nc2c(ncn2[C@H]2C=C[C@@H](CO)C2)c(NC2CC2)[n:1]1,0.0
Abacavir,Nc1nc2c(ncn2[C@H]2C=C[C@@H](CO)C2)c(NC2CC2)[n:1]1,Nc1nc2c(ncn2[C@H]2C=C[C@@H](CO)C2)c(NC2CC2)[n+:1]1[O-],N-oxidation,CYP rules from GLORY (phase 1),Nc1nc2c(ncn2[C@H]2C=C[C@@H](CO)C2)c(NC2CC2)[n:1]1,0.01
Abacavir,Nc1nc2c(ncn2[C@H]2C=C[C@@H](CO)C2)c(NC2CC2)[n:2]1,Nc1nc2c(ncn2[C@H]2C=C[C@@H](CO)C2)c(NC2CC2)[n+:2]1[O-],N-oxidation_(-N=),Phase 1 SyGMa rules,Nc1nc2c(ncn2[C@H]2C=C[C@@H](CO)C2)c(NC2CC2)[n:2]1,0.01
Ibrutinib,Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@@H]1CCCN(C(=O)C=[CH2:1])C1,Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@@H]1CCCN(C(=O)C[CH2:1]SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C1,"glutathione_conjugation_(alpha,beta-unsaturated_carbonyl)",GST rules (phase 2),Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@@H]1CCCN(C(=O)C=[CH2:1])C1,0.84
Ibrutinib,Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@@H]1CCCN(C(=O)[CH:1]=[CH2:2])C1,Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@@H]1CCCN(C(=O)[CH:1](O)[CH2:2]O)C1,vinyl_oxidation,Phase 1 SyGMa rules,Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@@H]1CCCN(C(=O)C=[CH2:2])C1,0.73
Ibrutinib,Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@@H]1CCCN(C(=O)[CH:1]=[CH2:2])C1,Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@@H]1CCCN(C(=O)[CH:1]2O[CH2:2]2)C1,epoxidation,CYP rules from GLORY (phase 1),Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@@H]1CCCN(C(=O)C=[CH2:2])C1,0.73
Sitagliptin,O=C(C[C@@H](Cc1cc(F)c(F)cc1F)[NH2:1])N1CCn2c(nnc2C(F)(F)F)C1,O=C(C[C@@H](Cc1cc(F)c(F)cc1F)[NH:1]O)N1CCn2c(nnc2C(F)(F)F)C1,amine hydroxylation,CYP rules from GLORY (phase 1),O=C(C[C@@H](Cc1cc(F)c(F)cc1F)[NH2:1])N1CCn2c(nnc2C(F)(F)F)C1,0.73
Sitagliptin,O=C(C[C@@H](Cc1cc(F)c(F)cc1F)[NH2:2])N1CCn2c(nnc2C(F)(F)F)C1,CC(=O)[NH:2][C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,N-acetylation_(aliphatic_NH2),NAT rules (phase 2),O=C(C[C@@H](Cc1cc(F)c(F)cc1F)[NH2:2])N1CCn2c(nnc2C(F)(F)F)C1,0.6
Sitagliptin,O=C(C[C@@H](Cc1cc(F)c(F)cc1F)[NH2:2])N1CCn2c(nnc2C(F)(F)F)C1,O=C(O)C1OC([NH:2][C@@H](CC(=O)N2CCn3c(nnc3C(F)(F)F)C2)Cc2cc(F)c(F)cc2F)C(O)C(O)C1O,N-glucuronidation_(aliphatic_NH2),UGT rules (phase 2),O=C(C[C@@H](Cc1cc(F)c(F)cc1F)[NH2:2])N1CCn2c(nnc2C(F)(F)F)C1,0.68
Rivaroxaban,O=C(NC[C@@H]1OC(=O)N(c2ccc(N3CCOCC3=O)cc2)[CH2:1]1)c1ccc(Cl)s1,O=C(NC[C@@H]1OC(=O)N(c2ccc(N3CCOCC3=O)cc2)[CH:1]1O)c1ccc(Cl)s1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C(NC[C@@H]1OC(=O)N(c2ccc(N3CCOCC3=O)cc2)[CH2:1]1)c1ccc(Cl)s1,0.64
Rivaroxaban,O=C(NC[C@@H:4]1OC(=O)N(c2ccc(N3CCOCC3=O)cc2)[CH2:1]1)c1ccc(Cl)s1,O=C(NC[C@H:4](O)[CH3:1])c1ccc(Cl)s1,carbamate cleavage,CYP rules from GLORY (phase 1),O=C(NC[C@@H]1OC(=O)N(c2ccc(N3CCOCC3=O)cc2)[CH2:1]1)c1ccc(Cl)s1,0.64
Rivaroxaban,O=C(NC[C@H]1[CH2:1]N(c2ccc(N3CCOCC3=O)cc2)C(=O)[O:2]1)c1ccc(Cl)s1,O=C1COCCN1c1ccc(N(C(=O)[OH:2])[CH3:1])cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),O=C(NC[C@@H]1OC(=O)N(c2ccc(N3CCOCC3=O)cc2)[CH2:1]1)c1ccc(Cl)s1,0.64
Rivaroxaban,O=C(NC[C@@H]1OC(=O)N(c2ccc(N3CCOCC3=O)cc2)[CH2:2]1)c1ccc(Cl)s1,O=C(NC[C@@H]1OC(=O)N(c2ccc(N3CCOCC3=O)cc2)[CH:2]1O)c1ccc(Cl)s1,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,O=C(NC[C@@H]1OC(=O)N(c2ccc(N3CCOCC3=O)cc2)[CH2:2]1)c1ccc(Cl)s1,0.64
Rivaroxaban,O=C(NC[C@@H]1O[C:1](=O)N(c2ccc(N3CCOCC3=O)cc2)[CH2:2]1)c1ccc(Cl)s1,O=C(NC[C@H](O[CH:1]=O)[CH:2]=O)c1ccc(Cl)s1,N-dealkylation,CYP rules from GLORY (phase 1),O=C(NC[C@@H]1OC(=O)N(c2ccc(N3CCOCC3=O)cc2)[CH2:2]1)c1ccc(Cl)s1,0.64
Rivaroxaban,O=C(NC[C@H:1]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@@:1]1(O)CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C(NC[C@H:1]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.01
Rivaroxaban,O=C(NC[C@H:3]1C[N:1](c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C:3](=O)C[NH:1]c1ccc(N2CCOCC2=O)cc1)c1ccc(Cl)s1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),O=C(NC[C@H:3]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.01
Rivaroxaban,O=C(NC[C@@H:4]1OC(=O)N(c2ccc(N3CCOCC3=O)cc2)[CH2:1]1)c1ccc(Cl)s1,O=C(NC[C@H:4](O)[CH3:1])c1ccc(Cl)s1,carbamate cleavage,CYP rules from GLORY (phase 1),O=C(NC[C@H:4]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.01
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3C(=O)C[O:2]C[CH2:1]3)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc(N(C(=O)C[OH:2])[CH3:1])cc2)C(=O)O1)c1ccc(Cl)s1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3C(=O)COC[CH2:1]3)cc2)C(=O)O1)c1ccc(Cl)s1,0.73
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3C(=O)[CH2:3]OC[CH2:1]3)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc(N(C(=O)[CH:3]=O)[CH3:1])cc2)C(=O)O1)c1ccc(Cl)s1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3C(=O)COC[CH2:1]3)cc2)C(=O)O1)c1ccc(Cl)s1,0.73
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3C(=O)COC[CH2:1]3)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc(N3C(=O)COC[CH:1]3O)cc2)C(=O)O1)c1ccc(Cl)s1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3C(=O)COC[CH2:1]3)cc2)C(=O)O1)c1ccc(Cl)s1,0.73
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3C(=O)COC[CH2:2]3)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc(N3C(=O)COC[C:2]3=O)cc2)C(=O)O1)c1ccc(Cl)s1,oxidation_(amine_in_a_ring),Phase 1 SyGMa rules,O=C(NC[C@H]1CN(c2ccc(N3C(=O)COC[CH2:2]3)cc2)C(=O)O1)c1ccc(Cl)s1,0.73
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3C(=O)COC[CH2:2]3)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc(N3C(=O)COC[CH:2]3O)cc2)C(=O)O1)c1ccc(Cl)s1,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,O=C(NC[C@H]1CN(c2ccc(N3C(=O)COC[CH2:2]3)cc2)C(=O)O1)c1ccc(Cl)s1,0.73
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3[C:1](=O)COC[CH2:2]3)cc2)C(=O)O1)c1ccc(Cl)s1,O=[CH:1]COC[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3C(=O)COC[CH2:2]3)cc2)C(=O)O1)c1ccc(Cl)s1,0.73
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)[cH:1]c2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)[c:1](O)c2)C(=O)O1)c1ccc(Cl)s1,aromatic hydroxylation,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)[cH:1]c2)C(=O)O1)c1ccc(Cl)s1,0.02
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)[cH:3]c2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)[c:3](O)c2)C(=O)O1)c1ccc(Cl)s1,aromatic_hydroxylation_(ortho_to_nitrogen),Phase 1 SyGMa rules,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)[cH:3]c2)C(=O)O1)c1ccc(Cl)s1,0.02
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)c[cH:1]2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)c[c:1]2O)C(=O)O1)c1ccc(Cl)s1,aromatic hydroxylation,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)c[cH:1]2)C(=O)O1)c1ccc(Cl)s1,0.01
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)c[cH:3]2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)c[c:3]2O)C(=O)O1)c1ccc(Cl)s1,aromatic_hydroxylation_(ortho_to_nitrogen),Phase 1 SyGMa rules,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)c[cH:3]2)C(=O)O1)c1ccc(Cl)s1,0.01
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1c[cH:1]c(Cl)s1,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1c[c:1](O)c(Cl)s1,aromatic hydroxylation,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1c[cH:1]c(Cl)s1,0.06
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1cc[c:1](Cl)s1,NC(CCC(=O)NC(CS[c:1]1ccc(C(=O)NC[C@H]2CN(c3ccc(N4CCOCC4=O)cc3)C(=O)O2)s1)C(=O)NCC(=O)O)C(=O)O,glutathione_conjugation_(aromatic_nucleophilic_substitution),GST rules (phase 2),O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1cc[c:1](Cl)s1,0.15
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)[s:1]1,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)C1=CC=C(Cl)[S:1]1=O,S-oxidation,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)[s:1]1,0.11
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)[s:2]1,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)C1=CC=C(Cl)[S:2]1=O,sulfide_oxidation_(c-S-c),Phase 1 SyGMa rules,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)[s:2]1,0.11
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1sc(Cl)c[cH:1]1,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1sc(Cl)c[c:1]1O,aromatic hydroxylation,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1sc(Cl)c[cH:1]1,0.02
Rivaroxaban,O=C(NC[C@H]1[CH2:1]N(c2ccc(N3CCOCC3=O)cc2)C(=O)[O:2]1)c1ccc(Cl)s1,O=C1COCCN1c1ccc(N(C(=O)[OH:2])[CH3:1])cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)[O:2]1)c1ccc(Cl)s1,0.0
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)[C:2](=O)[O:3]1)c1ccc(Cl)s1,O=[C:2]=[O:3],carbamate cleavage,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)[O:3]1)c1ccc(Cl)s1,0.0
Rivaroxaban,O=C(NC[C@@H]1O[C:1](=O)N(c2ccc(N3CCOCC3=O)cc2)[CH2:2]1)c1ccc(Cl)s1,O=C(NC[C@H](O[CH:1]=O)[CH:2]=O)c1ccc(Cl)s1,N-dealkylation,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)[C:1](=O)O1)c1ccc(Cl)s1,0.78
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)[C:2](=O)O1)c1ccc(Cl)s1,O=C(NC[C@@H](CNc1ccc(N2CCOCC2=O)cc1)O[C:2](=O)O)c1ccc(Cl)s1,hydrolysis_(urea_or_carbonate),Phase 1 SyGMa rules,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)[C:2](=O)O1)c1ccc(Cl)s1,0.78
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)[C:2](=O)O1)c1ccc(Cl)s1,O=C(NC[C@H](O)CN(c1ccc(N2CCOCC2=O)cc1)[C:2](=O)O)c1ccc(Cl)s1,hydrolysis_(urea_or_carbonate),Phase 1 SyGMa rules,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)[C:2](=O)O1)c1ccc(Cl)s1,0.78
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)[C:2](=O)[O:3]1)c1ccc(Cl)s1,O=[C:2]=[O:3],carbamate cleavage,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)[C:2](=O)O1)c1ccc(Cl)s1,0.78
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3CC[O:2]C[C:1]3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc(N(CC[OH:2])[CH:1]=O)cc2)C(=O)O1)c1ccc(Cl)s1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3CCOC[C:1]3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.79
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3C[CH2:3]OC[C:1]3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc(N(C[CH:3]=O)[CH:1]=O)cc2)C(=O)O1)c1ccc(Cl)s1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3CCOC[C:1]3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.79
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3[C:1](=O)COC[CH2:2]3)cc2)C(=O)O1)c1ccc(Cl)s1,O=[CH:1]COC[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3CCOC[C:1]3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.79
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3CC[O:4]C[C:1]3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=[CH:1]C[OH:4],N-dealkylation of morpholine,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3CCOC[C:1]3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.79
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3CCOC[C:2]3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc(NCCOC[C:2](=O)O)cc2)C(=O)O1)c1ccc(Cl)s1,hydrolysis_(tertiary_amide),Phase 1 SyGMa rules,O=C(NC[C@H]1CN(c2ccc(N3CCOC[C:2]3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.79
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3CCO[CH2:1]C3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc(N3CCO[CH:1](O)C3=O)cc2)C(=O)O1)c1ccc(Cl)s1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3CCO[CH2:1]C3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.76
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc([N:1]3CCO[CH2:1]C3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc([NH:1]C(=O)[CH3:1])cc2)C(=O)O1)c1ccc(Cl)s1,N-dealkylation of morpholine,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3CCO[CH2:1]C3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.76
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3C(=O)[CH2:3]OC[CH2:1]3)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc(N(C(=O)[CH:3]=O)[CH3:1])cc2)C(=O)O1)c1ccc(Cl)s1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3CCO[CH2:3]C3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.76
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3CCO[CH2:3]C3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc(N(CCO)C(=O)[CH2:3]O)cc2)C(=O)O1)c1ccc(Cl)s1,O-dealkylation_(aliphatic),Phase 1 SyGMa rules,O=C(NC[C@H]1CN(c2ccc(N3CCO[CH2:3]C3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.76
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3C(=O)C[O:2]C[CH2:1]3)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc(N(C(=O)C[OH:2])[CH3:1])cc2)C(=O)O1)c1ccc(Cl)s1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3CC[O:2]CC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.02
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3CC[O:2]C[C:1]3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc(N(CC[OH:2])[CH:1]=O)cc2)C(=O)O1)c1ccc(Cl)s1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3CC[O:2]CC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.02
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3CC[O:4]C[C:1]3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=[CH:1]C[OH:4],N-dealkylation of morpholine,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3CC[O:4]CC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.02
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc([N:2]3CC[O:5]CC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc([NH:2]C(=O)C[OH:5])cc2)C(=O)O1)c1ccc(Cl)s1,N-dealkylation_(morpholine),Phase 1 SyGMa rules,O=C(NC[C@H]1CN(c2ccc(N3CC[O:5]CC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.02
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3C[CH2:1]OCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc(N3C[CH:1](O)OCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3C[CH2:1]OCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.84
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc([N:1]3C[CH2:1]OCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc([NH:1]C(=O)CO[CH3:1])cc2)C(=O)O1)c1ccc(Cl)s1,N-dealkylation,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3C[CH2:1]OCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.84
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc(N3C[CH2:3]OC[C:1]3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc(N(C[CH:3]=O)[CH:1]=O)cc2)C(=O)O1)c1ccc(Cl)s1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc(N3C[CH2:3]OCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.84
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc([N:1]3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc([N+:1]3([O-])CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,N-oxidation,CYP rules from GLORY (phase 1),O=C(NC[C@H]1CN(c2ccc([N:1]3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.02
Rivaroxaban,O=C(NC[C@H]1CN(c2ccc([N:2]3CC[O:5]CC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1CN(c2ccc([NH:2]C(=O)C[OH:5])cc2)C(=O)O1)c1ccc(Cl)s1,N-dealkylation_(morpholine),Phase 1 SyGMa rules,O=C(NC[C@H]1CN(c2ccc([N:2]3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.02
Rivaroxaban,O=C(NC[C@H:3]1C[N:1](c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C:3](=O)C[NH:1]c1ccc(N2CCOCC2=O)cc1)c1ccc(Cl)s1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),O=C(NC[C@H]1C[N:1](c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.02
Rivaroxaban,O=C(NC[C@H]1C[N:1](c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[C@H]1C[N+:1]([O-])(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,N-oxidation,CYP rules from GLORY (phase 1),O=C(NC[C@H]1C[N:1](c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.02
Rivaroxaban,O=C(NC[C@H:1]1C[N:1](c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(NC[CH2:1]OC(=O)[NH:1]c1ccc(N2CCOCC2=O)cc1)c1ccc(Cl)s1,N-dealkylation,CYP rules from GLORY (phase 1),O=C(NC[C@H]1C[N:1](c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.02
Rivaroxaban,O=C(NC[C@@H]1OC(=O)[N:1](c2ccc(N3CCOCC3=O)cc2)[CH2:1]1)c1ccc(Cl)s1,O=C1COCCN1c1ccc([NH:1][CH3:1])cc1,carbamate cleavage,CYP rules from GLORY (phase 1),O=C(NC[C@H]1C[N:1](c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.02
Dolutegravir,O=C(NCc1ccc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)N1[C@H](C2)OCC[C@H]1[CH3:1],O=C(NCc1ccc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)N1[C@H](C2)OCC[C@H]1[CH2:1]O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C(NCc1ccc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)N1[C@H](C2)OCC[C@H]1[CH3:1],0.01
Rivaroxaban,O=C(N[CH2:1][C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=C(N[CH:1](O)[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C(N[CH2:1][C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.04
Rivaroxaban,O=C(N[CH2:2][C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,O=C1COCCN1c1ccc(N2C[C@H]([CH:2]=O)OC2=O)cc1,N-dealkylation,CYP rules from GLORY (phase 1),O=C(N[CH2:2][C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.04
Rivaroxaban,O=C(N[CH2:3][C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,NC(=O)c1ccc(Cl)s1.O=C1COCCN1c1ccc(N2C[C@H]([CH2:3]O)OC2=O)cc1,N-dealkylation_(R-NHCH2-alkyl),Phase 1 SyGMa rules,O=C(N[CH2:3][C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,0.04
Clopidogrel,O=C(O[CH3:1])[C@H](c1ccccc1Cl)N1CCc2sccc2C1,O=C(O[CH2:1]O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C(O[CH3:1])[C@H](c1ccccc1Cl)N1CCc2sccc2C1,0.01
Pomalidomide,O=C1CCC(N2C(=O)c3cccc([NH2:1])c3C2=O)C(=O)N1,O=C1CCC(N2C(=O)c3cccc([NH:1]O)c3C2=O)C(=O)N1,amine hydroxylation,CYP rules from GLORY (phase 1),O=C1CCC(N2C(=O)c3cccc([NH2:1])c3C2=O)C(=O)N1,0.29
Pomalidomide,O=C1CCC(N2C(=O)c3cccc([NH2:2])c3C2=O)C(=O)N1,CC(=O)[NH:2]c1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,N-acetylation_(aniline),NAT rules (phase 2),O=C1CCC(N2C(=O)c3cccc([NH2:2])c3C2=O)C(=O)N1,0.71
Pomalidomide,O=C1CCC(N2C(=O)c3cccc([NH2:2])c3C2=O)C(=O)N1,O=C1CCC(N2C(=O)c3cccc([NH:2]C4OC(C(=O)O)C(O)C(O)C4O)c3C2=O)C(=O)N1,N-glucuronidation_(aniline),UGT rules (phase 2),O=C1CCC(N2C(=O)c3cccc([NH2:2])c3C2=O)C(=O)N1,0.12
Pomalidomide,O=C1CCC(N2C(=O)c3cccc([NH2:2])c3C2=O)C(=O)N1,O=C1CCC(N2C(=O)c3cccc([NH:2]O)c3C2=O)C(=O)N1,N-oxidation_(aniline),Phase 1 SyGMa rules,O=C1CCC(N2C(=O)c3cccc([NH2:2])c3C2=O)C(=O)N1,0.29
Pomalidomide,O=C1CCC(N2C(=O)c3cccc([NH2:2])c3C2=O)C(=O)N1,O=C1CCC(N2C(=O)c3cccc([NH:2]S(=O)(=O)O)c3C2=O)C(=O)N1,sulfation_(aniline),SULT rules (phase 2),O=C1CCC(N2C(=O)c3cccc([NH2:2])c3C2=O)C(=O)N1,0.24
Lenalidomide,O=C1CCC(N2Cc3c(cccc3[NH2:1])C2=O)C(=O)N1,O=C1CCC(N2Cc3c(cccc3[NH:1]O)C2=O)C(=O)N1,amine hydroxylation,CYP rules from GLORY (phase 1),O=C1CCC(N2Cc3c(cccc3[NH2:1])C2=O)C(=O)N1,0.39
Lenalidomide,O=C1CCC(N2Cc3c(cccc3[NH2:2])C2=O)C(=O)N1,CC(=O)[NH:2]c1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,N-acetylation_(aniline),NAT rules (phase 2),O=C1CCC(N2Cc3c(cccc3[NH2:2])C2=O)C(=O)N1,0.68
Lenalidomide,O=C1CCC(N2Cc3c(cccc3[NH2:2])C2=O)C(=O)N1,O=C1CCC(N2Cc3c(cccc3[NH:2]C3OC(C(=O)O)C(O)C(O)C3O)C2=O)C(=O)N1,N-glucuronidation_(aniline),UGT rules (phase 2),O=C1CCC(N2Cc3c(cccc3[NH2:2])C2=O)C(=O)N1,0.41
Lenalidomide,O=C1CCC(N2Cc3c(cccc3[NH2:2])C2=O)C(=O)N1,O=C1CCC(N2Cc3c(cccc3[NH:2]O)C2=O)C(=O)N1,N-oxidation_(aniline),Phase 1 SyGMa rules,O=C1CCC(N2Cc3c(cccc3[NH2:2])C2=O)C(=O)N1,0.39
Lenalidomide,O=C1CCC(N2Cc3c(cccc3[NH2:2])C2=O)C(=O)N1,O=C1CCC(N2Cc3c(cccc3[NH:2]S(=O)(=O)O)C2=O)C(=O)N1,sulfation_(aniline),SULT rules (phase 2),O=C1CCC(N2Cc3c(cccc3[NH2:2])C2=O)C(=O)N1,0.29
Rivaroxaban,O=C1COCCN1c1ccc(N2C[C@H](CN[C:2](=O)c3ccc(Cl)s3)OC2=O)cc1,NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1.O=[C:2](O)c1ccc(Cl)s1,hydrolysis_(secondary_amide),Phase 1 SyGMa rules,O=C1COCCN1c1ccc(N2C[C@H](CN[C:2](=O)c3ccc(Cl)s3)OC2=O)cc1,0.67
Rivaroxaban,O=C1COCCN1c1ccc(N2C[C@H](C[NH:1]C(=O)c3ccc(Cl)s3)OC2=O)cc1,O=C(c1ccc(Cl)s1)[NH2:1],N-dealkylation,CYP rules from GLORY (phase 1),O=C1COCCN1c1ccc(N2C[C@H](C[NH:1]C(=O)c3ccc(Cl)s3)OC2=O)cc1,0.02
Rivaroxaban,O=C1COCCN1c1ccc(N2C[C@H](C[NH:1]C(=O)c3ccc(Cl)s3)OC2=O)cc1,O=C1COCCN1c1ccc(N2C[C@H](C[N:1](O)C(=O)c3ccc(Cl)s3)OC2=O)cc1,amine hydroxylation,CYP rules from GLORY (phase 1),O=C1COCCN1c1ccc(N2C[C@H](C[NH:1]C(=O)c3ccc(Cl)s3)OC2=O)cc1,0.02
Lurasidone,O=C1[C@@H]2[C@@H]3C[C@H]([C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc4ccccc24)CC1)[CH2:1]C3,O=C1[C@@H]2[C@@H]3C[C@H]([C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc4ccccc24)CC1)[CH:1](O)C3,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@@H]3C[C@H]([C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc4ccccc24)CC1)[CH2:1]C3,0.2
Lurasidone,O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(c3nsc4ccccc34)CC2)[C:3](=O)[C@H]2[C@@H]3[CH2:1]C[C@@H]([CH2:1]3)[C@@H:1]12,O=C(N(C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1)[CH:3]=O)[CH2:1][C@@H](C[CH3:1])[CH3:1],deformylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H](C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c3nsc4ccccc34)CC1)[C@H]1CC[C@@H]2[CH2:1]1,0.14
Lurasidone,O=C1[C@@H]2[C@H](C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c3nsc4ccccc34)CC1)[C@H]1CC[C@@H]2[CH2:1]1,O=C1[C@@H]2[C@H](C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c3nsc4ccccc34)CC1)[C@H]1CC[C@@H]2[CH:1]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H](C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c3nsc4ccccc34)CC1)[C@H]1CC[C@@H]2[CH2:1]1,0.14
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H:1](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@:1](O)(C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H:1](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.07
Lurasidone,O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(c3nsc4ccccc34)CC2)[C:3](=O)[C@@H]2[C@H]3[CH2:1]C[C@H]([CH2:1]3)[C@H:1]12,O=C(N(C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1)[CH:3]=O)[CH2:1][C@H](C[CH3:1])[CH3:1],deformylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H:1]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.08
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H:1]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@:1]2(O)C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H:1]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.08
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H:2]2C(=O)[N:1]1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C(C1=[CH:2][C@@H]2CC[C@H]1C2)[NH:1]C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,deformylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H:2]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.08
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H:2]2C(=O)[N:1]1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C([C@@H]1[C@H]2CCC(=[CH:2]1)C2)[NH:1]C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,deformylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H:2]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.08
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H:2]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@:2]2(O)C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H:2]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.08
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H:1]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@:1]1(O)CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H:1]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.03
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H:1]1CN1CCN(c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@@:1]1(O)CN1CCN(c2nsc3ccccc23)CC1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H:1]1CN1CCN(c2nsc3ccccc23)CC1,0.06
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN([c:2]2nsc3ccccc32)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCNCC1.O=[c:2]1[nH]sc2ccccc21,oxidative_deamination_(aromatic),Phase 1 SyGMa rules,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN([c:2]2nsc3ccccc32)CC1,0.07
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2c3ccccc3s[n:1]2)CC1,O=C(O)C1OC([n+:1]2sc3ccccc3c2N2CCN(C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)CC2)C(O)C(O)C1O,N-glucuronidation_(aromatic_=n-),UGT rules (phase 2),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2c3ccccc3s[n:1]2)CC1,0.09
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2n[s:1]c3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(C2=N[S:1](=O)c3ccccc32)CC1,thiophene_oxidation,Phase 1 SyGMa rules,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2n[s:1]c3ccccc23)CC1,0.68
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3c2ccc[cH:1]3)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3c2ccc[c:1]3O)CC1,aromatic hydroxylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3c2ccc[cH:1]3)CC1,0.01
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3c[cH:1]ccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3c[c:1](O)ccc23)CC1,aromatic hydroxylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3c[cH:1]ccc23)CC1,0.03
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3c[cH:5]ccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3c[c:5](O)ccc23)CC1,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3c[cH:5]ccc23)CC1,0.03
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3cc[cH:1]cc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3cc[c:1](O)cc23)CC1,aromatic hydroxylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3cc[cH:1]cc23)CC1,0.04
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccc[cH:1]c23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccc[c:1](O)c23)CC1,aromatic hydroxylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccc[cH:1]c23)CC1,0.01
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)C[CH2:1]1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)C[CH:1]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)C[CH2:1]1,0.08
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1[CH2:1]CN(c2nsc3ccccc23)C[CH2:2]1,O=[CH:2]CN(C[CH3:1])c1nsc2ccccc12,N-dealkylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)C[CH2:1]1,0.08
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)C[CH2:2]1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)C[C:2]1=O,oxidation_(amine_in_a_ring),Phase 1 SyGMa rules,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)C[CH2:2]1,0.08
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)C[CH2:2]1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)C[CH:2]1O,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)C[CH2:2]1,0.08
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1[CH2:1]CN(c2nsc3ccccc23)C[CH2:2]1,O=[CH:2]CN(C[CH3:1])c1nsc2ccccc12,N-dealkylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)C[CH2:2]1,0.08
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1C[CH2:1]N(c2nsc3ccccc23)[CH2:2]C1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN(C[CH3:1])C[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)[CH2:1]C1,0.08
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)[CH2:1]C1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)[CH:1](O)C1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)[CH2:1]C1,0.08
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1C[N:1]1CCN(c2nsc3ccccc23)[CH2:1]C1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1C[NH:1]CCN(c1nsc2ccccc12)[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)[CH2:1]C1,0.08
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1C[CH2:1]N(c2nsc3ccccc23)[CH2:2]C1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN(C[CH3:1])C[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)[CH2:2]C1,0.08
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)[CH2:2]C1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)[C:2](=O)C1,oxidation_(amine_in_a_ring),Phase 1 SyGMa rules,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)[CH2:2]C1,0.08
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)[CH2:2]C1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)[CH:2](O)C1,"aliphatic_hydroxylation_(sec_carbon_next_to_SP2,in_a_ring)",Phase 1 SyGMa rules,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)[CH2:2]C1,0.08
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CC[N:1](c2nsc3ccccc23)C[CH2:1]1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN(CC[NH:1]c1nsc2ccccc12)[CH3:1],N-dealkylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CC[N:1](c2nsc3ccccc23)CC1,0.09
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CC[N:1](c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CC[N+:1]([O-])(c2nsc3ccccc23)CC1,N-oxidation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CC[N:1](c2nsc3ccccc23)CC1,0.09
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1C[N:5]1CC[N:2](c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1C[NH:5]CC[NH:2]c1nsc2ccccc12,N-dealkylation_(piperazine),Phase 1 SyGMa rules,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CC[N:2](c2nsc3ccccc23)CC1,0.09
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1C[N:2]1CC[N:5](c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1C[NH:2]CC[NH:5]c1nsc2ccccc12,N-dealkylation of piperazine,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CC[N:5](c2nsc3ccccc23)CC1,0.09
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1C[N:1]1CCN(c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1C[N+:1]1([O-])CCN(c2nsc3ccccc23)CC1,N-oxidation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1C[N:1]1CCN(c2nsc3ccccc23)CC1,0.11
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1C[N:1]1CCN(c2nsc3ccccc23)CC1,c1ccc2c(N3CC[NH:1]CC3)nsc2c1,N-dealkylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1C[N:1]1CCN(c2nsc3ccccc23)CC1,0.11
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1C[N:2]1CCN(c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1C[N+:2]1([O-])CCN(c2nsc3ccccc23)CC1,N-oxidation_(tertiary_N),Phase 1 SyGMa rules,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1C[N:2]1CCN(c2nsc3ccccc23)CC1,0.11
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1C[N:2]1CC[N:5](c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1C[NH:2]CC[NH:5]c1nsc2ccccc12,N-dealkylation of piperazine,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1C[N:2]1CCN(c2nsc3ccccc23)CC1,0.11
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1C[N:5]1CC[N:2](c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1C[NH:5]CC[NH:2]c1nsc2ccccc12,N-dealkylation_(piperazine),Phase 1 SyGMa rules,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1C[N:5]1CCN(c2nsc3ccccc23)CC1,0.11
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1[CH2:1]N1CCN(c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1[CH:1](O)N1CCN(c2nsc3ccccc23)CC1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1[CH2:1]N1CCN(c2nsc3ccccc23)CC1,0.28
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1[CH2:2]N1CCN(c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1[CH:2]=O,N-dealkylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1[CH2:2]N1CCN(c2nsc3ccccc23)CC1,0.28
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1[CH2:4]N1CCN(c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1[CH2:4]O.c1ccc2c(N3CCNCC3)nsc2c1,N-dealkylation_(tertiaryN-CH2-alkyl),Phase 1 SyGMa rules,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1[CH2:4]N1CCN(c2nsc3ccccc23)CC1,0.28
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCC[CH2:1][C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCC[CH:1](O)[C@H]1CN1CCN(c2nsc3ccccc23)CC1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCC[CH2:1][C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.03
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CC[CH2:1]C[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CC[CH:1](O)C[C@H]1CN1CCN(c2nsc3ccccc23)CC1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CC[CH2:1]C[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.11
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CC[CH2:2]C[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CC[CH:2](O)C[C@H]1CN1CCN(c2nsc3ccccc23)CC1,aliphatic_hydroxylation_(sec_carbon_in_a_ringA),Phase 1 SyGMa rules,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CC[CH2:2]C[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.11
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1C[CH2:1]CC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1C[CH:1](O)CC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1C[CH2:1]CC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.05
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1C[CH2:2]CC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1C[CH:2](O)CC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,aliphatic_hydroxylation_(sec_carbon_in_a_ringA),Phase 1 SyGMa rules,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1C[CH2:2]CC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.05
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@H]1[C@H](CN2CCN(c3nsc4ccccc34)CC2)CCC[CH2:1]1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@H]1[C@H](CN2CCN(c3nsc4ccccc34)CC2)CCC[CH:1]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@H]1[C@H](CN2CCN(c3nsc4ccccc34)CC2)CCC[CH2:1]1,0.18
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1[CH2:1][C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1[CH:1](O)[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1[CH2:1][C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.08
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1[CH2:2][C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=[CH:2][C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,N-dealkylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1[CH2:2][C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.08
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1[CH2:4][C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C1NC(=O)[C@H]2[C@@H]3CC[C@@H](C3)[C@@H]12.O[CH2:4][C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,N-dealkylation_(tertiaryN-CH2-alkyl),Phase 1 SyGMa rules,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1[CH2:4][C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.08
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H:2]2C(=O)[N:1]1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C(C1=[CH:2][C@@H]2CC[C@H]1C2)[NH:1]C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,deformylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)[N:1]1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.02
Lurasidone,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H:2]2C(=O)[N:1]1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C(C1=[CH:2][C@H]2CC[C@@H]1C2)[NH:1]C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,deformylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)[N:1]1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.02
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H:2]2C(=O)[N:1]1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C([C@@H]1[C@H]2CCC(=[CH:2]1)C2)[NH:1]C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,deformylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)[N:1]1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.02
Lurasidone,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H:2]2C(=O)[N:1]1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C([C@H]1[C@@H]2CCC(=[CH:2]1)C2)[NH:1]C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,deformylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)[N:1]1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.02
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)[N:1]1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)[N+:1]1([O-])C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,N-oxidation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)[N:1]1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.02
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)[N:1]1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)[NH:1]1,N-dealkylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)[N:1]1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.02
Lurasidone,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2[C:2](=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C(NC[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1)[C@@H]1[C@H]2CC[C@H](C2)[C@@H]1[C:2](=O)O,hydrolysis_(tertiary_amide),Phase 1 SyGMa rules,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2[C:2](=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.13
Lurasidone,O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(c3nsc4ccccc34)CC2)[C:3](=O)[C@H]2[C@@H]3[CH2:1]C[C@@H]([CH2:1]3)[C@@H:1]12,O=C(N(C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1)[CH:3]=O)[CH2:1][C@@H](C[CH3:1])[CH3:1],deformylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2[C:3](=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.13
Lurasidone,O=[C:1]1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2[C:3](=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=[CH:1]N(C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1)[CH:3]=O,deformylation,CYP rules from GLORY (phase 1),O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2[C:3](=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.13
Lurasidone,O=C1[C@H]2[C@@H]3CC[C@@H:1](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C1[C@H]2[C@@H]3CC[C@@:1](O)(C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C1[C@H]2[C@@H]3CC[C@@H:1](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.07
Lurasidone,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H:1]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@@:1]2(O)C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H:1]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.08
Lurasidone,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H:2]2C(=O)[N:1]1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C(C1=[CH:2][C@H]2CC[C@@H]1C2)[NH:1]C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,deformylation,CYP rules from GLORY (phase 1),O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H:2]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.08
Lurasidone,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H:2]2C(=O)[N:1]1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C([C@H]1[C@@H]2CCC(=[CH:2]1)C2)[NH:1]C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,deformylation,CYP rules from GLORY (phase 1),O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H:2]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.08
Lurasidone,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H:2]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@@:2]2(O)C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,aliphatic_hydroxylation_(tert_carbon_next_to_SP2),Phase 1 SyGMa rules,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H:2]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.08
Lurasidone,O=[C:1]1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2[C:3](=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=[CH:1]N(C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1)[CH:3]=O,deformylation,CYP rules from GLORY (phase 1),O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2[C:1](=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.13
Lurasidone,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2[C:2](=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,O=C(NC[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1)[C@H]1[C@@H]2CC[C@@H](C2)[C@H]1[C:2](=O)O,hydrolysis_(tertiary_amide),Phase 1 SyGMa rules,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2[C:2](=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.13
Lurasidone,O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(c3nsc4ccccc34)CC2)[C:3](=O)[C@@H]2[C@H]3[CH2:1]C[C@H]([CH2:1]3)[C@H:1]12,O=C(N(C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1)[CH:3]=O)[CH2:1][C@H](C[CH3:1])[CH3:1],deformylation,CYP rules from GLORY (phase 1),O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2[C:3](=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,0.13
Lurasidone,O=C1[C@H]2[C@H]3C[C@@H]([C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc4ccccc24)CC1)[CH2:1]C3,O=C1[C@H]2[C@H]3C[C@@H]([C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc4ccccc24)CC1)[CH:1](O)C3,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O=C1[C@H]2[C@H]3C[C@@H]([C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc4ccccc24)CC1)[CH2:1]C3,0.2
Ticagrelor,OCCO[C@H]1C[C@@H](n2nnc3c(N[C@@H]4C[C@H]4c4ccc(F)c(F)c4)nc(SCC[CH3:1])nc32)[C@H](O)[C@@H]1O,OCCO[C@H]1C[C@@H](n2nnc3c(N[C@@H]4C[C@H]4c4ccc(F)c(F)c4)nc(SCC[CH2:1]O)nc32)[C@H](O)[C@@H]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),OCCO[C@H]1C[C@@H](n2nnc3c(N[C@@H]4C[C@H]4c4ccc(F)c(F)c4)nc(SCC[CH3:1])nc32)[C@H](O)[C@@H]1O,0.08
Ticagrelor,OCCO[C@H]1C[C@@H](n2nnc3c(N[C@@H]4C[C@H]4c4ccc(F)c(F)c4)nc(SCC[CH3:3])nc32)[C@H](O)[C@@H]1O,O=[C:3](O)CCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,carboxylation_(primary_carbon_next_to_sec_carbon),Phase 1 SyGMa rules,OCCO[C@H]1C[C@@H](n2nnc3c(N[C@@H]4C[C@H]4c4ccc(F)c(F)c4)nc(SCC[CH3:3])nc32)[C@H](O)[C@@H]1O,0.08
Ticagrelor,OCCO[C@H]1C[C@@H](n2nnc3c(N[C@@H]4C[C@H]4c4ccc(F)c(F)c4)nc(SCC[CH3:3])nc32)[C@H](O)[C@@H]1O,OCCO[C@H]1C[C@@H](n2nnc3c(N[C@@H]4C[C@H]4c4ccc(F)c(F)c4)nc(SCC[CH2:3]O)nc32)[C@H](O)[C@@H]1O,aliphatic_hydroxylation_(primary_carbon_next_to_sec_carbon),Phase 1 SyGMa rules,OCCO[C@H]1C[C@@H](n2nnc3c(N[C@@H]4C[C@H]4c4ccc(F)c(F)c4)nc(SCC[CH3:3])nc32)[C@H](O)[C@@H]1O,0.08
Abacavir,OC[C@@H]1C=C[C@H](n2cnc3c(NC4CC4)nc([NH2:1])nc32)C1,OC[C@@H]1C=C[C@H](n2cnc3c(NC4CC4)nc([NH:1]O)nc32)C1,amine hydroxylation,CYP rules from GLORY (phase 1),OC[C@@H]1C=C[C@H](n2cnc3c(NC4CC4)nc([NH2:1])nc32)C1,0.02
Abacavir,OC[C@@H]1C=C[C@H](n2cnc3c(NC4CC4)nc([NH2:2])nc32)C1,CC(=O)[NH:2]c1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,N-acetylation_(aniline),NAT rules (phase 2),OC[C@@H]1C=C[C@H](n2cnc3c(NC4CC4)nc([NH2:2])nc32)C1,0.21
Abacavir,OC[C@@H]1C=C[C@H](n2cnc3c(NC4CC4)nc([NH2:2])nc32)C1,O=C(O)C1OC([NH:2]c2nc(NC3CC3)c3ncn([C@H]4C=C[C@@H](CO)C4)c3n2)C(O)C(O)C1O,N-glucuronidation_(aniline),UGT rules (phase 2),OC[C@@H]1C=C[C@H](n2cnc3c(NC4CC4)nc([NH2:2])nc32)C1,0.03
Abacavir,OC[C@@H]1C=C[C@H](n2cnc3c(NC4CC4)nc([NH2:2])nc32)C1,O=S(=O)(O)[NH:2]c1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,sulfation_(aniline),SULT rules (phase 2),OC[C@@H]1C=C[C@H](n2cnc3c(NC4CC4)nc([NH2:2])nc32)C1,0.13
Abacavir,OC[C@@H]1C=C[C@H](n2cnc3c(NC4CC4)nc([NH2:2])nc32)C1,OC[C@@H]1C=C[C@H](n2cnc3c(NC4CC4)nc([NH:2]O)nc32)C1,N-oxidation_(aniline),Phase 1 SyGMa rules,OC[C@@H]1C=C[C@H](n2cnc3c(NC4CC4)nc([NH2:2])nc32)C1,0.02
Empagliflozin,OC[C@@H]1[C@@H](O)[C@H](O)[C@@H:1](O)[C@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[O:2]1,OC[C@H]([C@@H](O)[C@H](O)[CH2:1]O)[OH:2],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[O:2]1,0.0
Empagliflozin,OC[C@@H]1[C@@H:1](O)[C@H](O)[C@@H](O)[C@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[O:2]1,O[C@H]([C@@H](O)[CH2:1]O)[C@H](c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1)[OH:2],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[O:2]1,0.0
Empagliflozin,OC[C@H:1]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@@:1]1(O)O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),OC[C@H:1]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.0
Empagliflozin,OC[C@H:3]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H:1](O)[C@@H](O)[C@@H]1O,O=[C:3](CO)[C@@H](O)[C@H](O)[CH2:1]O,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),OC[C@H:3]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.0
Empagliflozin,OC[C@H]1O[C@@H:1](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@:1](O)(c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H:1](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.04
Empagliflozin,OC[C@H]1O[C@@H:3](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H:1]1O,O=[C:3](c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1)[C@H](O)[C@@H](O)[CH2:1]O,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H:3](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.04
Empagliflozin,OC[C@H]1O[C@@H:3](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H:3](O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1,O-dealkylation_(aliphatic),Phase 1 SyGMa rules,OC[C@H]1O[C@@H:3](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.04
Empagliflozin,OC[C@H]1O[C@@H](c2cc(Cc3ccc(O[C@H]4CCOC4)cc3)c(Cl)[cH:1]c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2cc(Cc3ccc(O[C@H]4CCOC4)cc3)c(Cl)[c:1](O)c2)[C@H](O)[C@@H](O)[C@@H]1O,aromatic hydroxylation,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2cc(Cc3ccc(O[C@H]4CCOC4)cc3)c(Cl)[cH:1]c2)[C@H](O)[C@@H](O)[C@@H]1O,0.0
Empagliflozin,OC[C@H]1O[C@@H](c2cc(Cc3ccc(O[C@H]4CCOC4)cc3)c(Cl)[cH:4]c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2cc(Cc3ccc(O[C@H]4CCOC4)cc3)c(Cl)[c:4](O)c2)[C@H](O)[C@@H](O)[C@@H]1O,aromatic_hydroxylation_(meta_to_carbon),Phase 1 SyGMa rules,OC[C@H]1O[C@@H](c2cc(Cc3ccc(O[C@H]4CCOC4)cc3)c(Cl)[cH:4]c2)[C@H](O)[C@@H](O)[C@@H]1O,0.0
Empagliflozin,OC[C@H]1O[C@@H](c2cc(Cc3ccc(O[C@H]4CCOC4)cc3)c(Cl)c[cH:1]2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2cc(Cc3ccc(O[C@H]4CCOC4)cc3)c(Cl)c[c:1]2O)[C@H](O)[C@@H](O)[C@@H]1O,aromatic hydroxylation,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2cc(Cc3ccc(O[C@H]4CCOC4)cc3)c(Cl)c[cH:1]2)[C@H](O)[C@@H](O)[C@@H]1O,0.08
Empagliflozin,OC[C@H]1O[C@@H](c2cc(Cc3ccc(O[C@H]4CCOC4)cc3)c(Cl)c[cH:5]2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2cc(Cc3ccc(O[C@H]4CCOC4)cc3)c(Cl)c[c:5]2O)[C@H](O)[C@@H](O)[C@@H]1O,aromatic_hydroxylation_(para_to_carbon),Phase 1 SyGMa rules,OC[C@H]1O[C@@H](c2cc(Cc3ccc(O[C@H]4CCOC4)cc3)c(Cl)c[cH:5]2)[C@H](O)[C@@H](O)[C@@H]1O,0.08
Empagliflozin,OC[C@H]1O[C@@H](c2cc[c:1](Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,NC(CCC(=O)NC(CS[c:1]1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(O[C@H]2CCOC2)cc1)C(=O)NCC(=O)O)C(=O)O,glutathione_conjugation_(aromatic_nucleophilic_substitution),GST rules (phase 2),OC[C@H]1O[C@@H](c2cc[c:1](Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.1
Empagliflozin,OC[C@H]1O[C@@H](c2cc[c:1](Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2cc[c:1](O)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,oxidative dehalogenation benzyl,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2cc[c:1](Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.01
Dapagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OC[CH3:1])cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OC[CH2:1]O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OC[CH3:1])cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.03
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4[CH2:1]CO[CH2:3]4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,O=[CH:3][C@@H](Oc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1)[CH3:1],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@@H]4COC[CH2:1]4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.14
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@@H]4COC[CH2:1]4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@@H]4COC[CH:1]4O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@@H]4COC[CH2:1]4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.14
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@@H]4C[O:2]C[CH2:1]4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H](C[OH:2])[CH3:1])cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@@H]4COC[CH2:1]4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.14
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@@H]4COC[CH2:2]4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@@H]4COC[CH:2]4O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,aliphatic_hydroxylation_(sec_carbon_in_a_ringB),Phase 1 SyGMa rules,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@@H]4COC[CH2:2]4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.14
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@@H]4CO[CH2:1]C4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@@H]4CO[CH:1](O)C4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@@H]4CO[CH2:1]C4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.41
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@@H:1]4CO[CH2:3]C4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,O=[CH:3]C[CH2:1]Oc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@@H]4CO[CH2:3]C4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.41
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@@H:1]4CO[CH2:3]C4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,O=[CH:3]C[CH2:1]Oc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H:1]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.3
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H:1]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@@:1]4(O)CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H:1]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.3
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H:1]4CC[O:2]C4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[CH2:1]CC[OH:2])cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H:1]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.3
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H:3]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,O=[C:3]1CCOC1,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H:3]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.3
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H:3]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O.O[C@H:3]1CCOC1,O-dealkylation_(aromatic),Phase 1 SyGMa rules,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H:3]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.3
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H:9]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,C1C[CH2:9]CO1,oxidation of 4-substituted anisole to quinone (substituent not a leaving group),CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H:9]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.3
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)[cH:1]c3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)[c:1](O)c3)c2)[C@H](O)[C@@H](O)[C@@H]1O,aromatic hydroxylation,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)[cH:1]c3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.0
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)[cH:3]c3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)[c:3](O)c3)c2)[C@H](O)[C@@H](O)[C@@H]1O,aromatic_hydroxylation_(ortho_to_oxygen),Phase 1 SyGMa rules,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)[cH:3]c3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.0
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)c[cH:1]3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)c[c:1]3O)c2)[C@H](O)[C@@H](O)[C@@H]1O,aromatic hydroxylation,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)c[cH:1]3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.01
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)[cH:1]2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)[c:1]2O)[C@H](O)[C@@H](O)[C@@H]1O,aromatic hydroxylation,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)[cH:1]2)[C@H](O)[C@@H](O)[C@@H]1O,0.0
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)[cH:3]2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)[c:3]2O)[C@H](O)[C@@H](O)[C@@H]1O,aromatic_hydroxylation_(ortho_to_2_substituents),Phase 1 SyGMa rules,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)[cH:3]2)[C@H](O)[C@@H](O)[C@@H]1O,0.0
Empagliflozin,OC[C@H:3]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H:1](O)[C@@H](O)[C@@H]1O,O=[C:3](CO)[C@@H](O)[C@H](O)[CH2:1]O,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H:1](O)[C@@H](O)[C@@H]1O,0.0
Empagliflozin,OC[C@@H]1[C@@H](O)[C@H](O)[C@@H:1](O)[C@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[O:2]1,OC[C@H]([C@@H](O)[C@H](O)[CH2:1]O)[OH:2],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H:1](O)[C@@H](O)[C@@H]1O,0.0
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H:1](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C:1](O)(O)[C@@H](O)[C@@H]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H:1](O)[C@@H](O)[C@@H]1O,0.0
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H:2](O)[C@@H](O)[C@@H]1O,OC[C@H]1OC(c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)=[CH:2][C@@H](O)[C@@H]1O,dehydration_next_to_SP2_b,Phase 1 SyGMa rules,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H:2](O)[C@@H](O)[C@@H]1O,0.0
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H:1](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C:1](O)(O)[C@@H]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H:1](O)[C@@H]1O,0.0
Empagliflozin,OC[C@H]1O[C@@H:3](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H:1]1O,O=[C:3](c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1)[C@H](O)[C@@H](O)[CH2:1]O,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H:1]1O,0.0
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H:1]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C:1]1(O)O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H:1]1O,0.0
Empagliflozin,OC[C@@H]1[C@@H:1](O)[C@H](O)[C@@H](O)[C@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[O:2]1,O[C@H]([C@@H](O)[CH2:1]O)[C@H](c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1)[OH:2],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H:1]1O,0.0
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCO[CH2:1]4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCO[CH:1]4O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCO[CH2:1]4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.33
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4[CH2:1]CO[CH2:3]4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,O=[CH:3][C@@H](Oc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1)[CH3:1],oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCO[CH2:3]4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.33
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCO[CH2:3]4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OCC[C@H](Oc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1)[CH2:3]O,O-dealkylation_(aliphatic),Phase 1 SyGMa rules,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCO[CH2:3]4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.33
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@@H]4C[O:2]C[CH2:1]4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H](C[OH:2])[CH3:1])cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CC[O:2]C4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.05
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H:1]4CC[O:2]C4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[CH2:1]CC[OH:2])cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CC[O:2]C4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.05
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc([O:2][C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc([OH:2])cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,oxidative ether cleavage to one alcohol and one aldehyde/ketone,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc([O:2][C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.04
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc([O:7][C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c(CC3(O)C=CC(=[O:7])C=C3)c2)[C@H](O)[C@@H](O)[C@@H]1O,oxidation of 4-substituted anisole to quinone (substituent not a leaving group),CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc([O:7][C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.04
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c([CH2:1]c3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c([CH:1](O)c3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),OC[C@H]1O[C@@H](c2ccc(Cl)c([CH2:1]c3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.62
Empagliflozin,OC[C@H]1O[C@@H](c2ccc(Cl)c([CH2:2]c3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OC[C@H]1O[C@@H](c2ccc(Cl)c([CH:2](O)c3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,benzylic_hydroxylation_(c-CH2-CR),Phase 1 SyGMa rules,OC[C@H]1O[C@@H](c2ccc(Cl)c([CH2:2]c3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0.62
Empagliflozin,O[C@@H]1[C@@H](O)[C@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)O[C@H](C[OH:2])[C@H]1O,O=C(O)C1OC([O:2]C[C@H]2O[C@@H](c3ccc(Cl)c(Cc4ccc(O[C@H]5CCOC5)cc4)c3)[C@H](O)[C@@H](O)[C@@H]2O)C(O)C(O)C1O,O-glucuronidation_(aliphatic_hydroxyl),UGT rules (phase 2),O[C@@H]1[C@@H](O)[C@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)O[C@H](C[OH:2])[C@H]1O,0.13
Empagliflozin,O[C@@H]1[C@@H](O)[C@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)O[C@H](C[OH:2])[C@H]1O,O=S(=O)(O)[O:2]C[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,sulfation_(aliphatic_hydroxyl),SULT rules (phase 2),O[C@@H]1[C@@H](O)[C@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)O[C@H](C[OH:2])[C@H]1O,0.45
Empagliflozin,O[C@@H]1[C@@H](O)[C@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)O[C@H]([CH2:1]O)[C@H]1O,O[C@@H]1[C@@H](O)[C@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)O[C@H]([CH:1](O)O)[C@H]1O,aliphatic hydroxylation,CYP rules from GLORY (phase 1),O[C@@H]1[C@@H](O)[C@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)O[C@H]([CH2:1]O)[C@H]1O,0.25
Empagliflozin,O[C@@H]1[C@@H](O)[C@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)O[C@H]([CH2:2]O)[C@H]1O,O=[C:2](O)[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,primary_alcohol_oxidation_(aliphatic),Phase 1 SyGMa rules,O[C@@H]1[C@@H](O)[C@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)O[C@H]([CH2:2]O)[C@H]1O,0.25
